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Abstract 
Overprescription of antibiotics is one of the causes of the increasing incidence of antibiotic 
resistance. Bacteria are constantly evolving and able to develop resistance to new antibiotics by 
producing β-lactamases, thus causing the standard treatments to be ineffective. Furthermore, genes 
for antibiotic resistance can be transferred between unrelated species. β-Lactamases are classified 
into serine-β-lactamases (SBLs) and metallo-β-lactamases (MBLs). Clavulanic acid is a well-known 
inhibitor that can effectively inhibit serine β-lactamases (SBLs). Nonetheless, society is in urgent 
need of metallo-β-lactamase (MBL) inhibitors as clinically approved inhibitors for MBLs are not 
yet available. IMP-1, a clinically significant MBL has been reported to cause antibiotic resistance 
associated with infections such as pneumonia and wound infections. IMP-1 shows the 
characteristics of MBLs with di-Zn ions in the active site. One of the zinc ions in IMP-1 is ligated 
by three imidazoles of histidines, while the other zinc ion is ligated by the carboxylate of an aspartic 
acid, the imidazole of a histidine and the thiolate of a cysteine. 
 
 
In this research, novel inhibitors against IMP-1 MBL were designed based on the excellent 
competitive inhibition properties of L-captopril and D-captopril, compound RS-4.2, and compound 
5.1. Modelling studies were done by docking these newly designed molecules into IMP-1 enzyme 
(PDB code: 1JJT) using Molegro Virtual Docker (MVD) software. Thiolate group of the designed 
compounds was predicted to bind to both zinc ions and the carboxylate and amide carbonyl groups 
of the compounds were predicted to form hydrogen bond or electrostatic interactions with the 
amino acid residues of the IMP-1 active site. Due to these favourable interactions, the MVD 
software predicted that the designed compounds would have high inhibition potencies against the 
enzyme.      
 
Syntheses of the designed molecules were completed via esterification of the starting materials, 
coupling reaction and lastly hydrolysis to remove both methyl ester and thioester. Eight series of 
compounds were synthesised including L- and D-proline derivatives (thiols and dicarboxylic acids), 
D-captopril derivatives, pipecolinic acid derivatives, phenylglycine derivatives, 2-aminopyridine 
derivatives, 2-amino-6-picolinic acid derivatives and diaminobenzoic acid derivatives. All of the 
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synthesised compounds including the novel inhibitors and their precursors were tested against 
freshly expressed and purified IMP-1 enzyme. The expression process includes transformation, 
inoculation, enzyme expression and cell harvesting. The enzyme was purified via two-steps 
purification by using SP-Sepharose cation exchange column and Sepharacyl S-200 gel filtration 
size exclusion column. The yield of the enzyme obtained was 12 mg per 2 litres of culture. Among 
the compounds synthesised in this study, thiols 2.1.1 – 2.1.3 (Ki = 2.2 ± 0.6 to 9.9 ± 4.2 µM) and 
compounds 5.2 – 5.4 (Ki = 2.1 ± 0.8 to 4.3 ± 2.0 µM) are the most potent compounds against IMP-
1. All of the compounds tested inhibit IMP-1 by competitive inhibition mode except compounds 5.2 
– 5.4, which uncompetitively inhibit the enzyme.    
 
 
 
Screening of compounds synthesised as purple acid phosphatase (PAP) inhibitors were also 
performed against IMP-1 enzyme since PAPs, similar to IMP-1, are metallohydrolases with two 
metal ions in the active site. Only compounds 6.10 and 6.14 are potent enough to be further tested 
for their Ki values determination. Compound 6.10 has low inhibition potency against IMP-1 and 
inhibits the enzyme by uncompetitive inhibition (Ki = 71 ± 50 µM). Compound 6.14 inhibits IMP-1 
competitively with a Ki value of 5.4 ± 2.5 µM. 
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Chapter 1.0  INTRODUCTION 
 
Diseases such as pneumonia, diarrhea and tuberculosis can be caused by pathogenic bacteria. 
Bacterial infections can cause mild diseases or extreme illnesses that can lead to death. In 2013, 
bacterial infections involving pneumonia and diarrheal disease were reported to be the leading 
causes of fatality among children less than 5 years old.1, 2 Estimated annual death counts of children 
under 5 years old caused by pneumonia and diarrheal disease were 935 000 and 760 000, 
respectively. On the other hand, tuberculosis (TB) was the second greatest killer among adults in 
2013.3 TB affected 9 million people and killed 1.5 million in that year. TB is considered as one of 
the leading causes of death among women aged 15 – 44. Normally, a healthy immune system is 
able to protect us from bacterial infections. However, we need antibiotics to treat serious infections. 
 
1.1 Antibiotics Mode of Action 
 
Based on their mechanisms of action, antibiotics can be classified as either bactericidal or 
bacteriostatic. Bactericidal antibiotics such as β-lactam antibiotics 1.1 to 1.4 (Figure 1.1) target the 
bacterial cell wall by inhibiting cell wall synthesis, thus killing the bacteria. Bacteriostatic 
antibiotics such as tetracycline 1.5 and spectinomycin 1.6  (Figure 1.2) limit bacterial growth by 
interfering with protein synthesis.4, 5  
 
 
Figure 1.1. Bactericidal antibiotics (β-lactam antibiotics). 
 
 
Figure 1.2. Bacteriostatic antibiotics. 
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β-Lactam antibiotics have bactericidal effects because they are capable of inhibiting bacterial cell 
wall synthesis. These antibiotics function by preventing the peptidoglycan cross-linking process, 
which is important to maintain cell wall structural integrity (Figure 1.3). Enzymes known as 
penicillin-binding proteins (PBPs, also known as transpeptidase enzyme) are responsible for 
peptidoglycan cross-linking (Figure 1.4a). Resemblances between the structure of four-membered 
lactam ring in β-lactam antibiotics and D-alanyl-D-alanine 1.7a moiety on peptidoglycan monomers 
(building blocks) (Figure 1.4) facilitates the binding of these antibiotics to PBP’s active site, thus 
rendering the cross-linking process between individual units of peptidoglycan during cell wall 
synthesis.6 The irreversible inhibition of PBPs (Figure 1.4b) leads to improperly made cell wall and 
bacterial lysis (Figure 1.3). 
 
 
Figure 1.3. Inhibition of the synthesis of bacterial cell wall by bactericidal antibiotics such as 
penicillin G 1.8a (see ref. 7). 
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Figure 1.4. A) Cross-linking process in bacterial cell wall synthesis. B) Irreversible inhibition of 
PBP enzyme (see ref. 8). D-alanyl-D-alanine 1.7a (in A) and penicillin G 1.8a (in B) chemical 
structure resemblances were marked with red. 
 
Tetracycline 1.5 is an example of a bacteriostatic antibiotic that interferes with the binding of 
transfer ribonucleic acid (t-RNA) – amino acid complexes during protein synthesis in bacteria, thus 
inhibits the linking process between amino acids to form peptide chains (Figure 1.5).7 Since 
bacteria need new proteins to make new cells, bacteriostatic antibiotics can limit bacterial growth. 
 
 
Figure 1.5. Bacteriostatic tetracyclines interfering with protein synthesis of bacteria. mRNA: 
messenger ribonucleic acid (transfers genetic information from DNA to ribosome), tRNA: transfer 
ribonucleic acid (delivers specific amino acids to ribosome according to genetic information 
transferred by the mRNA, ribosome: the site for protein synthesis in a cell (see ref. 7).  
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1.2 β-Lactam Antibiotics 
 
Bacterial infections can be cured by a standard treatment using β-Lactam antibiotics.9 The common 
chemical structure in all β-lactam antibiotics is a four-membered β-lactam ring (Figure 1.6). 
 
 
Figure 1.6. β-Lactam ring.  
 
Instead of a sulfur containing five-membered ring (thiazolidine ring) fused to the β-lactam ring in 
penicillins 1.1, cephalosporins 1.2 (Figure 1.1) have a six-membered ring (dihydrothiazine ring). 
Although the carbapenems 1.3 (Figure 1.1) have similar structure to the penicillins (five-membered 
ring fused to the lactam ring), there is a carbon atom replaces the sulfur atom present in penicillin 
and an additional double bond in the five-membered ring. Unlike most other β-lactam antibiotics, 
the monobactam’s 1.4 backbone structure only possesses a monocyclic azetidin-2-one.9-12  
 
1.2.1 The Beginning of β-Lactam Antibiotics 
 
Penicillin 1.1 (Figure 1.1) was discovered by Alexander Fleming in 1928, while doing a study on 
Staphylococcus.13 Fleming extracted penicillin 1.1 from a mould, Penicillium notatum.14 However, 
penicillin 1.1 was not used to treat infections until the 1940s because Fleming was unable to purify 
enough penicillin for clinical study. 
 
In August 1940, Ernst Chain and co-workers reported that penicillin 1.1 successfully cured cats, rats 
and mice from infections caused by Streptococcus pyogenes, Staphylococcus aureus and 
Clostridium septique.15 A clinical test of penicillin 1.1 involving ten patients infected by 
Staphylococcus aureus was successfully conducted and extensively described a year later.16 Then, 
in June 1941, Florey and Heatly went to the USA to seek aid in penicillin 1.1 mass production for a 
large-scale clinical test that involved a hundred human subjects. Later, in the Northern Regional 
Research Laboratory, Department of Agriculture, Illinois, Florey and Heatly managed to isolate 
Penicillium chrysogenum, a new Penicillium strain which yielded 6 times as much penicillin 1.1 per 
millilitre of culture filtrate than the strains used before.17 
 
This effort slowly attracted a few pharmaceutical firms, such as E.R. Squibb & Sons, Charles Pfizer 
& Co., Merck & Co., and the U.S. government. Furthermore, the need to treat wounded soldiers 
NH
O
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during the second world war also demanded mass production of penicillin.18, 19 Consequently, 
clinical tests were able to be conducted in large-scale in the USA and in England from the end of 
1942 to 1943.20-25 Penicillin G 1.8a (Figure 1.4. b)) was finally available commercially in 1945 in 
the United States, the same year when Fleming, Florey and Chain received the Nobel Prize in 
Medicine.26 
 
The introduction of penicillin G 1.8a marked a new era in the medical world where previously fatal 
infections such as meningitis, tuberculosis and pneumonia could be successfully treated. Armstrong 
et al. reported that mortality caused by infectious diseases in the USA decreased from 797 per 
100,000 individuals in 1900 (before the introduction of penicillin G 1.8a) to 36 per 100,000 
individuals in 1980.27 
 
1.2.2 Extractions and Syntheses of β-Lactam Molecules 
 
During the early era of penicillin 1.1 discovery, Fleming and his co-workers, Craddock and Ridley, 
purified penicillin 1.1 that was released into the fermentation broth by evaporating the broth while 
keeping the pH at 6.9 or below, followed by extraction using ether, alcohol, or acetone.28 This 
technique has become the foundation for subsequent penicillin 1.1 isolation. 
 
 
Figure 1.7. 6-Aminopenicillanic acid, 6-APA 1.9. 
 
In 1959, Sheehan modified the penicillin structure by acylating 6-aminopenicillanic acid, 6-APA 
1.9 (Figure 1.7), to produce phenoxymethylpenicillin which is commonly known as penicillin V 
1.10 (Figure 1.8).29 6-APA 1.9 was found by scientists at Beecham Group, a British pharmaceutical 
company in 1958 from the Penicillium mould fermentations.30 Subsequently, there was a constant 
development of semi-synthetic β-lactam compounds by addition of side chains to 6-APA 1.9. 
Methicillin 1.11 (Figure 1.8) was introduced as inhibitor of penicillinase, an enzyme that was able 
to specifically inactivate penicillin.31 Then, a penicillin analogue, carbenicillin 1.12 (Figure 1.8) 
was introduced in 1967. Carbenicillin 1.12 bears a carboxyl group that replaces the amino group in 
ampicillin 1.13.32 
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Figure 1.8. Penicillin analogues. 
 
At the same time, researchers continued to explore the natural sources. Newton and Abraham 
reported the structure of cephalosporin N 1.14 in 1954 (Figure 1.9).33 Later, they isolated 
cephalosporin C 1.15 (Figure 1.9) in 1961 from Cephalosporium acremonium strain.34 
Cephalosporin C 1.15 formed a new β-lactam antibiotics family with a 7-aminocephalosporinic 
acid, 7-ACA 1.16 (Figure 1.10). Starting from 7-ACA 1.16, researchers have been able to 
synthesise a few cephalosporin generations with potent broad-spectrum activity.35  
 
 
Figure 1.9. Cephalosporin N and cephalosporin C. 
 
 
Figure 1.10. 7-Aminocephalosporinic acid, 7-ACA 1.16. 
 
Bacteria also produce compounds that show bactericidal effects such as carbapenem 1.3 and 
monobactam 1.4 (Figure 1.1). Carbapenem 1.3 was isolated from Streptomyces spp.36 while 
monobactam 1.4 was isolated from Pseudomonas acidophila37, Chromobacterium violaceum38 and 
Agrobacterium radiobacter.39 
 
Different penicillin compounds can be obtained by using different strains, different culture media 
and by adjusting culture conditions.40 E.R. Squibb & Sons successfully crystallised and analysed 
penicillin from the United States strain.18 Later, Florey’s group also managed to crystallise the 
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compound from a different strain called the English strain.41 Florey and his co-workers reported that 
they used mainly 2-pentenylpenicillin (Penicillin F 1.17) strain for the English clinical trials while 
the United States penicillin (Penicillin G 1.8a) was mostly benzyl-penicillin (Figure 1.11).42  
 
 
Figure 1.11. Penicillin F 1.17. 
 
1.3 Antibiotic Resistance Caused by β-Lactamases  
 
Antibiotic resistance is a very serious health crisis where bacteria become resistant to antibiotics to 
which they were previously sensitive. At the very beginning, resistance to penicillin was exploited 
by Fleming to isolate pure cultures of Salmonella typhi, Escherichia coli and Haemophilus 
influenzae.14 This was done when the extracted penicillin eliminated Staphylococcus and 
Streptococcus contamination. This report aroused curiosity among scientists, as some bacteria are 
affected by penicillin but others are not. In 1940, Abraham and Chain isolated penicillinase, an 
enzyme that was able to specifically inactivate penicillin.43 Abraham et al. also proved that if 
Staphylococcus is continuously cultured in the presence of the antibiotic, it would develop 
resistance against the antibiotic.16 
 
Resistance to β-lactam antibiotics occurs when the bacteria produce β-lactamase enzymes to resist 
the antibiotic mode of action. β-Lactamase enzymes are capable of hydrolysing the four-membered 
azetidin-2-one ring (lactam ring) of β-lactam antibiotics, consequently deactivating them (Figure 
1.12).44 
 
Figure 1.12. Hydrolysis of β-lactam ring (see ref. 45). 
 
Nowadays, antibiotic resistance is increasing as antibiotics are overprescribed.46 Since bacteria are 
able to evolve resistance to new antibiotics and can transfer genes for antibiotic resistance between 
unrelated species47 (see Section 1.3.2), standard treatments become ineffective, consequently 
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causing long-lasting sickness, higher expenditure for the medicines and greater mortality risks.48 At 
the same time, infections will continue to spread.  
 
According to the World Health Organization (WHO), in 2013, 480 000 cases of TB were reported 
to be multi-drug resistant (MDR-TB). Out of the MDR-TB cases, 3.5% were new cases while 
20.5% were treated in the past. More than 50% of the reported cases were in India, China and the 
Russian Federation.3, 48 This form of TB is unable to be cured using the standard anti-TB 
treatments. It needs longer treatment courses with more expensive medicines and health-care 
resources, but less effective and higher risk of death.48 
 
The Ambler scheme classifies β-lactamases into Classes A, B, C and D (Figure 1.13) based on their 
sequence of amino acids.49 Classes A, C and D are serine-β-lactamases (SBLs). Class B β-
lactamases are also known as metallo-β-lactamases (MBLs) and are a class of metalloenzyme that 
contains one or two zinc ions in their active site. The active sites for B1, B2 and B3 subclasses of 
MBL are shown in Figure 1.13. 
  
 
Figure 1.13. Classification of MBLs. 
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1.3.1 Serine β-lactamases (SBLs) 
 
Serine β-lactamases (SBLs) are so-called because their active sites have a serine residue, which 
functions as a nucleophile.47 The enzymes that are classified as SBLs and their substrates are listed 
in Table 1.1.50 
 
Table 1.1.  Classification of SBLs  (see ref. 45 and 50). 
Subclass Enzymes Substrates 
PC1 Penicillins 
TEM-1, TEM-2, SHV-1 Penicillins, first and second 
generation of cephalosporins 
TEM-3, SHV-2, CTX-M-15, PER-1, 
VEB-1 
Extended-spectrum cephalosporins, 
monobactams 
TEM-30, SHV-10 Penicillins 
TEM-50 Extended-spectrum cephalosporins, 
monobactams 
PSE-1, CARB-3 Carbenicillin 
RTG-4 Carbenicillin, cefepime 
CepA Extended-spectrum cephalosporins 
A 
KPC-2, IMI-1, SME-1 Carbapenems 
E. coli AmpC, P99, ACT-1, CMY-2, 
FOX-1, MIR-1 
Cephalosporins 
C 
GC1, CMY-37 Cephalosporins 
OXA-1, OXA-10  Cloxacillin 
OXA-11, OXA-15  Extended-spectrum cephalosporins D 
OXA-23, OXA-48  Carbapenems 
 
1.3.2 Metallo-β-lactamases (MBLs) 
 
Metallo-β-lactamases (MBLs) use a hydroxyl group bound to the zinc ion in the active site as the 
nucleophile and are able to hydrolyse a broad range of common β-lactam antibiotics such as 
penicillins 1.1, cephalosporins 1.2, as well as carbapenems 1.3 (Figure 1.1).47 Bush categorised the 
MBLs into B1, B2 and B3 subclasses (Table 1.2) and later updated the scheme as more MBL 
enzymes were discovered.51-53 Hydrolysis of the peptide bond in β-lactam antibiotics by MBLs 
from B1 subclass involves either one or two zinc ions in the active site.54 The example of a B1 
 10 
subclass MBL is IMP-1 enzyme from Serratia marcescens55 (Section 1.3.2.1). The B2 subclass 
MBLs need only one zinc ion for their activity56 and includes CphA from Aeromonas hydrophilia.57 
B3 subclass MBLs such as L1 enzyme from Xanthomonas maltophilia need both zinc ions in the 
active site to catalyze an effective hydrolysis of β-lactam ring in antibiotics.58 Table 1.2 summarises 
the B1, B2 and B3 subclasses MBLs including the amino acid residues, which chelate the zinc ions 
in their active sites. 
 
Table 1.2.  Updated classification of class B MBLs  (see ref. 59). 
Protein binding ligands 
Subclass 
Example 
of 
enzymes 
Spectrum 
Zn 1 site Zn 2 site 
Effect of Zn 
binding 
B1 
BcII 
IMP-1 
CcrA 
VIM 
GIM-1 
SPM-1 
NDM-1 
Broad 
spectrum 
3 Histidines Asparagine 
Cysteine 
Histidine 
Binding of 2 Zn2+ 
ions for optimal 
hydrolysis 
B2 
CphA 
Sfh-1 
ImiS 
High 
specificity for 
hydrolysing 
carbapenems 
2 Histidine 
1 Asparagine 
Asparagine 
Cysteine 
Histidine 
Binding of 2nd Zn2+ 
ions is inhibitory 
B3 
L1 
FEZ-1 
GOB-1 
CAU-1 
High 
specificity for 
hydrolysing 
cephalosporins 
3 Histidine Asparagine 
2 Histidine 
 
Binding of 2 Zn2+ 
ions for optimal 
hydrolysis 
 
The research discussed in this thesis deals particularly with imipenemase (IMP-1) from the B1 
subclass of MBLs since levels of IMP-1 produced by pathogens such as Acinetobacter spp. and 
Pseudomonas aeruginosa are clinically significant.9, 47 IMP-1 can efficiently hydrolyse a broad 
range of substrates thus making this enzyme capable of conferring resistance to various kinds of 
drugs including penicillins, cephalosporins and carbapenems.60 Numerous cases of antibiotic 
resistance involving IMP-1 have been reported around the world, associated with infections such as 
pneumonia, urosepsis, bacteriemia and wound infections, including deaths.61 Although many potent 
IMP-1 inhibitors have been reported in the literature, none of these inhibitors are clinically 
approved and safe to be co-administered with β-lactam antibiotics.9 Therefore, the development of 
novel IMP-1 MBL inhibitors is needed to respond to the emerging threat of antibiotic resistance.47  
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1.3.2.1 Imipenemase (IMP-1) 
 
 
Figure 1.14.  Crystal structure of IMP-1 MBLs (PDB code: 1JJT) with αββα protein folds (see ref. 
62 and 45). 
 
The structure of IMP-1 has been solved by x-ray crystallography. IMP-1 shows the expected 
structural features of MBLs with di-Zn2+ ions in the active site and αββα protein folds, which 
consists of two β-sheets in the middle and solvent-exposed α-helices (Figure 1.14).63 IMP-1 is 
classified as B1 type where one of the zinc ions is ligated by three imidazoles of histidines, while 
the other zinc ion is ligated by the carboxylate of an aspartic acid, the imidazole of a histidine and 
the thiolate of a cysteine (Figure 1.15).64 Glu 60, Val 61 and Trp 64 residues in the active site of 
IMP-1 are known as the flexible loop, which closes over enzyme-bound substrate for effective 
enzyme catalysis.9, 65  
 
Figure 1.15.  Active site residues of IMP-1, a B1 subclass type MBL (PDB code: 1JJT). Standard 
numbering for the ligating residues is indicated (see ref. 62,66 and 45). 
IMP-1 was the first MBL found in a Pseudomonas aeruginosa strain from Japan in 1988.67 The 
strain contained a resistance gene called bla IMP, which was transferable to other Pseudomonas 
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strains. Three years later, Osano et al. reported that Serratia marcescens from Okazaki, Japan was 
also carrying the same gene.68 Furthermore, there were also reports in 1999 concerning Klebsiella 
pneumoniae from Singapore and Acinetobacter baumannii from Europe that carried IMP-1 and 
carbapenems resistance.69, 70 
 
1.4 Antibiotic Deactivation Mechanisms 
 
1.4.1 Deactivation Mechanism by SBLs 
The proposed deactivation mechanism in an SBL involves the activation of water molecules by Glu 
166 to generate (b) and (d) through acylation and deacylation respectively. Drawz and Bonomo 
suggested that the acylation mechanism showed in Figure 1.16 may exist in competition with the 
activation of Ser 70 by Lys 73.71 The acylation step results in the C-N bond cleavage as shown in 
(c). The deacylation follows to restore the serine moiety and release the deactivated β-lactam 
antibiotic (Figure 1.16). 
 
 
Figure 1.16. Proposed deactivation mechanism of penicillin by a class A SBL. Dashed lines 
represent hydrogen bonds and salt bridges (see ref. 71). 
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Clavulanic acid 1.18, sulbactam 1.19 and tazobactam 1.20 (Figure 1.17) are clinically available 
inhibitors of SBLs and are co-administrated with β-lactam antibiotics. As these compounds’ 
chemical structures are similar to β-lactam antibiotics, these inhibitors irreversibly bind to SBLs to 
form stable, inactive Ser – clavulanic acid complexes (Figure 1.18), consequently leaving the 
antibiotics free to produce the bactericidal effects by inhibition of the bacterial cell wall synthesis.72, 
73 However, these clinically used inhibitors of SBLs are not effective against MBLs.73 
 
 
Figure 1.17. Clinically useful SBL inhibitors (see ref. 72). 
 
 
Figure 1.18. Irreversible inhibition mechanism of an SBL by clavulanic acid (see ref. 71 and 45). 
 
1.4.2 Deactivation Mechanisms by MBLs 
 
MBLs are able to deactivate a broad spectrum of β-lactam antibiotics, including penicillins 1.1, 
cephalosporins 1.2 and carbapenems 1.3 (Figure 1.1).74 Furthermore, some MBLs are reported to 
even hydrolyse serine β-lactamase (SBL) inhibitors such as sulbactam 1.19 and tazobactam 1.20 
(Figure 1.17).74 
 
Figure 1.19. Proposed catalytic deactivation mechanism for B1 MBLs (see ref. 46). 
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Figure 1.19 shows a proposed catalytic deactivation mechanism for B1 type MBLs.46 As shown in 
the figure, both zinc ions coordination secures an optimum binding orientation between the 
antibiotic and the nucleophile (zinc-bound hydroxide ion). Attack of the nucleophile on the lactam 
carbonyl carbon subsequently resulting in the cleavage of the amide bond, followed by the 
stabilisation of the expelled β-lactam nitrogen by the active site’s second zinc ion.  
 
A new MBL from the B1 subclass called NDM-1 was found by Yong et al. in 2009.75 The first 
NDM-1 was isolated from Klebsiella pneumoniae and Escherichia coli. This new B1 enzyme 
becomes a serious threat globally as incidences involving NDM-1 have been reported continuously 
all over the world.76  
 
1.5 Current Lead Compounds 
 
It is well known that clavulanic acid 1.18 (Figure 1.17) can effectively inhibit serine β-lactamases 
(SBLs) mechanism.47 However, this compound is not active against MBLs.77 Hence, society is in 
urgent need of MBLs inhibitors as clinically approved inhibitors for MBLs are not yet available. 
Furthermore, levels of MBLs produced by pathogens such as Acinetobacter spp. and 
Pseudomonasa aeruginosa that can resist various kind of drugs are clinically significant.47  
 
IC50, Ki, Kic and Kiuc are commonly used to indicate the potency of the inhibitors. The more potent 
inhibitors show smaller values of IC50, Ki, Kic and Kiuc. IC50 is the inhibitor concentration needed to 
inhibit the enzyme activity by half. Ki is defined as the inhibition constant for the equilibrium 
between the bound and unbound forms of the inhibitor to the enzyme. Kic and Kiuc are the 
competitive and uncompetitive inhibition constants, respectively. In competitive inhibition mode, 
inhibitor will compete with the substrate to bind to the active site of the enzyme. This will prevent 
the formation of enzyme – substrate complex since binding of inhibitor and substrate to the enzyme 
at the same time is not possible. In uncompetitive inhibition mode, inhibitor will only bind to the 
enzyme – substrate complex, thus preventing the enzyme from hydrolysing the substrate. In other 
words, the inhibitor inactivates the enzyme – substrate complex.78 
 
1.5.1 Thiols as IMP-1 Inhibitors 
Low molecular weight thiols 1.21 – 1.29 were reported by Goto et al. to be effective and reversible 
inhibitors of IMP-1 (Figure 1.20).64 The most potent thiol inhibitors from this report were 2-
mercaptopropionic acid 1.24 followed by mercaptoacetic acid 1.22 with the Ki values of 0.19 µM 
and 0.23 µM, respectively. Goto et al. suggested that the thiols of these compounds coordinate to 
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Zn2+ ions in the enzyme’s active site, consequently preventing the coordination of Zn2 with the 
water molecule (Wat2), thus inhibiting the catalytic deactivation mechanism (see Section 1.4.2).   
 
Figure 1.20. Low molecular weight thiol inhibitors of IMP-1 (see ref. 64). 
 
Thioester derivatives 1.30 and 1.31 (Table 1.3) were reported by Hammond et al. to be potent 
competitive inhibitors of IMP-1 with the IC50 values ranged from 0.0004 to 240 µM. Hammond et 
al. suggested that thiol products formed after the hydrolysis of these thioesters by the enzyme were 
also competitive inhibitors of IMP-1.79, 80  
 
Table 1.3. Thioester inhibitors and their IC50 against IMP-1 (see ref. 79 and 80). 
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R1 R2 
IC50 (µM) 
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Thiols 1.32 - 1.34 (Figure 1.21 and Table 1.4) were reported to be irreversible inhibitors of IMP-1 
by Kurosaki et al.81, 82 The crystallography studies of compounds 1.32 and 1.33 proved that during 
inhibition, the thiol group of these compounds coordinate both zinc ions in the IMP-1 enzyme’s 
active site. The irreversible inhibition mechanism of IMP-1 by compound 1.33 is shown in Figure 
O
O
SR1
O
COOH
R2
1.31
O
O
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1.22. This mechanism results in a covalent bonding between Lys 224 of the enzyme and compound 
1.33, thus inactivating the enzyme irreversibly.  
 
 
Figure 1.21. Thiol inhibitors prepared by Kurosaki et al. (see ref. 81 and 82). 
 
Table 1.4. Ki values of thiol inhibitors prepared by Kurosaki et al. (see ref. 81 and 82). 
Inhibitor Ki (µM) 
1.32 3.452 ± 0.030 
1.33 0.423 ± 0.013 
1.34a 1.10 ± 0.06 
1.34b 1.3 ± 0.1 
1.34c 0.14 ± 0.01 
1.34d 0.28 ± 0.01 
1.34e 0.16 ± 0.01 
 
 
Figure 1.22. Irreversible inhibition mechanism shows by compound 1.33 in the IMP-1 enzyme (see 
ref. 81 and 45). 
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1.5.2 Dicarboxylic Acids as IMP-1 Inhibitors 
 
Table 1.5. Phthalic acids 1.35 synthesised by Hiraiwa et al. and their IC50 values agaist IMP-1 (see 
ref. 83). 
 
Compound R IC50 (µM) 
1.35a CH3 160 
1.35b  13.2 
1.35c 
 
0.968 
1.35d 
 
2.44 
1.35e 
 
1.75 
1.35f 
 
1.55 
1.35g 
 
207 
1.35h 
 
17.9 
1.35i 
 
2.25 
 
A series of phthalic acid derivatives 1.35 (Table 1.5) prepared by Hiraiwa et al. was reported to be 
potent inhibitors of IMP-1.83 These compounds are proposed to inhibit IMP-1 by interaction of both 
carboxylate groups with the two zinc ions in the active site. The IC50 values reported for this series 
ranged from 0.968 to 207 µM. 
 
R
COOH
COOH
OH
ONa
OH
OH
COOH
COOH
COOH
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Figure 1.23. Compound 1.36. 
 
Toney et al. discovered that 2,3-(S,S)-disubstituted derivative of succinic acid 1.36 (Figure 1.23) 
displayed an excellent inhibitory effect against IMP-1 (IC50 = 0.009 µM) from a screening done on 
the Merck chemical collection. The crystal structure of the inhibitor 1.36 – IMP-1 complex 
confirmed that both carboxylate groups of this compound bind to both zinc ions in the active site 
(Figure 1.24).84 As shown in Figure 1.23, one of the carboxylate groups of compound 1.36 interacts 
with Asn 233. The other carboxylic group interacts with Asn 233 and Lys 224. In addition, the 
aromatic substituents of the compound form interactions with the conserved hydrophobic amino 
acid region in the flexible loop of the IMP-1 enzyme.85  
 
 
Figure 1.24. Crystal structure of compound 1.36 – IMP-1 (PDB code: 1JJT) complex (see ref. 84 
and 85).  
 
 
 
 
 
 
 
 
O
O
HOOC COOH
O
O
 20 
1.5.3 Sulfonamides as IMP-1 Inhibitors 
 
Table 1.6. Sulfonamide inhibitors of IMP-1 (see ref. 86). 
Compound  IC50 (µM) 
 a b c  
R1 R2 = 
   
1.37 
 
 16 3.8 2.2 
1.38 
 
 17.5 6.3 3.0 
1.39 
 
 25 13 4.6 
1.40 
 
 55 19 7.0 
1.41 
 
 150 55 13.5 
1.42 
 
 40 10 4.5 
1.43 
 
 10 4.8 1.6 
1.44 
 
 10 4.0 1.6 
1.45 
 
 20 6.2 2.4 
 
A study of the inhibitory effects of a family of N-arylsulfonyl hydrazones by Siemann et al. 
identified compounds 1.43c and 1.44c (Table 1.6) as novel inhibitors of IMP-1 with IC50 = 1.6 µM 
for both the compounds.86 A docking study done by Siemann et al. on compound 1.37c (IC50 = 2.2 
µM) predicted that sulfonamide inhibitors interact with the enzyme through one of the oxygen 
atoms to the amide group of Asn 233 (N 167) via a hydrogen bond in the active site (Figure 1.25). 
OH OCH3
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 21 
Compound 1.37c was also predicted to have electrostatic interactions to one of the zinc ions and the 
NH3+ of Lys 224 (K 161) through the sulfonamide group’s nitrogen atom. These studies also 
proposed that bulky aromatic groups are needed on both sides of the sulfonyl hydrazones to be 
potent IMP-1 inhibitors. The 9-anthracene ring at R2 position of compound 1.37c was predicted to 
have a van der Waals interaction with Trp 64 (W 28). The t-butyl group of 1.37c was expected to 
form van der Waals interactions with the hydrophobic pocket around Phe 87 (F 51), Glu 59 (E 23) 
and Val 61 (V 25). In addition, the aromatic group at the R1 position was predicted to have a 
hydrophobic interaction with the carboxylate carbon atom of the Asp 120 (D 81) side chain.  
 
 
Figure 1.25. Docking image of compound 1.37c – IMP-1 enzyme complex (see ref. 86). 
 
1.5.4 IMP-1 Inhibitor Research in the McGeary Group 
 
A joint study with Prof. Schenk’s laboratory (The University of Queensland) in fragment-based 
screening of compounds from the MaybridgeTM library and L-captopril 1.38a identified ten potent 
fragments 1.39 – 1.48 with potential for development as inhibitors of IMP-1 (Figure 1.26, Ki = 0.51 
~ 1.51 mM).66 Fragment 1.48 was the only fragment that was found to inhibit IMP-1 solely by 
competitive inhibition mode with a Ki value of 0.97 mM, while the other fragments screened 
showed mixed inhibition mode (both competitive and uncompetitive mode) against the IMP-1 
enzyme. This study also confirmed that chromogenic cephalosporin CENTA 1.49 (Figure 1.27) is a 
suitable substrate for IMP-1 inhibitor screening. The release of compound 1.51 after the hydrolysis 
of CENTA 1.49 by IMP-1 produces a yellow solution during bioassay analysis which can easily be 
measured at λmax = 405 nm.  
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Figure 1.26. Fragments 1.39 – 1.48 from MaybridgeTM library and L-captopril 1.38a (see ref. 66). 
 
 
Figure 1.27. Hydrolysis of CENTA 1.49 by IMP-1. 
 
Derivatives of 1,2,4-triazole-3-thiol were synthesised from fragment 1.48 and tested against IMP-1 
by Faridoon et al. within this laboratory and showed moderate inhibition.47 The most potent 
compound reported in this study was compound 1.52 (Figure 1.28), which was the synthetic 
intermediate towards the synthesis of 1,2,4-triazole-3-thiols, with Kic = 11 ± 4 µM against IMP-1. 
Among the 1,2,4-triazole-3-thiol derivatives synthesised, compound 1.53 possessed the lowest Kic 
value (75 ± 30 µM). 
 
 
Figure 1.28. New inhibitors prepared by Faridoon et al. (see ref. 47). 
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Thiol carboxylic acids 1.54 – 1.57 were recently synthesised by Dr Arjomandi during his PhD work 
(Figure 1.29).45 All of the thiol carboxylic acids synthesised exhibited competitive inhibition mode 
with the Ki values ranging from 0.086 to 9.39 µM. The most potent inhibitor from this series was 
compound 1.57a (Kic = 11 µM).   
 
 
Figure 1.29. Thiol carboxylic acid inhibitors of IMP-1 synthesised by Omid Arjomandi. a: n = 1, b: 
n = 2, c: n = 3 (see ref. 45). 
 
1.6 Summary 
 
Bacterial infections can result in life-threatening illnesses if not treated immediately. Although a 
healthy immune system in our body can protect us from these infections, antibiotics may still be 
needed to treat serious infections.  
 
β-Lactam antibiotics are classified as bactericidal antibiotics. β-Lactam antibiotics target the 
bacterial cell wall by inhibiting cell wall synthesis. Common β-lactam antibiotics including 
penicillin, cephalosporin, carbapenem and monobactam have a β-lactam ring as the core structure. 
 
As antibiotics are overprescribed, antibiotic resistance strains have emerged. Bacteria have started 
to become resistant to antibiotics because they can produce β-lactamases to inactivate the 
antibiotics. There are a few classes of MBL inhibitors reported by researchers including thiols, 
dicarboxylic acids and sulfonamides. However, none of these compounds are clinically approved as 
inhibitors of MBLs. This research is focused on developing IMP-1 MBL inhibitors because 
pathogens such as Acinetobacter spp. and Pseudomonas aeruginosa produce clinically significant 
levels of IMP-1 that can resist various kinds of drugs. 
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1.7 Research Aims 
 
The overall aim of this research is to develop novel and potent inhibitors of metallo-β-lactamases 
(MBLs) to combat antibiotic resistance. The specific aims of this research are:  
i. to design novel inhibitors against IMP-1 MBL, based on lead compounds. 
ii. to visualise the predicted binding mode of the newly designed inhibitor molecules by 
molecular modelling using Molegro Virtual Docker (MVD) software. 
iii. to synthesise the designed IMP-1 MBL inhibitors. 
iv. to express and purify IMP-1 enzyme. 
v. to examine the inhibition activities of the synthesised compounds by bioassay tests of these 
compounds against the expressed and purified IMP-1 MBL. 
vi. to optimise the structures of these compounds to develop improved inhibitors with enhanced 
inhibition activity against IMP-1 MBL. 
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Chapter 2.0 DEVELOPMENT OF POTENT INHIBITORS OF MBLs 
BASED ON L- & D-CAPTOPRIL  
 
2.1 L- & D-Proline Derivatives (Thiols) 
 
2.1.1 Introduction 
 
Figure 2.1.1.  L-Captopril and D-captopril. 
 
L-Captopril 1.38a and D-captopril 1.38b (Figure 2.1.1) are stereoisomers that competitively inhibit 
MBLs (Table 2.1.1).1 L-Captopril 1.38a is a well-known drug that inhibits human angiotensin 
converting enzyme (ACE). ACE is responsible for converting angiotensin I to angiotensin II and 
consequently leads to high blood pressure. Therefore, L-captopril 1.38a is clinically used to treat 
hypertension. On the other hand, D-captopril 1.38b can only be obtained by synthesising it from D-
proline and not effective against the ACE.1, 2 
 
Coordination through the sulfur in thiol inhibitors including L-captopril 1.38a and D-captopril 1.38b 
to both the zinc metal ions of the dizinc (B1 and B3 class) MBLs is thought to be crucial during 
inhibition because the zinc ions play important roles in the hydrolysis of the β-lactam ring in β-
lactam antibiotics (see Section 1.4.2).3 Nevertheless, according to crystallography studies reported 
by Liénard et al., D-captopril 1.38b can coordinate to the zinc metal ions in CphA (a monozinc 
MBL from B2 subclass) through the carboxylate group (Figure 2.1.2).4, 5 The versatility in the 
coordination between D-captopril 1.38b and the metal ions in monozinc and dizinc metalloenzymes 
allows D-captopril 1.38b to bind metalloenzymes from B1, B2 and B3 subclass MBLs.5 
Furthermore, both L-captopril 1.38a and D-captopril 1.38b gave encouraging inhibition activity 
against B1, B2 and B3 class MBLs as shown in Table 2.1.1, making them interesting lead 
compounds in designing novel broad-spectrum inhibitors of MBLs.  
 
N
O SH
COOH
D-Captopril, 1.38b
N
O SH
L-Captopril, 1.38a
COOH
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Figure 2.1.2.  Crystal structure of CphA (PDB code: 2QDS) and D-captopril 1.38b complex. 
Colours: Green – Zn; blue – nitrogen; red – oxygen; yellow – sulfur; grey – carbon atom of D-
captopril 1.38b (see ref. 4). 
 
Table 2.1.1.  Competitive inhibition constants for captopril in B1, B2 and B3 MBLs (µM).a 
B1 B2 B3 
Compound NDM-1 b 
(µM) 
IMP-1 c 
(µM) 
BcII c 
(µM) 
CphA c 
(µM) 
L1 c 
(µM) 
L-Captopril 1.38a 202 d 12.5 ± 2.4 65 ± 5 950 ± 80 - 
D-Captopril 1.38b 7.9 d - 45 ± 5 72 ± 6 20 d 
a see ref. 5, b IC50 value, c Ki value, d standard deviation less than 20%, - (no value) 
indicates not determined. 
 
The preferred binding mode of a potential inhibitor molecule in an enzyme such as IMP-1 can be 
modelled by simulating the docking of the molecule in the enzyme’s active site.6, 7 The knowledge 
obtained from the simulation can be used for chemical structure modifications of the lead 
compounds to enhance the interactions of the potential inhibitors with the target enzyme. Molegro 
Virtual Docker (MVD),8 GOLD,9 Surflex,10 Glide,11 and FlexX12 are examples of docking software 
available for this purpose. In this project, Molegro Virtual Docker (MVD) software was used as it 
produces highly accurate docking results. In a study involving docking of flexible ligands into 77 
proteins, MVD was reported to be able to correctly predict the binding interactions of 87% of the 
complexes. In the same study, Glide, Surflex, Flexx and GOLD were reported to have 82%, 75%, 
58% and 78% accuracy, respectively.13  
 35 
The crystal structure of enzyme IMP-1 (PDB code: 1JJT) was downloaded from Protein Data Bank 
(PDB)14 to be used for the docking study. Figure 2.1.3 shows an image of D-captopril 1.38b docked 
into the IMP-1 (PDB code: 1JJT) active site reported by Vella et al.15 The binding mode displayed 
by D-captopril 1.38b – IMP-1 complex in Figure 2.1.3 is similar to that observed in the crystal 
structure of BlaB (PDB code: 1M2X),4 another B1 type MBL, and D-captopril 1.38b complex 
(Figure 2.1.4) where D-captopril 1.38b coordinates its sulfur atom to both metal ions in the active 
site of IMP-1 in a bridging mode.15 At the same time, the carboxylate group oxygen of D-captopril 
1.38b binds to an accessible amino acid residue (NH3+ of Lys 167 and NH2 of Asp 119).1, 16  
 
 
Figure 2.1.3. D-Captopril 1.38b docked into the active site of IMP-1 (PDB code: 1JJT). Trp 64 and 
Glu 60 of the flexible loop adjacent to the active site are shown in ‘stick’ presentation. Colours: 
Blue – nitrogen; red – oxygen; white – carbon on IMP-1; green – carbon on D-captopril; yellow – 
sulfur; purple – zinc ions (see ref. 15). 
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Figure 2.1.4.  Crystal structure of BlaB (PDB code: 1M2X) and D-captopril 1.38b complex. 
Colours: Green – Zn; blue – nitrogen; red – oxygen; yellow – sulfur; grey – carbon atom of D-
captopril 1.38b (see ref. 4). 
 
In this chapter, the design of thiol derivatives of L- and D-proline as potent inhibitors against IMP-1 
MBL enzyme based on the lead compounds L- and D-captopril is reported. This includes the 
modification of chemical structures and docking study of the newly designed potent inhibitors 
bound in the active site of IMP-1 enzyme. The syntheses of the new potent inhibitor compounds 
and the kinetic assay study of these compounds are also discussed in this chapter.  
 
2.1.2 Results and Discussion 
 
2.1.2.1 Design of Novel Inhibitors Based on L- & D-Captopril 
 
Based on the encouraging inhibition properties of L-captopril 1.38a and D-captopril 1.38b, which 
were reported to inhibit class B1, B2 and B3 metallo-β-lactamases,1 some structural modifications 
of the molecule are expected to enhance the inhibition activity against MBLs including IMP-1.  
 
New derivatives of L-proline (2.1.1a, 2.1.2a and 2.1.3a, Figure 2.1.5) and the corresponding 
derivatives of D-proline (2.1.1b, 2.1.2b and 2.1.3b, Figure 2.1.5) were designed to investigate the 
effects of increasing the distance between the carboxylate group and the thiol on the inhibitory 
activity. This was also done to determine the optimum distance needed for the best inhibition 
activity.  
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The newly designed inhibitors retain the key binding features of both L-captopril 1.38a and D-
captopril 1.38b. All of these compounds maintain the thiol, carbonyl and carboxylate groups as 
these moieties have important interactions with amino acids in the IMP-1 active site (see Figure 
2.1.7 and 2.1.8 in Section 2.1.2.2). The interactions between these groups and IMP-1 were known to 
contribute to the inhibition activity.1, 16 However, the methyl group at C6 was excluded from the 
chemical structure of these newly designed inhibitors since there is no important interaction 
observed in the modelling results of L-captopril 1.38a and D-captopril 1.38b in the IMP-1 active site 
(Figure 2.1.7 and 2.1.8 in Section 2.1.2.2). This was also confirmed by the crystal structure of BlaB 
(PDB code: 1M2X)4 and D-captopril 1.38b complex (Figure 2.1.4). Furthermore, the synthesis route 
could be simplified by omitting the methyl group from the structure of the new potent inhibitors. 
  
 
Figure 2.1.5.  L-Captopril 1.38a, D-captopril 1.38b and the newly designed inhibitors. 
 
2.1.2.2 Computational Modelling 
 
Computational modelling is commonly used in drug designing and has proved to be a useful tool to 
assist in visualising the predicted binding interactions of inhibitor – enzyme complexes. The 
predicted binding interactions observed from the modeling results can be used to identify new 
inhibitors and predict the inhibition potencies of the new inhibitor compounds.17, 18 
 
In this work, all the docking studies were done using the crystal structure of IMP-1 MBL (PDB 
code 1JJT) downloaded from the Protein Data Bank (PDB).14 IMP-1 is a monomeric protein but 
appears dimeric when crystallized (chain A and B). Each chain contains 221 amino acids with 
identical residues and two zinc ions in the active site. Only chain A was used for the docking study 
(chain B was deleted from the MVD workspace) since the active sites of both chain A and chain B 
are identical. Before the docking simulation, all water molecules were removed from all the crystal 
structure. Glu 60, Val 61 and Trp 64 residues were marked as flexible since these residues are 
known as the flexible loop of IMP-1.19 Thiols and carboxylic acids of the potent inhibitors were 
converted to thiolate and carboxylate groups in the MVD workspace as the preparation before the 
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docking simulation. This was because the inhibition assay of the inhibitors against IMP-1 was 
modelled at pH=7. The pKa of carboxylic acids are normally ~4.2 and they would mainly exist as 
carboxylate at pH=7. Thiols were expected to appear unionized as the pKa of thiols are ~8. 
However, the ionization ability of the sulfur was enhanced due to the coordination of the sulfur 
atom to the acidic zinc atoms in the enzyme’s active site, resulting in the deprotonation of the thiols. 
As the MVD software is unable to predict these chemical changes, preparation of the potent 
inhibitor molecules such as converting the carboxylic acids to carboxylates and the thiols to 
thiolates are necessary before the docking.20   
 
As mentioned in Section 2.1.1, MVD was used in all the docking studies, because it produces high 
accuracy in predicting the binding interactions of compound – enzyme complexes compared to 
GOLD, Surflex, Glide, and FlexX.13 MVD generates MolDock scores (Escore) to represent the 
binding affinities of the compounds bound to the enzyme’s active site based on the predicted 
binding interactions. Larger negative values of Escore indicate that the compounds have higher 
binding affinities to the enzyme. Escore is defined by the total of the protein-inhibitor interaction 
energy (Einter) and the inhibitor’s internal energy (Eintra).8 
 
Escore = Einter + Eintra            (equation 2.2.1)  
 
Based on the spectral data of the synthesised potent inhibitor compounds 2.1.1 – 2.1.3, these 
compounds might exist as pair of rotamers with the ratio varying from 3:1 to 4:1 (see details in 
Section 2.1.2.3).  
 
Compounds containing amide functional groups can exist as pairs of rotamers. This occurs because 
of restricted rotation around the bond between the nitrogen atom and the carbonyl carbon atom of 
the amide group.21 The unusually high rotational energy barrier of this bond is due to delocalisation 
of the electron lone pair of the nitrogen atom into the π-bond of the carbonyl group (Figure 2.1.6). 
This leads to sp2-hybridisation of the nitrogen atom, partial single bond character of the C-O bond 
and partial double bond character of the C-N bond.22 Thus, the amide functional group is forced to 
be in planar and both cis- and trans- geometrical isomers are possible. Rotamers are most 
commonly observed for tertiary amides since both geometric isomers are usually of similar energy, 
and hence both may readily be observed. Another proline derivative, L-alanyl-L-proline was also 
reported to usually exist in both cis- and trans- isomers (Figure 2.1.7).23, 24 In general, the most 
stable isomer seems to have minimised steric repulsion between the R3 group on the carbonyl 
carbon and the substituents on the nitrogen atom.25 Throughout this study, rotamers were appointed 
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trans and cis when the R3 group on the carbonyl carbon is trans and cis, respectively, to the larger 
substituent on the nitrogen atom (Figure 2.1.7). 
 
 
Figure 2.1.6. Resonance structures in amides. 
 
 
Figure 2.1.7. trans- and cis- forms of L-alanyl-L-proline. 
 
Based on the consideration that compounds 2.1.1 – 2.1.3 might exist as rotamers, these compounds 
and their corresponding rotamers (Figure 2.1.8 (a)) were docked in the active site of IMP-1 using 
MVD for the docking studies. In addition, docking simulations of L-captopril 1.38a, D-captopril 
1.38b and the corresponding rotamers (Figure 2.1.8 (b))21, 26 in the IMP-1 active site were also done 
as references as well as to compare with the crystal structure of BlaB (PDB code: 1M2X)4 and D-
captopril 1.38b complex. 
 
 
Figure 2.1.8. (a) Synthesised compounds 2.1.1 – 2.1.3 and the corresponding rotamers. a: L-
isomers, b: D-isomers. (b) L-Captopril 1.38a, D-captopril 1.38b and the corresponding rotamers. 
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Table 2.1.2. MolDock scores generated by MVD for L-captopril 1.38a, D-captopril 1.38b, 
compounds 2.1.1 – 2.1.3 and the corresponding rotamers docked in the IMP-1 active site. 
         
 MolDoc Scorea (kcal/mol) 
Compound cis trans 
L-Captopril 1.38a -178 -147 
D-Captopril 1.38b -155 -173 
2.1.1a -155 -144 
2.1.1b -176 -149 
2.1.2a -172 -146 
2.1.2b -177 -167 
2.1.3a -176 -148 
2.1.3b -179 -168 
a Docking score calculated by Molegro Virtual Docker (MVD) software. Larger negative values 
indicate higher binding affinities of inhibitor – IMP-1, thus suggesting a more stable system. 
 
Table 2.1.2 shows the MolDock scores for all the compounds docked in the active site of IMP-1 
enzyme. From the results, it can be concluded that all cis- conformers were predicted to have 
comparable binding affinities with the enzyme since all of the MolDock scores of these compounds 
were calculated to be around the same values except for D-captopril 1.38b and compound 2.1.1a 
with slightly smaller negative value of MolDoc scores (-155 kcal/mol each). This means, D-
captopril 1.38b and compound 2.1.1a were predicted to have lower binding affinities compared to 
the other cis- conformers. 
 
On the other hand, while comparing the isomer pairs with trans- conformations (L-captopril 1.38a' 
and D-captopril 1.38b', 2.1.2a' and 2.1.2b', 2.1.3a' and 2.1.3b') the D-isomers were calculated to 
have larger negative values of MolDoc scores compared to the L-isomers, thus the binding affinities 
of the D-isomers were predicted to be higher compared to their L-isomers. The binding affinities of 
these compounds between the L-isomers were predicted to be comparable since all of the MolDock 
scores of these compounds were calculated to be around the same values. The same conclusion was 
N COOH
O SHn
2.1.1a: n = 1
2.1.2a: n = 2 
2.1.3a: n = 3
N COOH
O SHn
2.1.1b: n = 1
2.1.2b: n = 2 
2.1.3b: n = 3
N COOH
OHS n
2.1.1a': n = 1
2.1.2a': n = 2 
2.1.3a': n = 3
N COOH
OHS n
2.1.1b': n = 1
2.1.2b': n = 2 
2.1.3b': n = 3
 41 
also applicable when the D-isomers of all the docked potent inhibitor compounds were compared 
between each other except for compound 2.1.1b' with the smallest negative value of MolDock score 
(-149 kcal/mol). The largest (negative value) MolDoc score calculated for the synthesised 
compounds with trans- conformation was -168 kcal/mol (compound 2.1.3b') but still smaller than 
the calculated MolDoc score for D-captopril 1.38b' (-173 kcal/mol). Therefore, MVD predicted that 
the binding affinities of the cis- conformers would be lower than D-captopril 1.38b.  
 
When the comparison was done between the cis- and trans- conformers of all the docked 
compounds, cis- conformers were predicted to have higher binding affinities since the calculated 
MolDock score values were larger (negative value) compared to their trans- conformers. The only 
exception was for D-captopril 1.38b (-155 kcal/mol) where its calculated MolDoc score was smaller 
(negative value) than its corresponding rotamer, D-captopril 1.38b' (-173 kcal/mol).  
 
The MolDock scores calculated by MVD were based on the binding interactions predicted from the 
docking simulation of potent inhibitor compounds into the IMP-1 active site. These binding 
interactions could be observed from the docking images generated by MVD software and shown in 
the following figures (Figure 2.1.7 - Figure 2.1.11). As mentioned earlier in this section (Section 
2.1.2.2), the docking studies were done on all of the designed compounds and their corresponding 
rotamers, together with the L-captopril 1.38a and D-captopril 1.38b and their corresponding 
rotamers.  
 
Figure 2.1.9 shows the docking result of L-captopril 1.38a (cis- form), in the active site of IMP-1 
(see Appendix A1 for the docking result of L-captopril 1.38a'). L-captopril 1.38a was predicted to 
have a higher binding affinity compared to its corresponding rotamer, L-captopril 1.38a'. L-
Captopril 1.38a was predicted to coordinate to both metal ions in a bridging mode via its thiolate 
group in the IMP-1 active site with the bond lengths of 2.0 Å for both interactions. One of the 
oxygens of carboxylate group of L-captopril 1.38a was predicted to have a hydrogen bond 
interaction with the backbone NH group of Asn 233 (O-H distance 1.8 Å) and an electrostatic 
interaction with the NH3+ group of Lys 224 (O-N distance 3.14 Å). Another carboxylate group 
oxygen of L-captopril 1.38a was predicted to have two electrostatic interactions with the IMP-1 
active site: with one of the zinc ions (2.8 Å) and NH3+ of Lys 224 (O-N distances 3.0 Å). 
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L-captopril 1.38a 
 
Figure 2.1.9.  Docking of L-captopril 1.38a into the IMP-1 active site. Colours: Blue – nitrogen; red 
– oxygen; grey – carbon; yellow – sulfur; magenta – Zn ions. 
 
D-captopril 1.38b' (trans- conformer) was predicted to have a higher binding affinity compared to 
its corresponding rotamer, D-captopril 1.38b (see Appendix A1 for the docking result of L-captopril 
1.38b). Like L-captopril 1.38a mentioned above, D-captopril 1.38b' was also predicted to 
coordinates through the thiol group to both metal ions in a bridging mode in the IMP-1 active site 
(both distances are 2.0 Å, Figure 2.1.10). D-Captopril 1.38b' was also predicted to have a hydrogen 
bond with the backbone NH group of Asn 233 through the amide carbonyl group with the O-H 
distance of 1.9 Å. Both oxygens of the carboxylate group were predicted to have electrostatic 
interactions with the NH3+ group of Lys 224 (O-N distances 2.6 and 2.9 Å). Then, there was another 
electrostatic interaction between D-captopril 1.38b' and one of the zinc ions with the distance of 3.0 
Å. 
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1.38b' 
 
Figure 2.1.10.  Docking of D-captopril 1.38b' (trans- conformer) into IMP-1 active site. Colours: 
Blue – nitrogen; red – oxygen; grey – carbon; yellow – sulfur; magenta – Zn ions. 
 
The binding mode displayed by IMP-1 – L-captopril 1.38a complex in Figure 2.1.9 and IMP-1 – D-
captopril 1.38b' complex in Figure 2.1.10 were similar to that observed in the crystal structure of 
BlaB, another B1 type MBL, and D-captopril 1.38b complex shown in Figure 2.1.4.4, 15, 16 The 
sulfur atoms of both L- and D-captopril were predicted to interact with both zinc ions in the IMP-1 
active site in the same manner as D-captopril 1.38b – BlaB (PDB code: 1M2X) complex. 
 
The docking result of the newly designed compound 2.1.1b (cis- form) is shown in Figure 2.1.11. 
The MVD predicted that compound 2.1.1b would have the highest binding affinity among 
compounds 2.1.1, based on the calculated MolDock score (see Appendix A1 for the docking result 
of the rest of the compounds 2.1.1). Similar to Captopril 1.38, compound 2.1.1b was predicted to 
coordinate to both metal ions via its thiolate group in the IMP-1 active site with the bond lengths of 
2.0 Å for both interactions. In addition, two additional electrostatic interactions were possible 
between both of the carboxylate group oxygens of 2.1.1b and one of the zinc ions with the distances 
N
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of 2.4 Å and 3.6 Å. Both of the oxygen atoms of the carboxylate group in 2.1.1b were also 
predicted to have two more electrostatic interactions with the NH3+ of Lys 224 (O-N distances 2.6 
Å and 3.7 Å). However, it was predicted that there were no nearby amino acid residues in the active 
site to bind with the amide carbonyl group of compound 2.1.1b.  
 
 
2.1.1b 
 
Figure 2.1.11.  Docking of compound 2.1.1b into IMP-1 active site. Colours: Blue – nitrogen; red – 
oxygen; grey – carbon; yellow – sulfur; magenta – Zn ions. 
 
Compound 2.1.2b was predicted by the MVD to have the highest binding affinity among 
compounds 2.1.2, based on the calculated MolDock score (see Appendix A1 for the docking result 
of the rest of the compounds 2.1.2). Interactions that can be observed in the docking result of 
compound 2.1.2b were also similar to the docking result of captopril 1.38 where the thiolate group 
of compound 2.1.2b was predicted to be coordinated to both metal ions in the IMP-1 active site (1.9 
Å and 2.0 Å, Figure 2.1.12). As shown in Figure 2.1.12, a hydrogen bond was predicted between 
one of the oxygens of the carboxylate group and the SH group of Cys 221 with the O-H distance of 
3.1 Å. The other oxygen of the carboxylate group was predicted to have two electrostatic 
interactions with NH3+ of Lys 224 (O-N distance 2.7 Å) and one of the zinc ions (3.7 Å). There was 
also an electrostatic interaction predicted between one of the carboxylate group oxygens with one of 
the zinc ions in the active site (2.0 Å). 
N COOH
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2.1.2b 
 
Figure 2.1.12.  Docking of compound 2.1.2b into IMP-1 active site. Colours: Blue – nitrogen; red – 
oxygen; grey – carbon; yellow – sulfur; magenta – Zn ions. 
 
Compound 2.1.3b (cis- conformer) was predicted to have the highest binding affinity among all of 
the compounds docked in this chapter (see Appendix A1 for the docking result of the rest of the 
compounds 2.1.3). As shown in Figure 2.1.13, compound 2.1.3b exhibits similar predicted 
interactions of the thiolate group with both zinc ions in the active site, as can be seen in the docking 
result of compound 2.1.2b in the IMP-1 active site. The predicted distances for the coordination of 
the thiolate group and both zinc ions were 1.9 and 2.0 Å. Both of the oxygens of the carboxylate 
were predicted to bind to the NH3+ group of Lys 224 by electrostatic interactions with the O-N 
distances of 2.8 and 3.7 Å. In addition, both of the carboxylate group oxygens were predicted to 
form one electrostatic interaction each with one of the zinc ions (2.5 and 3.6 Å). Since compound 
2.1.3b was calculated to have the highest binding affinity with the IMP-1 among all compounds in 
this chapter, it was expected that this compound would have the highest potency against IMP-1 as 
well. The kinetic assays were performed on these compounds to determine the inhibition potency 
against IMP-1 enzyme and are discussed in Section 2.1.2.5.  
 
 
N
O SH
COOH
 46 
 
2.1.3b 
 
Figure 2.1.13.  Docking of compound 2.1.3b into IMP-1 active site. Colours: Blue – nitrogen; red – 
oxygen; grey – carbon; yellow – sulfur; magenta – Zn ions. 
 
In conclusion, all of the compounds in this chapter were predicted to have interactions with both of 
the zinc ions in the active site of IMP-1 with the distances around 1.9 – 2.0 Å. Thus, these 
compounds were expected to have good inhibition potencies against IMP-1 enzyme as interactions 
with both zinc ions are crucial during inhibition because the zinc ions play important roles in the 
hydrolysis of the β-lactam ring in β-lactam antibiotics.3 Compound 2.1.3b was predicted to have the 
highest binding affinity, thus expected to be the most potent compound against IMP-1 among 
compounds 2.1.1 – 2.1.3.  
  
The results generated from the docking simulations were only predictions of the binding 
interactions and binding affinities of the potent inhibitors in the enzyme active site. These results 
may not accurately reflect the binding interactions and affinities in the inhibitor-enzyme 
complexes.27, 28 More reliable data could be obtained experimentally from kinetic assays of the 
inhibitors against the target enzyme which provide the inhibition potencies and the inhibition modes 
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of the inhibitors. However, the docking studies are still useful to assist in visualising the predicted 
binding interactions of inhibitor-enzyme complexes in the drug designing processes.   
 
2.1.2.3 Synthesis 
 
The proposed synthetic route to the newly designed inhibitors 2.1.1 - 2.1.3 from L-proline 2.1.4a 
and D-proline 2.1.4b is shown in Scheme 2.1.1. Acid chlorides 2.1.8 – 2.1.10 would be prepared by 
reacting the corresponding carboxylic acids 2.1.5 – 2.1.7 with thionyl chloride, based on the method 
reported by Hussein et al.29 Then, reaction of the acid chlorides 2.1.8 – 2.1.10 with the starting 
materials L-proline 2.1.4a and D-proline 2.1.4b, would provide compounds 2.1.11 – 2.1.13.30 
Finally, acid hydrolysis of compounds 2.1.11 – 2.1.13 was proposed to remove the thioester group 
to form the final products 2.1.1 - 2.1.3. 
 
 
Scheme 2.1.1. Proposed synthetic route of new inhibitors 2.1.1 - 2.1.3. a: L-isomers, b: D-isomers. 
 
Firstly, the preparation of carboxylic acid 2.1.5 was achieved by following a standard procedure, 
where thioacetic acid 2.1.14 reacted with bromoacetic acid 2.1.15 in aqueous sodium bicarbonate 
solution as shown in Scheme 2.1.2.31 The formation of compound 2.1.5 was confirmed by the 
characteristic singlet signals at 3.70 (SCH2COOH) and 2.37 ppm (CH3COS) in the 1H NMR 
spectrum. The 31.2 ppm (CH2) signal in the 13C NMR spectrum further confirmed the successful 
construction of S-C bond of carboxylic acid 2.1.5.    
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Scheme 2.1.2. Preparation of compound 2.1.5.  
 
Preparation of carboxylic acid 2.1.6 was achieved by stirring thioacetic acid 2.1.14 and acrylic acid 
2.1.16 at 100°C for 90 minutes (Scheme 2.1.3).32 The success of the reaction was proved by two 
triplet signals at 3.08 (SCH2CH2) and 2.67 ppm (SCH2CH2) and a singlet signal at 2.31 ppm (CH3) 
in the 1H NMR spectrum of the product. A signal at 30.5 ppm (CH2S) in 13C spectrum also 
confirmed that the synthesis of carboxylic acid 2.1.6 was successful. 
 
 
Scheme 2.1.3. Preparation of compound 2.1.6. 
 
As shown in Scheme 2.1.4, synthesis of the carboxylic acid 2.1.7 was completed by the reaction of 
potassium thioacetate 2.1.17 and 4-chlorobutyric acid 2.1.18 in dry DMF at room temperature for 2 
hours.33 The successful construction of carboxylic acid 2.1.7 was confirmed by two triplet signals at 
2.91 and 2.42 ppm (belonging to SCH2 and CH2COOH respectively), a singlet at 2.31 ppm 
(CH3COS) and a pentet at 1.89 ppm (SCH2CH2). The formation of S-C bond was verified by 30.6 
ppm signal in 13C spectrum. 
 
 
Scheme 2.1.4. Preparation of compound 2.1.7. 
According to the proposed synthetic route in Figure 2.1.1, the first step was to heat compounds 
2.1.5 – 2.1.7 under reflux with thionyl chloride for 3 hours to give the acid chlorides 2.1.8 – 2.1.10 
(Scheme 2.1.1).29 Then, without purification, compound 2.1.8 – 2.1.10 would be directly reacted 
with proline 2.1.4a – b in 2 M aqueous sodium hydroxide to construct the coupled products 2.1.11 
– 2.1.13.30 
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Compound 2.1.5 was heated to reflux with thionyl chloride for 3 hours. The remaining thionyl 
chloride was evaporated and the resulting crude product was directly stirred with L-proline 2.1.4a in 
2 M aqueous sodium hydroxide. Unfortunately, these reactions were unable to provide the desired 
coupling product 2.1.11a (Scheme 2.1.5). Low resolution electrospray ionisation mass spectrometry 
measurements (ESI-MS) analysis of the crude reaction mixture was unable to detect a peak at m/z 
230 [M - H]- (negative mode) or m/z 254 [M + Na]+ (positive mode) belonging to 2.1.11a and the 
1H NMR spectrum of the crude suggested that no reaction occurred since both starting materials 
maintained their original signals. In addition, there was no signal assignable to the products were 
observed.  
 
Scheme 2.1.5.  Attempted preparation of acid chloride 2.1.8 and compound 2.1.11a. 
 
There is a possibility that the reaction did not occur because the conversion of carboxylic acid 2.1.5 
to acid chloride 2.1.8 was not completed. The 1H NMR analysis of the crude product after the 
reaction of carboxylic acid 2.1.5 with thionyl chloride showed that compound 2.1.5 maintained the 
original signals. Later, optimisation of this reaction done by Daniel Tan and Sara Musaddiq within 
the McGeary Group successfully substituted –OH group in carboxylic acid 2.1.5 with –Cl group by 
reacting the carboxylic acid 2.1.5 with oxalyl chloride (4 equivalent) in dry chloroform at room 
temperature for 2 hours (Scheme 2.1.6). This reaction was optimized based on the reaction reported 
by Boyer et al. which took 12 hours to complete with 1.5 equivalent of oxalyl chloride used.34 
 
 
Scheme 2.1.6. Successful conversion of carboxylic acid 2.1.5 to acid chloride 2.1.8.  
 
However, for this work, HBTU coupling was proposed to prepare the coupled products  (Scheme 
2.1.7). HBTU ((2-(1H-benzotriazole-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate) 
(Figure 2.1.14) is a well-known coupling reagent that works efficiently in mild conditions (room 
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temperature, short reaction time) and gives excellent yield.35, 36 This coupling reagent is commonly 
used for amide bond formation between amines and carboxylic acids in the presence of a base.37 
 
 
Figure 2.1.14. (2-(1H-benzotriazole-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate 
(HBTU). 
 
The newly proposed synthetic route would start by esterifying proline 2.1.4 by reacting proline 
2.1.4 with methanol in thionyl chloride to afford the methyl ester 2.1.19.38 Then, a coupling reaction 
of the methyl ester 2.1.19 with carboxylic acid 2.1.5 – 2.1.7 by HBTU would give products 2.1.20 – 
2.1.22.20 Next, compounds 2.1.20 – 2.1.22 would undergo an acid hydrolysis to restore the 
carboxylic acid and thiol functional groups in products 2.1.1 – 2.1.3. 
 
 
Scheme 2.1.7. Newly proposed synthetic route of compounds 2.1.1 – 2.1.3. a: L-isomers, b: D-
isomers.  
                                                                                                                                                                                                                                          
Firstly, the free carboxylic acid in the starting material 2.1.4 needed to be protected to prevent 
possible coupling reaction at the carboxylic acid group. This was done by stirring L-proline 2.1.4a 
with thionyl chloride in methanol at room temperature to introduce the methyl ester group to the 
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starting material, L-proline 2.1.4a (Scheme 2.1.8).38 The overnight reaction gave methyl ester 
2.1.19a with an obvious addition of singlet signal at 3.85 ppm (COOCH3) in the 1H NMR spectrum. 
The appearance of a peak at m/z 130 [M + H]+ in the ESI-MS also confirmed the successful 
formation of methyl ester 2.1.19a.  
 
 
Scheme 2.1.8. Synthesis of methyl ester 2.1.19a. 
 
The same reaction was repeated on D-proline 2.1.4b, but this time the reaction mixture was heated 
to reflux to give methyl ester 2.1.19b (Scheme 2.1.9).39 By heating the reaction mixture under 
reflux, only 3 hours were needed to provide methyl ester 2.1.19b compared to overnight for the 
same reaction at room temperature. Both methyl ester 2.1.19a and 2.1.19b have identical signals in 
the 1H NMR spectra.     
  
 
Scheme 2.1.9. Synthesis of methyl ester 2.1.19b. 
 
Next, the coupling reaction of methyl ester 2.1.19 with compounds 2.1.5 – 2.1.7 using HBTU was 
achieved with N,N-diisopropylethylamine (DIPEA) and THF at room temperature (Scheme 
2.1.10).20 This reaction successfully constructed the coupled products 2.1.20 – 2.1.22 with high 
yields. 
 
The addition of singlet signal at 2.36 ppm (CH3COS) in the 1H NMR spectra, and a peak at m/z 268 
[M + Na]+ found in the ESI-MS confirmed the formation of coupling products 2.1.20a – b. In 
addition, the appearance of multiplet signals at 2.99 − 2.93 ppm (NCOCH2CH2) and a triplet signal 
at 2.58 ppm (NCOCH2CH2) in the 1H NMR spectra proved that coupled products 2.1.21a – b were 
successfully synthesised. ESI-MS analyses that showed the existence of a peak at m/z 282  [M + 
Na]+ confirmed the effective synthesis of thioesters 2.1.21a – b. For the coupled products 2.1.22a – 
b, an additional signal in the 1H NMR spectra were observed at 2.91, 2.44 ppm (both are triplet of 
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doublet, NCOCH2CH2CH2 and NCOCH2CH2CH2 respectively) and 1.89 − 1.82 ppm (multiplet, 
NCOCH2CH2CH2). A peak at m/z 296 [M + Na]+ in the ESI-MS spectrum also confirmed the 
successful formation of the coupled products 2.1.22a – b. In addition, all the coupled products 
2.1.20 – 2.1.22 had a common singlet signal around 2.3 ppm (CH3COS) in their 1H NMR spectra.  
 
 
Scheme 2.1.10. Synthesis of coupled products 2.1.20 – 2.1.22. a: L-isomers, b: D-isomers. 
 
Although the synthesis of the coupled products 2.1.20 – 2.1.22 proceeded smoothly, there were 
additional signals in both the 1H and 13C NMR spectra of these compounds that caused difficulties 
in the reaction product analyses. In the 1H NMR spectra of these compounds, signals belonging to 
NCH and CH3COS appeared in pairs, with the ratio varying from 3:1 to 4:1, which suggested the 
possibility of the existence of rotamers (Figure 2.1.15). Melander et al. and Deng et al. also 
suggested that proline containing peptides might cause multiple signals in high-performance liquid 
chromatography due to the stable cis- and trans- conformations caused by the rotation 
restrictions.23, 24   
 
 
Figure 2.1.15. Proposed conformation of rotamers of coupled compounds 2.1.20 – 2.1.22. a: L-
isomers, b: D-isomers. 
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Usually, organic chemists will solve the complicated 1H NMR spectra problem by changing the 
NMR solvent or conducting variable-temperature (VT) NMR experiments. However, Hu et al. 
introduced a simpler alternative to make the reaction product analyses easier; 1D selective 
chemical-exchange NMR experiments.40 All of the techniques listed above helped in distinguishing 
rotamers from diastereomers in compound systems.40 In this project, techniques such as changing 
the NMR solvent, variable-temperature (VT) NMR experiments and 1D selective chemical-
exchange NMR experiments were done on the coupled product 2.1.21a to confirm the existence of 
rotamers in the system (Figure 2.1.16).  
 
Al-Horani and Desai have studied the 1H NMR spectra of the N-acyltetrahydroisoquinolines 
rotamers.41 They noted that the chemical shift differences between the signals arising from each pair 
of protons in each rotamer generally decreased as the solvent polarity increased. In some cases, sets 
of signals that were distinct in non-polar solvents became coincident in polar solvents. Based on 
these observations, the authors suggested that the inter-conversion rate of the rotamers increased 
with the increased solvent polarity. Therefore the effect of solvent polarity on the 1H NMR 
spectrum of compound 2.1.21a was investigated by switching the NMR solvent from MeOD to 
DMSO. The coupled product 2.1.21a in MeOD has a water signal, X that appeared at 4.56 ppm 
(Figure 2.1.17 (a)). In DMSO, the water signal was eliminated (Figure 2.1.17 (b)), but other signals 
remain the same. Furthermore, the two doublet of doublets became farther apart as the polarity of 
the solvent increased. Hence, in this case, changing the NMR solvent could not provide any proof 
of the existence of the rotamers. 
 
 
Figure 2.1.16. Proposed conformation of rotamers of coupled product 2.1.21a. 
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Figure 2.1.17. A part of 1H NMR spectrum of the coupled product 2.1.21a (a) in MeOD showing 
two doublet of doublets belonging to NCH and a water signal, X at 4.56 ppm (b) in DMSO at 25°C  
(c) in DMSO at 45°C. 
 
 
 
 
 55 
Next, VT NMR experiments were conducted at 25°C and 45°C using coupled product 2.1.21a in 
DMSO (Figure 2.1.17 (b) and (c)). In these experiments, we focused on the –NCH signals of the 
coupled product 2.1.21a at 4.27 ppm and 4.58 ppm, which we believed to belong to the 
corresponding rotamer.  It was expected that higher temperature would merge both doublet of 
doublets as the two conformers would interconvert rapidly at high temperature. Furthermore, the 
activation barrier for tertiary amide rotation was reported to be around 14 – 15 kcal/mol with the 
coalescence temperature at 27°C. However, the coalescence temperature for compound 2.1.21a 
might be higher since the two doublet of doublets were still too far away from forming a single 
signal even at	45°C (Figure 2.1.17 (c)). This might be because of the stability of cis- and trans- 
conformations of the coupled product 2.1.21a and proline containing compounds that would not 
interconvert even at high temperature.23, 24  
 
Attempts to confirm the existence of rotamers were continued by 1D selective chemical-exchange 
NMR experiments via 1D NOE difference experiment. Chemical exchange means any 
reorganization where a nucleus in a system moves between two or more environments resulting in 
changes in NMR parameters.42 In this experiment, the signal at 4.27 ppm in the 1H NMR spectrum 
belonging to NCH of the coupled product 2.1.21a was selected as a target to be irradiated, resulting 
in the disappearance of the signal. At the same time, the intensity of the signals such as the 
multiplet signals belonging to NCHCH2 at 2.26 – 2.19 and 2.03 – 1.93 ppm that were connected to 
the irradiated NCH through space were enhanced according to the nuclear Overhauser effect. NOE 
difference spectrum resulting from subtraction of the 1H NMR spectrum from the 1D NOE 
spectrum produced a negative signal for the irradiated 4.27 ppm, while the enhanced regions 
produced positive signals (not shown). A different proton which was experiencing chemical 
exchange with the NCH in the irradiated region, produced a second negative signal at 4.58 ppm, 
leading to two negative signals in the NOE difference spectrum (Figure 2.1.18). Thus, this 
information proved that the 4.58 ppm belongs to the corresponding rotamer of the coupling product 
2.1.21a.40   
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Figure 2.1.18. NOE difference spectrum of coupling product 2.1.21a after irradiation of signal 4.27 
ppm. 
 
The next reaction was to hydrolyse both methyl ester and thioester of the coupled compounds 
2.1.20 – 2.1.22 in one step. This was proposed to be done by acid hydrolysis using 2 M 
hydrochloric acid at room temperature. However, an overnight stirring of coupling compound 
2.1.20b and 2.1.21b was unable to provide the desired hydrolysed compounds 2.1.1b and 2.1.2b 
(Scheme 2.1.11). Analysis of the 1H NMR spectrum and the ESI-MS of the crude mixture from the 
reaction clearly proved that the starting material remained unreacted and no signals assignable to 
the products detected.      
 
Scheme 2.1.11. Acid hydrolysis using 2 M HCl. 
 
As 2 M hydrochloric acid might be too weak to hydrolyse the esters, the next attempt was done on 
the coupled compound 2.1.20a using 6 M hydrochloric acid. After an overnight stirring at room 
temperature, the coupled compound 2.1.20a was converted to compound 2.1.23a where only the 
thioester group had been successfully hydrolysed (Scheme 2.1.12). This was confirmed by the 
remaining methyl ester signal at 3.70 ppm in the 1H NMR spectrum of the crude product. A peak at 
m/z 226  [M + Na]+ in the ESI-MS analysis also proved the formation of 2.1.23a.  
 
N COOMe
O S
O
n
2.1.20b: n = 1
2.1.21b: n = 2
N COOH
O SHn
2.1.1b: n = 1
2.1.2b: n = 2
2 M HCl
r.t., Ar, overnight
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Scheme 2.1.12. Acid hydrolysis using 6 M HCl. 
 
The thiolate anion (RS-) is relatively a weaker base compared to the methoxy anion (MeO-), thus 
making it more reactive and a better leaving group.43 In other words, it is easier to remove the acyl 
group of a thioester than removing it from a methyl ester. Therefore, this explains why 6 M 
hydrochloric acid was able to hydrolyse the thioester but not the methyl ester. 
 
As attempt to remove both the methyl ester and the thioester via acid hydrolysis was unsuccessful, 
base hydrolysis using 2 M sodium hydroxide in methanol was proposed as the alternative to 
complete the aim. As a start, this reaction was trialled on compound 2.1.23a to further hydrolyse it 
to compound 2.1.1a. As expected, stirring compound 2.1.23a with 2 M sodium hydroxide in 
methanol at room temperature for two hours followed by work up with 2 M hydrochloric acid was 
able to yield the hydrolysed compound 2.1.1a (Scheme 2.1.13). The loss of the methyl ester signal 
in the 1H NMR spectrum marked the successful formation of the hydrolysed compound 2.1.1a. 
 
 
Scheme 2.1.13. Base hydrolysis of compound 2.1.23a. 
 
Next, the same reaction was repeated on the coupled compound 2.1.22a. After 2 hours reaction, the 
carboxylic acid and thiol groups of compound 2.2.3a were successfully restored. This was proved 
by the absence of both signals of the methyl ester and the thioester from the 1H NMR spectrum of 
2.1.3a.  
 
Scheme 2.1.14. Attempt to hydrolyse both esters of coupled compound 2.1.22a. 
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O SH
2.1.23a
6 M HCl
r.t., Ar, overnight
N COOMe
O SH
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O SH
2.1.1a
1. 2 M NaOH, MeOH
    r.t., Ar, 2 h
2. 2 M HCl
48%
N COOMe
O S
 2.1.22a
N COOH
O
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1. 2 M NaOH, MeOH
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O
SH100%
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The syntheses of all the final compounds 2.1.1 – 2.1.3 were achieved from base hydrolysis of the 
coupled compounds 2.2.20 – 2.1.22 (Scheme 2.1.15). The successful formation of the compounds 
was confirmed by the absence of thioester and methyl ester signals in the 1H NMR and 13C NMR 
spectra. Like the coupled compounds 2.2.20 – 2.1.22, these final compounds exist as pair of 
rotamers with the ratio varying from 3:1 to 4:1. Based on the energy calculation performed by 
Chem3D44 modelling program, trans- conformers 2.1.1' – 2.1.3' (Figure 2.1.6 (a)) were estimated 
to be predominant (data not included). This can be explained by the minimised steric hindrance 
between the carboxylic group, CH2 chain and thiol group.45         
 
All the final compounds (thiols) 2.1.1 – 2.1.3 were kept in sealed vials under argon as they are 
easily oxidised and forms disulfides. This phenomenon is common in thiols including captopril 
1.40.21 The crude yield for each hydrolysed compound is shown in Table 2.1.3. 
 
Scheme 2.1.15. Base hydrolysis of coupling product 2.1.20 – 2.1.22. a: L-isomers, b: D-isomers. 
 
Table 2.1.3. Crude yields for base hydrolysis reaction. 
Compounds Yield (%) Compounds Yield (%) 
 
100 
 
89 
 
99 
 
84 
 
100 
 
89 
 
N COOMe
O S
O
n
2.1.20a-b: n = 1
2.1.21a-b: n = 2 
2.1.22a-b: n = 3
N COOH
O SHn
2.1.1a-b: n = 1
2.1.2a-b: n = 2 
2.1.3a-b: n = 3
1. 2 M NaOH, MeOH
    r.t., Ar, 2 h
2. 2M HCl
N COOH
O SH
2.1.1a
N COOH
O SH
2.1.1b
N
O SH
2.1.2a
COOH N
O SH
2.1.2b
COOH
N COOH
O SH
2.1.3a
N COOH
O SH
2.1.3b
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Scheme 2.1.16. Synthesis of compound 2.1.1 – 2.1.3. a: L-isomers, b: D-isomers. 
 
In conclusion, the desired final compounds 2.1.1 – 2.1.3 were successfully synthesised via four 
steps reaction starting with methylation reaction of proline 2.1.4 in thionyl chloride. Then, coupling 
reaction of methyl ester 2.1.19 using HBTU and DIPEA in THF managed to construct the coupled 
products 2.1.20 – 2.1.22. Finally, base hydrolysis of the coupled products 2.1.20 – 2.1.22 
successfully removed both methyl ester and thioester in one step to give the desired final 
compounds 2.1.1 – 2.1.3.  
 
2.1.2.4 Enzyme Expression and Purification5, 46 
 
As the target compounds were successfully synthesised, testing of the inhibitory properties of these 
compounds needed to be conducted against the IMP-1 enzyme. Therefore, the IMP-1 enzyme was 
expressed and purified based on a recombinant expression system previously designed by Dr Peter 
Vella.5, 46 The recombinant expression system contains the gene encoding IMP-1 generated via 
automated gene synthesis (DNA2.0) in the pET-47b(+) vector (Figure 2.1.19). The relevant IMP-1 
gene sequence and the translated amino acid sequence are shown in Figure 2.1.20. The inferred 
open reading frame amino acid sequence was highlighted in yellow. The pET-47b(+) expression 
vector  was used to transform BL21 (DE3) E. coli competent cells using the heat-shock method.5  
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N
H
COOH
MeOH, SOCl2
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N
H.HCl
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O
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O
DIPEA, HBTU, THF
r.t., overnight
N COOMe
O S
O
n
2.1.20a-b: n = 1
2.1.21a-b: n = 2 
2.1.22a-b: n = 3
N COOH
O SHn
2.1.1a-b: n = 1
2.1.2a-b: n = 2 
2.1.3a-b: n = 3
2 M NaOH, r.t., 2 h
then 2 M HCl
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Figure 2.1.19. Map of the pET-47b(+) expression vector containing the gene encoding IMP-1 (see 
ref. 47). Features: IMP-1 – gene encoding IMP-1 from P. aeruginosa (see ref. 5); lacI – lactose 
operon repressor E. coli (strain K12) (see ref. 48); rop – repressor of primer (see ref. 49); ori – 
origin of replication (see ref. 50); KanR – kanamycin resistance protein (see ref. 51); f1 ori – f1 
phage-derived ori (see ref. 52).  
 
GGCATCCAAGCAGCAAGCGCGTTACGCCGTGGGTCGATGTTTGATGTTATGGAGCAGCAACGATGTTACG 
CAGCAGGGCAGTCGCCCTAAAACAAAGTTAGAAAAGGAAAAGTATGAGCAAGTTATCTGTATTCTTTATA 
TTTTTGTTTTGCAGCATTGCTACCGCAGCAGAGTCTTTGCCAGATTTAAAAATTGAAAAGCTTGATGAAG 
GCGTTTATGTTCATACTTCGTTTGAAGAAGTTAACGGGTGGGGCGTTGTTCCTAAACATGGTTTGGTGGT 
TCTTGTAAATGCTGAGGCTTACCTAATTGACACTCCATTTACGGCTAAAGATACTGAAAAGTTAGTCACT 
TGGTTTGTGGAGCGTGGCTATAAAATAAAAGGCAGCATTTCCTCTCATTTTCATAGCGACAGCACGGGCG 
GAATAGAGTGGCTTAATTCTCGATCTATCCCCACGTATGCATCTGAATTAACAAATGAACTGCTTAAAAA 
AGACGGTAAGGTTCAAGCCACAAATTCATTTAGCGGAGTTAACTATTGGCTAGTTAAAAATAAAATTGAA 
GTTTTTTATCCAGGCCCGGGACACACTCCAGATAACGTAGTGGTTTGGTTGCCTGAAAGGAAAATATTAT 
TCGGTGGTTGTTTTATTAAACCGTACGGTTTAGGCAATTTGGGTGACGCAAATATAGAAGCTTGGCCAAA 
GTCCGCCAAATTATTAAAGTCCAAATATGGTAAGGCAAAACTGGTTGTTCCAAGTCACAGTGAAGTTGGA 
GACGCATCACTCTTGAAACTTACATTAGAGCAGGCGGTTAAAGGGTTAAACGAAAGTAAAAAACCATCAA 
AACCAAGCAACTAAATTTCTAACAAGTCGTTGCAGCACGCCACTACTGCTGGGAGAAAATTTTTG 
(a) 
 
MSKLSVFFIFLFCSIATAAESLPDLKIEKLDEGVYVHTSFEEVNGWGVVPKHGLVVLVNAEAYLIDTPFT 
AKDTEKLVTWFVERGYKIKGSISSHFHSDSTGGIEWLNSRSIPTYASELTNELLKKDGKVQATNSFSGVN 
YWLVKNKIEVFYPGPGHTPDNVVVWLPERKILFGGCFIKPYGLGNLGDANIEAWPKSAKLLKSKYGKAKL 
VVPSHSEVGDASLLKLTLEQAVKGLNESKKPSKPSN 
(b) 
Figure 2.1.20. (a) IMP-1 nucleotide sequence, (b) Translated amino acid sequence of IMP-1 
showing the inferred open reading frame (highlighted in yellow). 
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The expressed IMP-1 enzyme was purified by ion exchange and size exclusion chromatography. An 
SP-sepharose cation exchange column was utilised during the first step of purification to separate 
protein molecules based on their net surface charges. In this column, a negatively charged cation 
exchange resin is used to separate the targeted protein with net positive charge by eluting the 
protein over a salt gradient.53 Then, the second step of purification was carried out using a 
Sepharacyl S-200 gel filtration size exclusion column. A gel filtration size exclusion column 
separates the proteins based on their sizes with an aqueous solution as the mobile phase to elute the 
protein of interest.54  
 
Yield of the purified enzyme was 12 mg per 2 litres of culture (reported yields were generally 15-20 
mg per 2 litres)5 with the specific activity of 11 µmol min-1 mg-1 toward penicillin G 1.8a. Specific 
activity of enzyme is defined by the enzyme units of activity per mg of enzyme (U/mg). A unit of 
enzyme activity (U) is the release of 1 µmol of product per minute (µmol/min).55 Therefore, the 
enzyme specific activity is expressed in µmol min-1 mg-1. Specific activity relates the enzyme units 
to the amount of protein in the sample and gives a measurement of enzyme purity in the mixture.  
 
After the two steps column, the purity of the IMP-1 enzyme obtained was confirmed by SDS-PAGE 
analysis (sodium dodecyl sulfate polyacrylamide gel electrophoresis). During electrophoresis, 
fractionation of the proteins by approximate size occurred and a band around 25 kDa (based on 
relative distance traveled by the band on the SDS-PAGE gel compared to molecular weight size 
markers) was clearly observed (Figure 2.1.21). The expected value from the sequence of IMP-1 is 
27 KDa.5 
 
Figure 2.1.21. SDS-PAGE of the fractions collected after enzyme purification, stained using Bio-
Safe Coomassie G-250. Track 1: molecular weight markers. Tracks 5-6: collected fractions with 
pure enzyme. 
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2.1.2.5 Kinetic Assays 
 
Kinetic assays against the expressed and purified IMP-1 were performed to determine the inhibitory 
activities of the synthesised compounds. These include the determination of inhibition constant (Ki) 
value and inhibition mode of each inhibitor (competitive, uncompetitive or mixed-mode inhibition).  
 
Firstly, a screening assay of all the synthesised compounds was carried out against IMP-1 to select 
the compounds with considerable percentage inhibition. Based on the results of the screening assay, 
further testing of the selected compounds would be carried out to determine the inhibition constant 
values, Ki and mode of inhibition of the compounds against IMP-1 enzyme. DMSO was needed to 
assist the solubility of the compounds for kinetic assays as all the kinetics assays were performed in 
aqueous buffer. The screening assay was performed in HEPES X buffer (50 mM HEPES, 0.1 M 
NaCl, 100 µM ZnCl2, pH 7) using the substrate penicillin G 1.8a (500 µM) at 25°C. The rate of 
penicillin G 1.8a consumption was monitored at 235 nm (ε = 936 M-1 cm-1).46 The final 
concentrations of IMP-1 and bovine serum albumin (BSA, for enzyme stability) were 10 nM and 20 
µg/mL, respectively. Final concentrations for every inhibitor were 100, 10 and 1 µM.  
 
The results of the screening assay are shown in Table 2.1.4 and 2.1.5. From Table 2.1.4, it can be 
concluded that the methyl esters 2.1.19 did not show encouraging inhibition activity even at 100 
µM. As the purpose of this study is to improve the inhibition potency of the inhibitors of IMP-1, 
compounds 2.1.19 were not considered as the potent compounds to be further tested for IMP-1 
inhibitors. Then, coupled compounds 2.1.20 – 2.1.22 showed low inhibition activity against IMP-1 
at 100 µM and no inhibition at all at lower concentrations (10 and 1 µM). This was expected as 
none of these compounds contained free thiol groups in their chemical structure to coordinate to the 
zinc metal ions in the enzyme active site. As mentioned before, interactions of the inhibitors with 
both zinc ions in the active site are crucial during inhibition because the metal ions play important 
roles in the hydrolysis of β-lactam ring in β-lactam antibiotics.3  
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Table 2.1.4. Inhibition percentage of intermediates 2.1.19 – 2.1.22 against IMP-1 enzyme. 
 % Inhibition a 
Compounds 100 µM 10 µM 1 µM 
 
54 15 5 
 
- - - 
 
18 - - 
 
12 - - 
 
22 - - 
 
- - - 
 
50 - - 
2.1.19a
N
H.HCl
COOMe
2.1.19b
N
H.HCl
COOMe
N COOMe
O S
2.1.20a
O
N COOMe
O S
2.1.20b
O
N
O S
2.1.21a
COOMe
O
N
O S
2.1.21b
COOMe
O
N COOMe
O S
2.1.22a
O
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19 - - 
a - (no value) indicates no inhibition. 
 
On the other hand, all hydrolysed compounds 2.1.1 – 2.1.3 (final compounds) showed excellent 
inhibition activities at 100 µM including compound 2.1.3b with the lowest value of 93% (Table 
2.1.5). The unavailable data under 10 µM column for compound 2.1.3b might be due to the 
technical error during the test. However, because of the excellent inhibition percentage of 
compound 2.1.3b at 100 µM, this compound was considered potent to be selected for further 
analysis. Compound 2.1.2a and 2.1.2b even have moderate inhibition activity at the lowest 
concentration tested (1µM). Therefore, all the final compounds 2.1.1 – 2.1.3 were chosen to be 
further tested against the IMP-1 enzyme to determine their Ki values and inhibition modes. 
 
Table 2.1.5. Inhibition percentage of final compounds 2.1.1 – 2.1.3 against IMP-1 enzyme. 
 % Inhibition a 
Compounds 100 µM 10 µM 1 µM 
 
100 49 - 
 
100 49 - 
 
100 94 41 
 
100 52 47 
N COOMe
O S
2.1.22b
O
N COOH
O SH
2.1.1a
N COOH
O SH
2.1.1b
N
O SH
2.1.2a
COOH
N
O SH
2.1.2b
COOH
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100 79 11 
 
93 - - 
a - (no value) indicates no inhibition. 
 
As all the final compounds 2.1.1 – 2.1.3 have considerable percentage inhibition against IMP-1, 
these compounds were selected for further testing to determine the Ki values and the inhibition 
modes. The tests (inhibition assay against IMP-1) were performed in HEPES X buffer (50 mM 
HEPES, 0.1 M NaCl, 100 µM ZnCl2, pH 7) using the substrate penicillin G 1.8a (800 – 1600 µM). 
The rate of penicillin G 1.8a consumption was monitored at 235 nm (ε = 936 M-1 cm-1).46 The final 
concentrations of IMP-1 and bovine serum albumin (BSA, for enzyme stability) were 10 nM and 20 
µg/mL, respectively. Five inhibitor concentrations were prepared for the tests, based on the 
Screening Assay results. 
 
Kic and Kiuc represent the inhibition constants for competitive inhibition mode and inhibition 
constants for uncompetitive inhibition modes, respectively. Kic and Kiuc can be determined by fitting 
the inhibition data obtained from the inhibition assay against IMP-1 to Equation 2.1.2 using 
WinCurveFit (Kevin Raner Software). In Equation 2.1.2, Vmax = maximum rate of product 
formation, [S] = substrate concentration, [I] inhibitor concentration, and KM = Michaelis constant.56  
 
(Equation 2.1.2) 
 
 
Solving equation 2.1.2 will give both Kic and Kiuc values. However, for example, if the 
uncompetitive inhibition constant, Kiuc value was very large (mM or M range), this value was 
ignored and the inhibition mode was deemed to be essentially completely competitive. 
 
The Michaelis constant, KM is defined as the substrate concentration when the reaction rate is at half 
maximum. KM indicates the substrate affinity for the enzyme where a small KM means only a small 
N COOH
O SH
2.1.3a
N COOH
O SH
2.1.3b
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amount of substrate needed to make the enzyme saturated. Therefore, low substrate concentration is 
required to reach the maximum reaction rate.57 KM value is dependent on the substrate and the 
enzyme and was determined by fitting the inhibition data to Equation 2.1.2 using WinCurveFit 
(Kevin Raner Software). 
 
Table 2.1.6 shows the Ki values of the final compounds 2.1.1 – 2.1.3 against the IMP-1 enzyme and 
Figure 2.1.22 shows the steady-state inhibition data of IMP-1 by compound 2.1.1b. Note that 
compounds 2.1.1 – 2.1.3 exist as mixtures of rotamers that undergo inter-conversion during the 
lifetime of the kinetic assay. The combined contributions to inhibition of IMP-1 by each rotamer of 
the compounds resulted in the Ki values determined by the kinetic assay. All compounds tested 
show encouraging inhibitory activity with competitive inhibition constant, Kic value ranged from 
2.2 ± 0.6 to 9.9 ± 4.2 µM. Since uncompetitive inhibition constant, Kiuc values of these compounds 
are very large (mM or M range), the compounds were inhibiting IMP-1 enzyme solely by 
competitive inhibition. 
 
The results also showed that the final compounds 2.1.1 – 2.1.3 demonstrate an improvement on the 
Ki values compared to the lead compound, L-captopril with Ki = 12.5 ± 2.4 µM. However, 
compounds 2.1.2a and 2.1.3a show comparable Ki values with L-captopril (9.9 ± 4.2 and 7.2 ± 4.1, 
respectively). The obvious difference in the chemical structure between compounds 2.1.1 – 2.1.3 
and L-captopril besides the distance of the thiol and the carboxylate group is lack of methyl group at 
C6. Thus, it can be concluded that Ki value can be improved by omitting this methyl group from the 
chemical structure of the inhibitors. This was confirmed by the modelling results of L-captopril 
1.38a and D-captopril 1.38b in the IMP-1 active site (Figure 2.1.5 and 2.1.6 in Section 2.1.2.2) 
where there is no important interaction observed. The crystal structure of BlaB (PDB code: 1M2X)4 
and D-captopril 1.38b complex (Figure 2.1.3) also supported this conclusion. However, there is no 
significant trend in the Ki values based on either different isomers or the distance between the 
carboxylate group and the thiol since the values were around the same numbers. The docking 
results also suggested comparable binding affinities for all compounds 2.1.1 – 2.1.3 based on the 
calculated MolDock scores (Table 2.1.2). In conclusion, all final compounds are potent inhibitors 
against IMP-1 with low micromolar Ki values ranged from 2.2 ± 0.6 to 9.9 ± 4.2 µM. These values 
show encouraging improvements compared to the lead compound, L-captopril with Ki = 12.5 ± 2.4 
µM.  
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Table 2.1.6. Ki values of novel inhibitors against IMP-1 enzyme. 
Compounds Kic (µM) a Compounds Kic (µM) a 
 
2.2 ± 0.6 
 
2.3 ± 1.5 
 
9.9 ± 4.2 
 
2.9 ± 0.9 
 
7.2 ± 4.1 
 
5.8 ± 4.0 
a Values are mean of duplicate measurements ± SEM. 
 
 
 
Figure 2.1.22. Steady-state inhibition of IMP-1 by compound 2.1.1b at pH 7.0. Penicillin G 1.8a 
concentrations ranged from 800 – 1600 µM, and 2.1.1b concentrations ranged from 0 to 10 µM (!: 
10 µM, !: 7 µM, ": 4 µM). Values are mean of duplicate measurements ± SEM. Data was 
analysed by non-linear regression using equation 2.1.2. 
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2.1.3 Summary 
 
Novel inhibitors against the IMP-1 MBL were designed based on the encouraging competitive 
inhibition properties of L-captopril and D-captopril. Virtual docking of these newly designed 
molecules into the active site of the IMP-1 enzyme (PDB code: 1JJT) using Molegro Virtual 
Docker (MVD) software showed a favourable binding mode with the enzyme.   
 
Synthesis of the designed IMP-1 inhibitors was completed via four steps reaction starting from 
methylation of L- and D-proline, coupling and lastly base hydrolysis to remove both methyl ester 
and thioester.  
 
IMP-1 expression and purification was done in approximately two weeks. The expression process 
includes transformation, inoculation, enzyme expression and cell harvesting. Then, enzyme 
purification was done using two columns; SP-Sepharose cation exchange column and Sepharacyl S-
200 gel filtration size exclusion column. 12 mg of purified enzyme was obtained per 2 litres of 
culture with the specific activity of 11 µmol min-1 mg-1 toward penicillin G 1.8a. Specific activity 
relates the enzyme units to the amount of protein in the sample and gives a measurement of enzyme 
purity in the mixture. It is the amount of product formed by IMP-1 per minute per milligram of the 
total proteins.  
 
A total of 14 synthesised compounds including the novel inhibitors and their precursors were tested 
against IMP-1 enzyme. Then, all final compounds (6 compounds) were chosen for further testing to 
determine their Ki values. All of the final compounds competitively inhibit the IMP-1 with the Ki 
value of these compounds ranged from 2.2 ± 0.6 to 9.9 ± 4.2 µM, which shows improvement 
compared to the lead compound, L-captopril with Ki = 12.5 ± 2.4 µM. However, different isomers 
and the distance between the carboxylate group and the thiol have no effect on the Ki values.  
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2.1.4 Experimental 
 
Computational Modelling 
Computational modelling was done using Molegro Virtual Docker (MVD) software.8 Chemical 
structures of the inhibitors were generated from CORINA website.58 The IMP-159 crystal structure 
(PDB Code: 1JJT) was used for docking. Crystal structure of IMP-1 was prepared for docking by 
removing water molecules, detecting cavities and defining the active site. As the loop residues of 
IMP-1 are known to be flexible, residues Glu 60, Val 61 and Trp 64 were marked as flexible in the 
docking simulation.19 The highest docking score of the inhibitor - enzyme complex was selected as 
the docking result. 
 
General Experimental 
All chemical reagents were of analytical grade unless stated otherwise. Petroleum ether (b.p. 40 – 
60°C) was distilled before use. Flash column chromatography was carried out with Merck Kieselgel 
60. NMR experiments were recorded on 300, 400 and 500 MHz spectrometers (Bruker, 
Rheinstetten, Germany). 2D NMR experiments were recorded on a 500 MHz spectrometer (Bruker, 
Rheinstetten, Germany). Chemical shifts are reported in parts per million (ppm) on a δ scale, 
relative to the solvent peak (CDCl3 δH 7.24, δC 77.0; CD3OH δH 3.30, δC 49.0; (CD3)2SO δH 
2.49, δC 39.5). Coupling constants (J) are reported in hertz and signal multiplicities are described as 
singlet (s), doublet (d), doublet of doublet (dd), doublet of triplet (dt), triplet (t), quartet (q), pentet 
(p), multiplet (m), or broad (b). Low resolution electrospray ionisation mass spectrometry 
measurements (ESI-MS) were carried out on a Bruker Esquire HCT (High Capacity 3D ion trap) 
instrument with a Bruker ESI source. High resolution electrospray ionisation (HRMS) accurate 
mass measurements were carried out on a Bruker MicrOTOF-Q (quadrupole – Time of Flight) 
instrument with a Bruker ESI source. Accurate mass measurements were carried out with external 
calibration using sodium formate as reference calibrant. 
 
2-(Acetylthio)acetic acid (2.1.5) 
 
Sodium hydrogen carbonate (42 g, 0.50 mol) was added slowly to a solution of thioacetic acid (20 
mL, 0.30 mol) and bromoacetic acid (30 g, 0.20 mol) in water (300 mL). The mixture was stirred 
overnight at room temperature. The solution was then acidified to pH = 1 using concentrated HCl 
(32%) and extracted with ethyl acetate (2 × 300 mL). The organic layer was washed with water (3 × 
S
O
OH
O
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300 mL), dried (Na2SO4) and concentrated under reduced pressure to give 15 g (51%) of the desired 
product as a yellow oil. 1H NMR (400 MHz, CDCl3): δ 3.70 (s, 2H, SCH2COOH), 2.37 (s, 3H, 
CH3COS). 13C NMR (100 MHz, CDCl3): δ 193.9 (SCOCH3), 174.0 (COOH), 31.2 (CH2), 30.1 
(CH3). The NMR spectra are consistent with literature.34  
 
3-(Acetylthio)propanoic acid (2.1.6) 
 
Thioacetic acid (10 mL, 140 mmol) was added to acrylic acid (8 mL, 100 mmol) under argon at 
room temperature and the reaction mixture was stirred for 30 minutes. The reaction was then stirred 
at 100°C for 90 minutes. The formation of crystals was observed as the temperature was reduced to 
room temperature. Excess thioacetic acid was removed under reduced pressure and ethyl acetate 
(100 mL) was added to the residue. The organic solution was then washed with water (3 × 100 mL), 
dried (Na2SO4) and concentrated under reduced pressure to give 10 g (62%) of the desired product 
as white solid. M.p. 51.8 – 54.3 °C (lit. 52 – 54 °C).60 1H NMR (400 MHz, CDCl3): δ 3.08 (t, J = 
6.9 Hz, 2H, SCH2CH2), 2.67 (t, J = 6.9 Hz, 2H, CH2COOH), 2.31 (s, 3H, CH3COS). 13C NMR 
(100 MHz, CDCl3): δ 195.5 (SCOCH3), 177.7 (COOH), 34.1 (CH3COS), 30.5 (CH2S), 23.8 
(CH2COOH). The NMR spectra are consistent with literature.61  
 
4-(Acetylthio)butanoic acid (2.1.7) 
 
Potassium thioacetate (26 g, 0.20 mol) was added portion wise to a solution of 4-chlorobutyric acid 
(20 mL, 0.20 mol) in dry DMF (125 mL) at room temperature and stirred under argon for 2 hours. 
The solvent was removed under reduced pressure. Ethyl acetate (200 mL) was added to the residue 
and washed with 5% HCl (2 × 200 mL) and water (3 × 150 mL), dried over sodium sulfate and 
concentrated to give 25 g (75%) of the desired product as brown oil. 1H NMR (400 MHz, CDCl3): δ 
2.91 (t, J = 7.2 Hz, 2H, SCH2CH2), 2.42 (t, J = 7.3 Hz, 2H, CH2COOH), 2.31 (s, 3H, CH3COS), 
1.89 (p, J = 7.3 Hz, 2H, SCH2CH2). 13C NMR (100 MHz, CDCl3): δ 195.7 (SCOCH3), 178.5 
(COOH), 32.5 (CH2COOH), 30.6 (CH2S), 28.2 (CH3COS), 24.6 (CH2CH2S). The NMR spectra are 
consistent with literature.33  
 
 
 
O
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O
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Unsuccessful attempt to synthesise (2-(acetylthio)acetyl)-L-proline (2.1.11a) 
 
A mixture of 2-(acetylthio)acetic acid 2.1.5 (1.0 g, 7.5 mmol) and thionyl chloride (5.4 mL, 74.5 
mmol) was heated to reflux for 3 h under argon. The excess thionyl chloride was removed using an 
aspirator. The resulting liquid residue was subsequently co-evaporated with toluene (3 × 5 mL) to 
ensure that all the excess thionyl chloride was removed to provide 1.0 g of a black oil. The next 
reaction procedure was carried out as described in the literature.30 The black oil (1.0 g) and 2 M 
NaOH (2.4 mL) was added alternatingly (in about 10 portions) to an ice cooled solution of L-
proline 2.1.4a (0.5 g, 4.3 mmol) in 2 M NaOH (2.2 mL) and stirred. The temperature of the mixture 
was kept between 5 – 10°C. The ice water bath was replaced by water at room temperature and 
vigorous stirring was continued for an hour. The alkaline solution was extracted with diethyl ether 
(4 × 15 mL). The diethyl ether extracts were discarded and the aqueous layer were acidified by 5 
mL HCl to pH = 3. The acidified water layer was extracted with ethyl acetate (4 × 50 mL). The 
organic solvent was evaporated under reduced pressure to give 0.4 mg of a black oil (mixture of the 
starting materials 2.1.4a and 2.1.5).      
 
(S)-2-Carbomethoxypyrrolidine hydrochloride (2.1.19a) 
 
The reaction procedure was carried out as described in the literature.38 Thionyl chloride (1.0 mL, 13 
mmol) was added dropwise to a solution of L-proline 2.1.4a (1.0 g, 8.7 mmol) in methanol (34 mL) 
at 0°C. The reaction mixture was allowed to stir overnight at room temperature. The excess SOCl2 
and methanol were then removed under reduced pressure to give 1.6 g (100%) crude as a yellow oil. 
This compound was used in the next step without further purification. 1H NMR (400 MHz, MeOD): 
δ 4.45 − 4.41 (m, 1H, NCHCOOMe), 3.85 (s, 3H, OCH3), 3.42 − 3.34 (m, 2H, NCH2), 2.47 − 2.38 
(m, 1H, NCHCH2CHA), 2.18 − 2.03 (m, 3H, NCHCH2CHB). 13C NMR (100 MHz, MeOD): δ 170.5 
(COOMe), 60.7 (NCH), 53.9 (OCH3), 47.2 (NCH2), 29.3 (NCHCH2), 24.5 (NCHCH2CH2). The 
NMR spectra are consistent with literature.62 ESI-MS, m/z: 130 [M + H]+. 
 
 
 
 
N COOH
O S
O
N
H.HCl
COOMe
 72 
(R)-2-Carbomethoxypyrrolidine hydrochloride (2.1.19b) 
 
The reaction procedure was carried out as described in the literature.39 A solution of D-proline 
2.1.4b (1.0 g, 8.7 mmol) and thionyl chloride (1.3 mL, 17 mmol) in methanol (25 mL) were heated 
to reflux for 3 hours. The excess SOCl2 and methanol were then removed under reduced pressure to 
give 1.6 g (100%) as yellow oil. This compound was used in the next step without further 
purification. 1H NMR (300 MHz, MeOD): δ 4.45 − 4.40 (m, 1H, NCHCOOMe), 3.85 (s, 3H, 
OCH3), 3.41 − 3.33 (m, 2H, NCH2), 2.48 − 2.37 (m, 1H, NCHCH2CHA), 2.19 − 2.01 (m, 3H, 
NCHCH2CHB), consistent with literature.63 13C NMR (100 MHz, MeOD): δ 170.5 (COOMe), 60.7 
(NCH), 53.9 (OCH3), 47.2 (NCH2), 29.3 (NCHCH2), 24.5 (NCHCH2CH2), consistent with 
literature.62 ESI-MS, m/z: 130 [M + H]+.  
 
General procedure for the preparation of compounds 2.1.20 – 2.1.22 
A mixture of carbomethoxypyrrolidine hydrochloride (2.1.19) (0.5 g, 3.0 mmol), compound 2.1.5 - 
2.1.7 (1.5 eq.), DIPEA (5.2 mL, 30 mmol) and HBTU (1.7 g, 4.5 mmol) in THF (11 mL) was 
stirred overnight at room temperature. The solvent was then evaporated under reduced pressure and 
ethyl acetate (20 mL) was added to the crude product. The mixture was washed with water (20 mL) 
and brine (2 × 20 mL), dried (Na2SO4) and concentrated under reduced pressure. The crude product 
was purified by column chromatography (first ethyl acetate/petroleum ether (1:2), then 100% ethyl 
acetate) to give yellow oils. 
 
(S)-1-(2-(Acetylthio)acetyl)pyrrolidine-2-carboxylic acid (2.1.20a)   
 
Yield = 478 mg (65%). 1H NMR (300 MHz, DMSO): δ 4.76:4.29 (1:4) (dd, J = 4.5, 8.8 Hz, 1H, 
NCH), 3.82 (d, J = 2.5, 2H, NCOCH2), 3.61 (s, 3H, OCH3), 3.64 − 3.58 (m, 2H, NCH2), 2.35:2.33 
(3:1) (s, 3H, CH3COS), 2.20 − 2.10 (m, 1H, NCHCHACH2), 1.94 − 1.80 (m, 3H, NCHCHBCH2); 
13C NMR (100 MHz, DMSO): δ 194.7 (SCOCH3), 172.5 (COOCH3), 166.9:165.7 (3:1) 
(NCOCH2), 58.9:58.8 (1:3) (NCH), 52.1 (COOCH3), 47.2:47.1 (3:1) (NCH2), 32.3 (CH2S), 30.3 
(CH3COS), 29.1 (NCHCH2), 24.6 (NCHCH2CH2). ESI-MS, m/z: 268 [M + Na]+. HRMS calculated 
for C10H15NNaO4S 268.0614, found 268.0611. 
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(R)-1-(2-(Acetylthio)acetyl)pyrrolidine-2-carboxylic acid (2.1.20b) 
 
Yield = 847 mg (100%). 1H NMR (400 MHz, DMSO): δ 4.77:4.27 (1:4) (dd, J = 2.4:4.3, 8.6:8.8 
Hz, 1H, NCH), 3.83 (d, J = 2.5, 2H, NCOCH2), 3.59 (s, 3H, OCH3), 3.63 − 3.57 (m, 2H, NCH2), 
2.35:2.33 (3:1) (s, 3H, CH3COS), 2.19 − 2.11 (m, 1H, NCHCHACH2), 1.95 − 1.81 (m, 3H, 
NCHCHBCH2); 13C NMR (100 MHz, DMSO): δ 194.3 (SCOCH3), 172.1 (COOCH3), 165.4:164.6 
(3:1) (NCOCH2), 58.9:58.7 (1:3) (NCH), 51.8 (COOCH3), 46.8:46.5 (3:1) (NCH2), 32.1 (CH2S), 
30.1 (CH3COS), 28.8 (NCHCH2), 24.4 (NCHCH2CH2). ESI-MS, m/z: 268 [M + Na]+. HRMS 
calculated for C10H15NNaO4S 268.0614, found 268.0605. 
 
(S)-1-(3-(Acetylthio)propanoyl)pyrrolidine-2-carboxylic acid (2.1.21a) 
 
Yield = 903 mg (100%). 1H NMR (400 MHz, MeOD): δ 4.58:4.41 (1:3) (dd, J = 2.4:4.0, 8.6:8.6 Hz, 
1H, NCH), 3.75:3.70 (1:4) (s, 3H, OCH3), 3.63 − 3.52 (m, 2H, NCH2), 3.13 − 3.05 (m, 2H, 
NCOCH2CH2), 2.66 (t, J = 7.2, 2H, NCOCH2CH2), 2.30:2.29 (4:1) (s, 3H, CH3COS), 2.26 − 2.19 
(m, 1H, NCHCHACH2), 2.03 − 1.93 (m, 3H, NCHCHBCH2); 13C NMR (100 MHz, MeOD): δ 198.3 
(SCOCH3), 174.5 (COOCH3), 172.0 (NCOCH2), 60.5:60.0 (1:4) (NCH), 53.2:52.7 (1:3) 
(COOCH3), 48.1:47.3 (3:1) (NCH2), 34.9:34.8 (4:1) (NCOCH2), 30.4 (CH3COS), 31.7:29.9 (1:4) 
(NCHCH2), 25.3:23.1 (4:1) (NCHCH2CH2), 25.0:24.8 (1:4) (NCOCH2CH2S). ESI-MS, m/z: 282 
[M + Na]+. HRMS calculated for C11H17NNaO4S 282.0770, found 282.0767. 
 
(R)-1-(3-(Acetylthio)propanoyl)pyrrolidine-2-carboxylic acid (2.1.21b) 
 
Yield = 892 mg (100%). 1H NMR (400 MHz, MeOD): δ 4.58:4.41 (1:3) (dd, J = 4.2, 8.8 Hz, 1H, 
NCH), 3.75:3.70 (1:4) (s, 3H, OCH3), 3.63 − 3.52 (m, 2H, NCH2), 3.11 − 3.05 (m, 2H, 
NCOCH2CH2), 2.66 (t, J = 7.0, 2H, NCOCH2CH2), 2.30:2.29 (4:1) (s, 3H, CH3COS), 2.26 − 2.19 
(m, 1H, NCHCHACH2), 2.03 − 1.95 (m, 3H, NCHCHBCH2); 13C NMR (100 MHz, MeOD): δ 197.4 
(SCOCH3), 174.4 (COOCH3), 172.1 (NCOCH2), 60.7:60.2 (1:3) (NCH), 53.1:52.7 (1:3) 
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(COOCH3), 48.3:47.6 (3:1) (NCH2), 35.4:35.2 (1:3) (NCOCH2), 30.4 (CH3COS), 32.1:30.2 (1:3) 
(NCHCH2), 25.7:23.4 (3:1) (NCHCH2CH2), 25.4:25.0 (1:3) (NCOCH2CH2S). ESI-MS, m/z: 282 
[M + Na]+. HRMS calculated for C11H17NNaO4S 282.0770, found 282.0775. 
 
(S)-1-(4-(Acetylthio)butanoyl)pyrrolidine-2-carboxylic acid (2.1.22a) 
 
Yield = 1.1 g (100%). 1H NMR (400 MHz, MeOD): δ 4.59:4.41 (1:3) (dd, J = 2.6:4.3, 8.7:8.7 Hz, 
1H, NCH), 3.77:3.69 (1:4) (s, 3H, OCH3), 3.65 − 3.54 (m, 2H, NCH2), 2.91 (td, J = 2.8, 7.2 Hz, 
2H, NCOCH2CH2CH2), 2.44 (td, J = 3.4, 7.3 Hz, 2H, NCOCH2CH2CH2), 2.31:2.28 (4:1) (s, 3H, 
CH3COS), 2.26 − 2.21 (m, 1H, NCHCHACH2), 2.15 − 1.94 (m, 3H, NCHCHBCH2), 1.89 − 1.82 
(m, 2H, NCOCH2CH2CH2); 13C NMR (100 MHz, MeOD): δ 197.3 (SCOCH3), 174.4 (COOCH3), 
173.5 (NCOCH2), 60.2 (NCH), 52.7 (COOCH3), 48.4 (NCH2), 33.8 (CH2S), 30.5 (CH3COS), 30.2 
(NCHCH2), 29.2 (NCOCH2), 25.9 (NCOCH2CH2), 25.7 (NCHCH2CH2). ESI-MS, m/z: 296 [M + 
Na]+. HRMS calculated for C12H19NNaO4S 296.0927, found 296.0938. 
 
(R)-1-(4-(Acetylthio)butanoyl)pyrrolidine-2-carboxylic acid (2.1.22b) 
 
Yield = 862 mg (100%). 1H NMR (400 MHz, MeOD): δ 4.59:4.41 (1:4) (dd, J = 2.6:4.3, 8.7:8.7 Hz, 
1H, NCH), 3.77:3.69 (1:4) (s, 3H, OCH3), 3.65 − 3.54 (m, 2H, NCH2), 2.92 (td, J = 2.8, 7.2 Hz, 
2H, CH3COSCH2), 2.44 (td, J = 3.0, 7.4 Hz, 2H, NCOCH2), 2.31 (s, 3H, CH3COS), 2.28 − 2.14 
(m, 1H, NCHCHACH2), 2.03 − 1.94 (m, 3H, NCHCHBCH2), 1.89 − 1.82 (m, 2H, 
NCOCH2CH2CH2); 13C NMR (100 MHz, MeOD): δ 197.4 (SCOCH3), 174.5 (COOCH3), 173.5 
(NCOCH2), 60.2 (NCH), 52.7 (COOCH3), 48.4 (NCH2), 33.8 (CH2S), 30.5 (CH3COS), 30.2 
(NCHCH2), 29.2 (NCOCH2), 25.9 (NCOCH2CH2), 25.7 (NCHCH2CH2). ESI-MS, m/z: 296 [M + 
Na]+. HRMS calculated for C12H19NNaO4S 296.0927, found 296.0915. 
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Methyl (2-mercaptoacetyl)-L-prolinate (2.1.23a) 
 
HCl (6 M, 10 mL) was added to compound 2.1.20a (0.1 g, 0.4 mmol) in THF (1.5 mL) and the 
mixture was stirred overnight at room temperature under nitrogen. The solvent was evaporated 
under reduced pressure and ethyl acetate (10 mL) was added to the residue. The mixture was 
washed with brine (10 mL) and dried (Na2SO4). The organic solvent was evaporated under reduced 
pressure to give compound 2.1.23a as a yellow oil. 1H NMR (400 MHz, MeOD): δ 4.49:4.43 (1:4) 
(dd, J = 4.4, 8.6 Hz, 1H, NCH), 3.76 (d, J = 2.0, 2H, NCOCH2), 3.70 (s, 3H, OCH3), 3.63 − 3.50 
(m, 2H, NCH2), 2.29 − 2.16 (m, 1H, NCHCHACH2), 2.05 − 1.88 (m, 3H, NCHCHBCH2); 13C NMR 
(100 MHz, MeOD): δ 174.1 (COOCH3), 169.7 (NCOCH2), 60.7 (NCH), 52.7 (COOCH3), 47.5 
(NCH2), 34.0 (CH2S), 28.1 (NCHCH2), 25.8 (NCHCH2CH2). ESI-MS, m/z: 226 [M + Na]+. 
 
General procedure for the preparation of compounds 2.1.1 – 2.1.3 
NaOH (2 M, 6 eq.) was added to compound 2.1.20 – 2.1.22 (0.1 g) in degassed MeOH (1.3 mL) and 
the mixture was stirred for 2 hours at room temperature under nitrogen. The solvent was evaporated 
under reduced pressure and water (5 mL) was added to the residue. The mixture was acidified to 
pH=1 with 2 M HCl, extracted with ethyl acetate (3 × 5 mL) and dried (Na2SO4). The organic 
solvent was evaporated under reduced pressure to give the desired product as white hygroscopic 
solids. 
 
(S)-1-(2-Mercaptoacetyl)pyrrolidine-2-carboxylic acid (2.1.1a) 
 
Yield = 54 mg (100%). 1H NMR (400 MHz, MeOD): δ 4.62:4.41 (1:4) (dd, J = 2.7:4.0, 8.4:8.6 Hz, 
1H, NCH), 3.71 − 3.63 (m, 2H, NCH2), 3.36 (d, J = 2.8 Hz, 2 H, NCOCH2), 2.32 − 2.23 (m, 1H, 
NCHCHACH2), 2.07 − 2.00 (m, 3H, NCHCHBCH2); 13C NMR (100 MHz, MeOD): δ 175.4 
(COOH), 171.4 (NCOCH2), 60.6 (NCH), 48.5 (NCH2), 30.4 (COCH2S), 27.3 (NCHCH2), 25.7 
(NCHCH2CH2). ESI-MS, m/z: 188 [M - H]-. HRMS calculated for C7H10NO3S 188.0387, found 
188.0374. 
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(R)-1-(2-Mercaptoacetyl)pyrrolidine-2-carboxylic acid (2.1.1b) 
 
Yield = 68 mg (89%). 1H NMR (400 MHz, MeOD): δ 4.63:4.41 (1:4) (dd, J = 2.6:4.0, 8.4:8.6 Hz, 
1H, NCH), 3.71 − 3.63 (m, 2H, NCH2), 3.36 (d, J = 2.8 Hz, 2H, NCOCH2), 2.30 − 2.24 (m, 1H, 
NCHCHACH2), 2.07 − 2.00 (m, 3H, NCHCHBCH2); 13C NMR (100 MHz, MeOD): δ 175.4 
(COOH), 171.4 (NCOCH2), 60.6 (NCH), 48.5 (NCH2), 30.4 (COCH2S), 27.3 (NCHCH2), 25.7 
(NCHCH2CH2). ESI-MS, m/z: 188 [M - H]-. HRMS calculated for C7H10NO3S 188.0387, found 
188.0379. 
 
(S)-1-(3-Mercaptopropanoyl)pyrrolidine-2-carboxylic acid (2.1.2a) 
 
Yield = 78 mg (99%). 1H NMR (500 MHz, MeOD): δ 4.58:4.42 (1:3) (dd, J = 2.7:3.7, 8.7:8.7 Hz, 
1H, NCH), 3.68 − 3.57 (m, 2H, NCH2), 2.75 − 2.67 (m, 4H, NCOCH2CH2), 2.28 − 2.21 (m, 1H, 
NCHCHACH2), 2.04 − 1.98 (m, 3H, NCHCHBCH2); 13C NMR (100 MHz, MeOD): δ 175.7 
(COOCH3), 172.5 (NCOCH2), 60.2 (NCH), 48.4 (NCH2), 39.5 (NCOCH2), 30.4 (NCHCH2), 25.6 
(NCHCH2CH2), 20.4 (NCOCH2CH2S). ESI-MS, m/z: 202 [M - H]-. HRMS calculated for 
C8H12NO3S 202.0543, found 202.0553. 
 
(R)-1-(3-Mercaptopropanoyl)pyrrolidine-2-carboxylic acid (2.1.2b) 
 
Yield = 66 mg (84%). 1H NMR (500 MHz, MeOD): δ 4.57:4.42 (1:3) (dd, J = 2.7:3.7, 8.7:8.7 Hz, 
1H, NCH), 3.69 − 3.55 (m, 2H, NCH2), 2.81 − 2.67 (m, 4H, NCOCH2CH2), 2.27 − 2.21 (m, 1H, 
NCHCHACH2), 2.04 − 1.98 (m, 3H, NCHCHBCH2); 13C NMR (125 MHz, MeOD): δ 175.7 
(COOCH3), 172.5 (NCOCH2), 60.2 (NCH), 48.4 (NCH2), 39.5 (NCOCH2), 30.4 (NCHCH2), 25.6 
(NCHCH2CH2), 20.4 (NCOCH2CH2S). ESI-MS, m/z: 202 [M - H]-. HRMS calculated for 
C8H12NO3S 202.0543, found 202.0538. 
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(S)-1-(4-Mercaptobutanoyl)pyrrolidine-2-carboxylic acid (2.1.3a) 
 
Yield = 86 mg (100%). 1H NMR (400 MHz, MeOD): δ 4.56:4.41 (1:4) (dd, J = 2.6:3.9, 8.6:8.5 Hz, 
1H, NCH), 3.68 − 3.56 (m, 2H, NCH2), 2.57 − 2.47 (m, 4H, NCOCH2CH2CH2), 2.34 − 2.20 (m, 
1H, NCHCHACH2), 2.05 − 1.97 (m, 3H, NCHCHBCH2), 1.92 − 1.86 (m, 2 H, NCOCH2CH2CH2); 
13C NMR (100 MHz, MeOD): δ 175.8 (COOCH3), 173.8 (NCOCH2), 60.2 (NCH), 48.4 (NCH2), 
33.5 (CH2S), 30.4 (NCHCH2), 30.2 (NCOCH2), 25.7 (NCOCH2CH2), 24.5 (NCHCH2CH2). ESI-
MS, m/z: 216 [M - H]-. HRMS calculated for C9H14NO3S 216.0700, found 216.0698. 
 
(R)-1-(4-Mercaptobutanoyl)pyrrolidine-2-carboxylic acid (2.1.3b) 
 
Yield = 70 mg (89%). 1H NMR (400 MHz, MeOD): δ 4.57:4.40 (1:4) (dd, J = 2.6:3.8, 8.7:8.6 Hz, 
1H, NCH), 3.68 − 3.56 (m, 2H, NCH2), 2.57 − 2.47 (m, 4H, NCOCH2CH2CH2), 2.27 − 2.22 (m, 
1H, NCHCHACH2), 2.04 − 1.98 (m, 3H, NCHCHBCH2), 1.91 − 1.86 (m, 2H, NCOCH2CH2CH2); 
13C NMR (100 MHz, MeOD): δ 175.8 (COOCH3), 173.8 (NCOCH2), 60.2 (NCH), 48.4 (NCH2), 
33.5 (CH2S), 30.4 (NCHCH2), 30.2 (NCOCH2), 25.7 (NCOCH2CH2), 24.4 (NCHCH2CH2). ESI-
MS, m/z: 216 [M - H]-. HRMS calculated for C9H14NO3S 216.0700, found 216.0699. 
 
Enzyme Expression and Purification5, 46 
 
BL21 (DE3) E. coli competent cells were transformed by the expression vector pET47B-IMP-1 
plasmid using the heat-shock method.5 The cells were then grown in LB broth supplemented with 
ZnCl2 (25 µM) and kanamycin (50 µg/mL). IPTG (1 mM) was added when the optical density 
(OD600) reached 0.4 – 0.6. The cells were left for 24 hours at 25°C for the IMP-1 expression to take 
place. After 24 hours, centrifuging the cells at 5000 rpm for 20 minutes at 4°C gave pellet that was 
later suspended in HEPES A (50 mM HEPES, 500 µM ZnCl2, pH 7). Lysozyme (0.2 mg/mL) and 
one tablet of EDTA-free protease inhibitor cocktail (Roche) were added to the mixture followed by 
sonication to break the cell wall. MgCl2 (final concentration of 10 mM) and 1 µg/mL DNAse 
(Roche) was then added to the mixture. The mixture was left for 20 minutes at 0°C before 
centrifuging at 12500 rpm for 30 minutes at 4°C. The supernatant obtained was filtered through a 
0.22 µM membrane filter and concentrated to 5 mL before loading onto a SP-sepharose cation 
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exchange column (GE Healthcare).  
 
In the SP-sepharose cation exchange column, the enzyme was eluted with HEPES A over a gradient 
of 0 – 1.0 M NaCl. The fractions containing IMP-1 were collected and concentrated to 5 mL. The 5 
mL sample was later loaded on a Sepharacyl S-200 gel filtration size exclusion column (GE 
Healthcare) using HEPES A as the eluting buffer.  
 
Enzyme quantification was carried out by UV spectroscopic measurement at 280 nm (ε = 44620 M-
1 cm-1).46 For the general monitoring of IMP-1 enzyme activity during purification, cuvette assays 
were performed in HEPES buffer (50 mM HEPES, 0.1M NaCl, 100 µM ZnCl2, pH 7.0), using 
penicillin G 1.8a (500 µM final concentration) as the substrate. The rate of benzylpenicillin 
consumption was monitored at 235 nm (ε = 936 M-1 cm-1).46 
 
IMP-1 Screening Assays15 
96-well plate assays were performed in HEPES X buffer (50 mM HEPES, 0.1 M NaCl, 100 µM 
ZnCl2, pH 7) using the substrate penicillin G 1.8a at 25°C. The rate of penicillin G 1.8a 
consumption was monitored at 235 nm (ε = 936 M-1 cm-1). The final concentrations of penicillin G 
1.8a, IMP-1 and bovine serum albumin (BSA, for enzyme stability) were 500 µM, 10 nM and 20 
µg/mL, respectively. Final concentrations for every inihibitor were 100, 10 and 1 µM. 
 
IMP-1 Ki Assays15, 64 
96-well plate assays were performed in HEPES X buffer (50 mM HEPES, 0.1 M NaCl, 100 µM 
ZnCl2, pH 7) using the substrate penicillin G 1.8a (100 – 1000 µM). The rate of penicillin G 1.8a 
consumption was monitored at 235 nm (ε = 936 M-1 cm-1). The final concentrations were IMP-1 (10 
nM) and 20 µg/mL bovine serum albumin (BSA) for enzyme stability. Five inihibitor 
concentrations were prepared for the tests, based on the Screening Assay results. 
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2.2 D-Captopril Derivatives 
 
2.2.1 Results and Discussion 
 
2.2.1.1 Design of Novel Inhibitors Based on D-Captopril and Compounds 2.1.2 – 2.1.3 
 
As mentioned in Chapter 1, the aim of this project is to design, synthesise and test novel and potent 
inhibitors of IMP-1 MBL to combat antibiotic resistance. The development of the thiol derivatives 
of L- and D-proline as new potent IMP-1 inhibitors was discussed in Chapter 2.1. All of the 
compounds discussed in Chapter 2.1 showed encouraging inhibition potencies against IMP-1 with 
an improvement in the Ki values (2.2 ± 0.6 to 9.9 ± 4.2 µM) compared to the lead compound, L-
captopril (Ki = 12.5 ± 2.4 µM).  
 
In this chapter, the design of inhibitors against IMP-1 MBL enzyme based on D-captopril 1.38b and 
the new lead compounds 2.1.1 – 2.1.3 developed in Chapter 2.1 is reported. This includes the 
modification of the chemical structures and the docking study of the newly designed inhibitors 
bound in the active site of IMP-1 enzyme. The syntheses and the kinetic study of the new potent 
inhibitor compounds are also discussed in this chapter. 
  
 
Figure 2.2.1. D-Captopril 1.38b and the newly designed inhibitors 2.2.1a – c. 
 
As discussed in Chapter 2.1, D-captopril 1.38b was reported to be a potentially effective inhibitor of 
class B1, B2 and B3 MBLs.1 Based on this knowledge, some structural modifications of the D-
captopril 1.38b molecule are expected to improve the inhibition activity against MBLs including 
IMP-1. As shown in the docking image of D-captopril 1.38b in the IMP-1 active site (Figure 2.1.7), 
this molecule was predicted to have strong interactions with the residues in the IMP-1 active site 
through its thiol, carboxylate and carbonyl groups. Therefore, the new compounds 2.2.1a – c were 
designed to retain these key structures (Figure 2.2.1). Similar to compounds 2.1.1 – 2.1.3, 
compounds 2.2.1a – c were designed to have increasing distance between the carboxylate and the 
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thiol group of these compounds to investigate the effects on the inhibition potency. These new 
compounds were also designed to exclude the methyl group at C6 based on the finding that the 
omission of this methyl group could enhance the inhibition potency against IMP-1 (see details in 
Section 2.1.2.5). In addition to the modifications, a longer chain at C1 position was expected to 
improve the accessibility of these molecules to the binding site by stretching farther and as close as 
possible to the amino acid residues. The closer interaction distances were expected to strengthen the 
binding affinities of these newly designed compounds in the IMP-1 active site. The docking results 
of these compounds generated by MVD software will be discussed in Section 2.2.1.2.  
 
2.2.1.2 Computational Modelling 
 
As discussed in the previous chapter, computational modelling was performed using Molegro 
Virtual Docker (MVD) throughout this project to observe the predicted binding interactions of the 
synthesised compounds in the IMP-1 active site. The modelling results can be used to identify new 
potential inhibitors and also predict the likely inhibition potencies of the new inhibitors based on the 
calculated MolDoc scores (see details in Section 2.1.2.2).  
 
As proline-containing tertiary amides usually exist as a mixture of cis- and trans- rotamers,23, 24 the 
synthesised compounds 2.2.1a – c were expected to behave in the same way (Figure 2.2.2). These 
compounds also produced complicated NMR spectral data (see details in Section 2.2.1.3). 
Therefore, for the docking studies, all of the designed compounds 2.2.1a – c and their 
corresponding rotamers 2.2.1a' – c' were docked in the active site of IMP-1 using MVD. 
 
 
Figure 2.2.2. Synthesised compounds 2.2.1a – c and the corresponding rotamers 2.2.1a' – c'.  
 
The MolDoc scores for all the synthesised compounds 2.2.1a – c and their rotamers docked in the 
active site of the IMP-1 are shown in Table 2.2.1. Generally, all of the docked compounds have 
similar MolDoc scores except for the trans- conformation of compound 2.2.1a (compound 2.2.1a'), 
which was calculated to have the lowest negative value for the MolDoc score (-136 kcal/mol). 
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These results suggested that the compounds in this series would have comparable binding affinities 
to IMP-1. As for compound 2.2.1a', the MVD predicted that the binding affinity for this compound 
would be the lowest in this series based on the calculated MolDoc score value. On the other hand, 
compounds 2.2.1b' and 2.2.1c were predicted to have the highest binding affinities in the IMP-1 
active site since both of the compounds were calculated to have the largest negative value for their 
MolDoc scores.  
 
Table 2.2.1. MolDock scores generated by MVD for compounds 2.2.1a – c and the corresponding 
rotamers docked in the IMP-1 active site. 
 MolDoc Scorea (kcal/mol) 
 cis trans 
Compound 
  
2.2.1a -177 -136 
2.2.1b -172 -180 
2.2.1c -180 -177 
a
 Docking score calculated by Molegro Virtual Docker (MVD) software. Larger negative values 
indicate higher binding affinities of inhibitor – IMP-1, thus suggesting a more stable system. 
 
As mentioned earlier in this section, the molecular modelling studies were done on all of the 
designed and sythesised compounds in this series (D-captopril derivatives) to visualise their binding 
interactions in the IMP-1 active site. The docking images of the compounds 2.2.1a – c generated by 
the MVD software are shown in Figures 2.2.3 - 2.2.5.  
 
Figure 2.2.3 shows the docking result of compound 2.2.1a (cis- form) into the IMP-1 active site 
(cis- form was calculated to have larger negative value of MolDoc score compared to its 
corresponding trans- rotamer, 2.2.1a'. See Appendix A2 for the docking image of compound 
2.2.1a'). Similar to the D-captopril – IMP-1 complex (Figure 2.1.7), compound 2.2.1a was predicted 
to coordinate its thiolate group to both of the zinc ions in the active site of the enzyme (1.9 and 2.0 
Å). One of the oxygens of the carboxylate group of compound 2.2.1a was predicted to have an 
electrostatic interaction with one of the zinc ions and a hydrogen bond with the sulfhydryl group of 
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n
2.2.1a: n = 1
2.2.1b: n = 2 
2.2.1c: n = 3
N
O
O
OHS
OH
n
2.2.1a': n = 1
2.2.1b': n = 2 
2.2.1c': n = 3
 82 
Cys 221 (O – Zn2+ distance 2.0 Å and O – H distance 3.1 Å, respectively). Another oxygen of the 
carboxylate group from this new compound was predicted to have two electrostatic interactions; 
with one of the zinc ions (3.7 Å) and the NH3+ group of Lys 224 (O – N distance 2.6 Å). 
 
 
2.2.1a 
 
Figure 2.2.3. Docking of compound 2.2.1a into the active site of IMP-1. Colours: Blue – nitrogen; 
red – oxygen; grey – carbon; yellow – sulfur; magenta – Zn ions. 
 
The docking result of compound 2.2.1b' in the IMP-1 active site is shown in Figure 2.2.4. Based on 
the MolDoc score calculated by MVD software, compound 2.2.1b' was predicted to have higher 
binding affinity in the IMP-1 active site compared to its cis- conformer, 2.2.1b (See Appendix A2 
for the docking image of compound 2.2.1b). Compound 2.2.1b' was predicted to be coordinated to 
both metal ions in a bridging mode via the thiol group in the IMP-1 active site with the distances of 
2.0 Å for both interactions. A hydrogen bond was predicted to form between the amide carbonyl 
group of this compound with the side chain NH2 of Asn 233 (O – H distance 2.2 Å) and another one 
between the carboxylate group oxygen with the sulfhydryl group of Cys 221 (O – H distance 2.9 
Å). In addition, both oxygens of the carboxylate group of compound 2.2.1b' were predicted to have 
electrostatic interactions with one of the zinc ions (2.0 Å and 3.6 Å). One more electrostatic 
interaction was predicted between one of the carboxylate group oxygens with the NH3+ group of 
Lys 224 with the O – N distance of 2.6 Å.  
N
O
OH
O
O SH
 83 
 
2.2.1b' 
 
Figure 2.2.4. Docking of compound 2.2.1b' (trans- conformer of compound 2.2.1b) into the active 
site of IMP-1. Colours: Blue – nitrogen; red – oxygen; grey – carbon; yellow – sulfur; magenta – Zn 
ions. 
 
Compound 2.2.1c was predicted to have the highest binding affinity to IMP-1 together with 
compound 2.2.1b' with -180 kcal/mol as their calculated MolDoc scores. The trans- conformer, 
compound 2.2.1c' was calculated to have similar MolDoc score value (-177 kcal/mol), which means 
both rotamers of 2.2.1c were predicted to have comparable binding affinities in the enzyme active 
site (See Appendix A2 for the docking image of compound 2.2.1c'). Figure 2.2.5 shows the 
important interactions predicted between compound 2.2.1c and the IMP-1 by the MVD software. 
Like both compounds discussed earlier in this section, compound 2.2.1c was also predicted to 
coordinate to both zinc ions in the IMP-1 active site with the distance of 2.0 Å for each interaction. 
This compound was also predicted to form a hydrogen bond between its carboxylate group oxygen 
with the backbone NH group of Asn 233 (O – H distance 2.4 Å). The same oxygen of the 
carboxylate group of compound 2.2.1c was also predicted to have an electrostatic interaction with 
the NH3+ group of Lys 224 with the O – N distance of 3.6 Å. The other carboxylate oxygen was 
predicted to have two electrostatic interactions; one with the zinc ion (2.8 Å) and one with the NH3+ 
group of Lys 224 (O – N distance 2.9 Å).  
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2.2.1c 
 
Figure 2.2.5. Docking of compound 2.2.1c into the active site of IMP-1. Colours: Blue – nitrogen; 
red – oxygen; grey – carbon; yellow – sulfur; magenta – Zn ions. 
 
Overall, compounds 2.2.1 were expected to have comparable inhibition potencies to captopril 1.38 
and compounds 2.1.1 – 2.1.3 since the calculated MolDoc scores of these compounds are of similar 
values. The compounds, similar to captopril 1.38 and compounds 2.1.1 – 2.1.3, were predicted to 
have interactions with both zinc ions in the active site of IMP-1. This interaction was thought to be 
important to inhibit the IMP-1 activity, as the zinc ions play crucial roles in the catalytic hydrolysis 
of the β-lactam ring in β-lactam antibiotics (see section 1.2.3).3  
 
2.2.1.3 Synthesis 
 
The designed inhibitors 2.2.1a - c were proposed to be synthesised according to Scheme 2.2.1. 
Compound 2.2.4 would be synthesised by the etherification of the starting material, N-Boc-D-
prolinol 2.2.2.65 Next, selective removal of the tert-butyloxycarbonyl (Boc) group was proposed to 
yield compound 2.2.5. The construction of compounds 2.2.6 would be achieved by reacting 
N
O
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O
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compound 2.2.5 with the carboxylic acids 2.1.5 – 2.1.7.20 Finally, the removal of both the ethyl 
ester and thioester group by acid hydrolysis was expected to give the target compounds 2.2.1. 
 
 
Scheme 2.2.1. Proposed synthetic route of the newly designed inhibitors 2.2.1. 
 
Based on the proposed synthestic route in Scheme 2.2.1, compound 2.2.3 could be synthesised by 
etherification of N-Boc-D-prolinol 2.2.2. The etherification was attempted by reacting N-Boc-D-
prolinol 2.2.2 and ethyl bromoacetate 2.2.3 via phase transfer catalysis reaction in liquid-liquid 
system (water/toluene) with tetrabutylammonium hydrogen sulfate (TBAHS) (Scheme 2.2.2).65 The 
reaction between N-Boc-D-prolinol 2.2.2 and ethyl bromoacetate 2.2.3, which existed in two 
different phases, was thought to be possible with the role of tetrabutylammonium cation as the 
phase transfer catalyst in this reaction. The tetrabutylammonium cations would deliver the ionic 
species of compound 2.2.2 from the aqueous phase into the organic phase.66     
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Scheme 2.2.2. Attempt towards etherification of N-Boc-D-prolinol 2.2.2. 
 
However, this reaction was unable to yield the desired compound 2.2.4. The appearance of a peak at 
m/z 161 [M + Na]+ in the ESI-MS spectrum of the crude reaction mixture suggested the formation 
of bromoacetic acid 2.2.3b during the process, thus stopping the reaction (Scheme 2.2.3). A peak at 
m/z 224 [M + Na]+ belonging to N-Boc-D-prolinol 2.2.2 was also observed in the ESI-MS spectrum 
of the crude product, suggesting the existence of unreacted starting material. ESI-MS analysis of the 
crude reaction mixture was also unable to detect a peak at m/z 310 [M + Na]+ (positive mode) or 
m/z 286 [M - H]- (negative mode) belonging to compound 2.2.4. In addition, there was no signal 
assignable to the products observed in the 1H NMR spectrum of the crude mixture. 
 
 
Scheme 2.2.3. Formation of bromoacetic acid 2.2.3b during phase transfer catalysis reaction. 
 
As the attempt to obtain compound 2.2.4 was unsuccessful, a slight modification was done on the 
synthetic route by replacing ethyl bromoacetate 2.2.3 with tert-butyl bromoacetate 2.2.7. The new 
synthetic route after the modification is shown in Scheme 2.2.4. Firstly, etherification of the starting 
material, N-Boc-D-prolinol 2.2.2 would give compound 2.2.8.65 Then, compound 2.2.9 would be 
synthesised by selective removal of the Boc group. The construction of compounds 2.2.10 would be 
achieved by reacting compound 2.2.9 with the carboxylic acids 2.1.5 – 2.1.7.20 Lastly, the removal 
of both the tert-butyl ester and thioester group by acid hydrolysis would yield the target compounds 
2.2.1.   
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Scheme 2.2.4. The newly proposed synthetic route of the inhibitors 2.2.1. 
 
The attempt to construct compound 2.2.8 was done by repeating the phase transfer catalysis 
reaction and replacing ethyl bromoacetate 2.2.3 with tert-butyl bromoacetate 2.2.7 (Scheme 
2.2.5).65 After 3 hours of reaction at room temperature, compound 2.2.8 was successfully 
synthesised in 89% yield. The successful formation of compound 2.2.8 was proved by the 
appearance of an obvious singlet signal at 1.43 ppm in the 1H NMR spectrum belonging to the t-Bu-
H group and a signal at 28.5 ppm in the 13C NMR spectrum belonging to the t-Bu group. The 
appearance of a peak at m/z 338 [M + Na]+ in ESI-MS further confirmed the formation of 
compound 2.2.8. 
 
 
Scheme 2.2.5. Etherification of N-Boc-D-prolinol 2.2.2.  
 
Next, the selective removal of the Boc group of compound 2.2.8 in the presence of tert-butyl ester 
was expected to be achieved using HCl generated by the reaction of acetyl chloride and methanol 
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(Scheme 2.2.6). Nevertheless, the HCl produced from this reaction may have been too strong as this 
reaction also removed the tert-butyl group of compound 2.2.8. The removal of both protecting 
groups was confirmed by the loss of 2 singlet signals at 1.45 ppm and 1.43 ppm in the 1H NMR 
spectrum of the crude product, belonging to Boc-H and tert-butyl-H, respectively. The tert-butyl 
group was needed as the preparation for compound 2.2.8 for the next coupling reaction to prevent 
possible coupling reaction at that particular position.  
    
 
Scheme 2.2.6. Attempt to selectively remove Boc group from compound 2.2.8. 
 
The selective deprotection of the Boc group of compound 2.2.8 in the presence of tert-butyl ester 
was achieved using the method reported by Han et al.67 The reaction of compound 2.2.8 with 4 M 
HCl in anhydrous dioxane solution gave HCl salt 2.2.9 in an excellent yield (Scheme 2.2.7). This 
time, only the 1.45 ppm (Boc-H) signal was absent from the 1H NMR spectrum of the product 
2.2.9. A peak at m/z 216 [M + H]+ in the ESI-MS also confirmed the successful selective removal of 
the Boc group of compound 2.2.8. Due to the high polarity and hygroscopic nature of compound 
2.2.9, the next step was carried out without further purification of this compound.  
 
 
Scheme 2.2.7. Successful selective removal of the Boc group from compound 2.2.8. 
 
The coupling reaction of compound 2.2.9 with the carboxylic acids 2.15 – 2.17 using HBTU and 
DIPEA in THF were carried out using the method discussed in Section 2.1.2.3 (Scheme 2.2.8).20 As 
expected, these reactions managed to construct the coupled products 2.2.10a – c. The additional 
singlet signals belonging to SCOCH3 group were observed around 2.3 ppm in the 1H NMR spectra 
of the coupled products 2.2.10a – c. In addition, the appearance of the peaks at m/z 354 [M + Na]+, 
368 [M + Na]+ and 382 [M + Na]+ (belonging to 2.2.10a, 2.2.10b and 2.2.10c, respectively) in the 
ESI-MS analyses also proved that the constructions of the coupled products 2.2.10a – c were 
successful. However, the yields of these coupling reactions were very low. This might be because 
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of the steric hindrance caused by the long chain at C1, which may have slowed the coupling 
reactions. Coupling reagents like HBTU are known to degrade rapidly in basic solutions. Thus, in 
this case, most of the HBTU added in the reaction mixture might be decomposed before the 
coupling reaction took place.68  
     
 
Scheme 2.2.8. Synthesis of coupled products 2.2.10. 
 
Finally, the last step to synthesise the final compounds 2.2.1a – c was the deprotection of both tert-
butyl esters and the thioesters by acid hydrolysis. These reactions were performed by stirring the 
coupled products 2.2.1a – c with 6 M HCl at room temperature under nitrogen for an overnight to 
give the desired products 2.2.1a – c (Scheme 2.2.9). The absence of both singlet signals at around 
2.3 ppm (SCOCH3) and 1.4 ppm (tert-butyl-H) in the 1H NMR spectra of each final compound 
marked the successful removal of both ester groups. These were also supported by the appearance 
of the peaks at m/z 232 [M - H]- for 2.2.1a, 246 [M - H]- for 2.2.1b and 260 [M - H]- for 2.2.1c in 
the ESI-MS spectra. As mentioned in Section 2.2.1.2, the final compounds 2.2.1a – c were expected 
to exist in cis- and trans- conformations (Figure 2.2.2) resulting in complicated NMR spectra.23, 24 
All proton NMR signals of these compounds appeared as merged multiplet peaks except the singlet 
peaks at 4.1 ppm belonging to OCH2COO. The trans- conformers 2.2.1a' – c' (Figure 2.2.2) were 
estimated to be the preferred conformation based on the energy calculation by Chem3D44 (data not 
included). This can be explained by the minimised steric hindrance between the long chain at C1, 
CH2 chain and thiol group.45 
 
 
Scheme 2.2.9. Hydrolysis of the tert-butyl ester and the thioester from the coupled products 2.2.10. 
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The syntheses of the final compounds 2.2.1 were successfully achieved via 4 steps reaction starting 
with the etherification of the starting material, N-Boc-D-prolinol 2.2.2 followed by the selective 
deprotection of the Boc group in the presence of the tert-butyl ester to provide compound 2.2.9. The 
coupling reactions of compound 2.2.9 with the carboxylic acids 2.1.5 – 2.1.7 gave the coupled 
products 2.2.10a – c. Then, acid hydrolysis of these coupled products successfully yielded the final 
compounds 2.2.1a – c.       
 
2.2.1.4 Kinetic Assays 
 
The kinetic assays of all the final compounds were carried out to determine the Ki values and 
inhibition modes of these compounds against the IMP-1 enzyme. A screening assay was done prior 
to the kinetic assay to choose the compounds that showed considerable percentage inhibition 
against the IMP-1 enzyme. The results of the screening assay are shown in Table 2.2.2. The starting 
material 2.2.2, and compounds 2.2.8 and 2.2.9 showed low inhibition potencies even at the highest 
concentration tested (100 µM). On the other hand, the coupled products 2.2.10a – c showed 
comparable inhibition potencies with the final compounds, thiols 2.2.1a – c. This was quite 
surprising since there were no free thiol groups in the coupled products 2.2.10a – c to interact with 
the zinc ions in the IMP-1 active site. These coupled products 2.2.10a – c, together with the final 
compounds 2.2.1a – c were selected to be further tested against the IMP-1 enzyme to determine 
their Ki values and inhibition modes. However, as the inhibition percentages of these compounds 
were less than 50% at 100 µM, their Ki values against IMP-1 were predicted to be more than 100 
µM.  
Table 2.2.2. Inhibition percentage of N-Boc-D-prolinol 2.2.2 and all synthesised compounds 
against IMP-1 enzyme.  
 % Inhibitiona 
Compounds 100 µM 10 µM 1 µM 
 
N-Boc-D-prolinol 
2.2.2 
7 2 - 
 
2.2.8 
- - - 
N
Boc
OH
N
Boc
O
O
O
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2.2.9 
4 2 1 
 
2.2.10a 
22 7 0.4 ± 
2.2.10b 
11 4 0.4 
2.2.10c 
10 4 - 
 
2.2.1a 
19 5 - 
 
2.2.1b 
15 6 4 
 
2.2.1c 
23 - - 
a
 - (no value) indicates no inhibition. 
 
Table 2.2.3 shows the Ki values of the coupled compounds 2.2.10a – c and the final compounds 
2.2.1a – c against the IMP-1 enzyme. Since compounds 2.2.10a – c and 2.2.1a – c exist as mixtures 
of rotamers, the determined Ki values of these compounds consist of contributions to inhibition 
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from each rotamer of the compounds. All compounds tested show large Kic values ranged from 195 
± 111 to 1102 ± 52 µM, which means weaker inhibition potencies than compounds 2.1.2 – 2.1.3 
synthesised in Chapter 2 (Ki = 2.2 ± 0.6 to 9.9 ± 4.2 µM). These results contradicted the molecular 
docking results since the MVD software predicted comparable binding affinities between the final 
compounds 2.2.1a – c and the enzyme with compounds 2.1.2 – 2.1.3 based on the calculated 
MolDoc score values. The docking results may not accurately represent the binding interactions and 
affinities of the compound – enzyme complexes. 27, 28 However, the docking studies are still useful 
to assist in visualising the predicted binding interactions of inhibitor – enzyme complexes, 
consequently identifying new potent inhibitor compounds. 
 
Since the differences between compounds 2.2.1a – c and compounds 2.1.2 – 2.1.3 were only the 
distances between the proline rings and the carboxylate groups at C1 position, it can be concluded 
that increasing the distances would not improve the inhibition potencies of the compounds. 
Therefore, the new compounds designed after this series would maintain the short distances of the 
proline rings and the carboxylate groups at C1 position, similar to L- & D-captopril and compounds 
2.1.2 – 2.1.3.   
 
As the Kiuc values of these compounds are much larger (mM or M range, data not shown) than the 
Kic values, the compounds were inhibiting IMP-1 enzyme completely by competitive inhibition 
mode. The similar Kic values between the compounds tested indicated that even the coupled 
products 2.2.10a – c (thioesters) showed comparable inhibition potency against the IMP-1 enzyme 
with the final compounds 2.2.1a – c containing free thiol groups. This might be because the 
thioesters were hydrolysed in the enzyme’s active site to yield the corresponding thiols, 
consequently inhibiting the enzyme through the interactions of the free thiols and the zinc ions of 
the enzyme.69, 70 
 
Similar to the conclusion made in the previous chapter, there is no significant trend in the Ki values 
based on either different isomers or the distance between the carboxylate group and the thiol of the 
compounds since the values were around the same numbers. From this aspect, the docking results 
also suggested comparable binding affinities between compounds 2.2.1a – c based on the calculated 
MolDock scores (Table 2.2.1).  
 
As the conclusion, the attempt to improve the Ki values by increasing the distance between the 
proline ring and the carboxylate group at C1 position was unsuccessful. For the design of the next 
new compounds, the distance should be maintained as in the L- & D-captopril and compounds 2.1.2 
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– 2.1.3. 
     
Table 2.2.3. Ki values of the coupled products 2.2.10a – c and the final products 2.2.1a – c against 
IMP-1 enzyme. 
Compounds Kic (µM) a Compounds Kic (µM) a 
 
2.2.10a 
195 ± 111 
 
2.2.1a 
290 ± 146 
 
2.2.10b 
1102 ± 52 
 
2.2.1b 
390 ± 178 
 
2.2.10c 
288 ± 169 
 
2.2.1c 
363 ± 129 
a Values are mean of duplicate measurements ± SEM. 
 
2.2.2 Summary 
 
Three new compounds were designed based on the encouraging competitive inhibition properties of 
D-captopril and compounds 2.1.1 – 2.1.3. The docking images of these newly designed molecules 
docked into the IMP-1 enzyme (PDB: 1JJT) using Molegro Virtual Docker (MVD) showed a 
favorable binding mode with the enzyme with the calculated MolDoc scores indicating comparable 
inhibition potencies with compounds 2.1.1 – 2.1.3 synthesised in Chapter 2.1.    
 
Synthesis of the designed molecules was completed via four steps reaction starting from the 
etherification of N-Boc-D-prolinol, selective deprotection of the Boc group, coupling with the 
carboxylic acids and lastly acid hydrolysis to get the free thiols.  
 
A total of nine synthesised compounds and the starting material, N-Boc-D-prolinol were tested 
against the IMP-1 enzyme. From the screening assay, all final compounds (thiols) and their 
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corresponding thioesters were selected for kinetic assay analysis. All new compounds showed 
competitive inhibition activity with the Kic values ranged from 195 ± 111 to 1102 ± 52 µM, larger 
than the Kic values of the previous series (Ki = 2.2 ± 0.6 to 9.9 ± 4.2 µM). Therefore, increasing the 
distance of the carboxylate group from the proline rings was unable to improve the Ki values of the 
new compounds.   
 
 
2.2.3 Experimental 
 
(R)-tert-Butyl 2-((2-(tert-butoxy)-2-oxoethoxy)methyl)pyrrolidine-1-carboxylate (2.2.8) 
 
The reaction procedure was carried out as described in the literature.65 tert-Butyl bromoacetate 
2.2.7 (0.2 mL, 1.5 mmol) was added at room temperature to a mixture of tetrabutylammonium 
bisulfate (34 mg, 0.1 mmol), aqueous sodium hydroxide solution (994 mg, 25 mmol in water (1.0 
mL)) and toluene (1.5 mL), and then the mixture was cooled to 0°C. A solution of N-Boc-D-prolinol 
2.2.2 (200 mg, 1.0 mmol) in toluene (1.5 mL) was then added slowly. The reaction mixture was 
warmed to room temperature and then stirred for 3 hours. The phases were separated, and the 
aqueous phase was extracted with diethyl ether (2 x 5 mL). The combined organic phases were 
washed with saturated sodium chloride solution (5 mL), dried (Na2SO4) and concentrated under 
reduced pressure. The crude product was purified by column chromatography (silica gel) using 
ethyl acetate/petroleum ether (1:10) to yield 304 mg (97%) of desired product 22b as a yellow oil. 
1H NMR (400 MHz, CDCl3): δ 3.94 (s, 2H, OCH2COO), 3.92 – 3.88 (m, 1H, NCHCH2O), 3.60 
(dd, J = 3.6, 9.0 Hz, 1H, NCHCH2O), 3.42 (m, 1H, NCHCH2O), 3.30 (dd, J = 6.0, 7.6 Hz, 2H, 
NCH2), 2.07 – 2.02 (m, 1H, NCH2CH2CH2), 2.00 – 1.84 (m, 2H, NCH2CH2CH2), 1.82 – 1.73 (m, 
1H, NCH2CH2CH2), 1.45 (s, 9H, Boc-H), 1.43 (s, 9H, t-Bu-H); 13C NMR (100 MHz, CDCl3) δ 
169.6 (OCH2CO), 154.5 (NCO), 81.5 (OCH2COOC(CH3)3), 79.3 (NCOOC(CH3)3), 72.0 
(OCH2CO), 69.0 (NCHCH2), 56.3 (NCH), 46.6 (NCH2), 28.5 (OCH2COOC(CH3)3), 28.3 
(NCHCH2), 28.1 (NCOOC(CH3)3), 23.3 (NCH2CH2). ESI-MS, m/z: 338 [M + Na]+. HRMS 
calculated for C16H29NNaO5 338.1938, found 338.1927. 
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(R)-tert-Butyl 2-(pyrrolidin-2-ylmethoxy)acetate hydrochloride (2.2.9) 
 
Hydrogen chloride in dioxane solution (12 mL, 4 M) was added to (R)-tert-butyl 2-((2-(tert-
butoxy)-2-oxoethoxy)methyl)pyrrolidine-1-carboxylate 2.2.8 (190 mg, 0.6 mmol) at 0°C and the 
mixture was stirred for 10 minutes. The ice bath was removed and the mixture was stirred for 30 
minutes at room temperature. The solvent was removed by rotary evaporator and the residue was 
triturated with diethyl ether to give 147 mg of 2.2.9 (97%) as a yellow oil. 1H NMR (400 MHz, 
MeOD): δ 4.10 (s, 2H, OCH2COO), 3.85 – 3.80 (m, 3H, NCHCH2O), 3.68 – 3.64 (m, 2H, NCH2), 
2.17 – 1.98 (m, 4H, NCH2CH2CH2), 1.87 – 1.77 (m, 1H, NH), 1.48 (s, 9H, t-Bu-H); 13C NMR (100 
MHz, MeOD) δ 172.2 (OCH2CO), 83.8 (OC(CH3)3), 70.6 (NCHCH2O), 69.3 (OCH2CO), 60.8 
(NCH), 46.6 (NCH2), 28.3 ((CH3)3), 27.0 (NCHCH2), 24.8 (NCH2CH2). ESI-MS, m/z: 216 [M + 
H]+. HRMS calculated for C11H22NO3 216.1594, found 216.1600. 
 
General procedure for the preparation of compounds 2.2.10a – c 
A mixture of (R)-tert-butyl 2-(pyrrolidin-2-ylmethoxy)acetate hydrochloride (2.2.9) (30 – 100 mg, 
0.1 – 0.4 mmol), compound 2.1.5 - 2.1.7 (1.5 eq.), DIPEA (0.2 – 0.7 mL, 1.2 – 4.1 mmol) and 
HBTU (69 – 230 mg, 0.2 – 0.6 mmol) in THF (0.6 – 1 mL) was stirred for two days at room 
temperature. The solvent was then evaporated under reduced pressure and ethyl acetate (3 mL) was 
added to the crude product. The mixture was washed with water (3 mL) and brine (2 × 3 mL), dried 
(Na2SO4) and concentrated under reduced pressure. The crude product was purified by column 
chromatography using ethyl acetate/petroleum ether (1:2) to give the desired products. 
 
(R)-tert-Butyl 2-((1-(2-(acetylthio)acetyl)pyrrolidin-2-yl)methoxy)acetate (2.2.10a) 
 
Yellow oil (19 mg, 16%). 1H NMR (400 MHz, CDCl3): δ 4.21 (m, 1H, NCHCH2O), 3.92 (s, 2H, 
OCH2COO), 3.82 – 3.47 (m, 6H, SCH2, NCH2, NCHCH2), 2.36 (s, 3H, SCOCH3), 2.15 – 1.88 (m, 
4H, NCH2CH2CH2), 1.44 (s, 9H, t-Bu-H); 13C NMR (100 MHz, CDCl3) δ 194.8 (SCO), 169.6 
(NCO), 166.1 (OCH2CO), 81.5 (OC(CH3)3), 70.9 (NCHCH2O), 68.9 (OCH2CO), 57.2 (NCH), 
47.7 (NCH2), 33.2 (SCH2), 30.5 (SCOCH3), 28.1 ((CH3)3), 27.5 (NCHCH2), 24.3 (NCH2CH2). 
ESI-MS, m/z: 354 [M + Na]+. HRMS calculated for C15H25NNaO5S 354.1346, found 354.1334. 
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(R)-tert-Butyl 2-((1-(3-(acetylthio)propanoyl)pyrrolidin-2-yl)methoxy)acetate (2.2.10b) 
	
Yellow oil (51 mg, 36%). 1H NMR (400 MHz, CDCl3): δ 4.23 – 4.20 (m, 1H, NCHCH2O), 3.93 (s, 
2H, OCH2COO), 3.63 – 3.55 (m, 2H, NCHA, NCHCHAO), 3.44 – 3.31 (m, 2H, NCHB, 
NCHCHBO), 3.16 – 3.09 (m, 2H, SCH2CH2), 2.55 (t, J = 6.9 Hz, 2H, SCH2CH2), 2.29:2.29 (3:1) (s, 
3H, SCOCH3), 2.10 – 1.84 (m, 4H, NCH2CH2CH2), 1.45:1.44 (1:3) (s, 9H, t-Bu-H); 13C NMR 
(100 MHz, CDCl3) δ 196.3:196.2 (3:1) (SCO), 170.0:169.6 (1:3) (NCO), 169.6:169.2 (3:1) 
(OCH2CO), 81.7:81.4 (1:3) (OC(CH3)3), 70.1 (NCHCH2O), 68.9 (OCH2CO), 56.9:56.5 (1:3) 
(NCH), 47.2:45.6 (1:3) (NCH2), 34.9:34.2 (1:3) (SCH2), 30.5 (SCOCH3), 28.0 ((CH3)3), 27.4 
(SCH2CH2), 24.3 (NCHCH2), 24.1 (NCH2CH2). ESI-MS, m/z: 368 [M + Na]+. HRMS calculated 
for C16H27NNaO5S 368.1502, found 368.1513. 
 
(R)-tert-Butyl 2-((1-(4-(acetylthio)butanoyl)pyrrolidin-2-yl)methoxy)acetate (2.2.10c) 
 
Yellow oil (10 mg, 24%). 1H NMR (400 MHz, CDCl3): δ 4.21 – 4.20 (m, 1H, NCHCH2O), 3.92 (s, 
2H, OCH2COO), 3.63 – 3.54 (m, 2H, NCH2, NCHCH2O), 3.46 – 3.31 (m, 2H, NCH2, NCHCH2O), 
2.92 (t, J = 7.2 Hz, 2H, SCH2), 2.30 (s, 3H, SCOCH3), 2.10 –1.88 (m, 8H, NCOCH2CH2, 
NCH2CH2CH2), 1.44 (s, 9H, t-Bu-H); 13C NMR (100 MHz, CDCl3) δ 195.9 (SCO), 171.0 (NCO), 
169.8 (OCH2CO), 81.6 (OC(CH3)3), 71.3 (NCHCH2O), 69.1 (OCH2CO), 56.6 (NCH), 47.5 
(NCH2), 33.6 (SCH2CH2CH2), 30.8 (SCOCH3), 28.8 (SCH2), 28.3 ((CH3)3), 27.6 (NCHCH2), 24.8 
(NCH2CH2), 24.3 (SCH2CH2). ESI-MS, m/z: 382 [M + Na]+. HRMS calculated for C17H29NNaO5S 
382.1659, found 382.1664. 
 
General procedure for the preparation of compounds 2.2.1a – c 
HCl (6 M, 3 ml) was added to (R)-tert-butyl 2-((1-(2-(acetylthio)acetyl)pyrrolidin-2-
yl)methoxy)acetate 2.2.10 (20 mg, 0.1 mmol) in THF (0.8 ml) at room temperature under N2 and 
the reaction mixture was stirred overnight. The solvent was evaporated under reduced pressure and 
the crude mixture was dissolved in ethyl acetate (2 mL). The solution was washed with brine (1 
mL), dried (Na2SO4) and concentrated to yield brown oils. 
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(R)-2-((1-(2-Mercaptoacetyl)pyrrolidin-2-yl)methoxy)acetic acid (2.2.1a) 
	
Yield = 20 mg (100%). 1H NMR (400 MHz, MeOD): δ 4.20 − 4.14 (m, 1H, NCHCH2O), 4.03 (s, 
2H, OCH2COO), 3.66 − 3.52 (m, 6H, NCH2, NCHCH2O, SCH2CON), 2.08 − 1.93 (m, 4H, 
NCH2CH2CH2); 13C NMR (100 MHz, CDCl3) δ 174.1 (COOH), 170.3 (NCO), 73.8 (NCHCH2O), 
71.9 (OCH2COOH), 69.3 (NCH), 47.2 (NCH2), 30.5 (SCH2), 28.5 (NCHCH2), 23.7 (NCH2CH2). 
ESI-MS, m/z: 232 [M − H]−. HRMS calculated for C9H14NO4S 232.0649, found 232.0654. 
 
(R)-2-((1-(3-Mercaptopropanoyl)pyrrolidin-2-yl)methoxy)acetic acid (2.2.1b) 
	
Yield = 19 mg (100%). 1H NMR (400 MHz, CDCl3): δ 4.23 − 4.17 (m, 1H, NCHCH2O), 4.09 (s, 
1H, OCH2COO), 4.06 (s, 1H, OCH2COO), 3.63 − 3.50 (m, 4H, NCH2, NCHCH2O), 2.96 − 2.65 
(m, 4H, SCH2CH2), 2.00 − 1.89 (m, 4H, NCHCH2CH2); 13C NMR (100 MHz, CDCl3) δ 173.9 
(COOH), 172.5 (NCO), 73.6 (NCHCH2O), 71.9 (OCH2COOH), 69.0 (NCH), 46.8 (NCH2), 39.3 
(SCH2CH2), 28.4 (NCHCH2), 24.8 (NCH2CH2), 20.4 (SCH2). ESI-MS, m/z: 246 [M − H]−. HRMS 
calculated for C10H16NO4S 246.0800, found 246.0806. 
 
(R)-2-((1-(4-Mercaptobutanoyl)pyrrolidin-2-yl)methoxy)acetic acid (2.2.1c) 
	
Yield = 12 mg (76%). 1H NMR (400 MHz, CDCl3): δ 4.25 − 4.18 (m, 1H, NCHCH2O), 4.12 (s, 2H, 
OCH2COO), 3.67 − 3.50 (m, 4H, NCH2, NCHCH2O), 2.49 − 2.45 (m, 2H, SCH2), 2.12 − 1.84 (m, 
8H, NCHCH2CH2, SCH2CH2CH2); 13C NMR (100 MHz, CDCl3) δ 174.4 (COOH), 172.6 (NCO), 
73.7 (NCHCH2O), 72.0 (OCH2COOH), 62.4 (NCH), 46.9 (NCH2), 34.0 (SCH2CH2CH2), 29.5 
(NCHCH2), 28.4 (SCH2CH2), 25.8 (SCH2), 24.9 (NCH2CH2). ESI-MS, m/z: 260 [M − H]−. HRMS 
calculated for C11H18NO4S 260.0962, found 260.0952. 
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2.3 Dicarboxylic Acid Derivatives 
 
2.3.1 Results and Discussion 
 
2.3.1.1 Design of Novel Inhibitors Based on L- & D-Captopril and Compounds 2.1.2 – 2.1.3 
 
New derivatives of L-proline (2.1.1a, 2.1.2a and 2.1.3a, Figure 2.1.4) and the corresponding 
derivatives of D-proline (2.1.1b, 2.1.2b and 2.1.3b, Figure 2.1.4) were designed previously to 
investigate the effects of different isomers on the inhibition activity. These compounds were 
designed based on the encouraging inhibition properties of L-captopril 1.38a and D-captopril 1.38b, 
which were reported to inhibit class B1, B2 and B3 metallo-β-lactamases.1 The distances between 
the carboxylate and thiol groups were systematically varied to examine the effects on inhibition. 
This was also done to determine the optimum distance needed for the best inhibition activity. All 
synthesised compounds 2.1.1 – 2.1.3 showed encouraging inhibitory activity with the competitive 
inhibition constant, Kic value ranged from 2.2 ± 0.6 to 9.9 ± 4.2 µM. These compounds demonstrate 
an improvement on the Ki value compared to the lead compound, L-captopril 1.38a with Ki = 12.5 ± 
2.4 µM. However, there is no significant trend in the Ki values base on either different isomer or the 
length of sulfur containing chain. 
 
Next, optimisation of compounds 2.1.1 – 2.1.3 was done to further enhance the inhibition activity of 
the new inhibitors against IMP-1 MBL. This time, the thiol group that exists in 2.1.1 – 2.1.3 was 
replaced by a carboxylic acid group, transforming the compounds to dicarboxylic acid derivatives 
2.3.1 – 2.3.3 (Figure 2.3.1). Certain dicarboxylic acid derivatives are excellent inhibitors of IMP-1 
with IC50 value as low as 0.009 µM (compound 1.36, Figure 1.22).71, 72 These compounds inhibit 
IMP-1 by coordinating both carboxylic acid groups to both zinc ions in the active site (Section 
1.5.2, Figure 1.23).71, 72   
 
 
Figure 2.3.1. Newly designed dicarboxylic acid derivatives. 
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Except for the carboxylic group that replaced the thiol group in compounds 2.1.1 – 2.1.3, the newly 
designed compounds 2.3.1 – 2.3.3 maintained similar key structures to compounds 2.1.1 – 2.1.3. 
All of these compounds bear amide carbonyl groups and carboxylate groups as these moieties have 
important interactions with the amino acids in the IMP-1 active site (see details in Section 2.1.1). 
The interactions between these groups and IMP-1 are expected to contribute to excellent inhibition 
activity against the enzyme.1, 16 Furthermore, both carboxylic acid groups available in inhibitors 
such as compound 1.36 (Figure 1.23, Section 1.5.2) were proved to have bindings with both zinc 
ions in the IMP-1 active site.72 These bindings are thought to be crucial during the inhibition of 
IMP-1 enzyme because the zinc ions play important roles in the hydrolysis of the β-lactam ring in 
β-lactam antibiotics (see Section 1.4.2).3 
 
2.3.1.2 Computational Modelling 
 
The modeling studies for the designed compounds in this chapter were also performed using MVD 
software to visualise the predicted binding interactions between the compounds and the amino acid 
residues in the IMP-1 active site. Based on the spectral data of the synthesised compounds 2.3.1 – 
2.3.3, these compounds might exist as pairs of rotamers in a 3:1 ratio (Figure 2.3.2). Furthermore, 
proline containing compounds were reported to usually exist in the stable cis- and trans- 
rotamers.23, 24 Therefore, for the modelling studies, all of the designed compounds and their 
corresponding rotamers were docked in the active site of IMP-1 using MVD software. 
 
 
Figure 2.3.2. The designed compounds 2.3.1 – 2.3.3 and the corresponding rotamers.  
a: L-isomers, b: D-isomers. 
 
Table 2.3.1 shows the MolDoc scores calculated for compounds 2.3.1 – 2.3.3 and the corresponding 
rotamers. Overall, cis- conformers were calculated to have lower MolDoc scores (lower energy) 
compared to their trans- conformers. This means that MVD predicted that compounds 2.3.1 – 2.3.3 
with cis- conformations would have higher binding affinities in the enzyme active site compared to 
their trans- counterparts. Among the cis- conformers, the D-isomers were predicted to have higher 
binding affinities than the L-isomers, based on their calculated MolDoc scores. On the other hand, 
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L-isomers were calculated to have slightly higher binding affinities compared to the D-isomers 
when the comparison was done between the compounds with the trans- conformations.  
   
Table 2.3.1. MolDock scores generated by MVD for compounds 2.3.1 – 2.3.3 and the 
corresponding rotamers docked in the IMP-1 active site. 
 
          
 
 MolDoc Scorea (kcal/mol) 
Compound cis trans 
2.3.1a -138 -126 
2.3.1b -150 -125 
2.3.2a -140 -131 
2.3.2b -150 -126 
2.3.3a -154 -134 
2.3.3b -150 -131 
a Docking score calculated by Molegro Virtual Docker (MVD) software. Larger negative values 
indicate higher binding affinities of inhibitor – IMP-1, thus suggesting a more stable system.  
 
Based on the trend showed by the calculated MolDoc scores, as the distance between the 
carboxylate groups increased, the values of the MolDoc scores decreased. Thus, the farther the 
distance between the carboxylate groups, the higher the predicted binding affinities would be. On 
the other hand, compounds with scaffold structures that can hold the two carboxylates together were 
reported to be effective inhibitors against the MBLs since the closer carboxylates position aids in a 
favorable orientation to coordinate both zinc ions in the enzyme active site.73 Examples of 
compounds with scaffold structures are compound 2.3.A (alkene), 2.3.B and 2.3.C (ring structures) 
(Figure 2.3.3). 
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Figure 2.3.3. Compounds with scaffold structures. 
 
Compound 2.3.3a was predicted to have the highest binding affinity among the compounds in this 
series as this compound was calculated to have the lowest MolDoc score value (-154 kcal/mol). 
Therefore, compound 2.3.3a was predicted to be the most potent compound against IMP-1 enzyme 
among the synthesised compounds in this series. The docking images of the compounds 2.3.1 – 
2.3.3 in the IMP-1 active site generated by the MVD software are shown in Figures 2.3.4 - 2.3.6.  
 
 
2.3.1b 
 
Figure 2.3.4. Docking of compound 2.3.1b into the IMP-1 active site. 
Colours: Blue – nitrogen; red – oxygen; grey – carbon; yellow – sulfur; magenta – Zn ions. 
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Compound 2.3.1b was calculated to have the lowest MolDoc score among compounds 2.3.1 (see 
Appendix A3 for the docking images of the rest of compounds 2.3.1), which indicated that 
compound 2.3.1b was predicted to have the highest binding affinity in the IMP-1 active site. As 
shown in Figure 2.3.4, there were a total of six predicted interactions between oxygens of both 
carboxylic acids group and the two zinc ions with the distances of 2.0, 2.0, 2.3, 3.3, 4.0 and 4.0 Å. 
In addition to these interactions, an electrostatic interaction was predicted between one of the 
carboxylate group oxygens and the NH3+ group of Lys 224 (O-N distance 2.6 Å). A hydrogen bond 
was also predicted to form between one of the oxygens of the carboxylate group and the SH of Cys 
221 with the O-H distance of 3.0 Å. 
 
 2.3.2b 
 
Figure 2.3.5. Docking of compound 2.3.2b into the IMP-1 active site. 
Colours: Blue – nitrogen; red – oxygen; grey – carbon; yellow – sulfur; magenta – Zn ions. 
 
Figure 2.3.5 shows the docking image of compound 2.3.2b docked into the active site of the IMP-1 
enzyme. Compound 2.3.2b was predicted to have the highest binding affinity among compounds 
2.3.2 based on the lowest MolDoc score generated by the MVD software (see Appendix A3 for the 
docking images of the rest of compounds 2.3.2). Both of the carboxylic acids of compound 2.3.2b 
were predicted to interact with the two zinc ions in the enzyme active site through the oxygens via 5 
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electrostatic interactions (2.0, 2.0, 3.2, 3.7 and 3.9 Å). There was another electrostatic interaction 
predicted between the carboxylate group oxygen and the NH3+ group of Lys 224 with the O-N 
distance of 2.6 Å. Furthermore, two hydrogen bonds were predicted to form between the oxygens of 
the carboxylates and the NH of Asn 233 (O-H distance 2.0 Å) and SH of Cys 221 (O-H distance 2.8 
Å). 
 
2.3.3a 
 
Figure 2.3.6. Docking of compound 2.3.3a into the IMP-1 active site. 
Colours: Blue – nitrogen; red – oxygen; grey – carbon; yellow – sulfur; magenta – Zn ions. 
 
Compound 2.3.3a was calculated to have the lowest MolDoc score (-154 kcal/mol) among the 
compounds synthesised in this series (Figure 2.3.6, see Appendix A3 for the docking images of the 
rest of compounds 2.3.3), which means it was predicted to have the highest binding affinities among 
compounds 2.3.1 – 2.3.3. Similar to compound 2.3.2b, this compound was also predicted to interact 
with both zinc ions in the active site of IMP-1 via five electrostatic interactions through the oxygens 
of the carboxylate groups with the distances of 2.0, 2.0, 2.8, 3.2 and 3.7 Å. An electrostatic 
interaction was also predicted between one of the carboxylate group oxygen and the NH3+ group of 
Lys 224 with the O-N distance of 2.6 Å. The oxygens of the carboxylates of compound 2.3.3a were 
also predicted to have hydrogen bonding interactions with the NH2 of Asn 233 (O-H distance 1.7 Å) 
and SH of Cys 221 (O-H distance 3.0 Å). 
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Overall, all compounds in this series were predicted to have interactions with the two zinc ions in 
the enzyme active site through the oxygens of both carboxylate groups. The additional interactions 
were also expected between the molecules with the active site residues. Based on the calculated 
MolDoc score values of compounds 2.3.1 – 2.3.3 (-126 to -154 kcal/mol), these compounds were 
predicted to have slightly lower inhibition potencies against the IMP-1 enzyme compared to 
compounds 2.1.1 – 2.1.3 (MolDoc scores = -144 to -179 kcal/mol).  
 
2.3.1.3 Synthesis 
 
The proposed synthetic routes to the newly designed dicarboxylic acid inhibitors 2.3.1a and 2.3.1b 
from L-proline 2.1.4a and D-proline 2.1.4b are shown in Scheme 2.3.1. These procedures were also 
used to synthesise the previously designed compounds and discussed in earlier chapters. The 
synthesis of dicarboxylic acids 2.3.1a and 2.3.1b would start with the methylation of the prolines 
2.1.4 by reacting prolines 2.1.4 with thionyl chloride in methanol to afford methyl esters 2.1.19a.38, 
39 Then, coupling reactions of the methyl esters 2.1.19 with compound 2.3.4 by HBTU would give 
the coupled products 2.3.5a and 2.3.5b. Next, the coupled products 2.3.5a and 2.3.5b would 
undergo a base hydrolysis to cleave both esters to provide the dicarboxylic acids 2.3.1a and 2.3.1b. 
 
Scheme 2.3.1. Proposed synthetic route of dicarboxylic acids 2.3.1a and 2.3.1b. 
 
On the other hand, the dicarboxylic acid inhibitors 2.3.2 – 2.3.3 would be prepared in a single step 
according to the synthetic method proposed in Scheme 2.3.2. The starting materials 2.1.4 and 
succinic anhydride 2.3.6 would be heated to reflux in THF to obtain the dicarboxylic acids 2.3.2 
based on the procedures reported by Boutefnouchet et al.74 The same reaction would be utilised to 
synthesise the dicarboxylic acids 2.3.3 by replacing the succinic anhydride 2.3.6 with glutaric 
anhydride 2.3.7.   
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Scheme 2.3.2. Proposed synthetic route of the dicarboxylic acids 2.3.2 – 2.3.3. 
 
Synthesis of the dicarboxylic acids 2.3.1 started with introducing a methyl ester protecting group to 
the prolines 2.1.4 by stirring 2.1.4 and thionyl chloride in methanol at room temperature overnight 
to obtain the methyl esters 2.1.19 (see details in Section 2.1.2.3).38 The methyl esters 2.1.19 were 
directly reacted with methyl potassium malonate 2.3.4 in the presence of HBTU as the coupling 
reagent and DIPEA as the base in THF. An overnight reaction was able to construct the coupled 
compounds 2.3.5a – b in excellent yields.35, 36 The successful formations of the coupled products 
2.3.5a – b were marked by the appearance of a multiplet signal at 3.56 – 3.53 ppm (NCOCH2) in 
the 1H NMR spectra of the compounds and a peak at m/z 252 [M + Na]+ in the ESI-MS spectra. 
  
 
Scheme 2.3.3. Synthesis of the coupled compounds 2.3.5. a: L-isomer, b: D-isomer. 
 
The next step towards the synthesis of the dicarboxylic acids 2.3.1 was carried out by hydrolysing 
the coupled compounds 2.3.5 using 2 M NaOH. The syntheses were completed in 2 hours and gave 
the dicarboxylic acids 2.3.1 in good yields. The loss of 2 singlet signals (belonging to the esters) 
from the compounds 1H NMR spectra supported the successful formation of the dicarboxylic acids 
2.3.1. The ESI-MS analyses of the dicarboxylic acids 2.3.1 were supposed to detect m/z 200 [M - 
H]- (negative mode) or m/z 224 [M + Na]+ (positive mode). Instead, a peak at m/z 156 [M - H]- was 
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observed in both dicarboxylic acids 2.3.1a – b samples, suggesting that these compounds were 
decarboxylated during the ESI-MS analysis and formed compounds 2.3.8 (Figure 2.3.7). The 
decarboxylation of compounds 2.3.5 was not likely occured during the hydrolysis since all the 
carbonyl peaks of the dicarboxylic acids 2.3.1 (175.3 ppm (NCHCOOH), 170.7 ppm (NCOCH2), 
167.4 (CH2COOH)) were observed in the 13C spectra of these compounds. 
  
 
Scheme 2.3.4. Hydrolysis of the coupled compounds 2.3.5. 
 
 
Figure 2.3.7. Compound 2.3.8.   
 
Then, the synthesis of dicarboxylic acids 2.3.2 was achieved according to the proposed synthetic 
method (Scheme 2.3.2). Mixtures of prolines 2.1.4 and succinic anhydride 2.3.6 were heated to 
reflux in THF for six hours and continued by an overnight stirring at room temperature. 
Unfortunately, these reactions were unable to provide the desired product 2.3.2a and 2.3.2b 
(Scheme 2.3.5). The ESI-MS analysis was unable to detect a peak at m/z 214 [M - H]- (negative 
mode) or 238 [M + Na]+ (positive mode) belonging to 2.3.2a and 2.3.2b. 1H NMR spectrum of the 
crudes contained a mixture of signals belonging to both of the starting materials.  
 
 
Scheme 2.3.5. Attempt to prepare compounds 2.3.2a – b. 
 
The same reaction was also trialled on the proline methyl ester 2.1.19a. Firstly, a methyl group was 
introduced to L-proline 2.1.4a by heating  L-proline 2.1.4a under reflux with thionyl chloride in 
methanol for three hours (Scheme 2.3.6, see details in Section 2.1.2.3).39 Next, the methyl ester 
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2.1.19a and succinic anhydride 2.3.6 were heated to reflux in THF for six hours and continued by 
stirring at room temperature. However, no trace of compound 2.3.9 was detected from the crude 
sample of the reaction. A peak at m/z 130 [M + H]+ in the ESI-MS spectrum belonging to methyl 
ester 2.1.19a was still apparent. The 1H NMR spectrum of the crude mixture showed combinations 
of signals from both of the starting materials, suggesting that the reaction actually did not occur. A 
base was thought to be necessary in the reaction mixture to encourage the ring opening of succinic 
anhydride. 
   
 
Scheme 2.3.6. Attempt to prepare compound 20 from methyl ester 19. 
 
Scheme 2.3.7. Attempt to prepare compound 2.3.9 from methyl ester 2.1.19a. 
 
Therefore, the reaction was continued by adding DIPEA into the reaction mixture. After an 
overnight reaction at room temperature, 19% of the desired compound 2.3.9 was obtained (Scheme 
2.3.7). The appearance of a peak at m/z 252 [M + Na]+ (positive mode) and m/z 214 [M - H]- 
(negative mode) in the ESI-MS spectrum suggested the successful formation of the desired 
compound 2.3.9. Nevertheless, in spite of the obvious peaks in ESI-MS analysis, there were some 
unknown impurity signals at 3.69 and 3.66 ppm in the 1H NMR spectrum. 
 
Hence, another method reported by Santos et al. was proposed in order to prepare dicarboxylic 
acids 2.3.2 (Scheme 2.3.8).75 According to this method, the prolines 2.1.4 would be reacted with 
succinic anhydride 2.3.6 in the presence of triethylamine (TEA) as the base to construct the desired 
dicarboxylic acids 2.3.2.  
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Scheme 2.3.8. Proposed method to synthesise dicarboxylic acid 11. 
 
The proposed method was trialled on L-proline 2.1.4a. This time, the dicarboxylic acid 2.3.2a was 
successfully constructed after two hours stirring of proline 2.1.4a, succinic anhydride 2.3.6 and 
TEA in dry acetonitrile at 0°C. The addition of a multiplet signal at 2.71 – 2.53 ppm (4H, 
NCOCH2CH2) in the 1H NMR spectrum and a peak at m/z 238 [M + Na]+ observed in the ESI-MS 
spectrum confirmed the formation of dicarboxylic acid 2.3.2a. In addition, a signal at 3.98 ppm 
(1H) in the 1H NMR spectrum that belongs to NCH in L-proline was slightly shifted to 4.41 ppm. 
There was also an obvious addition of two carbonyl signals at 175.8 (NCOCH2) and 172.9 (COOH) 
in 13C NMR spectra of the carboxylic acid 2.3.2a. 
 
 
Scheme 2.3.9. Successful formation of dicarboxylic acid 2.3.2a. 
 
The same reaction was repeated on D-proline 2.1.4b and as expected, dicarboxylic acid 2.3.2b was 
also successfully synthesised (Scheme 2.3.10). Both dicarboxylic acids 2.3.2a and 2.3.2b have 
identical 1H NMR spectra.  
 
 
Scheme 2.3.10. Successful formation of dicarboxylic acid 2.3.2b. 
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Next, by replacing succinic anhydride 2.3.6 with glutaric anhydride 2.3.7, the same reaction was 
expected to give dicarboxylic acids 2.3.3a and 2.3.3b (Scheme 2.3.11). The appearance of multiplet 
signals at 2.38 – 2.32 ppm (4H, NCOCH2CH2CH2) and 1.91 – 1.83 ppm (2H, NCOCH2CH2CH2) in 
the 1H NMR spectra proved that the formation of the dicarboxylic acids 2.3.3a and 2.3.3b were 
successful. The NCH signal around 3.98 ppm in the L-proline 1H NMR spectra was also slightly 
shifted to 4.41 ppm. The addition of two carbonyl signals at 175.8 ppm (NCOCH2) and 173.8 ppm 
(COOH) in the 13C NMR spectra were also observed. The ESI-MS spectra that showed the 
existence of a peak at m/z 228 [M - H]- further approved the effective synthesis of the dicarboxylic 
acids 2.3.3a and 2.3.3b.  
 
 
Scheme 2.3.11. Successful formation of dicarboxylic acid 2.3.3a and 2.3.3b. 
 
Although the dicarboxylic acids 2.3.1 – 2.3.3 were successfully synthesised, there are additional 
signals in both the 1H and 13C NMR spectra of these compounds, suggesting the existence of 
multiple compounds in the reaction samples. The NCH signal in the 1H NMR spectra of all of these 
compounds appeared in pairs with 3:1 ratio. Similar to the previous synthesis of the new derivatives 
of L-proline (2.1.1a, 2.1.2a and 2.1.3a) and the corresponding derivatives of D-proline (2.1.1b, 
2.1.2b and 2.1.3b), this phenomenon suggests the existence of the rotamers (see Section 2.1.2.3). 
Based on the energy calculation performed by Chem3D44 modelling program, trans- conformers 
2.3.1' – 2.3.3' (Figure 2.3.2) were estimated to be predominant (data not included). This can be 
explained by the minimised steric hindrance between the two carboxylic groups and the CH2 
chain.45 The moderate yields of the dicarboxylic acids 2.3.1 – 2.3.3 synthesised might be because of 
the high polarity of the compounds, thus making them difficult to be extracted from the aqueous 
layers during the work up after the reactions.   
 
In conclusion, the desired dicarboxylic acids 2.3.1 were successfully synthesized via 3 steps 
developed during the syntheses of the previous compound series. The dicarboxylic acids 2.3.2 – 
2.3.3 were synthesised by the reaction of proline 2.1.4, succinic anhydride 2.3.6 (for 2.3.2a - b) or 
glutaric anhydride 2.3.7 (for 2.3.3a – b) and TEA in dry acetonitrile for two hours at 0 °C. 
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2.3.1.4 Kinetic Assays 
 
Before kinetic assays could be performed on the synthesised compounds, a screening test was first 
done to check the inhibition percentages of these compounds against the IMP-1 at three different 
concentrations. The results of the screening test are shown in Table 2.3.2. Note that compounds 
2.3.5, 2.3.1, 2.3.2 and 2.3.3 exist as mixtures of rotamers that undergo inter-conversion during the 
lifetime of the assay. The determined inhibition percentages consist of contributions to inhibition 
from each rotamer in the mixtures.  
 
Table 2.3.2. Screening results of the dicarboxylic acid derivatives against IMP-1. 
 % Inhibition a 
Compounds 100 µM 10 µM 1 µM 
 
Succinic anhydride 2.3.6 
4 4 7 
 
Glutaric anhydride 2.3.7 
- 4 5 
 
2.3.5a 
2 4 5 
 
2.3.5b 
- - - 
 
2.3.1a 
- - - 
 
2.3.1b 
- 1 3 
OO O
OO O
N COOMe
O COOMe
N COOMe
O COOMe
N COOH
O COOH
N COOH
O COOH
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2.3.2a 
- - - 
 
2.3.2b 
1 - - 
 
2.3.3a 
- - - 
 
2.3.3b 
- - - 
a
 - (no value) indicates no inhibition. 
 
The results were surprising since none of these compounds showed inhibition activities against the 
IMP-1 except for succinic anhydride, glutaric anhydride, compound 2.3.5a, 2.3.1b and 2.3.2b with 
very low percentage inhibitions. These screening results are contradicting the prediction generated 
by MVD, which suggested that the dicarboxylic acids 2.3.1 – 2.3.3 would have just slightly lower 
inhibition potencies compared to the thiol compounds 2.1.1 – 2.1.3. As mentioned in the previous 
chapters, the computational modelling results were only predictions of the binding interactions and 
binding affinities of the docked molecules in the enzyme active site. These results may not 
accurately represent the actual binding interactions and affinities in the molecule – enzyme 
complexes. 
 
A variety of scaffold such as alkene and ring structures (see Section 2.3.1.2, Figure 2.3.3) were 
effective in developing potent dicarboxylate MBL inhibitors by holding the two carboxylates close 
together as this orientation assists in the coordination of both carboxylates to the two zinc ions in 
the IMP-1 active site during the IMP-1 inhibition mechanism (see Section 1.5.2).73 Thus, 
compounds that hold the carboxylates farther apart such as dicarboxylate acids 2.3.1 – 2.3.3 might 
cause low inhibition potencies against the enzyme. 
 
N COOH
O COOH
N COOH
O COOH
N COOH
O COOH
N COOH
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Since the screening assay of the synthesised compounds in this series show no inhibition against the 
IMP-1, further test to determine the Ki values of these compounds were halted as the aim of this 
work was to develop inhibitors against the IMP-1 with improved inhibition potencies. Compounds 
that can constrain both carboxylates closer might be needed to increase the potencies of the new 
inhibitor compounds.  
 
 
2.3.2 Summary 
 
Modification of the chemical structure of the novel inhibitors against IMP-1 MBL were done based 
on the encouraging competitive inhibition properties of the previously synthesised L-proline and D-
proline derivatives (compounds 2.1.1 – 2.1.3) against the IMP-1 enzyme. However, the molecular 
modelling results generated by MVD suggested that the dicarboxylic acids 2.3.1 – 2.3.3 would have 
slightly lower inhibition potency compared to compounds 2.1.1 – 2.1.3.     
 
The dicarboxylic acids 2.3.1 were successfully synthesised from L-proline and D-proline via three 
steps reaction including acetylation of the prolines, coupling by HBTU and base hydrolysis. The 
dicarboxylic acids 2.3.2 – 2.3.3 were prepared according to the method reported by Santos et al. in 
just one step. 
 
All synthesised compounds including the succinic anhydride and glutaric anhydride were tested 
against the IMP-1. None of these compounds showed potential inhibition activity against the 
enzyme even at 100 µM. Therefore, the kinetic assays of this series were aborted.    
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2.3.3 Experimental 
 
The procedures for the preparation of compounds 2.1.19a – b and their spectral data were as 
described in Section 2.1.4.  
 
General procedure for the preparation of methyl-1-(3-methoxy-3-oxopropanoyl)pyrrolidine-
2-carboxylate (2.3.5) 
A mixture of carbomethoxypyrrolidine hydrochloride (100 – 720 mg, 0.6 – 4.3 mmol), methyl 
potassium malonate (0.1 – 1.0 g, 0.9 – 6.5 mmol), DIPEA (0.5 – 3.7 mL, 3.0 – 22 mmol) and 
HBTU (0.3 – 2.5 g, 0.9 – 6.5 mmol) in THF (2.1 - 15 ml) was stirred overnight at room 
temperature. The solvent was then evaporated under reduced pressure and ethyl acetate (8 mL) was 
added to the crude product. The mixture was washed with water (8 mL) and brine (2 × 8 mL), dried 
(Na2SO4) and concentrated under reduced pressure. The crude product was purified by column 
chromatography (first ethyl acetate/petroleum ether (1:2), then 100% ethyl acetate) to give a yellow 
oil. 
 
(S)-Methyl 1-(3-methoxy-3-oxopropanoyl)pyrrolidine-2-carboxylate (2.3.5a) 
 
Yield = 319 mg (100%). 1H NMR (500 MHz, DMSO): δ 4.66:4.28 (1:4) (dd, J = 2.2:4.3, 8.6:8.8 
Hz, 1H, NCH), 3.61 (s, 3H, OCH3), 3.60 (s, 3H, OCH3), 3.56 – 3.53 (m, 2H, NCOCH2), 3.51 − 
3.46 (m, 2H, NCH2), 2.20 − 2.13 (m, 1H, NCHCHACH2), 1.92 − 1.82 (m, 3H, NCHCHBCH2); 13C 
NMR (125 MHz, DMSO): δ 172.2 (NCHCOOCH3), 167.7 (NCOCH2), 164.5 (COOCH3), 
59.0:58.3 (1:4) (NCH), 51.8 (2 × COOCH3), 47.0 (NCOCH2), 41.5 (NCH2), 30.5:30.0 (1:4) 
(NCHCH2), 24.3:22.1 (4:1) (NCHCH2CH2). ESI-MS, m/z: 252 [M + Na]+. HRMS calculated for 
C10H15NNaO5 252.0842, found 252.0843. 
 
(R)-Methyl 1-(3-methoxy-3-oxopropanoyl)pyrrolidine-2-carboxylate (2.3.5b) 
 
Yield = 1.7 g (100%). 1H NMR (500 MHz, DMSO): δ 4.66:4.28 (1:4) (dd, J = 2.2:4.3, 8.6:8.8 Hz, 
1H, NCH), 3.61 (s, 3H, OCH3), 3.60 (s, 3H, OCH3), 3.56 – 3.53 (m, 2H, NCOCH2), 3.51 − 3.44 
(m, 2H, NCH2), 2.18 − 2.13 (m, 1H, NCHCHACH2), 1.92 − 1.82 (m, 3H, NCHCHBCH2); 13C NMR 
N COOMe
O COOMe
N COOMe
O COOMe
 114 
(125 MHz, DMSO): δ 172.1 (NCHCOOCH3), 167.7 (NCOCH2), 164.5 (COOCH3), 59.0:58.3 (1:4) 
(NCH), 51.8 (2 × COOCH3), 47.0 (NCOCH2), 41.5 (NCH2), 30.5:28.9 (1:4) (NCHCH2), 24.3:22.1 
(4:1) (NCHCH2CH2). ESI-MS, m/z: 252 [M + Na]+. HRMS calculated for C10H15NNaO5 252.0842, 
found 252.0841. 
 
General procedure for the hydrolysis of methyl-1-(3-methoxy-3-oxopropanoyl)pyrrolidine-2-
carboxylate (2.3.5) 
NaOH (2 M, 1.3 mL, 6 eq.) was added to methyl-1-(3-methoxy-3-oxopropanoyl)pyrrolidine-2-
carboxylate 2.3.5 (100 mg, 0.4 mmol) in MeOH (1.3 mL) and the mixture was stirred for 2 hours at 
room temperature under argon. The solvent was evaporated under reduced pressure and water (5 
mL) was added to the residue. The mixture was acidified to pH=2 with 2 M HCl, extracted with 
ethyl acetate (5 mL x 3) and dried (Na2SO4). The organic solvent was evaporated under reduced 
pressure and then co-evaporated with dichloromethane (3 x 5 mL) to give the desired product.  
 
(S)-1-(2-Carboxyacetyl)pyrrolidine-2-carboxylic acid (2.3.1a) 
 
Brown hygroscopic foam (63 mg, 72%). 1H NMR (400 MHz, MeOD): δ 4.60:4.44 (1:3) (dd, J = 
2.5:3.6, 8.3:8.7 Hz, 1H, NCH), 3.70 − 3.47 (m, 4H, NCH2, NCOCH2), 2.30 − 2.24 (m, 1H, 
NCHCHACH2), 2.06 − 2.00 (m, 3H, NCHCHBCH2); 13C NMR (100 MHz, MeOD): δ 175.3 
(NCHCOOH), 170.7 (NCOCH2), 167.4 (CH2COOH), 61.3:60.4 (1:5) (NCH), 47.7 (NCOCH2), 
44.2 (NCH2), 32.0:30.5 (1:5) (NCHCH2), 25.6:23.5 (4:1) (NCHCH2CH2). ESI-MS, m/z: 156 [M - 
H]- (de-carboxylated compound). HRMS calculated for C7H10NO3 156.0666, found 156.0680 (de-
carboxylated compound). 
 
(R)-1-(2-Carboxyacetyl)pyrrolidine-2-carboxylic acid (2.3.1b) 
 
Brown hydroscopic foam (52 mg, 60%). 1H NMR (300 MHz, MeOD): δ 4.59:4.44 (1:3) (dd, J = 
3.6, 8.4 Hz, 1H, NCH), 3.69 − 3.41 (m, 4H, NCH2, NCOCH2), 2.27 − 2.21 (m, 1H, NCHCHACH2), 
2.06 − 1.98 (m, 3H, NCHCHBCH2); 13C NMR (125 MHz, MeOD): δ 175.4 (NCHCOOH), 170.7 
(NCOCH2), 168.1 (CH2COOH), 61.3:60.3 (1:4) (NCH), 47.7 (NCOCH2), 44.5 (NCH2), 32.0:30.5 
(1:4) (NCHCH2), 25.5:23.5 (4:1) (NCHCH2CH2). ESI-MS, m/z: 156 [M - H]- (de-carboxylated 
N COOH
O COOH
N COOH
O COOH
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compound). HRMS calculated for C7H10NO3 156.0666, found 156.0669 (de-carboxylated 
compound). 
 
General procedure for the preparation of 1-(3-carboxypropanoyl)pyrrolidine-2-carboxylic 
acid 
Triethylamine (1.2 mL, 8.7 mmol) was added to a solution of L-proline/D-proline (500 mg, 4.3 
mmol) in dry acetonitrile at 0°C and the mixture was stirred for 15 minutes. Then, a solution of 
succinic anhydride (435 mg, 4.3 mmol) in dry acetonitrile was added dropwise at 0°C. The mixture 
was stirred for 2 hours at 0°C. The solvent was removed under reduced pressure and ethyl acetate 
(10 mL) was added to the residue. The product was extracted with pH 1 HCl solution (10 mL, 0.1 
M), and later re-extracted from the aqueous solution with ethyl acetate (6 × 40 mL) and dried 
(Na2SO4). The organic solvent was evaporated under reduced pressure to give yellow gum. The 
gum was treated with absolute ethanol (4 × 6 mL, then evaporated under reduced pressure) and 
dichloromethane (5 × 6 mL, then evaporated under reduced pressure) to give the desired product. 
 
(S)-1-(3-Carboxypropanoyl)pyrrolidine-2-carboxylic acid (2.3.2a) 
 
White hygroscopic foam (430 mg, 46%). 1H NMR (500 MHz, MeOD): δ 4.60:4.41 (1:3) (dd, J = 
2.7:3.7, 8.7:8.6 Hz, 1H, NCH), 3.67 − 3.61 (m, 2H, NCH2), 2.71 – 2.53 (m, 4H, NCOCH2CH2), 
2.26 − 2.20 (m, 1H, NCHCHACH2), 2.06 − 1.98 (m, 3H, NCHCHBCH2); 13C NMR (125 MHz, 
MeOD): δ 176.4 (NCHCOOH), 175.8 (NCOCH2), 172.9 (COOH), 61.0:60.2 (1:3) (NCH), 
48.2:47.7 (3:1) (NCH2), 30.4 (NCOCH2CH2), 30.1 (NCOCH2CH2), 25.6 (NCHCH2CH2), 23.6 
(NCHCH2). ESI-MS, m/z: 238 [M + Na]+. HRMS calculated for C9H13NNaO5 238.0686, found 
238.0680.   
 
(R)-1-(3-Carboxypropanoyl)pyrrolidine-2-carboxylic acid (2.3.2b) 
 
White hygroscopic foam (475 mg, 51%). 1H NMR (500 MHz, MeOD): δ 4.60:4.41 (1:3) (dd, J = 
2.7:3.7, 8.7:8.6 Hz, 1H, NCH), 3.67 − 3.61 (m, 2H, NCH2), 2.72 – 2.52 (m, 4H, NCOCH2CH2), 
2.25 − 2.20 (m, 1H, NCHCHACH2), 2.05 − 2.00 (m, 3H, NCHCHBCH2); 13C NMR (125 MHz, 
MeOD): δ 176.4 (NCHCOOH), 175.8 (NCOCH2), 172.9 (COOH), 61.0:60.2 (1:3) (NCH), 
N COOH
O COOH
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48.2:47.7 (3:1) (NCH2), 30.4 (NCOCH2CH2), 30.1 (NCOCH2CH2), 25.6 (NCHCH2CH2), 23.6 
(NCHCH2). ESI-MS, m/z: 214 [M - H]-. HRMS calculated for C9H12NO5 214.0721, found 
214.0726. 
 
General procedure for the preparation of 1-(4-carboxybutanoyl)pyrrolidine-2-carboxylic acid 
The reaction procedure was carried out as described in the literature.75 Triethylamine (1.2 mL, 8.7 
mmol) was added to a solution of L-proline/D-proline (500 mg, 4.3 mmol) in dry acetonitrile at 0°C 
and the mixture was stirred for 15 minutes. Then, a solution of glutaric anhydride (496 mg, 4.3 
mmol) in dry acetonitrile was added dropwise at 0°C. The mixture was stirred for 2 hours at 0°C - 
room temperature. The solvent was removed under reduced pressure and ethyl acetate (10 mL) was 
added to the residue. The product was extracted with pH 1 HCl solution (10 mL, 0.1 M), and later 
re-extracted from the aqueous solution with ethyl acetate (6 × 40 mL) and dried (Na2SO4). The 
organic solvent was evaporated under reduced pressure to give a yellow gum. The gum was treated 
with absolute ethanol (4 × 6 mL, then evaporated under reduced pressure) and dichloromethane (5 × 
6 mL, then evaporated under reduced pressure) to give the desired product. 
 
(S)-1-(4-Carboxybutanoyl)pyrrolidine-2-carboxylic acid (2.3.3a) 
 
Yellow gum (479 mg, 48%). 1H NMR (500 MHz, MeOD): δ 4.53:4.41 (1:3) (dd, J = 2.6:3.9, 
8.7:8.6 Hz, 1H, NCH), 3.66 − 3.54 (m, 2H, NCH2), 2.38 – 2.32 (m, 4H, NCOCH2CH2CH2), 2.26 − 
2.20 (m, 1H, NCHCHACH2), 2.04 − 1.98 (m, 3H, NCHCHBCH2), 1.91 – 1.83 (m, 2H, 
NCOCH2CH2CH2); 13C NMR (125 MHz, MeOD): δ 176.8 (NCHCOOH), 175.8 (NCOCH2), 173.8 
(COOH), 61.0:60.2 (1:3) (NCH), 48.4:47.5 (3:1) (NCH2), 33.9 (NCOCH2CH2CH2), 32.2 
(NCOCH2CH2CH2), 25.6 (NCHCH2CH2), 23.5 (NCHCH2), 21.4 (NCOCH2CH2CH2). ESI-MS, 
m/z: 228 [M - H]-. HRMS calculated for C10H14NO5 228.0877, found 228.0886. 
 
(R)-1-(4-Carboxybutanoyl)pyrrolidine-2-carboxylic acid (2.3.3b) 
 
Yellow gum (429 mg, 43%). 1H NMR (500 MHz, MeOD): δ 4.52:4.40 (1:3) (dd, J = 2.6:3.8, 
8.7:8.6 Hz, 1H, NCH), 3.66 − 3.54 (m, 2H, NCH2), 2.38 – 2.31 (m, 4H, NCOCH2CH2CH2), 2.27 − 
2.19 (m, 1H, NCHCHACH2), 2.05 − 1.98 (m, 3H, NCHCHBCH2), 1.93 – 1.84 (m, 2H, 
N COOH
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NCOCH2CH2CH2); 13C NMR (125 MHz, MeOD): δ 176.8 (NCHCOOH), 175.8 (NCOCH2), 173.8 
(COOH), 61.1:60.2 (1:3) (NCH), 48.4:47.6 (3:1) (NCH2), 33.9 (NCOCH2CH2CH2), 32.3 
(NCOCH2CH2CH2), 25.6 (NCHCH2CH2), 23.5 (NCHCH2), 21.4 (NCOCH2CH2CH2). ESI-MS, 
m/z: 252 [M + Na]+. HRMS calculated for C10H15NNaO5 252.0842, found 252.0842. 
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2.4 Pipecolinic Acid Derivatives. 
 
2.4.1 Results and Discussion 
 
2.4.1.1 Design of Novel Inhibitors Based on Compounds 2.1.2 – 2.1.3 
 
As mentioned in previous chapters, the aim of this project is to develop novel and potent inhibitors 
of IMP-1 MBL to combat antibiotic resistance. The development of the thiol derivatives of L- and 
D-proline as new IMP-1 inhibitors through design, synthesis and testing was discussed in Chapter 
2.1. All of the compounds (2.1.2 – 2.1.3) discussed in Chapter 2.1 showed encouraging inhibition 
potencies against IMP-1 with the Ki values ranging from 2.2 ± 0.6 to 9.9 ± 4.2 µM. This was a good 
improvement compared to the lead compound, D-captopril (Ki = 12.5 ± 2.4 µM). 
 
In this chapter, the design of pipecolinic acid derivatives as inhibitors against IMP-1 MBL enzyme 
based on the lead compounds 2.1.1 – 2.1.3 developed in Chapter 2.1 is reported. This includes the 
modification of the chemical structures and the docking studies of the molecules bound in the active 
site of IMP-1 enzyme. The syntheses and the kinetic study of the compounds are also discussed in 
this chapter. 
 
Figure 2.4.1. Pipecolinic acid derivatives 2.4.1 – 2.4.3. 
 
As discussed in Chapter 2.1, thiol compounds 2.1.1 – 2.1.3 were reported to inhibit the IMP-1 
enzyme solely by competitive inhibition mode with encouraging inhibition potency (Ki = 2.2 ± 0.6 
to 9.9 ± 4.2 µM). Some modifications of the thiols 2.1.1 – 2.1.3 molecular structures are expected to 
improve the inhibition potency of the molecules against the IMP-1. The docking images of thiols 
2.1.1 – 2.1.3 bound in the IMP-1 active site (Figures 2.1.8 – 2.1.10) show that these molecules are 
predicted to have strong interactions with the residues in the IMP-1 active site through its thiolate 
and carboxylate groups. Therefore, compounds 2.4.1 – 2.4.3 were designed to retain these key 
structures (Figure 2.4.1). The amide carbonyl group of these compounds was also maintained to 
allow easy synthesis of compounds 2.4.1 – 2.4.3 by utilising the established methods used in the 
preparation of the previous compound series. In addition, the five-membered ring in thiols 2.1.1 – 
N OH
OOHS
2.4.1: n = 1
2.4.2: n = 2 
2.4.3: n = 3
n
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2.1.3 was replaced by a six-membered ring to increase the hydrophobic interactions with the amino 
acid residues in the IMP-1 active site. Similar to thiols 2.1.1 – 2.1.3, compounds 2.4.1 – 2.4.3 were 
designed to have increasing distance between the carboxylate and the thiol groups of these 
compounds to investigate the effects on the inhibition potency. The docking results of these 
compounds generated by MVD software will be discussed in Section 2.4.1.2. 
 
2.4.1.2 Computational Modelling 
 
As discussed in the previous chapter, computational modelling was used throughout this project to 
visualise the predicted binding interactions of the synthesised compounds in the IMP-1 active site. 
The modelling studies were carried out using Molegro Virtual Docker (MVD) software. The 
modelling results can be used to identify new potential inhibitors and also predict the likely 
inhibition potencies of the new inhibitors based on the calculated MolDoc scores (see details in 
Section 2.1.2.2). 
 
Similar to the proline derivatives in the previous series, compounds 2.4.1 – 2.4.3 were expected to 
exist as a mixture of trans- and cis- rotamers as these compounds also contain tertiary amides 
(Figure 2.4.2). Murcko et al. also suggested that amide rotations are possible in pipecolinic acid 
derivatives.76 Although the final compounds 2.4.1 – 2.4.3 were synthesised from racemic 
pipecolinic acid 2.4.4 (see Section 2.4.1.3), the docking studies were performed on both L- & D-
isomers of the designed compounds 2.4.1a-b – 2.4.3a-b and their corresponding rotamers 2.4.1a'-b' 
– 2.4.3a'-b' using MVD software. 
 
Figure 2.4.2. The designed compounds 2.4.1 – 2.4.3 and the corresponding rotamers. 
a:  L-isomers, b:  D-isomers. 
 
The MolDoc scores for all of the compounds and their rotamers docked in the active site of the 
IMP-1 are shown in Table 2.4.1. All of the docked compounds were calculated to have similar 
MolDoc scores among the same conformations. Therefore, the trans- conformer of compound 
2.4.1a was predicted to have comparable binding affinities and inhibition potencies as the other 
compounds in the trans- conformations. The compounds in their cis- conformers also showed the 
2.4.1a-b: n = 1
2.4.2a-b: n = 2 
2.4.3a-b: n = 3
n
N
OHS
OH
O
2.4.1a'-b': n = 1
2.4.2a'-b': n = 2 
2.4.3a'-b': n = 3
n
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same pattern in their MolDoc scores. Compound 2.4.1a', for example was predicted to have 
comparable inhibition potency against the IMP-1 enzyme as the other compounds in cis- 
conformation since the calculated MolDoc scores of all the cis- conformers were also in similar 
values. On the other hand, when the comparison was done between the compounds with trans- and 
cis- conformations, the MolDoc scores of the cis- conformers were calculated to have larger 
negative values compared to their trans- counterparts. This indicates that the cis- conformers were 
predicted to have higher binding affinities in the IMP-1 active site compared to the trans- 
conformers.  
 
Table 2.4.1. MolDock scores generated by MVD for compounds 2.4.1 – 2.4.3 and the 
corresponding rotamers docked in the IMP-1 active site. 
          
 MolDoc Scorea (kcal/mol) 
Compound trans cis 
2.4.1a -126 -161 
2.4.1b -152 -157 
2.4.2a -132 -159 
2.4.2b -131 -162 
2.4.3a -143 -166 
2.4.3b -142 -161 
a
 Docking score calculated by Molegro Virtual Docker (MVD) software. Larger negative values 
indicate higher binding affinities of inhibitor – IMP-1, thus suggesting a more stable system. 
 
Compound 2.4.3a' was predicted to be the most potent inhibitor in this series against the IMP-1 as it 
was calculated to have the lowest MolDoc score (-166 kcal/mol). However, this value is slightly 
larger than the calculated value for thiols 2.1.1 – 2.1.3 (-172 – -179 kcal/mol). Therefore, 
compounds 2.4.1 – 2.4.3 were predicted to have slightly lower inhibition potency compared to 
thiols 2.1.1 – 2.1.3. 
 
N OH
OOHS
2.4.1a: n = 1
2.4.2a: n = 2 
2.4.3a: n = 3
n
N OH
OOHS
2.4.1b: n = 1
2.4.2b: n = 2 
2.4.3b: n = 3
n
2.4.1a': n = 1
2.4.2a': n = 2 
2.4.3a': n = 3
n
N
O SH
OH
O
2.4.1b': n = 1
2.4.2b': n = 2 
2.4.3b': n = 3
n
N
O SH
OH
O
 121 
As mentioned earlier, the molecular modelling studies were done on all of the designed and 
synthesised compounds in this series to visualise their predicted binding interactions in the IMP-1 
active site. The docking images of the compounds 2.4.1 – 2.4.3 generated by the MVD software are 
shown in Figures 2.4.3 - 2.4.5.  
 
2.4.1a' 
 
Figure 2.4.3. Docking of compound 2.4.1a' into the active site of IMP-1. Colours: Blue – nitrogen; 
red – oxygen; grey – carbon; yellow – sulfur; magenta – Zn ions. 
 
Figure 2.4.3 shows the docking result of compound 2.4.1a', the cis- form of compound 2.4.1a, 
docked into the IMP-1 active site. The MVD predicted that compound 2.4.1a' would have the 
highest binding affinity among compounds 2.4.1, based on the calculated MolDock score (see 
Appendix A4 for the docking result of the rest of compounds 2.4.1). Similar to all thiol compounds 
synthesised in the previous series, compound 2.4.1a' was predicted to coordinate to both zinc ions 
in a bridging mode via its thiolate group with the distances of 2.0 Å for each interaction. There were 
two hydrogen bonds predicted between compound 2.4.1a' and the Asn 233 in the enzyme active 
site: one was between the amide carbonyl oxygen and the side chain NH2 of Asn 233 (O-H distance 
2.3 Å) and another one between one of the carboxylate oxygens of this compound and the backbone 
NH group of Asn 233 (O-H distance 1.5 Å). In addition to these interactions, compound 2.4.1a' was 
also predicted to have eletrostatic interactions between its carboxylate group oxygens with the NH3+ 
group of Lys 224 (O-N distances 2.6 and 3.9 Å) and one of the zinc ions (O-Zn2+ distance 3.4 Å). 
N
O SH
OH
O
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2.4.2b' 
 
Figure 2.4.4. Docking of compound 2.4.2b' into the active site of IMP-1. Colours: Blue – nitrogen; 
red – oxygen; grey – carbon; yellow – sulfur; magenta – Zn ions. 
 
Compound 2.4.2b' was calculated to have the highest binding affinity among compounds 2.4.2, 
based on the calculated MolDock score (see Appendix A4 for the docking result of the rest of 
compounds 2.4.2). Interactions that can be observed in the docking image of compound 2.4.2b' 
were also similar to the docking result of compound 2.4.1a' where the thiolate group of compound 
2.4.2b' was predicted to be coordinated to both metal ions in the IMP-1 active site (2.0 Å for both 
interactions, Figure 2.4.4). As shown in Figure 2.4.4, there were also two additional electrostatic 
interactions between both oxygens of the carboxylate group and one of the zinc ions with the 
distances of 2.0 and 4.0 Å. There was also an electrostatic interaction predicted between one of the 
carboxylate group oxygens with the NH3+ group of Lys 224 in the active site with the O-N distance 
of 2.5 Å. 
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2.4.3a' 
 
Figure 2.4.5. Docking of compound 2.4.3a' into the active site of IMP-1. Colours: Blue – nitrogen; 
red – oxygen; grey – carbon; yellow – sulfur; magenta – Zn ions. 
 
Compound 2.4.3a' (cis- conformer) was predicted to have the highest binding affinity among all of 
the compounds docked in this chapter (MolDoc score = -166 kcal/mol). As shown in Figure 2.4.5, 
compound 2.4.3a' exhibits similar predicted interactions of the sulfur atom with both zinc ions in 
the active site, as can be seen in the docking result of compound 2.4.1a' and 2.4.2b' in the IMP-1 
active site. The predicted distances for the coordination of the thiol group and both zinc ions were 
2.0 Å for both interactions. Two additional interactions between both oxygens of the carboxylate 
group of this compound and one of the zinc ions (2.0 and 4.0 Å) might be the additional points that 
increased the binding affinity of compound 2.4.3a' with the IMP-1 active site. Two hydrogen bonds 
were also predicted to form between both the carboxylate group oxygens and the backbone NH of 
Asn 233 (O-H distance 2.6 Å) and the SH group of Cys 221 (O-H distance 3.1 Å). There was also 
an electrostatic interaction predicted between one of the carboxylate group oxygens and the NH3+ 
group of Lys 224 with the O-N distance of 2.9 Å. 
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In conclusion, all of the compounds in this chapter were predicted to have the interactions between 
the thiolates with both of the zinc ions in the active site of IMP-1 with the distances around 1.9 – 
2.0 Å. Thus, these compounds were expected to have good inhibition potencies against IMP-1 
enzyme as interactions with both zinc ions is crucial during inhibition because the zinc ions play 
important roles in the hydrolysis of β-lactam ring in β-lactam antibiotics.3 Compound 2.4.3a' was 
predicted to have the highest binding affinity, thus expected to be the most potent compound 
against IMP-1 among compounds 2.4.1 – 2.4.3. 
 
2.4.1.3 Synthesis 
 
Scheme 2.4.1 shows the proposed synthetic methods to prepare the newly designed inhibitors 2.4.1 
- 2.4.3 from pipecolinic acid 2.4.4. Conversion of carboxylic acids 2.1.5 – 2.1.7 to the 
corresponding acid chlorides 2.1.8 – 2.1.10 would be done by reacting the carboxylic acids 2.1.5 – 
2.1.7 with oxalyl chloride based on the optimised method mentioned in Section 2.1.2.3. Then, 
reaction of the acid chlorides 2.1.8 – 2.1.10 with pipecolinic acid 2.4.4, would provide compounds 
2.4.5 – 2.4.7.30 Finally, base hydrolysis of compounds 2.4.5 – 2.4.7 was proposed to remove the 
thioester group to form the final products 2.4.1 - 2.4.3. 
 
Scheme 2.4.1. Proposed synthestic route to the new inhibitors 2.4.1 – 2.4.3. 
 
The syntheses of the new compounds 2.4.1 – 2.4.3 were started with the conversion of carboxylic 
acids 2.1.5 – 2.1.7 to the acid chlorides 2.1.8 – 2.1.10 (Scheme 2.4.2). As discussed in Chapter 2.1, 
the attempt to substitute the -OH group in the carboxylic acid with -Cl group using thionyl chloride 
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was not fully achieved. Fortunately, the optimisation of this reaction using four equivalent of oxalyl 
chloride in dry chloroform successfully completed the conversion.34 The 1H NMR spectrum 
produced by the acid chloride 2.1.8 was consistent with the literature.34 The shifting of 3.70 ppm 
signal belonging to SCH2 in the 1H NMR spectrum of the carboxylic acid 2.1.5 to 4.16 ppm proved 
the successful substitution of the -OH group for a –Cl group. A signal belonging to SCH2CH2 of the 
acid chloride 2.1.9 in the 1H NMR spectrum also shifted from 2.67 ppm to 3.19. The 1H NMR 
spectrum of the acid chloride 2.1.9 was consistent with the spectrum reported by Vasil’eva et al.77 
As for acid chloride 2.1.10, the triplet signal at 2.42 ppm belonging to SCH2CH2CH2 in the 1H 
NMR spectrum also shifted from 2.42 ppm to 2.96 ppm, confirming the completed conversion of -
OH group to –Cl group. Attempts to run ESI-MS of all the acid chlorides failed, as these 
compounds are sensitive to moisture and easily converted back to the corresponding carboxylic 
acids during the sample preparations.     
 
 
Scheme 2.4.2. Optimised method to prepare acid chlorides 2.1.8 – 2.1.10. 
 
Due to the unstable nature of the acid chlorides 2.1.8 – 2.1.10, these compounds were used directly 
in the next reaction without further purification. The reactions to form amide bonds were based on 
the method reported by Bodanszky et al.30 were successful in synthesising the coupled compound 
2.4.5. The addition of a singlet signal at 2.32 ppm in the 1H NMR spectrum belonging to the 
SCOCH3 group proved the successful formation of the coupled compound 2.4.5. A peak at m/z 268 
[M + Na]+ observed in the ESI-MS spectrum further proved the formation of the coupled compound 
2.4.5. However, this reaction only gave 25% of the coupled compound 2.4.5 and was unable to 
provide the coupled compounds 2.4.6 and 2.4.7. This might be because of the moisture sensitive 
acid chlorides 2.1.8 – 2.1.10 were converted back to the inactive carboxylic acids 2.1.5 – 2.1.7 in 
the reaction mixtures during the overnight reaction before the formation of the amide bonds took 
place. 
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Scheme 2.4.3. Synthesis of the coupled compounds 2.4.5 – 2.4.7. 
 
Therefore, another coupling reaction method, HBTU coupling was proposed to form the amide 
bond and synthesise the coupled compounds. Before HBTU coupling reaction, the free carboxylic 
acid group of pipecolinic acid 2.4.4 needed protection to avoid possible coupling reactions from 
occurring at the carboxylic acid group position. Hence, pipecolinic acid 2.4.4 was heated to reflux 
with thionyl chloride in methanol for two hours to obtain the methyl ester 2.4.8.39 The successful 
formation of the methyl ester 2.4.8 was marked by the appearance of an obvious singlet signal at 
3.87 ppm in the 1H NMR spectrum of this compound (OCH3). A peak at m/z 144 [M + H]+ in the 
ESI-MS spectrum also supported the formation of compound 2.4.8. Next, the synthesis of the 
coupled compounds 2.4.9 and 2.4.10 were achieved via the HBTU coupling of the methyl ester 
2.4.8 with the carboxylic acids 2.1.6 and 2.1.7.20 The formation of the coupled compounds 2.4.9 
and 2.4.10 was proved by the appearance of singlet signals at around 2.3 ppm belonging to 
SCOCH3 in the 1H NMR spectra of the coupled compounds. The appearance of peaks at m/z 296 
and 310 [M + Na]+ also proved that the synthesis of the coupled compounds 2.4.9 and 2.4.10, 
respectively, were successfully achieved.    
 
Scheme 2.4.4. Successful formation of the coupled compounds 2.4.9 and 2.4.10 in high yields. 
 
The final step for the preparation of thiols 2.4.1 – 2.4.3 was base hydrolysis to restore both the 
carboxylic acid and thiol groups of the compounds (Scheme 2.4.5). The successful reactions were 
proved by the loss of the thioester signal from the 1H NMR spectrum of thiol 2.4.1 and both 
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thioester and methyl ester signals of thiols 2.4.2 and 2.4.3. Although thiols 2.4.1 – 2.4.3 were 
expected to exist as rotamers, neither the 1H or 13C NMR spectra produced by these thiols has 
additional signals, hence only one rotamer exist in the compound system.78 The trans- conformers 
2.4.1 – 2.4.3 (Figure 2.4.2) were estimated to be the only conformation presence based on the 
energy calculation by Chem3D44 (data not included). This can be explained by the minimised steric 
hindrance between the carboxylic group, CH2 chain and thiol group.45  
 
Scheme 2.4.5. Synthesis of the final compounds 2.4.1 – 2.4.3. 
 
In conclusion, the thiol 2.4.1 was synthesised via three steps reaction starting from the preparation 
of acid chloride 2.1.8 from the carboxylic acid 2.1.5. The reaction of pipecolinic acid 2.4.4 with the 
acid chloride 2.1.8 gave the coupled compound 2.4.5. Then, base hydrolysis of compound 2.4.5 
successfully yielded thiol 2.4.1. On the other hand, syntheses of thiols 2.4.2 and 2.4.3 were 
achieved via four steps reaction starting with methylation reaction of pipecolinic acid 2.4.4 using 
thionyl chloride. Then, coupling reaction of methyl ester 2.4.8 using HBTU and DIPEA in THF 
managed to construct the coupled products 2.4.9 – 2.4.10. Finally, base hydrolysis of the coupled 
products 2.4.9 – 2.4.10 successfully removed both methyl ester and thioester in one step to give the 
desired final compounds 2.4.2 – 2.4.3. 
 
2.4.1.4 Kinetic Assays 
As the purpose of this study is to improve the inhibition potency of the inhibitors of IMP-1, a 
screening assay of all the synthesised compounds in this series was carried out against the IMP-1 
enzyme to select the compounds with considerable percentage inhibitions. Compounds with 
inhibition percentages of more than 50% at 100 µM were considered as compounds with 
considerable percentage inhibitions since their Ki values were predicted to be less than 100 µM. 
Table 2.4.2 shows the screening assay results of compounds 2.4.4, 2.4.5, 2.4.8 – 2.4.10 and 2.4.1 – 
2.4.3 which were sythesised as racemates. From the table, it can be concluded that the compounds 
with both methyl ester and thioester (2.4.9 and 2.4.10) show very low inhibition activities against 
the IMP-1 enzyme. Interestingly, compound 2.4.5 with thioester and free carboxylic acid showed 
excellent inhibition activity at 100 µM. Although there was no free thiol in compound 2.4.5, the 
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compound’s carboxylic acid might replaced the thiol group to coordinate the zinc ions in the IMP-1 
active site, resulting in the inhibition of the enzyme. Then, as expected, all thiols 2.4.1 – 2.4.3 (final 
compounds) showed excellent inhibition activities at 100 µM and moderate inhibition activities at 
10 µM. Therefore, all final compounds 2.4.1 – 2.4.3 and compound 2.4.5 were chosen to be further 
tested against the IMP-1 enzyme to determine their Ki values and inhibition modes.    
  
Table 2.4.2. Screening results of the pipecolinic acid derivatives against the IMP-1. 
 % Inhibition a 
Compounds 100 µM 10 µM 1 µM 
 
Pipecolinic acid 2.4.4 
- 4 - 
 
2.4.8 
2 - 1 
 
2.4.5 
75 6 6 
 
2.4.9 
8 - 2 
 
2.4.10 
- 9 8 
 
 2.4.1 
100 46 - 
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2.4.2 
94 38 6 
  
2.4.3 
98 34 - 
a
 - (no value) indicates no inhibition. 
 
Table 2.4.3 shows the Ki values of the racemic thiols 2.4.1 – 2.4.3 and racemic compound 2.4.5 
against the IMP-1 enzyme. Pure enantiomers of these compounds might give different Ki values 
against the IMP-1. All thiols 2.4.1 – 2.4.3 show comparable inhibitory activities with thiols 2.1.1 – 
2.1.3 from the proline series reported in Chapter 2.1. This indicates that the replacement of the five-
membered ring in the proline derivatives with a six-membered ring was not successful in improving 
the Ki values. This might be because the six-membered ring in the pipecolinic acid derivatives have 
the same interactions as the five-membered ring with the IMP-1 active site residues, or there might 
be no interaction at all that can affect the binding affinities of the compounds, consequently causing 
no change to the Ki values. Similar to thiols 2.1.1 – 2.1.3 of the proline series, thiols 2.4.1 – 2.4.3 
also inhibit IMP-1 solely by competitive inhibition mode with the inhibition constant, Kic value 
ranged from 3.4 ± 1.3 to 10 ± 4 µM. With the Kic value of 3.4 ± 1.3 µM, thiol 2.4.1 is the most 
potent compound against the IMP-1 in this series. This was the opposite of the result generated by 
the MVD software in the modeling studies, which suggested thiol 2.4.3 as the compound with the 
highest binding affinity in the enzyme active site. Compound 2.4.5 was also found to be potent 
against IMP-1 with the Kic value of 24 ± 3 µM but its potency was two times lower compared to the 
lead compound L-captopril (Ki = 12.5 ± 2.4 µM). There is no significant trend in the Ki values based 
on the distance between the carboxylate and thiol groups since the values were comparable for thiol 
2.4.2 (n = 2) and thiol 2.4.3 (n = 3). As a conclusion, all final compounds (thiols 2.3.1 – 2.3.4) have 
encouraging inhibition activities against the IMP-1 with low micromolar Ki values ranged from 3.4 
± 1.3 to 10 ± 4 µM. These values show comparable potency with thiols 2.1.1 – 2.1.3 in Chapter 2.1 
(Ki = 2.2 ± 0.6 to 9.9 ± 4.2 µM). 
 
 
 
N OH
OOHS
N OH
OOHS
 130 
Table 2.4.3. Ki values of pipecolinic acid derivatives against the IMP-1 enzyme. 
Compounds Kic (µM) a 
 
2.4.5 
24 ± 3 
 
 2.4.1 
3.4 ± 1.3 
  
2.4.2 
10 ± 4 
  
2.4.3 
7.1 ± 1.7 
 a Values are mean of duplicate measurements ± SEM. 
 
2.4.2 Summary 
 
Novel inhibitors against the IMP-1 MBL were designed based on the encouraging competitive 
inhibition properties of thiols 2.1.1 – 2.1.3 developed in Chapter 2.1. Virtual docking of these newly 
designed molecules into the active site of the IMP-1 enzyme (PDB code: 1JJT) using Molegro 
Virtual Docker (MVD) software showed a favourable binding mode with the enzyme. 
 
Synthesis of the designed IMP-1 inhibitor 2.4.1 was completed via three steps reaction starting from 
the preparation of acid chloride 2.1.8 from the carboxylic acid 2.1.5, coupling of the acid chloride 
with pipecolinic acid, followed by base hydrolysis of compound 2.4.5 to successfully yield thiol 
2.4.1. On the other hand, syntheses of thiols 2.4.2 and 2.4.3 were achieved via four steps reaction 
starting with methylation of pipecolinic acid, coupling reaction of the methyl ester 2.4.8 using 
HBTU and finally the base hydrolysis of the coupled products 2.4.9 – 2.4.10 to remove both methyl 
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ester and thioester to give the desired final compounds 2.4.2 – 2.4.3. 
 
All of the synthesised compounds were tested against the IMP-1 enzyme. Then, all final compounds 
and compound 2.4.5 with the thioester and free carboxylic acid group were chosen for further 
testing to determine their Ki values. All of the compounds tested inhibit the IMP-1 by competitive 
inhibition mode with the Ki values ranging from 3.4 ± 1.3 to 10 ± 4 µM, comparable to thiols 2.1.1 
– 2.1.3. Therefore, replacement of the five-membered ring with a six-membered ring did not 
improve the Ki values. 
 
2.4.3 Experimental 
 
General procedure for the preparation of acid chlorides 
Oxalyl chloride (2.0 mL, 23 mmol) and dry DMF (40 µL) was added to a solution of acetylthio 
compound (0.25 eq.) in dry chloroform (2 mL). The mixture was stirred for two hours at room 
temperature under argon. The chloroform was removed under reduced pressure to give the desired 
product. This compound was used in the next step without further purification.  
 
S-(2-Chloro-2-oxoethyl) ethanethioate (2.1.8) 
 
Dark brown oil (0.9 g, 100%). 1H NMR (300 MHz, CDCl3): δ 4.16 (s, 2H, SCH2), 2.41 (s, 3H, 
CH3), consistent with literature.34 
 
S-(3-Chloro-3-oxopropyl) ethanethioate (2.1.9) 
 
Light yellow oil (1.0 g, 100%). 1H NMR (300 MHz, CDCl3): δ 3.21 − 3.18 (m, 2H, SCH2CH2), 3.12 
− 3.08 (m, 2H, SCH2CH2), 2.33 (s, 3H, CH3), consistent with literature.77 13C NMR (75 MHz, 
CDCl3): δ 195.0 (SCOCH3), 172.4 (COCl), 46.8 (SCH2CH2), 30.5 (SCH2), 23.9 (CH3). 
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S-(4-Chloro-4-oxobutyl) ethanethioate (2.1.10) 
 
Brown oil (1.1 g, 100%). 1H NMR (300 MHz, CDCl3): δ 2.96 (t, J = 5.3 Hz, 2H, SCH2CH2CH2), 
2.91 (t, J = 5.3 Hz, 2H, SCH2CH2CH2), 2.33 (s, 3H, CH3), 1.96 (p, J = 5.3 Hz, 2H, SCH2CH2CH2); 
13C NMR (75 MHz, CDCl3): δ 195.3 (SCOCH3), 173.2 (COCl), 45.5 (SCH2CH2CH2), 30.6 
(SCH2), 27.4 (CH3), 25.1 (SCH2CH2). 
 
1-(2-(Acetylthio)acetyl)piperidine-2-carboxylic acid (2.4.5) 
 
A mixture of pipecolinic acid (1.0 g, 7.7 mmol), S-(2-chloro-2-oxoethyl) ethanethioate (1.8 g, 12 
mmol) and DIPEA (6.7 ml, 39 mmol) in dry THF (21 ml) was stirred overnight at room 
temperature. The solvent was then evaporated under reduced pressure and ethyl acetate (20 mL) 
was added to the crude product. The mixture was washed with 5% hydrochloric acid solution (20 
mL) and the acid layer was extracted with ethyl acetate (2 × 30 mL). The combined organic layers 
were dried (Na2SO4) and concentrated under reduced pressure. The crude product was purified by 
column chromatography (ethyl acetate/petroleum ether (50% - 100%), then methanol/chloroform 
(50%)) to give 481 mg (25%) of the desired compound as yellow oil. 1H NMR (400 MHz, CDCl3): 
δ 5.25 (d, J = 5.1 Hz, 1H, NCH), 3.95 − 3.64 (m, 3H, SCH2, NCHA), 3.30 − 3.23 (m, 1H, NCHB), 
2.32 (s, 3H, SCOCH3), 2.24 − 2.21 (m, 1H, NCHCHA), 1.69 − 1.32 (m, 5H, NCHCHBCH2CH2); 
13C NMR (100 MHz, CDCl3): δ 194.6 (SCOCH3), 174.7 (COOH), 168.1 (NCOCH2), 52.5 (NCH), 
44.0 (NCH2), 31.9 (SCH2), 30.0 (CH3COS), 26.3 (NCHCH2), 25.0 (NCH2CH2), 20.6 
(NCHCH2CH2). ESI-MS, m/z: 268 [M + Na]+. HRMS calculated for C10H15NNaO4S 268.0614, 
found 268.0604. 
 
Methyl piperidine-2-carboxylate hydrochloride (2.4.8) 
 
The reaction procedure was carried out as described in the literature.39 Thionyl chloride (1.1 mL) 
was added dropwise to a solution of pipecolinic acid (1.0 g, 7.7 mmol) in methanol (25 mL) at 0°C. 
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The reaction mixture was then heated to reflux for two hours. The excess SOCl2 and methanol were 
then removed under reduced pressure to give 1.4 g (100%) methyl ester hydrochloride salt as a 
white solid. This compound was used in the next step without further purification. m.p. 203.3 – 
203.7°C (lit. 206 – 207°C).79 1H NMR (300 MHz, D2O): δ 4.08 (dd, J = 3.3, 11.6 Hz, 1H, NCH),  
3.87 (s, 3H, OCH3), 3.53 − 3.48 (m, 1H, NCHA), 3.12 − 3.03 (m, 1H, NCHB), 2.35 − 2.30 (m, 1H, 
NCHCHA), 1.94 − 1.65 (m, 5H, NCHCHBCH2CH2), consistent with literature.79 13C NMR (100 
MHz, DMSO): δ 171.8 (COOMe), 58.3 (NCH), 55.1 (OCH3), 27.2 (NCH2CH2), 22.9 (NCHCH2), 
22.8 (NCHCH2CH2). ESI-MS, m/z: 144 [M + H]+. HRMS calculated for C7H14NO2 144.1019, 
found 144.1023. 
 
General procedure for the preparation of the coupled compounds 2.4.9 and 2.4.10 
A mixture of methyl piperidine-2-carboxylate hydrochloride (0.5 g, 2.8 mmol), acetylthio 
compound (1.5 eq.), DIPEA (2.4 ml, 14 mmol) and HBTU (1.6 g, 4.2 mmol) in THF (11 ml) was 
stirred overnight at room temperature. The solvent was then evaporated under reduced pressure and 
ethyl acetate (20 mL) was added to the crude product. The mixture was washed with water (20 mL) 
and brine (2 × 20 mL), dried (Na2SO4) and concentrated under reduced pressure. The crude product 
was purified by column chromatography (ethyl acetate/petroleum ether (30% - 50%) to give a 
yellow oil. 
 
Methyl 1-(3-(acetylthio)propanoyl)piperidine-2-carboxylate (2.4.9) 
 
Yield = 935 mg (100%). 1H NMR (500 MHz, CDCl3): δ 5.34 (d, J = 4.2 Hz, 1H, NCH), 3.75 − 3.69 
(m, 1H, NCHA), 3.70 (s, 3H, COOCH3), 3.23 − 3.18 (m, 1H, NCHB), 3.17 − 3.07 (m, 2H, SCH2), 
2.69 − 2.64 (m, 2H, SCH2CH2), 2.30 (s, 3H, SCOCH3), 2.25 − 2.21 (m, 1H, NCHCHA), 1.74 − 1.57 
(m, 3H, NCHCHBCHACHA), 1.44 − 1.22 (m, 2H, NCHCH2CHBCHB); 13C NMR (125 MHz, 
CDCl3): δ 196.4 (SCOCH3), 171.8 (COOCH3), 171.0 (NCOCH2), 52.2 (COOCH3), 52.0 (NCH), 
43.2 (NCH2), 33.6 (SCHCH2), 30.5 (CH3COS), 26.6 (NCHCH2), 25.2 (NCH2CH2), 24.6 (SCH2), 
20.9 (NCHCH2CH2). ESI-MS, m/z: 296 [M + Na]+. HRMS calculated for C12H19NNaO4S 
296.0927, found 296.0921. 
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Methyl 1-(4-(acetylthio)butanoyl)piperidine-2-carboxylate (2.4.10) 
 
Yield = 792 mg (99%). 1H NMR (500 MHz, CDCl3): δ 5.35 (d, J = 5.4 Hz, 1H, NCH), 3.74 − 3.70 
(m, 1H, NCHA), 3.70 (s, 3H, COOCH3), 3.23 − 3.18 (m, 1H, NCHB), 2.94 − 2.89 (m, 2H, SCH2), 
2.45 − 2.40 (m, 2H, SCH2CH2CH2), 2.31 (s, 3H, SCOCH3), 2.29 − 2.21 (m, 1H, NCHCHA), 1.94 – 
1.88 (m, 2H, SCH2CH2CH2), 1.71 − 1.57 (m, 3H, NCHCHBCHACHA), 1.44 − 1.23 (m, 2H, 
NCHCH2CHBCHB); 13C NMR (125 MHz, CDCl3): δ 195.8 (SCOCH3), 172.1 (COOCH3), 171.9 
(NCOCH2), 52.2 (COOCH3), 51.9 (NCH), 43.3 (NCH2), 32.0 (SCH2CH2CH2), 30.6 (CH3COS), 
28.6 (SCH2), 26.6 (NCHCH2), 25.3 (NCH2CH2), 25.0 (SCH2CH2), 20.9 (NCHCH2CH2). ESI-MS, 
m/z: 310 [M + Na]+. HRMS calculated for C13H21NNaO4S 310.1083, found 310.1084. 
 
General procedure for the hydrolysis of the coupled compounds 2.4.5, 2.4.9 and 2.4.10 
An aqueous solution of 2 M NaOH (1.1 mL, 6 eq.) was added to the coupled compound 2.4.5 (or 
2.4.9 or 2.4.10) (100 mg) in degassed MeOH (1.1 mL) and the mixture was stirred for 2 hours at 
room temperature under argon. The solvent was evaporated under reduced pressure and water (5 
mL) was added to the residue. The mixture was acidified to pH=2 with 2 M HCl, extracted with 
ethyl acetate (5 mL x 3) and dried (Na2SO4). The organic solvent was evaporated under reduced 
pressure to give the desired product. 
 
1-(2-Mercaptoacetyl)piperidine-2-carboxylic acid (2.4.1) 
 
Yellow oil (60 mg, 73%). 1H NMR (500 MHz, CDCl3): δ 5.34 (d, J = 6.5 Hz, 1H, NCH), 3.80 − 
3.62 (m, 3H, SCH2, NCHA), 3.35 − 3.29 (m, 1H, NCHB), 2.31 − 2.28 (m, 1H, NCHCHA), 1.76 − 
1.40 (m, 5H, NCHCHBCH2CH2); 13C NMR (100 MHz, CDCl3): δ 174.7 (COOH), 170.8 
(NCOCH2), 52.3 (NCH), 44.3 (NCH2), 42.5 (SCH2), 26.2 (NCHCH2), 25.0 (NCH2CH2), 20.6 
(NCHCH2CH2). ESI-MS, m/z: 202 [M - H]-. HRMS calculated for C8H12NO3S 202.0543, found 
202.0534. 
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1-(3-Mercaptopropanoyl)piperidine-2-carboxylic acid (2.4.2) 
 
Yellow oil (77 mg, 97%). 1H NMR (500 MHz, CDCl3): δ 5.36 (d, J = 5.2 Hz, 1H, NCH), 3.75 − 
3.73 (m, 1H, NCHA), 3.26 − 3.20 (m, 1H, NCHB), 2.94 − 2.60 (m, 4H, SCH2CH2), 2.29 − 2.27 (m, 
1H, NCHCHA), 1.74 − 1.61 (m, 3H, NCHCHBCHACHA), 1.48 − 1.39 (m, 2H, NCHCH2CHBCHB); 
13C NMR (125 MHz, CDCl3): δ 175.6 (COOH), 171.7 (NCOCH2), 52.0 (NCH), 43.3 (NCH2), 37.5 
(SCHCH2), 26.3 (NCHCH2), 25.1 (NCH2CH2), 20.8 (NCHCH2CH2), 20.0 (SCH2). ESI-MS, m/z: 
240 [M + Na]+. HRMS calculated for C9H15NNaO3S 240.0665, found 240.0658. 
 
 
1-(4-Mercaptobutanoyl)piperidine-2-carboxylic acid (2.4.3) 
 
Yellow oil (86 mg, >100%). 1H NMR (500 MHz, CDCl3): δ 5.36 (d, J = 5.1 Hz, 1H, NCH), 3.79 − 
3.77 (m, 1H, NCHA), 3.26 − 3.21 (m, 1H, NCHB), 2.60 − 2.56 (m, 2H, SCH2), 2.54 − 2.46 (m, 2H, 
SCH2CH2CH2), 2.29 − 2.26 (m, 1H, NCHCHA), 1.95 – 1.91 (m, 2H, SCH2CH2CH2), 1.73 − 1.59 
(m, 3H, NCHCHBCHACHA), 1.49 − 1.32 (m, 2H, NCHCH2CHBCHB); 13C NMR (125 MHz, 
CDCl3): δ 175.8 (COOH), 173.1 (NCOCH2), 51.9 (NCH), 43.5 (NCH2), 31.5 (SCH2CH2CH2), 29.0 
(SCH2CH2), 26.3 (NCHCH2), 25.2 (NCH2CH2), 24.2 (SCH2), 20.8 (NCHCH2CH2). ESI-MS, m/z: 
254 [M + Na]+. HRMS calculated for C10H17NNaO3S 254.0821, found 254.0830. 
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Chapter 3.0  DEVELOPMENTS OF AMINOPYRIDINE DERIVATIVES 
 AS POTENT INHIBITORS OF MBLs 
 
3.1 2-Aminopyridine Derivatives 
 
3.1.1 Introduction 
 
The development of potent inhibitors of MBLs based on L- and D-captopril as the lead compounds 
was reported in the preceding chapters. Both L- and D-captopril competitively inhibit MBLs (see 
Table 2.1.1 in Section 2.1.1 for their potencies against the B1, B2 and B3 MBLs). The key structural 
features of L- and D-captopril such as the thiol, amide carbonyl and carboxylate groups play 
important roles in IMP-1 inhibition as these groups form interactions with the amino acid residues 
in the enzyme’s active site.1, 2 The removal of methyl group at C6 of L- and D-captopril to yield 
compounds 2.1.1 – 2.1.3 improved the inhibition potencies of thiols 2.1.1 – 2.1.3 against IMP-1 
(Chapter 2.1). However, the addition of a longer chain at C1 decreased the potencies of compounds 
2.2.1a-c against IMP-1 (Chapter 2.2). The replacement of the thiol group by a carboxylic acid group 
to give dicarboxylic acids 2.3.1 – 2.3.3 resulted in the loss of inhibition potencies against the 
enzyme (Chapter 2.3). Replacing the five-membered ring of prolines with a six-membered ring and 
maintaining the thiol and chain length at C1 gave compounds 2.4.1 – 2.4.3 with inhibition potencies 
that are comparable to the thiols 2.1.1 – 2.1.3. In this chapter, the development of derivatives of 2-
aminopyridine as inhibitors of IMP-1 is reported.   
 
3.1.2 Results and Discussion 
 
3.1.2.1 Design of Novel Inhibitors 
 
To date, thiols 2.1.1 – 2.1.3 are the most potent inhibitors of IMP-1 out of all synthesised 
compounds in this work. The thiol groups of these compounds were predicted to chelate both zinc 
ions in the IMP-1 enzyme active site to inhibit this enzyme (Section 2.1.2.2). The chelation of both 
metal ions is important for an effective inhibition since the zinc ions are involved in the amide bond 
cleavage of the β-lactam ring in β-lactam antibiotics.3 Therefore, the designed new compounds 
3.1.1 – 3.1.3 also contain thiol groups in their chemical structures (Figure 3.1.1). A pyridine ring 
was included in the structures of these new compounds as the ring was expected to form 
hydrophobic interactions with the hydrophobic regions of the enzyme active site (Trp 64, Val 61, 
Val 67 and Phe 87). Furthermore, the pyridine nitrogen in compound 3.1.4 was reported to 
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coordinate the zinc ion in CphA, a mono-zinc MBL (Figure 3.1.2).4 Compound 3.1.4 is a 
competitive inhibitor of CphA with a Ki value of 4.5 µM.5 Therefore, the combination of thiol 
group and pyridine ring was expected to enhance the inhibition potencies of the new compounds 
3.1.1 – 3.1.3. In addition, the distance between the carboxylate and the thiol groups was increased 
from compound 3.1.1 to 3.1.3 to investigate the effects on the inhibition constants.  
  
 
Figure 3.1.1. New derivatives of 2-aminopyridine.  
 
 
 
Figure 3.1.2. Crystal structure of compound 3.1.4 in the CphA active site showing the interaction of 
the compound through the carboxylate oxygen (red) and pyridine nitrogen (dark blue) with the zinc 
ion (grey sphere) (see ref. 4). 
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3.1.2.2 Computational Modelling 
 
The MVD software was employed to perform the molecular modelling of the newly designed 
compounds bound in the enzyme’s active site. The MolDoc scores generated by this software 
represent the binding affinities of the compounds and the enzyme based on the predicted binding 
interactions. The larger the negative values of the MolDoc scores suggest that the compounds 
would have higher binding affinities (Section 2.1.2.2). The predicted binding interactions could be 
observed from the docking images generated by the software.  
 
Table 3.1.1 shows the MolDoc scores for all the designed compounds 3.1.1 – 3.1.3. There were 
only small differences between the scores of each compound. Therefore it can be concluded that 
these compounds would have comparable binding affinities with the enzyme. There is also a slight 
decrease of the MolDoc score values from compound 3.1.1 to compound 3.1.3 indicating a slight 
increase in the predicted binding affinities and potencies from compound 3.1.1 to compound 3.1.3. 
However, these values are lower than the calculated values of MolDoc score for the thiols 2.1.1 – 
2.1.3. Therefore, the potency of the compounds in this series might be lower than the thiols 2.1.1 – 
2.1.3 reported in Chapter 2.1.       
 
Table 3.1.1. MolDock scores generated by MVD for compounds 3.1.1 – 3.1.3 docked in the IMP-1 
active site. 
Compound MolDoc Score a (kcal/mol) 
3.1.1 -126 
3.1.2 -129 
3.1.3 -132 
a
 Docking score calculated by Molegro Virtual Docker (MVD) software. Larger negative values 
indicate higher binding affinities of inhibitor – IMP-1. 
 
The docking images of compounds 3.1.1 – 3.1.3 are shown in Figures 3.1.3 – 3.1.5. Similar to the 
other thiol compounds discussed in the previous chapters, the sulfur of the thiolate group of 
compound 3.1.1 was predicted to coordinate both zinc ions in the IMP-1 active site (2.0 Å for both 
interactions, Figure 3.1.3). The amide carbonyl oxygen of this compound was predicted to have a 
hydrogen bond interaction with the side chain NH2 of Asn 233 with the O-H distance of 1.7 Å. In 
addition, there are hydrophobic interactions predicted between the pyridine ring of compound 3.1.1 
and Val 61 (distance between pyridine ring and Val 61 side chain: 3.4 Å), and Phe 87 (ring to ring 
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distance 4.3 Å). However, there is no interaction observed between the pyridine nitrogen of this 
compound either with the amino acid residues or the zinc ions of the IMP-1 enzyme. 
  
 
3.1.1 
 
Figure 3.1.3. Docking of compound 3.1.1 into the IMP-1 active site. Colours: Blue – nitrogen; red – 
oxygen; grey – carbon; yellow – sulfur; magenta – Zn ions. 
 
Figure 3.1.4 shows the docking result of compound 3.1.2 in the IMP-1 active site. This compound 
was also predicted to coordinate both zinc ions of the enzyme through its thiolate group (2.0 Å for 
both interactions). A hydrogen bond was also predicted between the amide carbonyl oxygen of 
compound 3.1.2 and the side chain NH2 of Asn 233 with the O-H distance of 3.1 Å. Hydrophobic 
interactions between the pyridine ring of this compound and the enzyme involve Phe 87 (ring to 
ring distance 3.5 Å) and Val 61 (distance between pyridine ring and Val 61 side chain: 4.2 Å). 
Similar to compound 3.1.1, there is no interaction predicted between the pyridine nitrogen and the 
enzyme. 
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3.1.2 
 
Figure 3.1.4. Docking of compound 3.1.2 into the IMP-1 active site. Colours: Blue – nitrogen; red – 
oxygen; grey – carbon; yellow – sulfur; magenta – Zn ions. 
 
Compound 3.1.3 was calculated to have the largest negative value of MolDoc score, thus predicted 
to be the most potent compound against the IMP-1 in this series. Compound 3.1.3 was also 
predicted to coordinate the zinc ions of the enzyme through its thiolate group with 2.0 Å as the 
distances from the sulfur atom of the thiolate to both zinc ions (Figure 3.1.5). Other than that, 
hydrophobic interactions were also predicted between the pyridine ring of this compound and Val 
67 (distance between pyridine ring and Val 67 side chain: 3.1 Å) and the main chain of Trp 64 
(distance between pyridine ring and Trp 64 main chain: 3.4 Å). There was also an addition of a 
hydrophobic interaction predicted between the compound’s alkyl chain and Trp 64 with the CH2 – 
Trp 64 ring distance of 4.2 Å that might contribute to the lowest MolDoc score of compound 3.1.3.  
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3.1.3 
 
Figure 3.1.5. Docking of compound 3.1.3 into the IMP-1 active site. Colours: Blue – nitrogen; red – 
oxygen; grey – carbon; yellow – sulfur; magenta – Zn ions. 
 
In conclusion, the thiolates of the new compounds 3.1.1 – 3.1.3 act similarly as the thiolates in 
thiols 2.1.1 – 2.1.3 in the IMP-1 active site: coordinate to both zinc ions, with the distances of 2.0 Å 
for each interaction. There is no interaction observed in the docking results between the pyridine 
nitrogens of these compounds and amino acid residues of the enzyme. The lack of interactions 
between these compounds and the IMP-1 active site might be the reason of the lower calculated 
MolDoc scores in Table 3.1.1. Compounds 3.1.1 – 3.1.3 were predicted to have lower inhibition 
activities against the IMP-1 compared to the thiols 2.1.1 – 2.1.3 as the calculated MolDoc scores of 
compounds 3.1.1 – 3.1.3 (-126 to -132 kcal/mol) were calculated to be higher compared to the 
MolDoc scores of thiols 2.1.1 – 2.1.3 (-144 to -179 kcal/mol). 
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3.1.2.3 Synthesis 
 
Syntheses of the designed compounds 3.1.1 – 3.1.3 were proposed to be completed by the similar 
methods used for the synthesis of compounds in the previous chapters (Scheme 3.1.1). The coupling 
reaction of the starting material, 2-aminopyridine 3.1.5 and the carboxylic acids would provide the 
coupled compounds 3.1.6 – 3.1.8. Then, the base hydrolysis of the coupled compounds would 
cleave the thioester and yield thiols 3.1.1 – 3.1.3 as the desired final compounds.    
 
 
Scheme 3.1.1. Proposed synthetic methods to prepare compounds 3.1.1 – 3.1.3. 
 
As proposed in Scheme 3.1.1, the coupling reactions of 2-aminopyridine 3.1.5 and the carboxylic 
acids 2.1.5 – 2.1.7 were carried out to synthesise the coupling compounds 3.1.6 – 3.1.8 (Scheme 
3.1.2).6 The overnight reactions in the presence of HBTU and DIPEA in THF gave the coupled 
compounds 3.1.6 – 3.1.8, but in low yields. This might be because of the low reactivity of the 
amino group of 2-aminopyridine 3.1.5 due to the delocalisation of the lone pair of the nitrogen of 
the amino group into the aromatic system. Furthermore, the ability of the nitrogen of the pyridine 
ring to accommodate electron density reduces the nucleophilicity of the amino group, consequently 
resulting in slower coupling reactions. Therefore, most of the HBTU added into the reaction might 
have been degraded due to the basic environment of the reactions, resulting in low production of the 
coupled compounds.7 The formation of the coupled compounds were proved by the addition of 
singlet signals belonging to the SCOCH3 group at 2.3 ppm in the 1H NMR spectra of compounds 
3.1.6 – 3.1.8. Two new signals were also observed in the 13C NMR spectra of compounds 3.1.6 – 
3.1.8 at 195 ppm and around 170 ppm belonging to the carbonyl groups of these compounds 
(SCOCH3 and NCOCH2, respectively). The existence of peaks at m/z 233, 247 and 261 [M + Na]+ 
in the ESI-MS spectra further confirmed the successful syntheses of compounds 3.1.6, 3.1.7 and 
3.1.8, respectively.       
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Scheme 3.1.2. HBTU coupling reaction of 2-aminopyridine and the carboxylic acids. 
 
Next, base hydrolysis of the coupled compounds 3.1.6 – 3.1.8 was carried out by stirring the 
coupled compounds with 2 M NaOH in methanol for two hours. This reaction successfully restored 
the thiol groups and gave the final compounds 3.1.1 – 3.1.3 in good yields. The loss of signals 
attributable to the SCOCH3 groups in the 1H NMR spectra supported the formation of the final 
compounds 3.1.1 – 3.1.3. Furthermore, peaks at m/z 191, 205 and 219 [M + Na]+ in the ESI-MS 
spectra also confirmed the successful hydrolysis reactions.  
 
 
Scheme 3.1.3. Hydrolysis of the coupled compounds 3.1.6 – 3.1.8.  
 
In conclusion, the syntheses of the desired final compounds 3.1.1 – 3.1.3 were successfully 
achieved in two steps reaction via the procedures proposed in Scheme 3.1.1. The coupled products 
3.1.6 – 3.1.8 were synthesised via the HBTU coupling reactions. The cleavage of the thioester 
groups in the coupled compounds were achieved by base hydrolysis of the coupled compounds 
3.1.6 – 3.1.8 and provided the final compounds 3.1.1 – 3.1.3 in good yields.     
 
 3.1.2.4 Kinetic Assays 
 
The results obtained from the screening assay of all synthesised compounds are shown in Table 
3.1.2. From the results, the starting material 3.1.5 and all thioesters (the coupled compounds) 3.1.6 
– 3.1.8 were found to have less than 50% inhibition at the highest compound concentration, 100 
µM. The results indicate that the Ki values of compound 3.1.5 – 3.1.8 would be more than 100 µM 
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against the IMP-1 enzyme. Therefore, these compounds were not further investigated through 
kinetic assays, as the purpose of this study is to develop inhibitors with improved inhibition potency 
against the IMP-1.  
 
As expected for thiol-containing compounds, the final compounds 3.1.1 – 3.1.3 show excellent 
inhibition percentage at 100 µM. Compounds 3.1.2 and 3.1.3 even have good inhibition percentage 
at 10 µM (inhibition percentage more than 50%). For that reason, final compounds 3.1.1 – 3.1.3 
(shaded rows) were considered potent enough to be chosen for further testing against IMP-1 to 
determine their Ki values and modes of inhibition.   
 
Table 3.1.2. Screening results of 2-aminopyridine derivatives against the IMP-1 enzyme. 
 % Inhibition a 
Compounds 100 µM 10 µM 1 µM 
 
2-Aminopyridine 3.1.5 
36 5 2 
 
3.1.6 
28 - - 
 
3.1.7 
37 1 - 
 
3.1.8 
32 - - 
 
3.1.1 
80 24 2 
 
3.1.2 
95 68 13 
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3.1.3 
100 70 15 
a
 - (no value) indicates no inhibition. 
 
The Ki values of the final compounds 3.1.1 – 3.1.3 are shown in Table 3.1.3. All final compounds 
show encouraging inhibition activities against IMP-1 and inhibited the enzyme completely by 
competitive inhibition mode since the uncompetitive inhibition constants, Kiuc values of these 
compounds are very large (mM or M range, data not shown). The kinetic assays provided similar 
results as predicted by the MVD software based on the calculated MolDoc values, where all final 
compounds show comparable inhibition potencies against IMP-1. However, there were no 
improvements in the Ki values of the final compounds 3.1.1 – 3.1.3 compared to the thiols 2.1.1 – 
2.1.3. Similar to the conclusions made in the previous chapters, there is no significant trend in the 
Ki values based on the differences in the distance between the carboxylate and thiol groups, as the 
values were comparable among the final compounds.  
 
Table 3.1.3. Ki values of 2-aminopyridine derivatives against the IMP-1 enzyme. 
Compounds Kic (µM) a 
 
3.1.1 
8.5 ± 3.2 
 
3.1.2 
4.8 ± 0.7 
 
3.1.3 
6.1 ± 0.7 
a Values are mean of duplicate measurements ± SEM. 
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3.1.3 Summary 
 
Three new compounds were designed to develop a series of potent inhibitors against the IMP-1 
based on the combination of encouraging competitive inhibition properties of thiols 2.1.1 – 2.1.3 
and the ability of pyridine nitrogen of compound 3.1.4 to chelate the zinc ion in a monozinc MBL 
CphA. However, the docking images of these newly designed molecules docked into the IMP-1 
enzyme (PDB: 1JJT) using Molegro Virtual Docker (MVD) showed lesser interactions compared to 
the thiols 2.1.1 – 2.1.3. The calculated MolDoc scores of the new compounds also indicate lower 
inhibition potencies compared to thiols 2.1.1 – 2.1.3 reported in Chapter 2.1. Therefore, design of 
the next new inhibitors of IMP-1 should consider the addition of functional groups that can form 
strong interactions with the conserved hydrogen bond donor region of the enzyme (Lys 224, Asn 
233 and Asp 236). Incorporation of hydrophobic groups into the new inhibitor chemical structures 
to create hydrophobic contacts with the enzyme’s conserved hydrophobic region (Val 61, Trp 64, 
Val 67 and Phe 87) could also be considered during the design of new potent inhibitor of IMP-1 
enzyme.8    
 
Synthesis of the designed molecules was completed via two steps reaction: coupling of the 2-
aminopyridine with the carboxylic acids and the base hydrolysis to get the desired final compounds 
with the free thiols.  
 
A total of 7 compounds including the starting material, 2-aminopyridine were tested against the 
IMP-1 enzyme. From the screening assay, all the final compounds with free thiols were selected for 
kinetic assay analysis. All final compounds showed competitive inhibition activity with the Kic 
values ranged from 4.8 ± 0.7 to 8.5 ± 3.2 µM, comparable with the Kic values of the thiols 2.1.1 – 
2.1.3 (Ki = 2.2 ± 0.6 to 9.9 ± 4.2 µM). However, the new compounds with pyridine ring in this 
series were unable to improve the Ki values against the IMP-1 enzyme. 
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3.1.4 Experimental 
 
General procedure for HBTU coupling reaction 
A mixture of 2-aminopyridine (500 mg, 5.3 mmol), acetylthio compound (1.5 eq.), DIPEA (4.6 mL, 
27 mmol) and HBTU (3.0 g, 8.0 mmol) in THF (11 ml) was stirred overnight at room temperature. 
The solvent was then evaporated under reduced pressure and ethyl acetate (20 mL) was added to the 
crude product. The mixture was washed with water (20 mL) and brine (20 mL), dried (Na2SO4) and 
concentrated under reduced pressure. The crude product was purified by column chromatography 
(ethyl acetate/petroleum ether (30%) to give the desired products. 
 
S-(2-Oxo-2-(pyridin-2-ylamino)ethyl) ethanethioate (3.1.6) 
 
Light yellow solid (439 mg, 39%). m.p. 74.7 – 76.3°C. 1H NMR (300 MHz, CDCl3): δ 8.78 (br, 1H, 
NH), 8.29 − 8.27 (m, 1H, NCH), 8.15 (d, J = 8.1 Hz, 1H, NCCH), 7.72 − 7.66 (m, 1H, NCCHCH), 
7.06 − 7.02 (m, 1H, NCHCH), 3.73 (s, 2H, SCH2), 2.44 (s, 3H, SCOCH3); 13C NMR (75 MHz, 
CDCl3): δ 195.4 (SCOCH3), 166.6 (NCOCH2), 151.0 (NCCH), 147.8 (NCH), 138.4 (NCCHCH), 
120.1 (NCHCH), 114.1 (NCCH), 34.1 (SCH2), 30.2 (CH3COS). ESI-MS, m/z: 233 [M + Na]+. 
HRMS calculated for C9H10N2NaO2S 233.0355, found 233.0358. 
 
S-(3-Oxo-3-(pyridin-2-ylamino)propyl) ethanethioate (3.1.7) 
 
Yellow hygroscopic solid (380 mg, 32%). 1H NMR (400 MHz, CDCl3): δ 8.89 (br, 1H, NH), 8.25 − 
8.22 (m, 2H, NCH, NCCH), 7.80 − 7.71 (m, 1H, NCCHCH), 7.08 − 7.05 (m, 1H, NCHCH), 3.22 
(t, J = 6.9 Hz, 2H, SCH2), 2.74 (t, J = 6.8 Hz, 2H, SCH2CH2), 2.33 (s, 3H, SCOCH3); 13C NMR 
(100 MHz, CDCl3): δ 195.8 (SCOCH3), 169.6 (NCOCH2), 151.1 (NCCH), 147.0 (NCH), 139.0 
(NCCHCH), 119.8 (NCHCH), 114.4 (NCCH), 37.2 (SCH2CH2), 30.6 (CH3COS), 24.3 (SCH2). 
ESI-MS, m/z: 247 [M + Na]+. HRMS calculated for C10H12N2NaO2S 247.0512, found 247.0503. 
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S-(4-Oxo-4-(pyridin-2-ylamino)butyl) ethanethioate (3.1.8) 
 
Yellow oil (1.00 g, 82%). 1H NMR (400 MHz, CDCl3): δ 8.85 (br, 1H, NH), 8.25 − 8.22 (m, 2H, 
NCH, NCCH), 7.75 − 7.70 (m, 1H, NCCHCH), 7.06 − 7.03 (m, 1H, NCHCH), 2.97 (t, J = 7.0 Hz, 
2H, SCH2), 2.49 (t, J = 7.3 Hz, 2H, SCH2CH2CH2), 2.34 (s, 3H, SCOCH3), 2.02 (p, J = 7.2 Hz, 2H, 
SCH2CH2CH2); 13C NMR (100 MHz, CDCl3): δ 195.9 (SCOCH3), 170.9 (NCOCH2), 151.3 
(NCCH), 147.0 (NCH), 138.9 (NCCHCH), 119.7 (NCHCH), 114.3 (NCCH), 35.9 
(SCH2CH2CH2), 30.6 (CH3COS), 28.3 (SCH2), 25.2 (SCH2CH2). ESI-MS, m/z: 261 [M + Na]+. 
HRMS calculated for C11H14N2NaO2S 261.0668, found 261.0668. 
 
General procedure for base hydrolysis  
An aqueous solution of NaOH (2 M, 3 eq.) was added to the coupled product (0.1 g) in MeOH (1 
mL) and the mixture was stirred for 2 hours at room temperature under argon. The solvent was 
evaporated under reduced pressure and water (5 mL) was added to the residue. The pH of water 
layer was reduced to pH=7 with 2 M HCl and extracted with ethyl acetate (5 mL x 3). The 
combined organic layers were washed with water (5 mL) and dried (Na2SO4). The organic solvent 
was evaporated under reduced pressure to give the desired product. 
 
2-Mercapto-N-(pyridin-2-yl)acetamide (3.1.1) 
 
Light yellow hygroscopic solid (67 mg, 84%). 1H NMR (500 MHz, CDCl3): δ 9.08 (br, 1H, NH), 
8.31 − 8.30 (m, 1H, NCH), 8.19 (d, J = 8.3 Hz, 1H, NCCH), 7.74 − 7.71 (m, 1H, NCCHCH), 7.09 
− 7.06 (m, 1H, NCHCH), 3.41 (d, J = 8.4 Hz, 2H, SCH2), 2.07 (t, J = 9.0 Hz, 1H, SH); 13C NMR 
(100 MHz, CDCl3): δ 167.9 (NCOCH2), 150.9 (NCCH), 147.9 (NCH), 138.5 (NCCHCH), 120.2 
(NCHCH), 113.9 (NCCH), 29.3 (SCH2). ESI-MS, m/z: 191 [M + Na]+. HRMS calculated for 
C7H8N2NaOS 191.0250, found 191.0249. 
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3-Mercapto-N-(pyridin-2-yl)propanamide (3.1.2) 
 
Yellow oil (61 mg, 74%). 1H NMR (500 MHz, CDCl3): δ 8.50 (br, 1H, NH), 8.28 − 8.27 (m, 1H, 
NCH), 8.22 (d, J = 8.4 Hz, 1H, NCCH), 7.73 − 7.70 (m, 1H, NCCHCH), 7.07 − 7.04 (m, 1H, 
NCHCH), 2.90 (dt, J = 6.7, 8.2 Hz, 2H, SCH2), 2.73 (t, J = 6.6 Hz, 2H, SCH2CH2), 1.70 (t, J = 8.4 
Hz, 1H, SH); 13C NMR (100 MHz, CDCl3): δ 169.4 (NCOCH2), 151.2 (NCCH), 147.7 (NCH), 
138.5 (NCCHCH), 119.9 (NCHCH), 114.2 (NCCH), 41.3 (SCH2CH2), 19.9 (SCH2). ESI-MS, m/z: 
205 [M + Na]+. HRMS calculated for C8H10N2NaOS 205.0406, found 205.0396. 
 
4-Mercapto-N-(pyridin-2-yl)butanamide (3.1.3) 
 
Colorless oil (50 mg, 60%). 1H NMR (500 MHz, CDCl3): δ 8.91 (br, 1H, NH), 8.27 − 8.25 (m, 1H, 
NCH), 8.24 (d, J = 8.5 Hz, 1H, NCCH), 7.76 − 7.73 (m, 1H, NCCHCH), 7.08 − 7.05 (m, 1H, 
NCHCH), 2.64 (dt, J = 7.0, 8.0 Hz, 2H, SCH2), 2.58 (t, J = 7.0 Hz, 2H, SCH2CH2CH2), 2.05 (p, J = 
7.0 Hz, 2H, SCH2CH2), 1.37 (t, J = 8.0 Hz, 1H, SH); 13C NMR (100 MHz, CDCl3): δ 170.9 
(NCOCH2), 151.1 (NCCH), 146.8 (NCH), 139.1 (NCCHCH), 119.8 (NCHCH), 114.2 (NCCH), 
35.7 (SCH2CH2CH2), 29.0 (SCH2CH2), 24.0 (SCH2). ESI-MS, m/z: 219 [M + Na]+. HRMS 
calculated for C9H12N2NaOS 219.0563, found 219.0570. 
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3.2 2-Amino-6-picolinic Acid Derivatives 
 
3.2.1 Introduction 
 
The most potent compounds (against the IMP-1) synthesised in this work are thiols 2.1.1 – 2.1.3 
(Chapter 2.1). In Chapter 3.1, incorporating a pyridine ring and a thiol group in the same compound 
produced a series of products (compounds 3.1.1 – 3.1.3) with comparable inhibition potencies with 
thiols 2.1.1 – 2.1.3. The docking images of compounds 3.1.1 – 3.1.3 exhibit lack of interactions of 
these compounds with the IMP-1 active site residues compared to previous series, especially thiols 
2.1.1 – 2.1.3. The next new compounds needed a functional group that can form strong interactions 
with the amino acid residues in the IMP-1 active site, consequently leading to high inhibition 
potencies against IMP-1.  
 
3.2.2 Results and Discussion 
 
3.2.2.1 Design of Novel Inhibitors 
 
The addition of a carboxylate group to compounds 3.1.1 – 3.1.3 would be expected to increase the 
interactions of these compounds with the hydrogen bond donor amino acids in the IMP-1 active site 
(Lys 224, Asn 233, Cys 221), resulting in enhanced inhibition potencies against the enzyme. 
Furthermore, the docking studies of the thiols 2.1.1 – 2.1.3 revealed that these compounds were 
predicted to have electrostatic interactions with IMP-1 through the oxygens of the carboxylate to 
the NH3+ group of Lys 224, SH group of Cys 221 and zinc ions (Section 2.1.2.2). The crystal 
structure of D-captopril 1.38b bound in the dizinc metalloenzyme BlaB active site, also proved that 
the carboxylate group oxygens of D-captopril 1.38b bound to the NH3+ group of Lys 167 and NH2 
group of Asp 119 (Section 2.1.1).1 Therefore, a series of new compounds 3.2.1 – 3.2.3 with the 
combination of pyridine ring, thiol and carboxylate groups was designed to be synthesised and 
tested against the IMP-1 (Figure 3.2.1). Similar to the previous compounds, the distance between 
the thiol and carboxylate groups of compounds 3.2.1 – 3.2.3 were systematically varied to 
investigate its effects on the inhibition activities. Molecular docking of these new compounds was 
also performed using the MVD software and the results are discussed in this chapter (Section 
3.2.1.2). 
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Figure 3.2.1. New derivatives of 2-amino-6-picolinic acid. 
 
3.2.2.2 Computational Modelling 
 
As expected, the calculated MolDoc scores of compounds 3.2.1 – 3.2.3 was successfully decreased 
from the MolDoc scores calculated for compounds 3.1.1 – 3.1.3 (Table 3.2.1). The results in Table 
3.2.1 suggest that there were additional interactions predicted between these compounds and the 
enzyme (Figures 3.2.2 – 3.2.4. These additional interactions will be discussed later in this section). 
The MolDoc score of compound 3.2.1 calculated by the MVD was decreased to -137 kcal/mol from 
-126 kcal/mol of compound 3.1.1. Similarly, the MolDoc scores of compounds 3.2.2 and 3.2.3 were 
predicted to decrease from -129 (compound 3.1.2) and -132 (compound 3.1.3) kcal/mol to -142 and 
-146 kcal/mol, respectively. The decreased MolDoc scores means compounds 3.2.1 – 3.2.3 were 
predicted to have higher inhibition potency against IMP-1 than compounds 3.1.1 – 3.1.3. There 
were only slight differences in the MolDoc scores between compounds 3.1.1 – 3.1.3, but compound 
3.2.3 was calculated to have the lowest MolDoc score, so was predicted to be the most potent 
compound against IMP-1 in this series. However, these values are still higher than the calculated 
values for thiols 2.1.1 -2.1.3 (Chapter 2.1).          
 
Table 3.2.1. MolDock scores generated by MVD for compounds 3.2.1 – 3.2.3 docked in the IMP-1 
active site. 
Compound MolDoc Scorea (kcal/mol) 
3.2.1 -137 
3.2.2 -142 
3.2.3 -146 
a
 Docking score calculated by Molegro Virtual Docker (MVD) software. Larger negative values 
indicate higher binding affinities of inhibitor – IMP-1. 
 
The interactions between compound 3.2.1 and the enzyme’s active site were predicted to be similar 
to those observed in the docking image of compound 3.1.1 bound in the IMP-1 active site (Figure 
3.2.2). The thiol group of compound 3.2.1 was predicted coordinate both zinc ions with 2.0 Å as the 
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distance for each interaction. The oxygen of amide carbonyl of this compound was predicted to 
form a hydrogen bond with the side chain NH2 of Asn 233 with the O-H distance of 2.6 Å. In 
addition to these interactions, there was another hydrogen bond predicted between the carboxylate 
oxygen of Asp 120 and the NH group of compound 3.2.1 (O-H distance 2.4 Å). There were also 
hydrophobic interactions predicted between the pyridine ring of compound 3.2.1 and the 
hydrophobic region of the enzyme lined by Phe 87 (pyridine ring – Phe 87 ring distance 2.7 Å), Val 
67 (pyridine ring – Val 67 backbone C chain distance 3.6 Å) and Val 61 (pyridine ring – Val 61 
backbone C chain distance 3.3 Å). However, there was no interaction predicted between compound 
3.2.1 and IMP-1 active site through the newly incorporated carboxylate group in the docking image 
of compound 3.2.1 – IMP-1 complex. 
 
3.2.1 
 
Figure 3.2.2. Docking result of compound 3.2.1 in the IMP-1 active site. Colours: Blue – nitrogen; 
red – oxygen; grey – carbon; yellow – sulfur; magenta – Zn ions. 
 
Compound 3.2.2 was predicted to have comparable interactions with the enzyme’s active site where 
the thiol group of this compound was coordinated to both zinc ions with distances of 2.0 and 1.9 Å 
(Figure 3.2.3). Instead of an interaction through the amide carbonyl, this compound was predicted 
to have a hydrogen bond between the pyridine nitrogen and the backbone NH of Asn 233 (N-H 
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distance 2.3 Å). Although there were no interactions observed between the amide carbonyl or 
pyridine ring (hydrophobic part) of compound 3.2.2 and the active site residue, the MolDoc score of 
this compound (-142 kcal/mol) was calculated to be lower compared to compound 3.1.2 (-129 
kcal/mol). This might be because of the additional interactions formed between the pyridine 
nitrogen of compound 3.2.2 and the Asn 233 (which is absent in compound 3.1.2 – IMP-1 complex) 
and the slightly nearer distance of the thiol group of this compound to one of the zinc ions (1.9 Å), 
thus contributing in the increased predicted binding affinity of compound 3.2.2 with the enzyme’s 
active site. Similar to compound 3.2.1, there was no predicted interaction between compound 3.2.2 
and IMP-1 active site through the carboxylate group since this moiety was positioned away from 
any hydrogen bond donor region in the enzyme’s active site as displayed in Figure 3.2.3. 
  
 
3.2.2 
 
Figure 3.2.3. Docking result of compound 3.2.2 in the IMP-1 active site. Colours: Blue – nitrogen; 
red – oxygen; grey – carbon; yellow – sulfur; magenta – Zn ions. 
 
With the calculated MolDoc score of -146 kcal/mol, compound 3.2.3 was predicted to be the most 
potent compound in this series. Furthermore, the MolDoc score of this compound was calculated to 
be lower than compound 3.1.3, which lack of one carboxylate group (-132 kcal/mol). Similar to 
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compounds 3.2.1 and 3.2.2, compound 3.2.3 was also predicted to interact with both zinc ions of the 
enzyme’s active site (S-Zn2+ distances 2.0 and 3.2 Å). The carboxylate oxygens of compound 3.2.3 
were predicted to have three electrostatic interactions with the enzyme’s active site: one with the 
zinc ion (3.3 Å) and two with the NH3+ of Lys 224 (O-N distances 2.3 Å for both interactions). 
There was only one hydrophobic interaction predicted between the pyridine ring of compound 3.2.3 
and Trp 64 with the ring to ring distance of 3.4 Å. The additional interactions exist between the 
carboxylate of this compound and the active site of IMP-1 might be the reason of the high binding 
affinity predicted by the MVD software.   
 
 
3.2.3 
 
Figure 3.2.4. Docking result of compound 3.2.3 in the IMP-1 active site. Colours: Blue – nitrogen; 
red – oxygen; grey – carbon; yellow – sulfur; magenta – Zn ions. 
 
In conclusion, compounds 3.2.1 – 3.2.3 (with carboxylate group) were calculated to have lower 
MolDoc scores compared to their corresponding compounds 3.1.1 – 3.1.3. However, the MolDoc 
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scores for compounds 3.2.1 – 3.2.3 are still higher than the MolDoc scores for thiols 2.1.1 – 2.1.3. 
All compounds (compounds 3.2.1 – 3.2.3 and compounds 3.1.1 – 3.1.3) have a thiol group, which 
coordinates both zinc ions of the enzyme for an effective inhibition.3 Nevertheless, compound 3.2.2 
was the only compound observed to have predicted interaction with the IMP-1 through its pyridine 
nitrogen. Then, only compound 3.2.3 was predicted to have interactions through its carboxylate 
group with the enzyme’s active site.        
 
3.2.2.3 Synthesis 
 
Scheme 3.2.1 shows the proposed synthetic route to compounds 3.2.1 – 3.2.3. Acetylation of 2-
amino-6-picoline was expected to give compound 3.2.5.9 Next, oxidation of compound 3.2.5 by 
potassium permanganate followed by protection of the free carboxylic acid as a methyl ester with 
concurrent cleavage of the amide would yield compound 3.2.6.10, 11 Coupling of compound 3.2.6 
with carboxylic acids would afford the coupled compounds 3.2.7 – 3.2.9.6 Finally, the synthesis of 
compounds 3.2.1 – 3.2.3 would be achieved by base hydrolysis of the coupled compounds 3.2.7 – 
3.2.9.     
 
 
Scheme 3.2.1. Proposed synthetic route to compounds 3.2.1 – 3.2.3. 
 
N N
H
O
S
O
N N
H
O
SH
HBTU coupling
O
SHO
O
Base hydrolysis
3.2.7: n = 1
3.2.8: n = 2
3.2.9: n = 3
3.2.1: n = 1
3.2.2: n = 2
3.2.3: n = 3
n
n
n
N NH2 N NH
O
N NH2.HCl
MeO
O
1. KMnO4, H2O
2. SOCl2, MeOH
MeO
O
HO
O
2-amino-6-picoline
3.2.4 3.2.5
3.2.6
Ac2O
 163 
The acetylation of 2-amino-6-picoline 3.2.4 was successfully achieved by stirring the starting 
material 3.2.4 with acetic anhydride in toluene at room temperature (Scheme 3.2.2).9 The overnight 
stirring of the reaction mixture in the presence of zinc chloride afforded the acetamide 3.2.5 in a 
good yield. The successful synthesis of compound 3.2.5 was confirmed by the addition of a singlet 
signal at 2.16 ppm (NCOCH3) in the 1H NMR spectrum of this compound. The signals observed in 
the 1H NMR spectra of compound 3.2.5 were consistent with the signals reported by Zafar et al.12 
Compound 3.2.5 was then reacted with potassium permanganate at 75°C using a standard procedure 
to produce a quantitative yield of the crude carboxylic acid 3.2.10.10 The crude 3.2.10 was used 
directly for the methylation reaction using thionyl chloride in methanol to give methyl ester 3.2.6.11 
The same reaction also cleaved the amide bond present in compound 3.2.10. The loss of the 
NCOCH3 singlet signal and the addition of a new singlet signal at 3.97 ppm in the 1H NMR 
spectrum that belonged to the metoxy group proved the successful formation of the methyl ester 
3.2.6. The pilot reactions to optimise the conditions for the three steps reaction (showed in Scheme 
3.2.2) to obtain the methyl ester 3.2.4 were performed by Camille Pratlong and Daniel Tan in the 
McGeary group. 
 
Scheme 3.2.2. Synthesis of compound 3.2.6 in three steps from 2-amino-6 picoline 3.2.4. 
 
Compound 3.2.6 was then reacted with carboxylic acids 2.1.5 – 2.1.7 to synthesise the coupled 
compounds 3.2.7 – 3.2.9 via HBTU coupling (Scheme 3.2.3).6 The overnight reactions at room 
temperature produced the desired coupled compounds in low yields. The reason might be similar to 
the low productions of the coupled compounds 3.1.6 – 3.1.8, which resulted from less reactive 
amino group of ethyl ester 3.2.6 (Section 3.1.2.3). The formation of the coupled compounds 3.2.7 – 
3.2.9 were confirmed with the obvious addition of a singlet signal at 2.3 ppm belonging to the 
SCOCH3 group in the 1H NMR spectra of these coupled compounds. Peaks at m/z 291, 305 and 319 
[M + Na]+ in the ESI-MS analyses also proved the successful formation of amide bonds in the 
coupled compounds 3.2.7, 3.2.8 and 3.2.9, respectively.  
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Scheme 3.2.3. HBTU coupling of compound 3.2.6 and the carboxylic acids. 
 
The coupled compounds 3.2.7 – 3.2.9 were subjected to base hydrolysis reactions to cleave the 
thioester and methyl ester groups of these compounds, consequently giving the final products 3.2.1 
– 3.2.3. The absence of signals attributable to both SCOCH3 and COOCH3 groups in the 1H NMR 
spectra marked the successful cleavage of the esters of compounds 3.2.7 – 3.2.9. The peaks at m/z 
211 [M - H]- of compound 3.2.1, 225 [M - H]- of compound 3.2.2 and 239 [M - H]- of compound 
3.2.3 in the ESI-MS spectra further confirmed the success of this reaction. The yields of these final 
compounds 3.2.1 – 3.2.3 were also low, which was thought to be due to the high polarity of the 
compounds, making it difficult to extract them from the aqueous layers during the work up 
processes.   
 
 
Scheme 3.2.4. Hydrolysis of the coupled compounds to yield final compounds 3.2.1 – 3.2.3. 
 
In conclusion, the final compounds 3.2.1 – 3.2.3 were obtained in five steps involving acetylation of 
2-amino-6-picoline, followed by oxidation, methylation and amide cleavage of compound 3.2.5, to 
afford compound 3.2.6. The coupling reactions between compound 3.2.6 and the carboxylic acids 
2.1.5 – 2.1.7 gave the coupled compounds 3.2.7 – 3.2.9. The syntheses of the final compounds 3.2.1 
– 3.2.3 were achieved by hydrolysis of the coupled compounds using 2 M NaOH. 
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3.2.2.4 Kinetic Assays  
 
A screening assay was conducted on all compounds available in this series, including the starting 
material, 2-amino-6-picoline 3.2.4. The results of the screening assay are shown in Table 3.2.2. 
Compounds 3.2.4 – 3.2.8 moderately inhibit IMP-1 at the highest compound concentration tested 
(100 µM). The coupled compounds 3.2.7 and 3.2.8 with thioester groups might be hydrolysed in the 
IMP-1 active site, subsequently inhibiting the enzyme by the corresponding thiols produced from 
the thioesters’ hydrolysis.13, 14 However, further testing of compounds 3.2.4 – 3.2.8 were halted 
since their inhibition percentages are less than 50% at 100 µM, thus suggesting their Ki values 
would be more than 100 µM (see Section 3.1.2.4). Compound 3.2.9 shows very low inhibition 
percentage at 100 µM and no inhibition at all at 10 and 1 µM.  
 
In contrast, all thiol compounds (final products 3.2.1 – 3.2.3) show excellent inhibition percentages 
at 100 µM and moderate inhibition percentages at 10 µM. Therefore, further testing of compounds 
3.2.1 – 3.2.3 were carried out to determine their inhibition potencies and inhibition modes. 
 
Table 3.2.2. Screening results of 2-amino-6-picoline derivatives against IMP-1. 
 % Inhibition a 
Compounds 100 µM 10 µM 1 µM 
 
2-amino-6-picoline 3.2.4 
47 1 - 
 
3.2.5 
35 4 2 
 
3.2.6 
19 2 - 
 
3.2.7 
46 6 - 
N NH2
N N
H
O
N NH2
MeO
O
N N
H
O
S
O
MeO
O
 166 
 
3.2.8 
49 14 3 
 
3.2.9 
2 - - 
 
3.2.1 
93 31 7 
 
3.2.2 
93 27 - 
 
3.2.3 
100 43 10 
a
 - (no value) indicates no inhibition. 
 
The Ki values of compounds 3.2.1 – 3.2.3 determined from the kinetic assays are shown in Table 
3.2.3. All compounds 3.2.1 – 3.2.3 show weaker inhibition potencies against IMP-1 (9.7 ± 4.0 to 31 
± 4 µM) than compounds 3.1.1 – 3.1.3 from the 2-aminopyridine series (4.8 ± 0.7 to 8.5 ± 3.2 µM). 
Therefore, the additional carboxylate group did not enhance the inhibition potencies of the new 
compounds. However, the MVD software predicted the opposite where compounds 3.2.1 – 3.2.3 
were calculated to have higher binding affinities compared to compounds 3.1.1 – 3.1.3 (Section 
3.2.2.2). As discussed in Chapter 2.1, the computational docking results were only predictions of 
the binding interactions and binding affinities of the inhibitor molecules in the enzyme active site. 
Therefore, the binding interactions predicted by MVD for compounds 3.2.1 – 3.2.3 might not 
accurately reflect the binding interactions in the inhibitor – enzyme complexes. 15, 16  
 
Similar to compounds 3.1.1 – 3.1.3, compounds 3.2.1 – 3.2.3 inhibited the IMP-1 solely by 
competitive inhibition mode. Although there are only slight differences in the Ki values, compound 
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3.2.3 with the farthest distance between thiol and carboxylate groups has the lowest Ki value among 
the compounds tested in this series (9.7 ± 4.0 µM).           
 
Table 3.2.3. Ki values of 2-amino-6-picoline derivatives against IMP-1 enzyme. 
Compounds Kic (µM) a 
 
3.2.1 
31 ± 4 
 
3.2.2 
17 ± 10 
 
3.2.3 
9.7 ± 4.0 
a Values are mean of duplicate measurements ± SEM. 
 
3.2.3 Summary 
 
New compounds of 2-amino-6-picoline derivatives (compounds 3.2.1 – 3.2.3) were designed 
based on the expectation that the addition of a carboxylate group to 2-aminopyridine derivatives 
3.1.1 – 3.1.3 would increase strong interactions with the IMP-1 enzyme active site residues, 
consequently enhancing the enzyme inhibition potencies. As expected, the MVD software 
predicted lower MolDoc scores, suggesting stronger inhibition potencies for the newly designed 
compounds 3.2.1 – 3.2.3 compared to 2-aminopyridine derivatives 3.1.1 – 3.1.3. 
 
There were three additional steps involved to incorporate a carboxylic acid group into 2-
aminopyridine derivatives 3.1.1 – 3.1.3 to synthesis the new compounds. 2-Amino-6-picoline was 
first acylated, oxidised and methylated to yield the methyl ester 3.2.6. The HBTU coupling of the 
methyl ester 3.2.6 afforded the coupled compounds 3.2.7 – 3.2.9 in low yields. Lastly, the base 
hydrolysis of the coupled compounds gave the final compounds 3.2.1 – 3.2.3. 
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All final compounds 3.2.1 – 3.2.3 were selected for further testing against IMP-1 enzyme based on 
their excellent inhibition percentage at 100 µM. These compounds show competitive inhibition 
mode with the Kic values ranging from 9.7 ± 4.0 to 31 ± 4 µM. However, these values indicate 
weaker inhibition potencies than 2-aminopyridine derivatives 3.1.1 – 3.1.3 with the Kic values of 
4.8 ± 0.7 to 8.5 ± 3.2 µM.  
 
 
3.2.4 Experimental 
 
N-(6-Methylpyridin-2-yl)acetamide (3.2.5) 
 
The reaction procedure was carried out as described in the literature.9 Acetic anhydride (48 mL, 
0.50 mol) was carefully added to a solution of 2-amino-6-picoline (28 g, 0.30 mol) and ZnCl2 (2.1 
g, 0.02 mol) in toluene (500 mL) at 0°C and stirred for 30 minutes. Stirring was continued 
overnight at room temperature. The solvent was removed under reduced pressure and the residue 
was dissolved in chloroform (500 mL). The organic layer was washed with aqueous saturated 
sodium bicarbonate solution (250 mL × 2) and brine (250 mL × 2) then dried (Na2SO4). The 
organic solvent was removed under reduced pressure. Recrystallisation of the residue from 
petroleum ether and ethyl acetate afforded 23 g (61%) of the desired product as a white solid. m.p. 
87.8 – 90.0°C (lit. 87 - 88°C).17 1H NMR (500 MHz, CDCl3): δ 8.06 (br, s, 1H, NH), 7.97 (d, J = 
8.0 Hz, 1H, H3), 7.57 (t, J = 8.0 Hz, 1H, H4), 6.87 (d, J = 8.0 Hz, 1H, H5), 2.42 (s, 3H, CH3), 2.16 
(s, 3H, NCOCH3), consistent with literature.12  
 
Methyl 6-aminopicolinate hydrochloride (3.2.6) 
 
The reaction procedure was carried out as described in the literature.10 A solution of compound 
3.2.5 (23 g, 0.20 mol) in water (200 mL) was heated at 75°C until dissolved completely. Potassium 
permanganate (122 g, 0.80 mol) was added in small portions over 75 minutes while stirring 
vigorously. The reaction mixture was stirred at 75°C for three hours. Later, additional potassium 
permanganate (61 g, 0.40 mol) was added to the mixture and stirring was continued overnight at 
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75°C. The reaction mixture was filtered through celite while still hot and rinsed with boiling water. 
The filtrate was concentrated to about 50 mL with the rotary evaporator and pH of the solution was 
adjusted to 4-5 with concentrated HCl. Water was then removed under reduced pressure to give 30g 
of the crude carboxylic acid and inorganic salts as a white solid. The carboxylic acid was dissolved 
in methanol (200 mL) and thionyl chloride (90 mL, 1.2 mol) was added dropwise to the solution at 
room temperature.11 Then, the reaction mixture was heated to reflux overnight. The excess thionyl 
chloride and methanol were removed under reduced pressure. Dichloromethane (100 mL) and water 
(100 mL) were then added to the residue. Solid sodium bicarbonate was added to the two layer 
solution until gas evolution ceased. The organic layer was separated, dried (Na2SO4) and 
concentrated. The crude product was purified by column chromatography (ethyl 
acetate/dichloromethane (30% - 70%) to afford 4.7 g (16%) of compound 3.2.5 as light yellow 
solid. m.p. 91.5 – 92.6°C (lit. 88 – 91.5°C).18 1H NMR 400 MHz, CDCl3): δ 7.58 (dd, J = 7.4, 0.8 
Hz, 1H, H4), 7.48 (dd, J = 7.4, 0.8 Hz, 1H, H3), 6.78 (d, J = 7.4 Hz, 1H, H5), 5.21 (br, s, 2H, NH), 
3.97 (s, 3H, OCH3), consistent with literature.10  
 
General procedure for HBTU coupling reaction 
A mixture of compound 3.2.6 (0.50 g, 2.7 mmol), acetylthio compound (1.5 eq.), DIPEA (5.7 ml, 
33 mmol) and HBTU (1.9 g, 4.9 mmol) in THF (11 ml) was stirred overnight at room temperature. 
The solvent was then evaporated under reduced pressure and ethyl acetate (20 mL) was added to the 
crude product. The mixture was washed with water (20 mL), saturated sodium bicarbonate (20 mL 
x 2) and brine (20 mL), dried (Na2SO4) and concentrated under reduced pressure. The crude product 
was purified by column chromatography (silica gel, ethyl acetate/petroleum ether (20% - 40%) to 
give the desired products. 
 
Methyl 6-(2-(acetylthio)acetamido)picolinate (3.2.7) 
 
Yellow hygroscopic solid (164 mg, 23%). 1H NMR (500 MHz, CDCl3): δ 8.71 (br, s, 1H, NH), 8.39 
(dd, J = 1.9, 7.3 Hz, 1H, H3), 7.88 − 7.83 (m, 2H, H5 and H4), 3.99 (s, 3H, COOCH3), 3.75 (s, 2H, 
SCH2), 2.44 (s, 3H, SCOCH3); 13C NMR (125 MHz, CDCl3): δ 194.6 (SCOCH3), 166.8 
(NCOCH2), 165.0 (COOCH3), 150.9 (C2), 145.9 (C6), 139.5 (C4), 121.5 (C5), 117.9 (C3), 53.0 
(COOCH3), 34.1 (SCH2), 30.3 (SCOCH3). ESI-MS, m/z: 291 [M + Na]+. HRMS calculated for 
C11H12N2NaO4S 291.0410, found 291.0413. 
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Methyl 6-(3-(acetylthio)propanamido)picolinate (3.2.8) 
 
White solid (100 mg, 13%). m.p. 121.1 – 122.9°C. 1H NMR (400 MHz, CDCl3): δ 8.43 (t, J = 4.6, 
1H, H3), 8.37 (br, s, 1H, NH), 7.89 – 7.84 (m, 2H, H5 and H4), 3.99 (s, 3H, COOCH3), 3.21 (t, J = 
6.7, 2H, SCH2), 2.72 (t, J = 6.7, 2H, SCH2CH2), 2.34 (s, 3H, SCOCH3); 13C NMR (100 MHz, 
CDCl3): δ 195.6 (SCOCH3), 169.9 (NCOCH2), 164.7 (COOCH3), 150.9 (C2), 145.3 (C6), 139.9 
(C4), 121.2 (C5), 118.0 (C3), 53.1 (COOCH3), 37.2 (SCH2CH2), 30.6 (SCOCH3), 24.2 (SCH2). 
ESI-MS, m/z: 305 [M + Na]+. HRMS calculated for C12H14N2NaO4S 305.0566, found 305.0570. 
 
Methyl 6-(4-(acetylthio)butanamido)picolinate (3.2.9) 
 
Yellow hygroscopic solid (179 mg, 23%). 1H NMR (500 MHz, CDCl3): δ 8.44 (dd, J = 2.1, 7.0 Hz, 
1H, H3), 7.89 − 7.85 (m, 2H, H5 and H4), 3.99 (s, 3H, COOCH3), 2.96 (t, J = 7.2 Hz, 2H, SCH2), 
2.49 (t, J = 7.2 Hz, 2H, SCH2CH2CH2), 2.34 (s, 3H, SCOCH3), 2.01 (p, J = 7.2 Hz, 2H, SCH2CH2); 
13C NMR (100 MHz, CDCl3): δ 195.6 (SCOCH3), 171.2 (NCOCH2), 164.8 (COOCH3), 151.1 
(C2), 145.3 (C6), 139.8 (C4), 121.1 (C5), 117.9 (C3), 53.1 (COOCH3), 35.9 (SCH2CH2CH2), 30.6 
(SCOCH3), 28.2 (SCH2), 24.9 (SCH2CH2). ESI-MS, m/z: 319 [M + Na]+. HRMS calculated for 
C13H16N2NaO4S 319.0723, found 319.0732. 
 
General procedure for base hydrolysis  
An aqueous solution of NaOH (2 M, 6 eq.) was added to the coupled product (50 mg) in degassed 
MeOH (0.60 mL) and the mixture was stirred for 2 hours at room temperature under argon. The 
solvent was evaporated under reduced pressure and water (2.5 mL) was added to the residue. The 
pH of water layer was reduced to pH=2 with 2 M HCl and extracted with dichloromethane (3 mL x 
2) and dried (Na2SO4). The organic solvent was evaporated under reduced pressure to give the 
desired product. 
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6-(2-Mercaptoacetamido)picolinic acid (3.2.1) 
 
White solid (19 mg, 47%). m.p. 166.4 – 168.6°C. 1H NMR (400 MHz, MeOD): δ 8.33 (br, d, J = 
7.6 Hz, 1H, H3), 7.95 (dd, J = 7.6, 0.8 Hz, 1H, H4), 7.87 (dd, J = 7.6, 0.8 Hz, 1H, H5), 3.39 (s, 2H, 
SCH2); 13C NMR (100 MHz, MeOD): δ 172.1 (NCOCH2), 167.7 (NCCOOH), 152.9 (C2), 147.8 
(C6), 140.8 (C4), 122.0 (C5), 118.8 (C3), 29.3 (SCH2). ESI-MS, m/z: 211 [M - H]-. HRMS 
calculated for C8H7N2O3S 211.0183, found 211.0188. 
 
6-(3-Mercaptopropanamido)picolinic acid (3.2.2) 
 
White hygroscopic solid (11 mg, 33%). 1H NMR (400 MHz, MeOD): δ 8.33 (br, d, J = 8.2 Hz, 1H, 
H3), 7.94 (dd, J = 8.2, 0.8 Hz, 1H, H4), 7.85 (dd, J = 7.5, 0.8 Hz, 1H, H5), 2.84 − 2.75 (m, 4H, 
SCH2CH2); 13C NMR (100 MHz, MeOD): δ 172.8 (NCOCH2), 167.8 (NCCOOH), 152.9 (C2), 
147.7 (C6), 140.7 (C4), 121.7 (C5), 118.9 (C3), 41.9 (SCH2CH2), 20.4 (SCH2). ESI-MS, m/z: 225 
[M - H]-. HRMS calculated for C9H9N2O3S 255.0339, found 225.0338. 
 
6-(4-Mercaptobutanamido)picolinic acid (3.2.3) 
 
White hygroscopic solid (27 mg, 66%). 1H NMR (400 MHz, MeOD): δ 8.31 (br, d, J = 8.2 Hz, 1H, 
H3), 7.93 (dd, J = 8.2, 0.9 Hz, 1H, H4), 7.84 (dd, J = 7.6, 0.9 Hz, 1H, H5), 2.61 − 2.57 (m, 4H, 
SCH2CH2CH2), 1.98 (p, J = 7.4 Hz, 2H, SCH2CH2CH2); 13C NMR (100 MHz, MeOD): δ 174.3 
(NCOCH2), 167.7 (NCCOOH), 152.9 (C2), 147.5 (C6), 140.8 (C4), 121.7 (C5), 118.9 (C3), 36.3 
(SCH2CH2CH2), 30.6 (SCH2CH2), 24.5 (SCH2). ESI-MS, m/z: 239 [M - H]-. HRMS calculated for 
C10H11N2O3S 239.0496, found 239.0501. 
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Chapter 4.0  DEVELOPMENTS OF PHENYLGLYCINE DERIVATIVES 
AS POTENT INHIBITORS OF MBLs 
 
4.1 Introduction 
 
 
Figure 4.1. B1 and B3 MBL inhibitor reported by Liénard et al. (see ref. 1).   
 
Compound R-4.1 (Figure 4.1) was reported by Liénard et al. to significantly inhibit B1 and B3 type 
MBLs (Table 4.1).1 The docking study of compound R-4.1 in complex with BcII (PDB code: 
1BVT)2, another B1 type MBL, predicted that the thiolate group of the inhibitor chelates both zinc 
ions in the enzyme’s active site and the carboxylate group forms an electrostatic interaction with 
Lys 171 (Figure 4.2).  
 
With the expectation that including bulky hydrophobic groups at C6 could increase the potencies of 
inhibitors against the MBLs, Liénard et al. synthesised compound RS-4.2 and tested it against B1, 
B2 and B3 subclasses MBLs (Figure 4.3). As shown in Table 4.1, compound RS-4.2 competitively 
inhibits MBLs with a Ki value as low as 0.019 ± 0.002 µM.1 Liénard et al. reported that they docked 
compound RS-4.2 into the IMP-1 active site, and that it showed similar predicted binding 
orientations to those of compound R-4.1, where the thiolate group chelates both zinc ions of the 
enzyme. They also reported predicted interactions between compound RS-4.2 and the hydrophobic 
residues of the enzyme (docking images were not reported in the literature).  
 
Based on the predicted binding orientations generated by the MVD software, all compounds 
reported in Chapter 2 to Chapter 3 exhibit limited interactions with the enzyme active site residues. 
Only the thiolate, carboxylate and amide carbonyl groups are bound to the active site of the enzyme 
(see Section 2.1.2.2). On the other hand, there are no interactions predicted between the ring of 
these compounds and the enzyme. Therefore, the existence of bulky hydrophobic groups in the 
chemical structure of these compounds might increase the possibilities of hydrophobic interactions 
with the conserved hydrophobic region of IMP-1 enzyme. 
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It was out of interest to investigate the potency of each enantiomer of compound RS-4.2 against the 
MBLs, especially the IMP-1 enzyme, as Liénard et al. used a racemic mixture of the compound for 
their tests. Furthermore, these compounds contain a bulky phenyl group at C6 that was expected to 
help in increasing hydrophobic interactions between these compounds and hydrophobic residues of 
IMP-1in the enzyme active site. This chapter discusses the design, molecular modelling, syntheses 
and kinetic assay studies of each enantiomer of compound RS-4.2, as well as some derivatives of 
this compound.  
 
 
Figure 4.2. Docking image of compound R-4.1 in the BcII (PDB code: 1BVT) enzyme active site 
(see ref. 1).  
 
Table 4.1. Competitive inhibition constants, Ki (µM) of compound RS-4.1 and R-4.2 (see ref. 1). 
 B1 B2 B3 
Compound IMP-1 BcII CphA L1 
R-4.1 68 ± 30 5.6 ± 0.3 - 6.5 ± 2 
RS-4.2 0.019 ± 0.002 7.7 ± 0.7 5.7 ± 2.0 1.8 ± 0.4 
 - (no value) indicates not determined. 
 
 
Figure 4.3. Broad-spectrum MBL inhibitor reported by Liénard et al. (see ref. 1). 
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4.2 Results and Discussion 
 
4.2.1 Design of Novel Inhibitors 
 
 
Figure 4.4. Derivatives of compound RS-4.2. 
 
Compounds 4.2a-b – 4.4a-b were designed based on compound RS-4.2 reported by Liénard et al. 
(Figure 4.4).1 These compounds retain the thiolate, carboxylic acid and aromatic groups as these 
key structures would have important interactions with the amino acids in the IMP-1 active site (see 
details in Section 4.2.2). The interactions of the thiolate group of these compounds with the zinc 
ions in the IMP-1 enzyme active site (coordination by a bridging mode) are expected to be similar 
to the other thiol inhibitors discussed in the previous chapters. The interactions between an inhibitor 
and both zinc ions in a di-zinc MBL are important for effective inhibition since the zinc ions are 
involved in the catalytic hydrolysis of the β-lactam ring in β-lactam antibiotics.3 The carboxylic 
acid group of compounds 4.2 – 4.4 is expected to make interactions with the hydrogen bond donors 
(Lys 224, Asn 233 and Asp 236) and hydrophobic interactions are expected through the phenyl ring 
and the hydrophobic region (Val 61, Val 67, Trp 64 and Phe 87) of the enzyme’s active site. In 
addition to the important key structures, compounds 4.2a-b – 4.4a-b were designed to have 
increasing distances between the thiolate and carboxylic acid groups to investigate the effects on 
inhibition constants.  
 
4.2.2 Computational Modelling 
 
The MVD software was employed throughout this project to perform molecular docking and 
generate docking images of the designed inhibitors bound in the IMP-1 enzyme’s active site. The 
MolDoc scores calculated by the software are shown in Table 4.2 and the docking results of 
compounds 4.2a-b – 4.4a-b docked in the IMP-1 active site are shown in Figures 4.5 – 4.7.  
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The R isomers of compounds 4.2 – 4.4 were calculated to have only slight differences in their 
MolDoc score values. Therefore, the values indicate that all the R isomers were predicted to have 
comparable binding affinities with the IMP-1 active site. On the other hand, the S isomers of these 
compounds were calculated to have larger differences in the MolDoc score values. Compound 4.4b 
was predicted to have the highest binding affinity of the S isomers. When the MolDoc scores of the 
R isomers were compared to the MolDoc scores of the S isomers, the R isomers were calculated to 
have larger negative values. Therefore, the R isomers were predicted to have higher binding 
affinities and more potent against the IMP-1 enzyme. The most potent compound in this series 
predicted by the MVD is compound 4.2a with a MolDoc score value of -173 kcal/mol. This 
MolDoc score is also similar to the values obtained for thiols 2.1.1 – 2.1.3 (Chapter 2.1), thus, 
compound 4.2a was predicted to have comparable inhibition potency to the thiols 2.1.1 – 2.1.3 
against the IMP-1.     
 
Table 4.2. MolDock scores generated by MVD for compounds 4.2a-b – 4.4a-b docked in the IMP-1 
active site. 
 MolDoc Scorea (kcal/mol) 
 R-isomer S-isomer 
Compound 
  
4.3 -163 -134 
4.2 -173 -152 
4.4 -169 -167 
a
 Docking score calculated by Molegro Virtual Docker (MVD) software. Larger negative values 
indicate higher binding affinities of inhibitor – IMP-1. 
 
Figures 4.5 – 4.7 below show the docking images generated by the MVD of all the R isomers, as the 
R isomers were calculated to have larger negative MolDoc scores compared to their corresponding 
S isomers. The docking images for the all S isomers can be found in Appendix A7.  
 
The predicted binding orientation of compound 4.3a in the active site of IMP-1 enzyme is as shown 
in the docking image below (Figure 4.5). As expected, the thiolate of this compound was predicted 
n
OH
O
HN
O
SH
4.3a (n = 1)
4.2a (n = 2)
4.4a (n = 3)
n
OH
O
HN
O
SH
4.3b (n = 1)
4.2b (n = 2)
4.4b (n = 3)
 178 
to coordinate to both zinc ions of the enzyme active site (1.9 Å and 2.0 Å). There was a hydrogen 
bond interaction predicted between the oxygen of amide carbonyl of compound 4.3a and the side 
chain NH2 of Asn 233 (O-H distance 1.5 Å). There were also two additional electrostatic 
interactions through both of the carboxylate group oxygens of this compound and the NH3+ group 
of Lys 224 (O-N distances 2.6 and 2.7 Å). In addition to the interactions mentioned above, 
compound 4.3a was predicted to have hydrophobic interactions between its phenyl group and the 
hydrophobic region of the enzyme active site lined by Trp 64 (ring to ring distance 3.5 Å) and Val 
67 (pyridine ring – Val 67 backbone C chain distance 3.4 Å).   
 
 
4.3a 
 
Figure 4.5. Docking of compound 4.3a into the IMP-1 active site. Colours: Blue – nitrogen; red – 
oxygen; grey – carbon; yellow – sulfur; magenta – Zn ions. 
 
Figure 4.6 shows compound 4.2a docked into the IMP-1 active site. Similar to compound 4.3a, the 
thiolate of compound 4.2a was predicted to interact with both the zinc ions of the enzyme with the 
distances of 2.0 Å for both interactions. The carboxylate group of this compound was also predicted 
to bind to one of the zinc ions through one of its oxygens (3.4 Å). A hydrogen bond was predicted 
to form between one of the oxygens of the carboxylate group of the compound and the backbone 
NH of Asn 233 (O-H distance 2.0 Å). There were two electrostatic interactions predicted between 
compound 4.3a and Lys 224 through both oxygens of the carboxylate group of this compound and 
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the NH3+ group of Lys 224 (O-N distances 2.6 and 2.8 Å). A hydrogen bond was predicted to form 
between the amide carbonyl group of compound 4.3a and the side chain NH2 of Asn 233 (O-H 
distance 2.7 Å). Furthermore, hydrophobic interactions were predicted between the aromatic ring of 
this compound with His 263 (pyridine ring – His 263 backbone C chain distance 3.2 Å) and Val 67 
(pyridine ring – Val 67 backbone C chain distance 3.2 Å). There was no interaction predicted 
between compound 4.3a and Trp 64 of IMP-1 since this compound was positioned far away from 
the residue.  
 
4.2a 
 
Figure 4.6. Docking of compound 4.2a into the IMP-1 active site. Colours: Blue – nitrogen; 
red – oxygen; grey – carbon; yellow – sulfur; magenta – Zn ions. 
 
Compound 4.4a was also predicted to coordinate to both zinc ions of the IMP-1 enzyme through it 
thiolate group (2.0 Å for both interactions, Figure 4.7). The similar interaction was observed in all 
thiol compounds molecular modeling studies throughout this work. The amide carbonyl group of 
compound 4.4a was predicted to form a hydrogen bond with the side chain NH2 of Asn 233 with 
the O-H distance of 2.1 Å. One of the carboxylate group oxygens of this compound was predicted 
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to have an electrostatic interaction to one of the zinc ions (3.7 Å) and to the NH3+ group of Lys 224 
(O-N distance 2.4 Å) while the other oxygen of the carboxylate group was predicted to bind with 
the SH group of Cys 221 by a hydrogen bond (O-H distance 2.9 Å). Hydrophobic interactions were 
also predicted between the phenyl group of compound 4.4a and Val 67 (pyridine ring – Val 67 
backbone C chain distance 3.9 Å) and Lys 224 (pyridine ring – Lys 224 backbone C chain distance 
3.0 Å).  
 
4.4a 
 
Figure 4.7. Docking of compound 4.4a into the IMP-1 active site. Colours: Blue – nitrogen; 
red – oxygen; grey – carbon; yellow – sulfur; magenta – Zn ions. 
 
In conclusion, all of compounds discussed above have similar interactions through their thiolate 
group to both zinc ions of the IMP-1 enzyme. Based on the observed interactions in the docking 
images of compounds 4.2 – 4.4, the carboxylate and amide carbonyl groups of these compounds 
also play significant role in increasing the predicted binding affinities in the enzyme active site 
through their interactions with the active site amino acid residues. Compound 4.2a was predicted to 
be the most potent compound of this series as it was calculated to have the largest negative value of 
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MolDoc score (-173). This value is comparable to the MolDoc score values calculated for the new 
lead compounds, thiols 2.1.1 – 2.1.3. 
 
4.2.3 Synthesis 
 
The phenylglycine derivatives 4.2 – 4.4 were proposed to be synthesised by the two-step procedure 
showed in Scheme 4.1. Similar procedures were used for the preparation of the previous compound 
series (Chapters 2.1, 2.2, 2.3, 2.4, 3.1 and 3.2). The HBTU coupling reaction between 
enantiomerically pure phenylglycine methyl ester hydrochlorides 4.5a – b and carboxylic acids 2.15 
– 2.17 would give the coupled products 4.6 – 4.8.4 Then, base hydrolysis of these coupled products 
would cleave both methyl ester and thioester to yield the final compounds 4.2 – 4.4. 
   
 
Scheme 4.1. Proposed synthesis route to phenylglycine derivatives 4.2 – 4.4. a: R isomers, b: S 
isomers. 
 
The first step in the synthesis of the phenylglycine derivatives 4.2 – 4.4 was the coupling of the 
commercially available starting materials 4.5a – b with the carboxylic acids 2.1.5 – 2.1.7 
(synthesised previously as described in Chapter 2.1) using HBTU and DIPEA in THF (Scheme 4.2). 
The syntheses of the coupled products 4.6 – 4.8 were successfully achieved with good to excellent 
yields5, 6 after an overnight stirring of the mixtures at room temperature. The addition of an obvious 
singlet signal at around 2.3 ppm (SCOCH3) in the 1H NMR spectra of the coupled products proved 
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the successful formation of these compounds. All of the coupled products 4.6 – 4.8 have similar 
signals at 56 ppm in their 13C NMR spectra belonging to NCH. Peaks at m/z 304, 318 and 332 [M + 
Na]+ in the ESI-MS spectra further approved the formation of compounds 4.6, 4.7 and 4.8, 
respectively. Both enantiomers of each compound displayed identical signals in their 1H NMR, 13C 
NMR and ESI-MS spectra. 
 
Scheme 4.2. HBTU coupling of the starting materials 4.5. a: R isomers, b: S isomers. 
 
The coupled products 4.6 – 4.8 were then hydrolysed using 2 M NaOH in methanol to reveal both 
thiol and carboxylic acid groups (Scheme 4.3). Two hours’ stirring followed by a treatment with 2 
M HCl successfully gave the final compounds 4.2 – 4.4. The loss of both thioester and methyl ester 
signals in the 1H and 13C NMR spectra of the products confirmed the success of the hydrolysis 
reactions. The appearance of peaks at m/z 224, 238 and 252 [M - H]- in the ESI-MS spectra of the 
final products also proved the formation of the final compounds 4.3, 4.2 and 4.4, respectively. 
 
 
Scheme 4.3. Synthesis of the final compounds 4.2 – 4.4. a: R isomers, b: S isomers. 
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1. 2 M NaOH, MeOH
    r.t., Ar, 2 h
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n = 1: 4.3a (100%),  4.3b (85%)
n = 2: 4.2a (100%),  4.2b (91%) 
n = 3: 4.4a (100%),  4.4b (92%)
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4.2.4 Kinetic Assays 
 
Kinetic assays of the final products were performed against IMP-1 to determine the inhibitory 
activities of the compounds. These include the determination of the inhibition constant, Ki value and 
inhibition mode of each inhibitor. Firstly, a screening assay of all the synthesised compounds was 
carried out against IMP-1 to select the compounds with considerable percentage inhibition. 
Racemic samples of compounds 4.2 – 4.4 (R:S = 1:1) were also prepared and screened against the 
enzyme. The results of the screening assay are shown in Table 4.3. From the Table, it can be 
concluded that the methyl ester hydrochlorides 4.5 showed very low inhibition activity even at 100 
µM. The coupled products 4.6 – 4.8 also showed low inhibition activity against the enzyme. As 
discussed in the previous chapters, this might be due to the absence of free thiols in the coupled 
products to chelate the zinc ions in the IMP-1 active site and inhibit the enzyme. The interactions of 
the molecules with both zinc ions in the active site of the enzyme are thought to be crucial during 
inhibition because the metal ions play important roles in the catalytic hydrolysis of β-lactam ring in 
β-lactam antibiotics.3 Therefore, the methyl ester hydrochlorides 4.5 and coupled products 4.6 – 4.8 
were not considered as the potent compounds to be further tested for IMP-1 inhibitors as the 
purpose of this study is to improve the inhibition potency of the inhibitors of IMP-1. On the other 
hand, all final products 4.2 – 4.4 showed excellent results at 100 µM. Compounds 4.3a-b and 4.2a 
were also excellent against the IMP-1 at 10 µM. The rest of the final products including the racemic 
samples were moderately potent in inhibiting the IMP-1 at 10 µM. Thus, all the final products 4.2 – 
4.4 (shaded rows in Table 4.3) were selected for kinetic assays to determine their Ki values and 
inhibition modes against the IMP-1 enzyme. 
 
Table 4.3. Inhibition percentage of the synthetic intermediates and the final products 4.2 – 4.4 
against IMP-1 enzyme. 
 % Inhibition a 
Compounds 100 µM 10 µM 1 µM 
 
(R)-phenylglycine methyl ester hydrochloride 4.5a 
4 - - 
 
(S)-phenylglycine methyl ester hydrochloride 4.5b 
8 4 2 
OMe
O
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O
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4.6a 
12 8 4 
 
4.6b 
32 3 - 
 
4.7a 
6 - - 
 
4.7b 
13 - - 
 
4.8a 
2 - - 
 
4.8b 
2 - - 
 
4.3a 
100 90 35 
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4.3b 
100 85 22 
 
4.2a 
100 83 15 
 
4.2b 
100 59 8 
 
4.4a 
100 62 7 
 
4.4b 
100 52 - 
 
RS-4.3 
99 51 2 
 
RS-4.2 
100 52 4 
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RS-4.4 
100 31 - 
a
 - (no value) indicates no inhibition. 
 
The Ki values determined by the kinetic assays of the selected compounds against the IMP-1 
enzyme are shown in Table 4.4. All of the compounds tested inhibit the IMP-1 enzyme completely 
by competitive inhibition mode since the uncompetitive inhibition constant values (Kiuc) of these 
compounds are very large (mM or M range, data not shown). Similar to the screening results of the 
final products, compounds 4.3a-b and 4.2a show encouraging inhibitory activities with competitive 
inhibition constant values (Kic) ranging from 2.6 ± 1.0 to 3.4 ± 0.8 µM. The MVD software also 
predicted that compound 4.2a would be the most potent compound in this series. Compounds 4.2b 
and 4.4a-b were slightly less potent with slightly higher Kic values (9.6 ± 3.7 to 11 ± 3 µM). The Kic 
values of the racemic samples (RS-4.2, RS-4.3 and RS-4.4) are 5.3 ± 1.3 to 8.5 ± 2.9 µM. However, 
no improvement could be made on the Kic values since the thiols 2.1.1 – 2.1.3 (2.2 ± 0.6 to 9.9 ± 4.2 
µM, Chapter 2.1).  
Table 4.4. Ki values of the final products against the IMP-1 enzyme. 
Compounds Kic (µM) a 
 
4.3a 
2.6 ± 1.0 
 
4.3b 
3.9 ± 2.0 
 
4.2a 
3.4 ± 0.8 
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4.2b 
9.6 ± 3.7 
 
4.4a 
9.9 ± 4.1 
 
4.4b 
11 ± 3 
 
RS-4.3 
5.3 ± 1.3 
 
RS-4.2 
7.5 ± 1.3 
 
RS-4.4 
8.5 ± 2.9 
a Values are mean of duplicate measurements ± SEM. 
 
Nevertheless, the Kic values determined by the kinetic assays of this series were very large 
compared to the reported Kic value of RS-4.2 (0.019 ± 0.002 µM). The reported predicted 
interactions of compound RS-4.2 were similar to the interactions observed from the docking results 
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of compounds 4.2 – 4.4 generated by the MVD software in this study. Therefore, the reasons for the 
large difference in the reported Ki value and the determined Ki values in this study were not fully 
understood. However, the chemical structure resemblances between compound RS-4.2 and thiol 
2.1.2 (Figure 4.8) make it possible for the two compounds to have comparable Ki values (Ki value 
of compound 2.1.2a is 9.9 ± 4.2 µM). Both compounds contain identical key structures that involve 
in the interactions between the molecules and the enzyme, which possibly contribute to the 
comparable inhibition potencies against IMP-1. The resemblances in the chemical structures also 
available in compound 2.4.2, which also has a comparable Ki value (10 ± 4.0 µM) with both 
compound RS-4.2 and thiol 2.1.2 (Chapter 2.4).  
 
 
Figure 4.8. The resemblances (marked in red) between the chemical structures of compound 4.2 and 
thiol 2.1.2. 
 
In conclusion, all final compounds show encouraging inhibition activities against the IMP-1 with 
low micromolar Ki values ranged from 2.6 ± 1.0 to 11 ± 3 µM. These values were comparable to the 
thiols 2.1.1 – 2.1.3 Ki values (2.2 ± 0.6 to 9.9 ± 4.2 µM). However, the Ki values of the final 
products are larger than the reported Ki value of compound RS-4.2 (0.019 ± 0.002 µM).    
 
4.3 Summary 
 
The final compounds in the phenylglycine derivative series were designed based on the excellent 
competitive inhibition properties RS-4.2 reported by Liénard et al. Molecular docking studies of 
these newly designed molecules in the active site of the IMP-1 enzyme (PDB code: 1JJT) using the 
MVD software showed similar binding mode to the thiols 2.1.1 – 2.1.3 in complex with the 
enzyme. 
 
Syntheses of the designed molecules were completed in just two steps reaction starting from 
commercially available R/S-phenylglycine methyl ester hydrochloride 4.5. The HBTU coupling and 
base hydrolysis reactions gave the final products with good to excellent yields. 
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All of the synthesised compounds and the starting materials were tested against the IMP-1 enzyme. 
All of the individual isomers of compounds 4.2 – 4.4 and their racemic mixtures competitively 
inhibit the IMP-1 with the Ki values of these compounds ranging from 2.6 ± 1.0 to 11 ± 3 µM, 
which were comparable with the thiols 2.1.1 – 2.1.3 (2.2 ± 0.6 to 9.9 ± 4.2 µM). However, these 
values are larger compared to the reported Ki value of compound RS-4.2 (0.019 ± 0.002 µM).   
 
 
4.4 Experimental 
 
General procedure for the preparation of compounds 4.6 – 4.8 
A mixture of phenylglycine methyl ester hydrochloride (500 mg, 2.5 mmol), acetylthio compound 
(1.5 eq.), DIPEA (2.0 ml, 12 mmol) and HBTU (1.4 g, 3.7 mmol) in THF (11 ml) was stirred 
overnight at room temperature. The solvent was then evaporated under reduced pressure and ethyl 
acetate (20 mL) was added to the crude product. The mixture was washed with water (20 mL) and 
brine (2 × 20 mL), dried (Na2SO4) and concentrated under reduced pressure. The crude product 
was purified by column chromatography (ethyl acetate/petroleum ether (30% - 60%)) to give the 
desired product. 
 
(R)-Methyl 2-(2-(acetylthio)acetamido)-2-phenylacetate (4.6a) 
 
Yellow solid (442 mg, 63%). m.p. 81.6 – 82.1°C. 1H NMR (500 MHz, CDCl3): δ 7.35 – 7.28 (m, 
5H, Ar-H), 7.20 (br d, J = 7.2 Hz, 1H, NH), 5.49 (d, J = 7.2 Hz, 1H, NHCH), 3.69 (s, 3H, 
COOCH3), 3.57 (dd, J = 3.6, 6.9 Hz, 2H, SCH2), 2.39 (s, 3H, SCOCH3); 13C NMR (75 MHz, 
CDCl3): δ 195.7 (SCOCH3), 170.9 (COOCH3), 167.4 (NCOCH2), 135.9 (NHCHC), 129.0 (2 × 
CCHCH), 128.6 (CCHCHCH), 127.1 (2 × CCHCH), 56.6 (NCH), 52.9 (COOCH3), 32.8 (SCH2), 
30.3 (SCOCH3). ESI-MS, m/z: 304 [M + Na]+. HRMS calculated for C13H15NNaO4S 304.0614, 
found 304.0607. 
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(S)-Methyl 2-(2-(acetylthio)acetamido)-2-phenylacetate (4.6b) 
 
Yellow solid (485 mg, 70%). m.p. 80.7 – 82.9°C. 1H NMR (500 MHz, CDCl3): δ 7.33 – 7.28 (m, 
5H, Ar-H), 7.19 (br d, J = 7.2 Hz, 1H, NH), 5.49 (d, J = 7.2 Hz, 1H, NHCH), 3.69 (s, 3H, 
COOCH3), 3.57 (dd, J = 3.6, 6.9 Hz, 2H, SCH2), 2.39 (s, 3H, SCOCH3); 13C NMR (75 MHz, 
CDCl3): δ 195.5 (SCOCH3), 170.9 (COOCH3), 167.4 (NCOCH2), 136.0 (NHCHC), 129.0 (2 × 
CCHCH), 128.6 (CCHCHCH), 127.1 (2 × CCHCH), 56.7 (NCH), 52.8 (COOCH3), 32.8 (SCH2), 
30.2 (SCOCH3). ESI-MS, m/z: 304 [M + Na]+. HRMS calculated for C13H15NNaO4S 304.0614, 
found 304.0614. 
 
(R)-Methyl 2-(3-(acetylthio)propanamido)-2-phenylacetate (4.7a) 
 
Yellow oil (688 mg, 94%). 1H NMR (500 MHz, CDCl3): δ 7.34 – 7.32 (m, 5H, Ar-H), 6.54 (br d, J 
= 7.2 Hz, 1H, NH), 5.56 (d, J = 7.2 Hz, 1H, NHCH), 3.71 (s, 3H, COOCH3), 3.10 (t, J = 6.9 Hz, 
2H, SCH2), 2.58 – 2.51 (m, 2H, SCH2CH2), 2.29 (s, 3H, SCOCH3); 13C NMR (75 MHz, CDCl3): δ 
196.0 (SCOCH3), 171.3 (COOCH3), 170.0 (NCOCH2), 136.3 (NHCHC), 129.0 (2 × CCHCH), 
128.6 (CCHCHCH), 127.3 (2 × CCHCH), 56.4 (NCH), 52.8 (COOCH3), 36.0 (SCH2CH2), 30.5 
(SCOCH3), 24.6 (SCH2). ESI-MS, m/z: 318 [M + Na]+. HRMS calculated for C14H17NNaO4S 
318.0770, found 318.0765. 
 
(S)-Methyl 2-(3-(acetylthio)propanamido)-2-phenylacetate (4.7b) 
 
Yellow hygroscopic solid (738 mg, 100%). 1H NMR (300 MHz, CDCl3): δ 7.35 – 7.30 (m, 5H, Ar-
H), 6.53 (br d, J = 7.2 Hz, 1H, NH), 5.56 (d, J = 7.2 Hz, 1H, NHCH), 3.71 (s, 3H, COOCH3), 3.10 
(t, J = 6.9 Hz, 2H, SCH2), 2.57 – 2.52 (m, 2H, SCH2CH2), 2.29 (s, 3H, SCOCH3); 13C NMR (75 
MHz, CDCl3): δ 196.0 (SCOCH3), 171.3 (COOCH3), 170.0 (NCOCH2), 136.3 (NHCHC), 129.0 (2 
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× CCHCH), 128.6 (CCHCHCH), 127.3 (2 × CCHCH), 56.4 (NCH), 52.8 (COOCH3), 36.0 
(SCH2CH2), 30.5 (SCOCH3), 24.6 (SCH2). ESI-MS, m/z: 318 [M + Na]+. HRMS calculated for 
C14H17NNaO4S 318.0770, found 318.0769. 
 
(R)-Methyl 2-(4-(acetylthio)butanamido)-2-phenylacetate (4.8a) 
 
Brown oil (730 mg, 95%). 1H NMR (500 MHz, CDCl3): δ 7.34 – 7.30 (m, 5H, Ar-H), 6.58 (br d, J 
= 7.2 Hz, 1H, NH), 5.56 (d, J = 7.2 Hz, 1H, NHCH), 3.71 (s, 3H, COOCH3), 2.92 – 2.85 (m, 2H, 
SCH2), 2.31 – 2.28 (m, 2H, SCH2CH2CH2), 2.30 (s, 3H, SCOCH3), 1.93 – 1.87 (m, 2H, SCH2CH2); 
13C NMR (75 MHz, CDCl3): δ 196.0 (SCOCH3), 171.4 (COOCH3), 171.3 (NCOCH2), 136.4 
(NHCHC), 129.0 (2 × CCHCH), 128.6 (CCHCHCH), 127.3 (2 × CCHCH), 56.4 (NCH), 52.8 
(COOCH3), 34.7 (SCH2CH2CH2), 30.6 (SCOCH3), 28.3 (SCH2), 25.4 (SCH2CH2). ESI-MS, m/z: 
332 [M + Na]+. HRMS calculated for C15H19NNaO4S 332.0927, found 332.0920. 
 
(S)-Methyl 2-(4-(acetylthio)butanamido)-2-phenylacetate (4.8b) 
 
Brown oil (808 mg, 100%). 1H NMR (300 MHz, CDCl3): δ 7.35 – 7.31 (m, 5H, Ar-H), 6.58 (br d, J 
= 7.2 Hz, 1H, NH), 5.56 (d, J = 7.2 Hz, 1H, NHCH), 3.71 (s, 3H, COOCH3), 2.92 – 2.86 (m, 2H, 
SCH2), 2.32 – 2.27 (m, 2H, SCH2CH2CH2), 2.30 (s, 3H, SCOCH3), 1.95 – 1.85 (m, 2H, SCH2CH2); 
13C NMR (75 MHz, CDCl3): δ 195.9 (SCOCH3), 171.4 (COOCH3), 171.3 (NCOCH2), 136.4 
(NHCHC), 129.0 (2 × CCHCH), 128.6 (CCHCHCH), 127.2 (2 × CCHCH), 56.4 (NCH), 52.8 
(COOCH3), 34.7 (SCH2CH2CH2), 30.6 (SCOCH3), 28.3 (SCH2), 25.4 (SCH2CH2). ESI-MS, m/z: 
332 [M + Na]+. HRMS calculated for C15H19NNaO4S 332.0927, found 332.0936. 
 
General procedure for the preparation of 4.2 – 4.4 
An aqueous solution of NaOH (2 M, 1 mL, 6 eq.) was added to the coupled compounds 4.6 – 4.8 
(100 mg) in MeOH (1 mL) and the mixture was stirred for 2 hours at room temperature under 
argon. The solvent was evaporated under reduced pressure and water (5 mL) was added to the 
residue. The mixture was acidified to pH=2 with 2 M HCl, extracted with ethyl acetate (5 mL x 3), 
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washed with water (5 mL) and dried (Na2SO4). The organic solvent was evaporated under reduced 
pressure to give the desired product. 
 
(R)-2-(2-Mercaptoacetamido)-2-phenylacetic acid (4.3a) 
 
Yellow gum (94 mg, 100%). 1H NMR (300 MHz, CDCl3): δ 7.63 (br d, J = 7.1 Hz, 1H, NH), 7.39 
– 7.33 (m, 5H, Ar-H), 5.53 (d, J = 7.1 Hz, 1H, NHCH), 3.28 – 3.24 (m, 2H, SCH2), 1.92 (t, J = 9.1 
Hz, 2H, SH); 13C NMR (75 MHz, CDCl3): δ 173.7 (COOH), 169.5 (NCOCH2), 135.4 (NHCHC), 
129.1 (2 × CCHCH), 128.9 (CCHCHCH), 127.3 (2 × CCHCH), 56.7 (NCH), 28.0 (SCH2). ESI-
MS, m/z: 224 [M - H]-. HRMS calculated for C10H10NO3S 224.0387, found 224.0389. 
 
(S)-2-(2-Mercaptoacetamido)-2-phenylacetic acid (4.3b) 
 
Yellow gum (69 mg, 85%). 1H NMR (300 MHz, CDCl3): δ 7.62 (br d, J = 7.1 Hz, 1H, NH), 7.39 – 
7.33 (m, 5H, Ar-H), 5.53 (d, J = 7.1 Hz, 1H, NHCH), 3.28 – 3.23 (m, 2H, SCH2), 1.92 (t, J = 9.1 
Hz, 2H, SH); 13C NMR (125 MHz, CDCl3): δ 173.5 (COOH), 169.5 (NCOCH2), 135.4 (NHCHC), 
129.2 (2 × CCHCH), 129.0 (CCHCHCH), 127.3 (2 × CCHCH), 56.7 (NCH), 28.0 (SCH2). ESI-
MS, m/z: 224 [M - H]-. HRMS calculated for C10H10NO3S 224.0387, found 224.0390. 
 
(R)-2-(3-Mercaptopropanamido)-2-phenylacetic acid (4.2a) 
 
Yellow gum (84 mg, 100%). 1H NMR (300 MHz, CDCl3): δ 7.39 – 7.32 (m, 5 H, Ar-H), 6.66 (br d, 
J = 6.9 Hz, 1H, NH), 5.56 (d, J = 6.9 Hz, 1H, NHCH), 2.80 – 2.72 (m, 2H, SCH2), 2.57 – 2.52 (m, 
2H, SCH2CH2), 1.61 (t, J = 8.4 Hz, 2H, SH); 13C NMR (75 MHz, CDCl3): δ 173.7 (COOH), 170.9 
(NCOCH2), 135.6 (NHCHC), 129.1 (2 × CCHCH), 128.9 (CCHCHCH), 127.4 (2 × CCHCH), 56.6 
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(NCH), 40.1 (SCH2CH2), 20.2 (SCH2). ESI-MS, m/z: 238 [M - H]-. HRMS calculated for 
C11H12NO3S 238.0543, found 238.0546. 
 
(S)-2-(3-Mercaptopropanamido)-2-phenylacetic acid (4.2b) 
 
Yellow gum (74 mg, 91%). 1H NMR (300 MHz, CDCl3): δ 7.39 – 7.32 (m, 5H, Ar-H), 6.61 (br d, J 
= 6.9 Hz, 1H, NH), 5.57 (d, J = 6.9 Hz, 1H, NHCH), 2.80 – 2.73 (m, 2H, SCH2), 2.57 – 2.52 (m, 
2H, SCH2CH2), 1.62 (t, J = 8.4 Hz, 2H, SH); 13C NMR (100 MHz, CDCl3): δ 173.6 (COOH), 
170.8 (NCOCH2), 135.5 (NHCHC), 129.1 (2 × CCHCH), 128.9 (CCHCHCH), 127.4 (2 × 
CCHCH), 56.6 (NCH), 40.1 (SCH2CH2), 20.2 (SCH2). ESI-MS, m/z: 238 [M - H]-. HRMS 
calculated for C11H12NO3S 238.0543, found 238.0545. 
 
(R)-2-(4-Mercaptobutanamido)-2-phenylacetic acid (4.4a) 
 
Yellow gum (87 mg, 100%). 1H NMR (300 MHz, CDCl3): δ 7.37 – 7.32 (m, 5H, Ar-H), 6.56 (br d, 
J = 6.9 Hz, 1H, NH), 5.55 (d, J = 6.9 Hz, 1H, NHCH), 2.58 – 2.46 (m, 2H, SCH2), 2.41 – 2.35 (m, 
2H, SCH2CH2CH2), 1.95 – 1.87 (m, 2H, SCH2CH2), 1.29 (t, J = 8.0 Hz, 2H, SH); 13C NMR (100 
MHz, CDCl3): δ 173.9 (COOH), 172.3 (NCOCH2), 135.7 (NHCHC), 129.1 (2 × CCHCH), 128.8 
(CCHCHCH), 127.4 (2 × CCHCH), 56.5 (NCH), 34.2 (SCH2CH2CH2), 29.2 (SCH2CH2), 23.9 
(SCH2). ESI-MS, m/z: 252 [M - H]-. HRMS calculated for C12H14NO3S 252.0700, found 252.0704. 
 
(S)-2-(4-Mercaptobutanamido)-2-phenylacetic acid (4.4b) 
 
Yellow gum (75 mg, 92%). 1H NMR (300 MHz, CDCl3): δ 7.37 – 7.32 (m, 5H, Ar-H), 6.51 (br d, J 
= 6.9 Hz, 1H, NH), 5.55 (d, J = 6.9 Hz, 1H, NHCH), 2.57 – 2.49 (m, 2H, SCH2), 2.41 – 2.36 (m, 
2H, SCH2CH2CH2), 1.95 – 1.84 (m, 2H, SCH2CH2), 1.29 (t, J = 8.0 Hz, 2H, SH); 13C NMR (125 
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MHz, CDCl3): δ 173.6 (COOH), 172.2 (NCOCH2), 135.7 (NHCHC), 129.1 (2 × CCHCH), 128.9 
(CCHCHCH), 127.4 (2 × CCHCH), 56.5 (NCH), 34.2 (SCH2CH2CH2), 29.1 (SCH2CH2), 23.9 
(SCH2). ESI-MS, m/z: 252 [M - H]-. HRMS calculated for C12H14NO3S 252.0700, found 252.0702. 
 
 
4.5 References 
 
1. Liénard, B. M. R.; Garau, G.; Horsfal, L.; Karsisiotis, A. I.; Damblon, C.; Lassaux, P.; 
Papamicael, C.; Roberts, G. C. K.; Galleni, M.; Dideberg, O.; Frère, J.-M.; Schofield, C. J. 
Structural Basis for the Broad-spectrum Inhibition of Metallo-β-lactamases by Thiols. Org. 
Biomol. Chem. 2008, 6, 2282-2294. 
2. Carfi, A.; Duee, E.; Galleni, M.; Frere, J. M.; Dideberg, O. 1.85 Å Resolution Structure of 
the Zinc(II) β-Lactamase from Bacillus cereus. Acta Crystallogr., Sect. D: Biol. Crystallogr. 1998, 
54, 313-323. 
3. Karsisiotis, A. I.; Damblon, C. F.; Roberts, G. C. K. A Variety of Roles for versatile zinc in 
Metallo-β-lactamases. Metallomics 2014, 6, 1181-1197. 
4. Arjomandi, O. K. Synthesis of Inhibitors of Metallo-β-lactamase (IMP-1). PhD Thesis, The 
University of Queensland, St. Lucia, Brisbane, 2015. 
5. Solange, A. HBTU: A Mild Activating Agent of Muramic Acid. Bioorg. Med. Chem. 1992, 
2, 571-574. 
6. Gluszok, S.; Goosens, L.; Depreux, P.; Henichart, J. P. Efficient Synthesis of 
Tetramethylsulfonylguanidines Between A Free Sulfonamide Group and HBTU. Tetrahedron Lett. 
2006, 47, 6087-6090. 
 
 
 
 
 
 
 195 
Chapter 5.0 DEVELOPMENTS OF 3,5-DIAMINOBENZOIC ACID 
DERIVATIVES AS POTENT INHIBITORS OF MBLs 
 
5.1 Introduction 
 
In Chapter 4, the development of compound 4.2 and its derivatives as inhibitors of IMP-1 was 
discussed. Compound 4.2 was found by Liénard et al. to be a broad spectrum MBL inhibitor and to 
competitively inhibit MBLs with a Ki value as low as 0.019 ± 0.002 µM against IMP-1 (Section 
4.1).1 In the same study, compound 5.1 (Figure 5.1) was also reported to competitively inhibit all 
the MBLs tested, with Ki values of less than 1 µM (Table 5.1).1 Docking studies of compound 5.1 – 
MBL complexes done by Liénard et al. suggested that this compound interacts with the enzymes 
through its thiolate group, which coordinates both zinc ions. The carboxylate group of compound 
5.1 was also predicted to bind to the conserved hydrogen-bond donor region of the MBLs (docking 
images were not reported in the literature).1 The conserved hydrogen-bond donor region in a B1 
subclass MBL such as IMP-1 is lined by Lys 224, Asn 233 and Asp 236.2  
 
Compound 5.1 shows excellent inhibition activity against IMP-1 (Ki = 0.36 ± 0.01 µM). Therefore, 
derivatives of this compound deserve further investigation to develop novel potent inhibitors of 
IMP-1 MBL. In this chapter, the design, computational modelling, syntheses and kinetic studies of 
the derivatives of compound 5.1 are reported. 
 
 
Figure 5.1. Broad spectrum MBL inhibitor (see ref. 1). 
 
Table 5.1. Competitive inhibition constants, Ki (µM) of compound 5.1 (see ref. 1). 
 B1 B2 B3 
Compound IMP-1 BcII CphA L1 FEZ-1 
5.1 0.36 ± 0.01 0.97 ± 0.2 0.09 ± 0.004 0.21 ± 0.01 0.3a 
a IC50. 
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5.2 Results and Discussion 
 
5.2.1 Design of Novel Inhibitors 
 
The new compounds 5.2 – 5.4 were designed to maintain the thiolate groups at both C3 and C5 
positions of compound 5.1, but with different distances between the thiolates and carboxylate group 
(Figure 5.2). The distance between the thiolates and carboxylate groups from compound 5.2 to 
compound 5.4 were systematically increased to investigate the effects on inhibition activities. As 
exhibited by common thiol inhibitors, the thiolates of the new compounds 5.2 – 5.4 would 
coordinate the zinc ions in the active site of IMP-1.3 Two thiolate groups for each compound were 
expected to bind to both zinc ions of IMP-1, thus strengthen the binding affinities of these 
compounds with the enzyme’s active site. The carboxylate group at C1 is also maintained as this 
group was predicted to have strong interactions with the enzyme’s active site residues.1 The amide 
carbonyl groups were introduced in the structure of the new compounds for easy synthesis using 
reagents prepared previously in this work (Section 2.1.2.3).4 Furthermore, the amide carbonyl is 
expected to form strong electrostatic interactions with the hydrogen-bonding region of the IMP-1. 
The aromatic ring of the new compounds 5.2 – 5.4 is expected to have interactions with the 
hydrophobic region of the IMP-1 (Val 67, Trp 64 and Phe 87). 
 
 
Figure 5.2. New compounds designed based on compound 5.1. 
 
5.2.2 Computational Modelling 
 
All of the new compounds 5.2 – 5.4 were docked into the active site of IMP-1 using MVD software 
to visualise the predicted binding orientation of these compounds and the enzyme. MolDoc scores 
and docking images of the newly designed compounds 5.2 – 5.4 generated by the software are 
shown in Table 5.2 and Figures 5.3 – 5.5, respectively. The MolDoc scores showed in Table 5.2 are 
clearly higher than the MolDoc scores calculated for thiols 2.1.1 – 2.1.3 (-144 kcal/mol to -179 
kcal/mol), which are still considered as the most potent compounds against IMP-1 synthesised in 
N
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this study. Hence, compounds 5.2 – 5.4 were predicted to have weaker binding affinities to the 
enzyme compared to the thiols 2.1.1 – 2.1.3. The values of the MolDoc scores are increasing with 
the increasing distance between the thiol and carboxylate groups, suggesting that the farther the 
distance between these groups, the weaker the binding affinities would be. Among all the final 
compounds in this series, compound 5.2 was predicted to be the most potent compound against the 
IMP-1 since the calculated MolDoc score of the compound is the lowest (-146 kcal/mol).   
 
Table 5.2. MolDock scores generated by MVD for compounds 5.2 – 5.4 docked in the IMP-1 active 
site. 
Compound MolDoc Scorea (kcal/mol) 
5.2 -146 
5.3 -108 
5.4 -97 
a
 Docking score calculated by Molegro Virtual Docker (MVD) software. Larger negative values 
indicate higher binding affinities of inhibitor – IMP-1.  
 
The binding interactions exhibits by compound 5.2 in the IMP-1 active site are shown in Figure 5.3. 
As this compound was calculated to have the lowest MolDoc score in this series, it has the strongest 
binding affinity with the enzyme. One of the thiolates of this compound was predicted to coordinate 
both zinc ions with the distances of 2.0 and 3.4 Å. The other thiolate of compound 5.2 was also 
predicted to coordinate one of the zinc ions from a farther distance (3.7 Å). In addition, one of the 
oxygens of the carboxylate group was also predicted to interact with both zinc ions (2.0 and 3.4 Å). 
There was a hydrogen bond predicted between compound 5.2 and the enzyme’s active site via the 
carboxylate oxygen of this compound and the side chain NH2 of Asn 233 (O-H distance 2.4 Å). An 
electrostatic interaction was also predicted between the amide carbonyl of compound 5.2 and the 
NH3+ of Lys 224 (O-N distance 2.8 Å). However, there are no interactions predicted between the 
aromatic ring of compound 5.2 and the active site residues of IMP-1.  
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5.2 
 
Figure 5.3. Docking of compound 5.2 into the IMP-1 active site. Colours: Blue – nitrogen; red – 
oxygen; grey – carbon; yellow – sulfur; magenta – Zn ions.  
 
Interactions observed in the docking result of compound 5.3 – IMP-1 is shown in Figure 5.4. For 
this compound, there is only one interaction predicted between one of the thiolates and one of the 
zinc ions (2.0 Å). The other zinc ion is too far away to interact with either thiolate of compound 5.3. 
One of the carboxylate oxygens was predicted to bind to one of the zinc ions, but with a distance of 
3.4 Å. The far distances between the key functional groups of compound 5.3 and the zinc ions were 
thought to be the main reason of higher calculated MolDoc score of compound 5.3 compared to the 
thiols 2.1.1 – 2.1.3. Both carboxylates oxygen atoms of compound 5.3 were predicted to have 
electrostatic interactions with the NH3+ of Lys 224 (O-N distances 2.3 Å for both interactions). 
There was also a hydrogen bond predicted to form between one of the carboxylate oxygens and the 
backbone NH group of Asn 233 (O-H distance 2.5 Å). In addition, the ring of compound 5.3 was 
predicted to have a hydrophobic interaction with the Trp 64 ring (ring to ring distance 3.6 Å).  
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5.3 
 
Figure 5.4. Docking of compound 5.4 into the IMP-1 active site. Colours: Blue – nitrogen; red – 
oxygen; grey – carbon; yellow – sulfur; magenta – Zn ions. 
 
Compound 5.4 was calculated to have the highest MolDoc score in this study with a value of -97 
kcal/mol, which suggests the weakest binding affinity with the enzyme. The interactions predicted 
between compound 5.4 and IMP-1 enzyme are shown in Figure 5.5. Only one thiolate of this 
compound was predicted to bind to one of the zinc ions with a distance of 2.0 Å. Both thiolates of 
compound 5.4 are positioned far away from the other zinc of the IMP-1 enzyme’s active site. One 
of the carboxylate oxygens was predicted to interact with the enzyme’s active site through the NH3+ 
of Lys 224 (electrostatic interaction with O-N distance of 3.0 Å), the SH group of Cys 221 
(hydrogen bonding interaction with O-H distance of 3.2 Å) and one of the zinc ions (2.7 Å). The 
other carboxylate oxygen was predicted to have a hydrogen bonding interaction with the backbone 
NH group of Asn 233 (O-H distance 2.2 Å) and an electrostatic interaction with the NH3+ of Lys 
224 (O-N distance of 2.8 Å). There was also a hydrophobic interaction predicted between the 
aromatic ring of compound 5.4 and the ring of Trp 64 (3.7 Å). Similar to the reason mentioned 
above, the high MolDoc score of compound 5.4 might be due to the far interaction distances 
between this compound and the enzyme’s active site residues.        
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5.4 
 
Figure 5.5. Docking of compound 5.4 into the IMP-1 active site. Colours: Blue – nitrogen; red – 
oxygen; grey – carbon; yellow – sulfur; magenta – Zn ions. 
 
In conclusion, although compounds 5.2 – 5.4 have two thiolate groups, only one of the thiolates is 
positioned close to one of the zinc ions (2.0 Å). The position of another thiolate group of these 
compounds is far from both of the zinc ions, which might be the reason of the high MolDoc scores 
compared to the thiols 2.1.1 – 2.1.3. The aromatic ring of compounds 5.2 – 5.4 was also predicted 
to have only one interaction (or none for compound 5.2) that might be considered as the cause of 
lower binding affinity of compounds 5.2 – 5.4.         
 
5.2.3 Synthesis 
 
Syntheses of the desired compounds 5.2 – 5.4 were proposed to be achieved in three steps from 3,5-
diaminobenzoic acid 5.5 (Scheme 5.1). Esterification of 3,5-diaminobenzoic acid 5.5 would give 
the dihydrochloride salt 5.6.5 HBTU coupling of the dihydrochloride salt 5.6 with carboxylic acids 
prepared previously (Section 2.1.2.3) was expected to afford coupled compounds 5.7 – 5.9.4 The 
last step involving base hydrolysis would cleave the esters and complete the syntheses of the final 
compounds 5.2 – 5.4.4    
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Scheme 5.1. Proposed synthetic procedures to synthesise compound 5.2 – 5.4. 
 
Similar to the esterification method applied in the syntheses of the previous compound series, 3,5-
diaminobenzoic acid 5.5 was stirred with thionyl chloride in methanol at room temperature 
(Scheme 5.2).5 After an overnight stirring, a thin layer chromatography analysis of the reaction 
mixture revealed that most of the starting material 5.5 was unreacted. This was expected since 3,5-
diaminobenzoic acid 5.5 was less reactive compared to the previously used starting materials. The 
low reactivity of 3,5-diaminobenzoic acid 5.5 is caused by low basicity of the amino group nitrogen 
due to electron-withdrawing effect of the phenyl ring.6 Therefore, the reaction mixture was refluxed 
for overnight to successfully obtain the dihydrochloride salt 5.6. The singlet signal observed at 3.9 
ppm belonging to OCH3 in the 1H NMR spectra of compound 5.6. A peak at m/z 167 [M + H]+ in 
the ESI-MS analysis of this compound also proved the formation of the dihydrochloride salt 5.6.   
 
 
Sheme 5.2. Esterification reaction of the starting material 5.5. 
 
The dihydrochloride salt 5.6 was then heated to reflux with the dicarboxylic acids 2.1.5 – 2.1.7 in 
the presence of HBTU and DIPEA in THF to construct the coupled compounds 5.7 – 5.9 (Scheme 
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5.3).4 The reaction progress was monitored by the thin layer chromatography analyses and extended 
for three days since there was a lot of unreacted dihydrochloride salt 5.6. Both amino groups of 
dihydrochloride salt 5.6 were also thought to have low reactivity (low basicity) due to the electron-
withdrawing characteristic of the aromatic ring of this compound,6 hence the slow reaction rate. The 
HBTU coupling reactions of compound 5.6 were only successful in providing low yields of the 
coupled compounds 5.8 and 5.9. A singlet signal at 2.4 ppm belonging to SCOCH3 group in the 1H 
NMR spectra of both compounds confirmed the successful construction of compounds 5.8 and 5.9. 
The ESI-MS analyses of these compounds further proved the formation of the coupled compounds 
5.8 and 5.9 by the appearance of peaks at m/z 449 and 477 [M + Na]+, respectively.     
 
 
Scheme 5.3. HBTU coupling of compound 5.6 and the carboxylic acids 2.1.5 – 2.1.7. 
 
 
Scheme 5.4. Synthesis of the coupled compounds 5.7 – 5.8. 
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As HBTU coupling was unsuccessful in promoting the coupling between the less reactive 
dihydrochloride salt 5.6 and and the dicarboxylic acids 2.1.5 and 2.1.6, acid chlorides 2.1.8 and 
2.1.9 were proposed to be employed in the coupling reactions to obtain the coupled compounds 5.7 
and 5.8 (Scheme 5.4). The preparation of acid chlorides 2.1.8 and 2.1.9 were done based on the 
optimised method discussed in Section 2.4.1.3. The acid chlorides were then reacted with the 
dihydrochloride salt 5.6 in DIPEA and THF at room temperature to yield the coupled compounds 
5.7 and 5.8.7 The addition of singlet signals at 2.4 ppm (SCOCH3) in the 1H NMR spectra of 
compounds 5.7 and 5.8 confirmed that the synthesis of both compounds successfully achieved. The 
ESI-MS analyses of these compounds also proved the successful formation of the coupled 
compounds 5.7 and 5.8 with the existence of peaks at m/z 421 and 449 [M + Na]+, respectively.    
 
Base hydrolysis of the coupled compounds 5.7 – 5.9 was carried out using 2 M NaOH in methanol. 
After two hours stirring under argon at room temperature, the desired compounds 5.2 – 5.4 with 
restored thiols and carboxylic acid groups were obtained in excellent crude yields. The absence of 
COOCH3 and SCOCH3 signals in the 1H NMR spectra marked the formation of these final 
compounds. Peaks at m/z 299, 327 and 355 [M - H]- verified the successful production of the final 
compounds 5.2, 5.3 and 5.4, respectively. 
 
 
Scheme 5.5. Base hydrolysis of the coupled compounds 5.7 – 5.9. 
 
5.2.4 Kinetic Assays 
A screening assay was performed on all synthesised compounds in this series against IMP-1 
enzyme. The starting material, 3,5-diaminobenzoic acid 5.5 was also tested in this screening assay. 
According to the screening results shown in Table 5.3, 3,5-diaminobenzoic acid 5.5 and the 
dihydrochloride salt 5.6 moderately inhibit IMP-1 enzyme at 100 µM. Interestingly, although the 
coupled compounds 5.7 – 5.9 do not have free thiols, they show excellent inhibition at 100 µM. The 
thioester groups of the coupled compounds 5.7 – 5.9 may have been hydrolysed by the enzyme, 
yielding free thiols that subsequently bind to both zinc ions and inhibit the anzyme.8, 9 However, the 
coupled compounds 5.7 – 5.9 have very low inhibition percentages at 10 µM. Thus, no further 
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testing involving these compounds were done, as the Ki values of these compounds against the 
IMP-1 would be higher than 10 µM (see Section 3.1.2.4). All final compounds 5.2 – 5.4 with free 
thiol groups show excellent IMP-1 inhibition activity at 100 µM and moderate inhibition activity at 
10 µM. Therefore, kinetic assay of the final compounds 5.2 – 5.4 were carried out to determine 
their Ki values against the IMP-1 and the inhibition mode of each compound.   
  
Table 5.3. Screening assay results of 3,5-diaminobenzoic acid derivatives against IMP-1. 
 % Inhibition a 
Compounds 100 µM 10 µM 1 µM 
 
3,5-Diaminobenzoic acid 5.5 
69 6 7 
 
5.6 
52 7 1 
 
5.7 
100 17 - 
 
5.8 
97 9 - 
 
5.9 
99 16 3 
NH2H2N
OHO
NH2.HClClH.H2N
OMeO
N
H
O
SN
H
O
S
OMeO
OO
N
H
O
N
H
O
OMeO
S
O
S
O
N
H
O
N
H
O
OMeO
SS
OO
 205 
 
5.2 
96 36 8 
 
5.3 
100 54 14 
 
5.4 
100 38 3 
a
 - (no value) indicates no inhibition. 
 
Table 5.4 shows the kinetic assay results of compounds 5.2 – 5.4 against the IMP-1. All of the 
compounds tested show encouraging inhibition potencies that are comparable to the thiols 2.1.1 – 
2.1.3 (Ki = 2.2 ± 0.6 to 9.9 ± 4.2 µM, Chapter 2.1). However, compounds 5.2 – 5.4 are completely 
uncompetitive IMP-1 inhibitors given that their competitive inhibition constant, Kic values are very 
large (mM or M range). These results indicate that compounds 5.2 – 5.4 do not prevent IMP-1 – 
substrate (in this case, benzylpenicillin) binding, but bind to the IMP-1 – substrate complexes to 
inactivate them. Therefore, formation of enzyme-substrate-inhibitor complex stops the substrate 
hydrolysis.10 The molecular docking results in Section 5.2.2 might explain the different inhibition 
mode exhibited by compounds 5.2 – 5.4, where the key functional groups are positioned a bit far (3 
to 4 Å) from the active site residues of IMP-1. Furthermore, thiolate groups of thiols 2.1.1 – 2.1.3 
were predicted to bind both zinc ions, but thiolate groups of compounds 5.2 – 5.4 were predicted to 
only coordinate one of the metal ions of the IMP-1 active site. The distance between the carboxylate 
and thiolate groups of compounds 5.2 – 5.4 does not give significant impact on the inhibition 
potencies as these compounds have comparable Ki values.   
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Table 5.4. Ki values of 3,5-diaminobenzoic acid derivatives against IMP-1. 
Compounds Kiuc (µM) a 
 
5.2 
4.3 ± 2.0 
 
5.3 
2.1 ± 0.8 
 
5.4 
3.5 ± 1.6 
a Values are mean of duplicate measurements ± SEM. 
 
5.3 Summary 
 
Compounds 5.2 – 5.4 were designed based on compound 5.1 reported by Liénard et al. that shows 
broad spectrum inhibitor properties with Ki values of less than 1 µM against all MBLs tested. 
Molecular docking images of these compounds predicted that only one thiolate group bound to one 
of the zinc ions in the active site of the IMP-1. In addition, distances of the other key structures of 
compounds 5.2 – 5.4 are a bit far to have interactions with the active site residues, thus the higher 
MolDoc scores than thiols 2.1.1 – 2.1.3.  
 
Syntheses of the designed molecules 5.2 – 5.4 were achieved via esterification reaction of 3,5-
diaminobenzoic acid followed by the coupling reaction to obtain the coupled compounds 5.7 – 5.9. 
The last step of the synthesis was base hydrolysis of the coupled compounds to successfully yield 
the desired final compounds 5.2 – 5.4.   
 
The starting material, 3,5-diaminobenzoic acid 5.5, together with all synthesised compounds in this 
series were tested against the IMP-1. Determination of the Ki values of the final compounds 5.2 – 
5.4 by the kinetic assays resulted in encouraging uncompetitive inhibition constant values of 2.1 ± 
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0.8 to 4.3 ± 2.0 µM. The distance between the carboxylate and thiolate groups does not have 
significant effect on the inhibition potencies of compounds 5.2 – 5.4.  
 
 
5.4 Experimental 
 
Methyl 3,5-diaminobenzoate dihydrochloride (5.6) 
 
The reaction procedure was carried out as described in the literature.5 Thionyl chloride (1.4 mL, 20 
mmol) was added dropwise to a solution of 3,5-diaminobenzoic acid 5.5 (2.0 g, 13 mmol) in 
methanol (100 mL) at 0°C. The reaction mixture was stirred overnight at room temperature. Then, 
the reaction was continued by heating the reaction mixture under reflux for overnight. The excess 
SOCl2 and methanol were then removed under reduced pressure to give 3.3 g (100%) of the desired 
compound as a dark grey hygroscopic powder. This compound was used in the next step without 
further purification. 1H NMR (400 MHz, MeOD): δ 7.87 (d, J = 2.1 Hz, 2H, H2, H6), 7.52 (t, J = 
2.1 Hz, 1H, H4), 3.95 (s, 3H, OCH3); 13C NMR (100 MHz, MeOD): δ 166.0 (COOMe), 136.9 (C3, 
5), 134.9 (C1), 122.2 (C2, 6), 120.6 (C4), 53.4 (OCH3). ESI-MS, m/z: 167 [M + H]+. HRMS 
calculated for C8H11N2O2 167.0815, found 167.0809. 
 
General procedure for the preparation of the coupled compounds 5.8 and 5.9 
A mixture of methyl-3,5-diaminobenzoate dihydrochloride 5.6 (0.5 g, 3.0 mmol), acetylthio 
compound (3 eq.), DIPEA (5.2 mL, 30 mmol) and HBTU (3.4 g, 9.0 mmol) in THF (11 mL) was 
heated to reflux for 3 days. The solvent was then evaporated under reduced pressure and 
dichloromethane (20 mL) was added to the crude product. The mixture was washed with sodium 
bicarbonate (20 mL), water (20 mL) and brine (20 mL), dried (Na2SO4) and concentrated under 
reduced pressure. The crude product was purified by column chromatography (ethyl 
acetate/petroleum ether (30% - 50%) to give a brown oil. 
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Methyl-3,5-bis(3-(acetylthio)propanamido)benzoate (5.8) 
 
Yellow hygroscopic solid (37 mg, 4%). 1H NMR (300 MHz, CDCl3): δ 8.14 (br, s, 1H, H4), 7.90 
(d, J = 1.8 Hz, 2H, H2, H6), 7.74 (br, s, 1H, NH), 3.90 (s, 3H, OCH3), 3.21 (t, J = 6.9 Hz, 4H, 2 × 
SCH2), 2.69 (t, J = 6.9 Hz, 4H, 2 × SCH2CH2), 2.36 (s, 6H, 2 × SCOCH3); 13C NMR (100 MHz, 
CDCl3): δ 196.5 (2 × SCOCH3), 169.4 (2 × NHCOCH2), 166.4 (COOMe), 138.5 (C3, 5), 131.4 
(C1), 116.5 (C2, 6), 115.3 (C4), 52.4 (COOCH3), 37.2 (2 × SCH2CH2), 30.6 (2 × SCOCH3), 24.7 
(2 × SCH2). ESI-MS, m/z: 449 [M + Na]+. HRMS calculated for C18H22N2NaO6S2 449.0811, found 
449.0797. 
 
Methyl-3,5-bis(4-(acetylthio)butanamido)benzoate (5.9) 
 
Brown oil (316 mg, 33%). 1H NMR (400 MHz, CDCl3): δ 8.13 (br, s, 1H, H4), 8.09 (br, s, 1H, 
NH), 7.93 (d, J = 1.6 Hz, 2H, H2, H6), 3.88 (s, 3H, OCH3), 2.96 (t, J = 7.0 Hz, 4H, 2 × SCH2), 
2.43 (t, J = 7.0 Hz, 4H, 2 × SCH2CH2CH2), 2.36 (s, 6H, 2 × SCOCH3), 2.00 (p, J = 7.0 Hz, 4H, 2 × 
SCH2CH2); 13C NMR (100 MHz, CDCl3): δ 196.6 (2 × SCOCH3), 170.7 (2 × NHCOCH2), 166.5 
(COOMe), 138.7 (C3, 5), 131.4 (C1), 116.4 (C2, 6), 115.3 (C4), 52.3 (COOCH3), 35.8 (2 × 
SCH2CH2CH2), 30.7 (2 × SCOCH3), 28.3 (2 × SCH2), 25.5 (2 × SCH2CH2). ESI-MS, m/z: 477 [M 
+ Na]+. HRMS calculated for C20H26N2NaO6S2 477.1124, found 477.1123. 
 
General procedure for the preparation of the coupled compounds 5.7 and 5.8 
A mixture of methyl-3,5-diaminobenzoate dihydrochloride 5.6 (0.5 g, 3.0 mmol), acid chloride (3.0 
eq.) and DIPEA (5.2 ml, 30 mmol) in dry THF (7 ml) was stirred overnight at room temperature. 
The solvent was then evaporated under reduced pressure. The crude product was purified by 
column chromatography (ethyl acetate/petroleum ether (50% - 100%), to give the desired 
compound. 
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Methyl-3,5-bis(2-(acetylthio)acetamido)benzoate (5.7) 
 
Yellow solid (213 mg, 26%). m.p. 161.8 – 163.1°C. 1H NMR (400 MHz, MeOD): δ 8.10 (t, J = 2.0 
Hz, 1H, H4), 7.98 (d, J = 2.0 Hz, 2H, H2, H6), 3.89 (s, 3H, OCH3), 3.81 (s, 4H, 2 × SCH2), 2.38 (s, 
6H, 2 × SCOCH3); 13C NMR (100 MHz, MeOD): δ 196.1 (2 × SCOCH3), 169.0 (2 × NHCOCH2), 
167.8 (COOMe), 140.5 (C3, C5), 132.5 (C1), 117.7 (C2, 6), 116.8 (C4), 52.8 (COOCH3), 34.8 (2 × 
SCH2), 30.0 (2 × SCOCH3). ESI-MS, m/z: 421 [M + Na]+. HRMS calculated for C16H18N2NaO6S2 
421.0498, found 421.0501. 
 
Methyl-3,5-bis(3-(acetylthio)propanamido)benzoate (5.8) 
 
Yellow hygroscopic solid (833 mg, 93%). 1H NMR (300 MHz, CDCl3): δ 8.14 (br, s, 1H, H4), 7.90 
(d, J = 1.8 Hz, 2H, H2, H6), 7.74 (br, s, 1H, NH), 3.90 (s, 3H, OCH3), 3.21 (t, J = 6.9 Hz, 4H, 2 × 
SCH2), 2.69 (t, J = 6.9 Hz, 4H, 2 × SCH2CH2), 2.36 (s, 6H, 2 × SCOCH3); 13C NMR (100 MHz, 
CDCl3): δ 196.5 (2 × SCOCH3), 169.4 (2 × NHCOCH2), 166.4 (COOMe), 138.5 (C3, 5), 131.4 
(C1), 116.5 (C2, 6), 115.3 (C4), 52.4 (COOCH3), 37.2 (2 × SCH2CH2), 30.6 (2 × SCOCH3), 24.7 
(2 × SCH2). ESI-MS, m/z: 449 [M + Na]+.  
 
General procedure for the preparation of the final compounds 5.2 – 5.4 
An aqueous solution of NaOH (2 M, 1.0 mL, 9 eq.) was added to the coupled compounds 5.7 – 5.9 
(0.1 g) in degassed MeOH (1.0 mL) and the mixture was stirred for 2 hours at room temperature 
under argon. The solvent was evaporated under reduced pressure and water (5 mL) was added to the 
residue. The mixture was acidified to pH=2 with 2 M HCl, extracted with ethyl acetate (5 mL x 2) 
and dried (Na2SO4). The organic solvent was evaporated under reduced pressure to give the desired 
product. 
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3,5-Bis(2-mercaptoacetamido)benzoic acid (5.2) 
 
Yellow gum (56 mg, 100%). 1H NMR (500 MHz, MeOD): δ 8.18 (t, J = 2.1 Hz, 1H, H4), 7.97 (d, J 
= 2.1 Hz, 2H, H2, H6), 3.31 (s, 4H, 2 × SCH2); 13C NMR (125 MHz, MeOD): δ 171.8 (2 × 
NHCOCH2), 169.0 (COOH), 140.4 (C3, 5), 133.0 (C1), 117.9 (C2, 6), 116.6 (C4), 29.3 (2 × 
SCH2). ESI-MS, m/z: 299 [M - H]-. HRMS calculated for C11H11N2O4S2 299.0166, found 
299.0168. 
 
3,5-Bis(3-mercaptopropanamido)benzoic acid (5.3) 
 
Yellow gum (71 mg, 92%). 1H NMR (400 MHz, MeOD): δ 8.19 (t, J = 2.0 Hz, 1H, H4), 7.96 (d, J 
= 2.0 Hz, 2H, H2, H6), 2.82 (t, J = 6.6 Hz, 4H, 2 × SCH2), 2.69 (t, J = 6.6 Hz, 4H, 2 × SCH2CH2); 
13C NMR (100 MHz, MeOD): δ 172.4 (2 × NHCOCH2), 169.3 (COOH), 140.4 (C3, 5), 133.1 (C1), 
117.8 (C2, 6), 116.8 (C4), 41.8 (2 × SCH2CH2), 20.8 (2 × SCH2). ESI-MS, m/z: 327 [M - H]-. 
HRMS calculated for C13H15N2O4S2 327.0479, found 327.0463. 
 
3,5-Bis(4-mercaptobutanamido)benzoic acid (5.4) 
 
Yellow gum (69 mg, 88%). 1H NMR (500 MHz, MeOD): δ 8.16 (t, J = 2.0 Hz, 1H, H4), 7.95 (d, J 
= 2.0 Hz, 2H, H2, H6), 2.59 – 2.48 (m, 8H, 2 × SCH2, 2 × SCH2CH2CH2), 2.00 – 1.94 (m, 4H, 2 × 
SCH2CH2); 13C NMR (125 MHz, MeOD): δ 174.0 (2 × NHCOCH2), 169.2 (COOH), 140.5 (C3, 5), 
133.0 (C1), 117.8 (C2, 6), 116.9 (C4), 36.3 (2 × SCH2CH2CH2), 31.0 (2 × SCH2CH2), 24.6 (2 × 
SCH2). ESI-MS, m/z: 355 [M - H]-. HRMS calculated for C15H19N2O4S2 355.0792, found 
355.0804. 
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Chapter 6.0 SCREENING OF COMPOUNDS SYNTHESISED AS 
PURPLE ACID PHOSPHATASE (PAP) INHIBITORS, 
AGAINST IMP-1. 
 
6.1 Introduction 
Research in the McGeary laboratory not only focuses on developing novel inhibitors of IMP-1 
MBL enzyme, but also involves the development of purple acid phosphatases (PAPs)1 inhibitors. 
PAPs are binuclear metallohydrolases with two heterovalent metal ions (Fe(III) – M(II), M = Fe, 
Zn, or Mn) in the active site that are involve in the hydrolysis of phosphoric esters, at acidic to 
neutral pH.1, 2 PAPs are thought to be involved in the pathomechanism of osteoporosis, a bone 
disorder in mammals, which happens when the rate of bone resorption exceeds the rate of bone 
formation.2   
    
Compounds 6.1 – 6.24 (Figure 6.1) were synthesised by Dr Hajar Pahmi to be developed as potent 
inhibitors of PAPs.3 Throughout her work, Dr Hajar Pahmi found that the presence of a phosphonic 
acid group in the inhibitors contributed to high potencies against PAP. It was of interest to 
investigate the potencies of these compounds against IMP-1, since both PAP and IMP-1 are 
binuclear metallohydrolase enzymes. Furthermore, mercaptophosphonate compounds such as 
compound 6.25 (Figure 6.2) was reported by Lassaux et al. to competitively inhibit B1, B2 and B3 
MBLs with the Ki values of 1, 5 and 0.4 µM, respectively.4 Molecular modelling studies performed 
by Lassaux et al. predicted that compound 6.25 binds to Zn1 of VIM-4 enzyme (PDB code: 
2WHG), a B1 type MBL, through two oxygens (O11 and O13) of its phosphonate group (Figure 
6.3). Similar interactions were observed in the crystal structure of compound 6.25 – CphA (B2 type 
MBL) complex, where the phosphonate group oxygens of this compound interact with the zinc ion 
in the CphA active site (Figure 6.4). The molecular modelling of compound 6.25 bound in the 
active site of FEZ-1, a B3 type MBL, revealed that two oxygens of the compound’s phosphonate 
group were predicted to interact with both zinc ions of FEZ-1 (Figure 6.5).4 As compounds 6.1 – 
6.24 also contain phosphonate groups, these compounds were expected to inhibit IMP-1 with the 
similar binding interactions, which involve two oxygens of the phosphonate groups and the zinc (or 
both zinc) ions. 
 
Screening of compounds 6.1 – 6.24 were carried out against the IMP-1 to select potent compounds 
with considerable inhibition percentages. Ki values of the selected compounds were then 
determined by kinetic assays and the results are discussed in this chapter.  
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Figure 6.1. Compounds synthesised as PAP inhibitors. 
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Figure 6.2. Mercaptophosphonate inhibitor of MBLs (see ref. 4). 
 
 
Figure 6.3. Docking image of compound 6.25 – VIM-4 (PDB code: 2WHG) (see ref. 4).  
 
 
Figure 6.4. Crstal structure of compound 6.25 – CphA showing the interactions of phosphonate 
group oxygens with the zinc ion (see ref. 4). 
 
Cl
Cl
P
SH
HO
OHO
6.25
 215 
 
Figure 6.5. Docking image of compound 6.25 – FEZ-1 (PDB code: 1JT1) (see ref. 4).   
  
6.2 Results and Discussion 
 
6.2.1 Kinetic Assays 
 
The screening assay results of compounds 6.1 – 6.24 against the IMP-1 are shown in Table 6.1. 
Compounds 6.2 – 6.5 modestly inhibit IMP-1 at 100 µM and show lower inhibition activity at 10 
and 1 µM. The addition of an ether group between the alkyl chain and the amide carbonyl of 
compound 6.1 increased the solubility and inhibition percentage of compound 6.6 to 60% from no 
inhibition at 100 µM. However, the same transformation of compound 6.5 could not improve the 
inhibition percentage of compound 6.7. The presence of ethoxy para substituent in compounds 6.8 
and 6.9 increased the inhibition activities of compound 6.3 and 6.4 to more that 50% at 100 µM. 
The unavailable data under 100 µM column for compound 6.10 might be due to the technical error 
during the test. However, this compound shows good inhibition at 10 µM with 63% activity. 
Compound 6.11 with an ether group between the alkyl chain and the amide carbonyl and a methoxy 
para substituent have moderate inhibition activity at 100 µM (52%).  
 
Furan-containing compounds 6.13 and 6.14 also show moderate inhibition at 100 µM. Compound 
6.14 even have 45% inhibition at 10 µM and 10% at 1 µM. The exchange of furan ring to thiophene 
ring is not effective in improving the inhibition of compounds 6.15 – 6.24. Only compounds 6.18 
and 6.24 exhibit good inhibition at 100 µM (60 and 71%, respectively), but the inhibition dropped 
significantly to ~10% at 10 µM.  
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Compounds 6.10 and 6.14 were selected for kinetic assay to determine their Ki values against IMP-
1 as both compounds have considerable activity at 10 µM. Despite the fact that other compounds 
such as compounds 6.6, 6.8, 6.9, 6.11, 6.18 and 6.24 have good inhibition percentage at 100 µM, 
their low percentage of inhibitions at 10 µM (less than 50%) make them not potent enough to be 
further tested by the kinetic assay (see Section 3.1.2.4).  
 
Table 6.1. Screening assay results of compounds 6.1 – 6.24 against IMP-1. 
 % Inhibition a 
Compounds 100 µM 10 µM 1 µM 
 
6.1 
- - 9 
 
6.2 
35 1 5 
 
6.3 
25 24 2 
 
6.4 
35 29 8 
 
6.5 
35 14 16 
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6.6 
60 36 2 
 
6.7 
21 12 - 
 
6.8 
53 26 2 
 
6.9 
77 22 - 
 
6.10 
- 63 8 
 
6.11 
52 21 - 
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6.12 
14 4 - 
 
6.13 
49 25 12 
 
6.14 
63 45 10 
 
6.15 
38 16 2 
 
6.16 
- - - 
 
6.17 
21 3 4 
 
6.18 
60 9 - 
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6.19 
18 7 - 
 
6.20 
- - - 
 
6.21 
10 - - 
 
6.22 
21 2 4 
 
6.23 
42 9 5 
 
6.24 
71 10 - 
a
 - (no value) indicates no inhibition. 
 
The kinetic assay results of compounds 6.10 and 6.14 against both IMP-1 and PAP are shown in 
Table 6.2. The kinetic assays of these compounds against PAP were performed by Dr Hajar Pahmi 
in the McGeary group. According to Table 6.2, compound 6.10 was found to inhibit IMP-1 by 
uncompetitive inhibition mode with quite high Kiuc value (71 ± 50 µM). In the other hand, this 
compound was found to inhibit PAP completely by competitive inhibition mode with the Kic value 
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of 5.7 ± 2.0 µM. This suggests that compound 6.10 is a potent lead compound to be further 
developed as inhibitor, which selectively targets PAP. Interestingly, even without free thiol group, 
compound 6.14 shows competitive inhibition mode against both IMP-1 and PAP (Kic = 5.4 ± 2.5 
and 1.4 ± 0.4, respectively). Therefore, to gain better understanding on how compound 6.14 might 
bind in the IMP-1 active site, a docking simulation of this compound bound to IMP-1 enzyme was 
performed using the MVD software and discussed in Section 6.2.2.       
 
Table 6.2. Ki values of compound 6.10 and 6.14 against IMP-1 and PAP. 
 IMP-1 a PAP b 
Compounds Kic (µM) c Kiuc (µM) c Kic (µM) Kiuc (µM) c 
 
6.10 
- 71 ± 50 5.7 ± 2.0 - 
 
6.14 
5.4 ± 2.5 - 1.4 ± 0.4 - 
a Values are mean of duplicate measurements ± SEM. 
b Kinetic assays were performed by Dr Hajar Pahmi. 
c - (no value) indicates a very large value (mM range), thus is irrelevant and hence neglected. 
 
6.2.2 Molecular Modelling 
 
The kinetic assay of compound 6.14 was carried out using a racemic mixture of the compound. 
However, molecular modelling of the compound was performed on both R- and S-isomers. The 
phosphonate was deprotonated before the docking simulations as the pKa of phosphonates are ~7. 
The molecular modelling results of R/S-6.14 are shown in Table 6.3. The R-isomer was calculated 
to have larger negative value of MolDoc score compared to its corresponding S-isomer. These 
results suggested that R-isomer might have higher binding affinity, thus more potent against the 
IMP-1 compared to the S-isomer. Figure 6.6 shows the predicted binding orientation of compound 
R-6.14 in the IMP-1 active site (see Appendix A6 for the docking image of compound S-6.14).    
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Table 6.3. MolDock scores generated by MVD for compounds R/S-6.14 docked in the IMP-1 active 
site. 
 MolDoc Score a (kcal/mol) 
 R-isomer S-isomer 
Compound 
  
6.14 -87 -23 
a
 Docking score calculated by Molegro Virtual Docker (MVD) software. Larger 
negative values indicate higher binding affinities of inhibitor – IMP-1. 
 
Surprisingly, there were no interactions predicted between the R-isomer of compound 6.14 with any 
of the zinc ions in the IMP-1 active site. The interactions observed in Figure 6.6 are more likely 
displaying an uncompetitive binding mode as compound R-6.14 is not interacting directly with the 
zinc ions. Compound R-6.14 was predicted to bind to the carboxyl oxygen of Gly 228 (hydrogen 
bond) through its NH group (O-H distance 2.4 Å). Another hydrogen bond was predicted between 
the amide carbonyl of this compound and the NH3+ group of Lys 224 with the O-H distance of 3.1 
Å. In addition to the interactions mentioned, this compound was also predicted to have hydrophobic 
interactions with the Asn 233 (alkyl chain to Asn 233 backbone chain distance 3.5 Å), Lys 167 
(alkyl chain to Lys 167 backbone chain distance 2.6 Å) and Leu 146 (alkyl chain to Leu 146 side 
chain C distance 1.9 Å).  
 
Throughout this work, molecular docking results are not always in agreement with the kinetic assay 
outcomes. Compound R-6.14 was found to inhibit IMP-1 completely by competitive inhibition 
mode by the kinetic studies since the Kiuc value of this compound is very large (M range). The 
binding orientations displayed by molecules – enzyme complexes in the docking results might not 
precisely reflect the actual binding orientations in the complexes as the molecular docking are only 
predicting the interactions and binding affinities of the docked molecules in the enzyme’s active 
site. Therefore, the inhibition potencies and inhibition modes determined experimentally by kinetic 
assay studies would be more reliable. Nevertheless, the docking studies are still useful in the drug 
designing process as this tool can assist in visualising the predicted binding interactions of 
molecules – enzyme complexes.  
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R-6.14 
 
Figure 6.6. Docking of compound R-6.14 into the IMP-1 active site. Colours: Blue – nitrogen; red – 
oxygen; grey – carbon; yellow – sulfur; magenta – Zn ions.  
 
 
6.3 Summary 
 
A total of 24 compounds synthesised by Dr Hajar Pahmi were screened against the IMP-1 enzyme. 
From the screening test results, none of the compounds show excellent inhibition activities against 
the enzyme. Compounds 6.6, 6.8, 6.9, 6.11, 6.18 and 6.24 have good inhibition percentage against 
the enzyme at 100 µM, but their activity at 10 µM decreased significantly. Therefore, these 
compounds were not considered potent enough for further testing. In the other hand, compounds 
6.10 and 6.14 were selected for kinetic assay studies as both compounds show moderate inhibition 
activities at 10 µM.  
 
From the kinetic assay results, compound 6.10 was found to inhibit IMP-1 by uncompetitive 
inhibition mode with the Kiuc  = 71 ± 50 µM. Compound 6.14 inhibits IMP-1 by competitive mode 
of inhibition with the Kic value of 5.4 ± 2.5 µM. The computational modelling result of compound 
6.14 docked into the IMP-1 active site are not in agreement with the competitive inhibition mode 
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determined by the kinetic assays, where this compound does not directly interacts with any of the 
zinc ions. However, there are a few hydrogen bonds and hydrophobic interactions predicted 
between this compound and the amino acid residues of IMP-1, thus leading to inhibition of the 
enzyme. 
 
 
6.4 Experimental 
 
All kinetic assays were carried out based on the procedure previously described in Section 2.1.2.5. 
 
IMP-1 Screening Assays5 
96-well plate assays were performed in HEPES X buffer (50 mM HEPES, 0.1 M NaCl, 100 µM 
ZnCl2, pH 7) using the substrate penicillin G 1.8a at 25°C. The rate of penicillin G 1.8a 
consumption was monitored at 235 nm (ε = 936 M-1 cm-1). The final concentrations of penicillin G 
1.8a, IMP-1 and bovine serum albumin (BSA, for enzyme stability) were 500 µM, 10 nM and 20 
µg/mL, respectively. Final concentrations for every inihibitor were 100, 10 and 1 µM. 
 
IMP-1 Ki Assays5, 6 
96-well plate assays were performed in HEPES X buffer (50 mM HEPES, 0.1 M NaCl, 100 µM 
ZnCl2, pH 7) using the substrate penicillin G 1.8a (100 – 1000 µM). The rate of penicillin G 1.8a 
consumption was monitored at 235 nm (ε = 936 M-1 cm-1). The final concentrations were IMP-1 (10 
nM) and 20 µg/mL bovine serum albumin (BSA) for enzyme stability. Five inihibitor 
concentrations were prepared for the tests, based on the Screening Assay results. 
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Chapter 7.0  CONCLUSIONS AND FUTURE WORK 
 
7.1 Conclusions 
 
Bacterial infections need to be treated immediately to avoid severe illnesses that are life threatening. 
Human bodies still need antibiotics to treat severe infections caused by bacteria. β-Lactam 
antibiotics are classified as bactericidal antibiotics, which inhibit the bacterial cell wall synthesis.1-3 
Penicillin, cephalosporin, carbapenem and monobactam are the examples of common β-lactam 
antibiotics with β-lactam ring as the core structure.4-6 Nowadays, bacteria can produce β-lactamases 
that can hydrolyse β-lactam ring, thus inactivating the β-lactam antibiotics.7 β-Lactamases can be 
devided into Classes A, B, C and D, where Classes A, C and D are serine-β-lactamases (SBLs) with 
serine residue acts as a nucleophile.8, 9 Class B β-lactamases are also called metallo-β-lactamases 
(MBLs) and use zinc-bound hydroxyl group in the active site as the nucleophile.9 Although a few 
classes of MBL inhibitors including thiols, dicarboxylic acids and sulfonamides were reported in 
the literature, none of these compounds are clinically approved.10 This research is focused on 
developing IMP-1 MBL inhibitors since level of IMP-1 production by pathogens such as 
Acinetobacter spp. and Pseudomonas eruginosa that can resist various kinds of drugs are clinically 
significant.9, 10  
 
Chapter 2.1 discussed the design, docking studies, syntheses and testing of thiols 2.1.1 – 2.1.3 
against IMP-1 enzyme. Thiols 2.1.1 – 2.1.3 were designed based on the lead compounds, L-
captopril’s and D-captopril’s encouraging competitive inhibition properties against MBLs.11 The 
docking studies of these thiols into the active site of IMP-1 enzyme (PDB code: 1JJT) using 
Molegro Virtual Docker (MVD) software showed favourable binding interactions with the enzyme 
active site.   
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Syntheses of the thiols 2.1.1 – 2.1.3 were completed via four steps reaction starting from 
esterification of L- and D-proline,12, 13 coupling reaction using HBTU14 and lastly base hydrolysis to 
cleave both methyl ester and thioester.14 All synthesised compounds including the thiols 2.1.1 – 
2.1.3 and their precursors were screened against IMP-1 enzyme. Kinetic assays were performed on 
the thiols 2.1.1 – 2.1.3 as these thiols have excellent inhibition percentage in the screening tests. 
The thiols 2.1.1 – 2.1.3 inhibit IMP-1 by competitive inhibition mode with the Ki values ranging 
from 2.2 ± 0.6 to 9.9 ± 4.2 µM. These thiols display an improvement in the Ki values compared to 
the lead compound, L-captopril with Ki = 12.5 ± 2.4 µM. Nevertheless, different isomers and the 
distance between the carboxylate group and the thiol have no effect on the Ki values. 
 
IMP-1 enzyme was expressed and purified in approximately two weeks. The IMP-1 expression was 
carried out via transformation, inoculation, enzyme expression and cell harvesting processes. The 
enzyme was then purified using two columns: SP-Sepharose cation exchange column and 
Sepharacyl S-200 gel filtration size exclusion column, and yielded 12mg per 2 litres of culture with 
the specific activity of 11 µmol min-1 mg-1 toward penicillin G 1.8a.15, 16 Specific activity shows the 
amount of product formed by IMP-1 per minute per milligram of the total proteins.  
 
In Chapter 2.2, design, docking simulations and syntheses of compounds 2.2.1a – 2.2.1c were 
reported. The design of these new compounds was based on the encouraging competitive inhibition 
properties of D-captopril and thiols 2.1.1 – 2.1.3 reported in Chapter 2.1. Longer chain at C1 was 
expected to improve the inhibition potencies of these compounds by forming favorable interactions 
with the amino acid residues of the enzyme. The docking images of compounds 2.2.1a – 2.2.1c in 
the IMP-1 enzyme’s active site using MVD also show favourable binding modes with the enzyme. 
The MVD software predicted that compounds 2.2.1a – 2.2.1c would have comparable inhibition 
potencies with thiols 2.1.1 – 2.1.3 based on the calculated MolDoc scores.  
   
 
 
Compounds 2.2.1a – 2.2.1c were synthesised via etherification of N-Boc-D-prolinol,17 selective 
deprotection of the Boc group,18 coupling with the carboxylic acids and lastly acid hydrolysis to 
N
O
O
O SH
OH
n
2.2.1a: n = 1
2.2.1b: n = 2 
2.2.1c: n = 3
1
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yield the free thiols.14 Screening tests against IMP-1 enzyme were performed on all nine 
synthesised compounds and the starting material, N-Boc-D-prolinol. Based on the screening assay 
results, compounds 2.2.1a – 2.2.1c and their corresponding thioesters (the coupled compounds 
2.2.10a – 2.2.10c) were selected for further testing to determine their Ki values. All compounds 
tested competitively inhibit IMP-1 with the Ki values ranging from 195 ± 111 to 1102 ± 52 µM, 
indicating a significant loss in the inhibition potencies of these compounds compared to thiols 2.1.1 
– 2.1.3. Thus, increasing the distance of the carboxylate group from the proline rings was unable to 
improve the Ki values of compounds 2.2.1a – 2.2.1c. 
 
Optimisation of the chemical structures of inhibitor compounds was continued based on the 
encouraging competitive inhibition properties of the previously synthesised L-proline and D-proline 
derivatives (thiols 2.1.1 – 2.1.3) against the IMP-1 enzyme and reported in Chapter 2.3. The design 
process of compounds 2.3.1 – 2.3.3 includes the replacement of the thiol group in thiols 2.1.1 – 
2.1.3 with a carboxylic group. However, the MVD software predicted that dicarboxylic acids 2.3.1 
– 2.3.3 would have slightly lower inhibition potencies than the thiols 2.1.1 – 2.1.3. 
 
 
 
The synthese of dicarboxylic acids 2.3.1a - b were completed via a three-steps reaction from L-
proline and D-proline. Esterification of the prolines12 followed by coupling reaction using HBTU 
and base hydrolysis successfully yielded the dicarboxylic acids 2.3.1a - b.14 On the other hand, 
dicarboxylic acids 2.3.2 – 2.3.3 were prepared according to the method reported by Santos et al. in 
just one step.19 
 
All synthesised compounds, succinic anhydride and glutaric anhydride were screened against IMP-
1 to select compounds with considerable inhibition percentages. However, kinetic assays of 
dicarboxylic acid series were aborted since none of these compounds showed potential inhibition 
activity against IMP-1 enzyme even at 100 µM compound’s concentration. 
 
The design, computational modelling, syntheses and testing of compounds 2.4.1 – 2.4.3 were 
N
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discussed in Chapter 2.4. Compounds 2.4.1 – 2.4.3 were designed based on the encouraging 
competitive inhibition properties of thiols 2.1.1 – 2.1.3 developed in Chapter 2.1 by replacing the 
five-membered ring of thiols 2.1.1 – 2.1.3 to a six-membered ring to increase the hydrophobicity of 
the ring, hence encourage hydrophobic interactions between these compounds and hydrophobic 
region of IMP-1 active site.20 Virtual docking of compounds 2.4.1 – 2.4.3 into the active site of 
IMP-1 enzyme (PDB code: 1JJT) using MVD software show that these compounds were predicted 
to have favourable binding mode with the enzyme where the thiol group of these compounds would 
bind to both zinc ions and the carboxylate and amide carbonyl group of the molecules would 
interact with the hydrogen bond donor region of the enzyme.20 
 
 
 
Synthesis of compound 2.4.1 was achieved via a three-steps reaction starting from the preparation 
of acid chloride 2.1.8 from the carboxylic acid 2.1.5, coupling reaction of acid chloride 2.1.8 with 
pipecolinic acid, followed by base hydrolysis of compound 2.4.5 to give thiol 2.4.1. On the other 
hand, a four-steps reaction was carried out to synthesise thiols 2.4.2 and 2.4.3 starting with 
esterification of pipecolinic acid, coupling reaction of the methyl ester 2.4.8 using HBTU and 
finally the hydrolysis of the coupled products 2.4.9 – 2.4.10 using NaOH to restore the carboxylic 
acid and thiol groups and give the desired final compounds 2.4.2 – 2.4.3. The final compounds 2.4.2 
– 2.4.3 and compound 2.4.5 with a thioester and a free carboxylic acid group were selected for 
kinetic analysis due to their excellent inhibition percentages in the screening tests of these 
compounds against IMP-1. All of the compounds tested inhibit IMP-1 solely by competitive 
inhibition mode with the Ki values ranging from 3.4 ± 1.3 to 10 ± 4 µM, which are comparable to 
thiols 2.1.1 – 2.1.3. These results indicate that replacing a five-membered ring with a six-membered 
ring does not affect the Ki values. 
 
The development of a series of inhibitors against IMP-1 was discussed in Chapter 3.1. The design 
of compounds 3.1.1 – 3.1.3 was based on the encouraging competitive inhibition of thiols 2.1.1 – 
2.1.3 and the ability of pyridine nitrogen of compound 3.1.4 to chelate the zinc ion in a monozinc 
MBL CphA. However, lesser interactions were predicted by the MVD software between 
N OH
OOHS
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2.4.2: n = 2 
2.4.3: n = 3
n
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compounds 3.1.1 – 3.1.3 and the enzyme’s active site as compared to the thiols 2.1.1 – 2.1.3. 
Therefore, compounds 3.1.1 – 3.1.3 were predicted to have lower inhibition potencies than thiols 
2.1.1 – 2.1.3 based on the calculated MolDoc scores.  
 
 
 
Only two steps were needed to achieve the syntheses of compounds 3.1.1 – 3.1.3: coupling reaction 
of 2-aminopyridine with the carboxylic acids 2.1.5 – 2.1.7 and base hydrolysis of the coupled 
compounds to afford the final compounds with the free thiols. All synthesised compounds and the 
starting material, 2-aminopyridine were screened against IMP-1 and final compounds 3.1.1 – 3.1.3 
were found to have excellent inhibition percentages. From kinetic assays of the final compounds, all 
of them were found to competitively inhibit IMP-1 with the Ki values ranging from 4.8 ± 0.7 to 8.5 
± 3.2 µM. These values indicate that compounds 3.1.1 – 3.1.3 also have comparable inhibition 
potencies with the thiols 2.1.1 – 2.1.3. However, the improvement in Ki values could not be 
achieved by this compounds series.   
 
Chapter 3.2 discussed the development of compounds 3.2.1 – 3.2.3 as inhibitors of IMP-1. An 
addition of a carboxylate group to compounds 3.1.1 – 3.1.3 was expected to increase strong 
interactions with the IMP-1 actives site residues, as this moiety would bind to the conserved 
hydrogen bond donor of IMP-1. Consequently, these strong interactions were predicted to enhance 
the inhibition potencies of compounds 3.2.1 – 3.2.3 against the enzyme. As expected, MolDoc 
Scores calculated by the MVD software for these compound suggested that compounds 3.2.1 – 
3.2.3 would have stronger inhibition potencies than compounds 3.1.1 – 3.1.3.        
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Three additional steps were employed to introduce the carboxylic acid group into compounds 
3.1.1 – 3.1.3 to achieve the syntheses of compounds 3.2.1 – 3.2.3. Acylation, oxidation and 
sterification of the starting material, 2-Amino-6-picoline yielded the desired methyl ester 3.2.6. 
HBTU coupling of the methyl ester 3.2.6 afforded the coupled compounds 3.2.7 – 3.2.9. The 
coupled compounds were then hydrolysed to give the final compounds 3.2.1 – 3.2.3. All final 
compounds were tested against IMP-1 enzyme and show competitive inhibition mode (Kic = 9.7 ± 
4.0 to 31 ± 4 µM). Therefore, compounds 3.2.1 – 3.2.3 have weaker inhibition potencies than 
compounds 3.1.1 – 3.1.3. In this series, compound 3.2.3 has the lowest Kic value (9.7 ± 4.0 µM).     
 
In chapter 4, the design of compounds 4.2 – 4.4 based on compound RS-4.2 reported by Liénard et 
al.20 was discussed. Compound RS-4.2 was reported to be an excellent competitive inhibitor of 
IMP-1 (Ki = 0.019 ± 0.002 µM). The MVD software predicted that compounds 4.2 – 4.4 in complex 
with the IMP-1 enzyme have similar binding mode to the thiols 2.1.1 – 2.1.3 – IMP-1 complexes. 
 
 
 
In just two steps, syntheses of compounds 4.2 – 4.4 were achieved from commercially available 
R/S-phenylglycine methyl ester hydrochloride 4.5. HBTU coupling of the methyl ester 
hydrochloride followed by hydrolysis of the coupled compounds successfully afforded the final 
products. Kinetic assays of the individual enantiomers and the racemic mixtures of the final 
compounds 4.2 – 4.4 show that these compounds inhibit IMP-1 by competitive inhibition mode and 
the Ki values are ranging from 2.6 ± 1.0 to 11 ± 3 µM. These values are comparable with the thiols 
2.1.1 – 2.1.3 Ki values, but larger compared to the reported value of compound RS-4.2 (0.019 ± 
0.002 µM). 
 
Compound 5.1 was also reported by Liénard et al. to have broad-spectrum inhibition properties.20 
Design, molecular dockings, syntheses and testing of new compounds 5.2 – 5.4 based on compound 
5.1 were reported in Chapter 5. Only one thiolate group of compounds 5.2 – 5.4 was predicted by 
MVD to bind to one of the zinc ions of the IMP-1 active site. The MVD predicted higher MolDoc 
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scores for compounds 5.2 – 5.4 compared to thiols 2.1.1 – 2.1.3 that might be due to farther 
distances of the key structures of these compounds from the active site residues and resulted in 
weaker compounds – enzyme interactions.   
 
 
 
The designed new molecules 5.2 – 5.4 were synthesised by esterification reaction of 3,5-
diaminobenzoic acid, coupling reaction and base hydrolysis. All synthesised compounds and the 
starting material, 3,5-diaminobenzoic acid were screened against IMP-1 and compounds 5.2 – 5.4 
were selected for kinetic assay analyses. Ki values of compounds 5.2 – 5.4 determined by the 
kinetic assays are between 2.1 ± 0.8 and 4.3 ± 2.0 µM. All of these compounds show uncompetitive 
inhibition mode.  
 
In Chapter 6, sreening of 24 compounds synthesised by Dr Hajar Pahmi against the IMP-1 enzyme 
was discussed. Out of 24 compounds, none of them have excellent inhibition activities against the 
enzyme. At 100 µM, compounds 6.6, 6.8, 6.9, 6.11, 6.18 and 6.24 show good inhibition activities, 
but their activity decreased significantly when the compounds concentrations was 10 µM. In the 
other hand, compounds 6.10 and 6.14 show moderate inhibition activities at 10 µM, hence selected 
for further testing against IMP-1. Compound 6.10 was found to inhibit IMP-1 by uncompetitive 
inhibition mode with a large Kiuc value (71 ± 50 µM). In contrast, compound 6.14 inhibits IMP-1 by 
competitive mode of inhibition with an encouraging Kic value of 5.4 ± 2.5 µM. However, 
computational modelling result of compound 6.14 – IMP-1 complex display an uncompetitive 
binding mode orientation, where this compound does not directly interacts with any of the zinc ions. 
A few hydrogen bonds and hydrophobic interactions were predicted in compound 6.14 – IMP-1 
complex that could lead to the inhibition of the enzyme. 
 
In conclusion, design of new molecules based on lead compounds, molecular docking studies, 
syntheses and testing of compounds against IMP-1 were performed throughout this work to develop 
new potent IMP-1 inhibitors. It is well known that clavulanic acid 1.18 can effectively inhibit serine 
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β-lactamases (SBLs) mechanism9 but this compound is not active against MBLs.21 MBLs inhibitors 
are urgently needed by the society since clinically approved inhibitors for MBLs are not yet 
available. Furthermore, levels of MBLs produced by pathogens such as Acinetobacter spp. and 
Pseudomonasa aeruginosa that can resist various kind of drugs are clinically significant.9  
 
The results generated from the docking simulations by Molegro software were only predictions of 
the binding interactions and binding affinities of the potent inhibitors in the enzyme active site. 
These results may not accurately reflect the binding interactions and affinities in the inhibitor-
enzyme complexes.22, 23 More reliable data could be obtained experimentally from kinetic assays of 
the inhibitors against the target enzyme which provide the inhibition potencies and the inhibition 
modes of the inhibitors. However, the docking studies are still useful to assist in visualising the 
predicted binding interactions of inhibitor-enzyme complexes in the drug designing processes. 
 
In this study, thiols 2.1.1 – 2.1.3 show the strongest competitive inhibition potencies and 
compounds 5.2 – 5.4 show the best uncompetitive inhibition potencies against IMP-1. Interactions 
between the key structures of the molecules and amino acid residues in the enzyme’s active site are 
the contributing factor to an efficient enzyme inhibition.11, 24 The existence of functional groups that 
can interact with the conserved hydrogen bond region and conserved hydrophobic region of the 
IMP-1 are important and proved to be effective in enhancing the inhibition potencies of inhibitor 
molecules.20 The findings obtained from this study could aid in the development of more potent 
IMP-1 inhibitors.  
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7.2 Future Work 
 
Among all compounds synthesised in this study, thiols 2.1.1 – 2.1.3 (Chapter 2.1) are the most 
potent compounds against IMP-1 with encouraging inhibition potencies (Kic = 2.2 ± 0.6 to 9.9 ± 4.2 
µM). The MVD software predicted a few important interactions between functional groups of these 
compounds and the amino acid residues in the enzyme’s active site. However, the interactions 
predicted by the software might not represent the actual binding orientations in the compounds – 
enzyme complexes. Therefore, X-ray crystallography analyses of thiols 2.1.1 – 2.1.3 bound in the 
IMP-1 active site should be done to determine the actual binding modes presence in the compound 
– IMP-1 enzyme complex crystal structures. The information obtained from the crystallography 
studies will be utilised in designing and optimising more potent inhibitor molecules in the future.  
 
Thiols 2.1.1 – 2.1.3 will also be tested against other enzymes from B1 and B3 MBL subclasses. 
Similar to IMP-1, the MBLs from these subclasses require two zinc ions in their active sites for 
activity. These thiols might give promising results since L- and D-captopril was reported to show 
competitive inhibition activity against B1 – B3 MBL subclasses (see Section 2.1.1). The next target 
enzymes would be New Delhi metallo-β-lactamase (NDM-1)25 from B1 subclass MBL and 
Adelaide imipenemase-1 (AIM-1)26 from B3 subclass MBL. Recently identified B4 MBL will also 
be a possible target for inhibition activity of thiols 2.1.1 – 2.1.3 as this class also needs two zinc 
ions for optimal β-lactam hydrolysis.27, 28       
 
Testing of the thiols 2.1.1 – 2.1.3 in bacteria that express MBLs will also be helpful to investigate 
the inhibition potencies of these compounds. Minimum inhibitory concentration (MIC) tests will be 
conducted to determine the concentration of thiols 2.1.1 – 2.1.3 required to restore the antibiotic 
activities of β-lactam antibiotics.29 The MIC values will then be compared with the Ki values of 
thiols 2.1.1 – 2.1.3 determined by the kinetic assay analyses performed in this work.     
 
Other than the encouraging inhibition potencies of thiols 2.1.1 – 2.1.3 against IMP-1, these 
compound series have the potentials to be developed as drugs since they are easier to be synthesised 
than the captopril. Based on the predicted binding orientations of these thiols with the enzyme 
generated by the MVD, only the thiolate, carboxylate and amide carbonyl groups are bound to the 
active site of the enzyme (see Section 2.1.2.2). There are no interactions predicted between the five-
membered ring of these compounds and the enzyme. Therefore, the chemical structure of thiols 
2.1.1 – 2.1.3 will be further optimised by attaching a bulky functional group to the five-membered 
ring of these compounds to create more possibilities of hydrophobic interactions with the conserved 
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hydrophobic region of IMP-1 enzyme.20 As discussed in all chapters in this thesis (except Chapter 
2.3 and 6), the thiolate group of the next new compounds is expected to coordinate both zinc ions of 
IMP-1, and the carboxylate and amide carbonyl groups are expected to bind via hydrogen bond to 
the amino acid residues in the conserved hydrogen bond donor of the enzyme. With the 
combination of thiolate, carboxylate, amide carbonyl and hydrophobic functional groups, the 
structurally optimized thiols are expected to have stronger binding affinities with the enzyme’s 
active site, consequently have higher inhibition potencies than thiols 2.1.1 – 2.1.3. Figure below 
shows the proposed new compounds to be developed as new potent inhibitors of IMP-1. 
 
 
 
As the acid hydrolysis reaction of the coupled compound 2.1.20a was unsuccessful in restoring both 
the thiol and carboxylic acid groups of thiol 2.1.1a (see Section 2.1.2.3), optimisation reactions will 
be conducted to find a suitable condition for this reaction. Firstly, overnight reactions with a range 
of different hydrochloric acid concentrations will be trialed on the coupled compound 2.1.20a at 
room temperature to choose an optimum acid concentration that can give thiol 2.1.1a with excellent 
yield. Then, the same reactions will be repeated by heating the reaction mixtures to reflux. Acid 
hydrolysis reaction of the coupled compound 2.1.20a by sulfuric acid will also be conducted to 
compare which acid is more effective in hydrolysing the coupled compound 2.1.20a to yield thiol 
2.1.1a. 
 
On the other hand, base hydrolysis of the coupled compound 2.1.20a using 2 M sodium hydroxide 
easily yielded thiol 2.1.1a after two hours reaction. It is out of interest to investigate the effect of 
base hydrolysis of the coupled compound 2.1.20a by replacing sodium hydroxide with potassium 
hydroxide. The first trial reaction will be conducted at room temperature using 2 M potassium 
hydroxide in methanol. The reaction time will be fixed to two hours to compare the yield of thiol 
2.1.1a with the yield obtained from base hydrolysis of the coupled compound 2.1.20a using 2 M 
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sodium hydroxide.  
 
 
 
 
One of the hardest tasks during this study was maintaining the stability of the purified IMP-1 
enzyme stock, as proteins are usually unstable outside their native environments. The conditions of 
buffer used to store the enzyme should be maintained properly to prevent enzyme degradation and 
loss of activity. The enzyme shelf life varies from a few days to years depending on the nature of 
the enzyme and the conditions used for enzyme storage. The enzyme was previously stored in 
buffer solution at 4°C. It could be used immediately when needed but totally inactive after a few 
weeks. Therefore, a new storage conditions should be applied to extend the shelf life of the enzyme. 
The purified enzyme will be prepared as single-use aliquotes in microtubes and will be frozen at -
20°C. The single-use aliquotes will prevent freeze-thaw cycles as freezing and thawing repeatedly 
decreases the enzyme’s stability. Adding 25 - 50% cryoprotectant such as glycerol to the purified 
enzyme helps to increase the enzyme’s stability by preventing the formation of ice crystals that can 
destroy the enzyme’s structure. Freezing the enzyme aliquotes at -20°C will protect the enzyme for 
up to one year. The single-use aliquotes with 25 - 50% glycerol can also be stored at -80°C for 
longer shelf life.30   
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Appendix A Docking Images of the Designed Potent New Inhibitors in the 
IMP-1 Active Site   
A1. L- & D-Proline Derivatives (Thiols)  
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A2. D-Captopril Derivatives 
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A3. L- & D-Proline Derivatives (Dicarboxylic Acids) 
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A4. Pipecolinic Acid Derivatives 
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A5. Phenylglycine Derivatives 
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A6. Screening of Compounds Synthesised as Purple Acid Phosphatase (PAP) 
Inhibitors, Against IMP-1 
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Appendix B Enzyme Expression and Purification 
 
Day 0  
 
Materials: 
1. Luria bertani (LB) Broth 
2. LB Agar 
3. Petri dish 
4. Kanamycin Stock (50 mg/ml) 
5. IPTG Stock (100 mM) 
6. Autoclave flask 
7. Shaker 
8. Water Bath (42°C) 
9. BL21(DE3) competent cells 
 
Preparation 
 
LB Agar (100 mL) 
Tryptone (1.0 g), yeast extract (0.5 g), NaCl (1.0 g) and agar (1.5 g) in MiliQ water (100 mL) were 
sterilised. The sterilised LB agar solution was then cooled to 55°C. Kanamycin stock (50 mg/mL) 
was added to the LB agar solution and mixed well. Then, the LB agar solution was poured into Petri 
dishes (~25 mL per Petri dish).   
 
LB Broth (500 mL) 
Tryptone (5.0 g), yeast extract (2.5 g) and NaCl (5.0 g) in MiliQ water (500 mL) were sterilised 
before used. 
 
TB Broth (500 mL) 
Tryptone (6.0 g), yeast extract (12 g) and glycerol (2.0 mL) in MiliQ water (450 mL) were sterilised 
before used.  
At the same time, 50 mL buffer (1.16 g KH2PO4 and 6.27 g K2HPO4 in 50 mL MiliQ water) was 
prepared separately and sterilised.  
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HEPES A Buffer (50 mM) 
HEPES (11.91 g) and ZnCl2 (1.0 mL, 500 mM) in MiliQ water (1.0 L) were filtered using 0.22 µm 
filter. 
 
HEPES B Buffer (50 mM)  
HEPES (11.91 g), NaCl (58.44 g) and ZnCl2 (1.0 mL, 500 mM) in MiliQ water (1.0 L) were filtered 
using 0.22 µm filter.  
 
HEPES X Buffer (50 mM) 
HEPES (11.91 g), NaCl (5.844 g) and ZnCl2 (0.2 mL, 500 mM) in MiliQ water (1.0 L). 
 
Day 1 
Transformation 
1. In the biological hood, 2 µL Plasmid Klebs and 50-100µL BL21 (DE3) Escherichia coli  
comptent cell were mixed in an Eppendorf tube. 
2. The Eppendorf tube content was cooled in ice for 25 - 30 minutes. 
3. The mixture was put in 42°C heating block (heat shock) for 40 - 45 seconds and then 
immediately placed in ice for 2 minutes. 
4. 750 µL of LB broth was added to the Eppendorf tube.  
5. The mixture was incubated for 1 - 1.5 hour at 37°C (with shaking). 
6. The mixture was centrifuged for 60 seconds and 500 µL of the supernatant was removed from 
the mixture. 
7. 50 - 100 µL of the mixture was spread on an LB agar plate. 
8. The plate was wrapped with parafilm and incubated at 37°C overnight (16 - 18 hours). 
 
Day 2 
Inoculation 
1. Single colony was picked using pipet tip and inoculated in 50mL falcon tube. The falcon tube 
was filled with 20 mL LB broth and 20 µL Kanamycin (50 mg/mL). 
2. The cells in the falcon tube were grown at 30°C in a shaker (200 RPM) for 12 - 16 hours 
(overgrow will create mutations). 
 
Day 3 
Enzyme Expression 
1. 500 µL of Kanamycin (50 mg/mL) stock was added to 0.5 L sterilized TB broth.  
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2. Then the falcon tube content (from inoculation) was poured into a 2 L flask containing 0.5 L 
TB broth and 500 µL of Kanamycin. 
3. Shake the flask in an incubator at 37°C (200 RPM) for 1 hour.  
4. Then 28 µL of ZnCl2 stock (500 mM) was added to the flask. 
5. Optical density (OD600) of the flask content was measured using spectrophotometer at 600 nm 
every 30 minutes.  
6. When the OD600 reached 0.6, 5.5 mL IPTG was added into the flask. Then, the flask was 
incubated at 30°C (200 RPM) for 24 hours. 
 
Day 4 
Harvesting the cells 
1. The flask content was transferred to centrifuge bottle and centrifuged at 5000 RPM for 20 
minutes. 
2. The cell pallet was transferred using a spatula from the centrifuge bottle to a 50 mL falcon 
tube. 
3. The cells were stored at -20°C.  
 
Day 5 
Preparation for Enzyme Purification 
1. In the biological hood, HEPES A buffer was added to the frozen bacterial cells in the falcon 
tube (approximately 18mL total volume). 
2. Approximately 3.6 mg solid lysozyme was added to the cells and the mixture was shook well 
and cooled for 30 minutes in ice.  
3. A tablet of protease inhibitor (without EDTA) was added to the falcon tube. 
4. The falcon tube content was sonicated 4 times (each time about 2 - 3 seconds) Ice was used to 
cool the cells after each sonication.  
5. Approximately 25µg DNAse was added to the falcon tube.  
6. Then, 0.25mL MgCl2 (1M) was added to the falcon tube content.  
7. The content of the falcon tube was cooled in the ice for 20 minutes.  
8. The falcon tube content was divided into 2 centrifuge tubes and centrifuged at 12500 RPM for 
32 minutes. 
9. The supernatant was collected in a labelled falcon tube (IMP-1 culture). 
10. The supernatant was filtered through 0.22 µm filter. 
11. Then, the filtered supernatant was concentrated using Millipore (Amicon ultra) centrifugal 
filter devices at 5000 speed to 5 mL sample. 
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12. The sample was transferred using a plastic pipette to another 15 mL falcon tube.  
 
Buffers for the Purification of enzyme (IMP-1) 
 
HEPES A HEPES B HEPES X (Assay Buffer) 
50 mM HEPES 
NO SALT 
500 µM ZnCl2 
pH 7, degassed 
50 mM HEPES 
1.0 M NaCl 
500 µM ZnCl2 
pH 7, Degas 
50 mM HEPES 
0.1 M NaCl 
100 µM ZnCl2 
pH 7, degassed 
HEPES 11.91 g 
NO SALT 
1 L milliQ water 
HEPES 11.91 g 
58.44 g NaCl 
1 L milliQ water 
HEPES 11.91 g 
5.844 g NaCl 
1 L milliQ water 
Used in SP Sepharose 16/10 
(Amersham Biosciences) along 
with HEPES B to create an 
eluting gradient. 
Used to dialyse out DNAse etc. 
Used in Gel filtration 
(superpose 12) 
Used in SP Sepharose 16/10 
(Amersham Biosciences) along 
with HEPES A to create an 
eluting gradient. 
Used for assay purposes 
 
Enzyme Purification 
IMP-1 purification required a two-step FPLC (Fast Performance Liquid Chromatography) method. 
 
Step 1. SP-Sepharose 16/10 (Amersham Biosciences) 
Step 2. Gel filtration, Hiprep 16/60 Sephacryl (superpose 12). 
 
For the general monitoring of IMP-1 enzyme activity during each FPLC method, cuvette assays 
were performed in HEPES X buffer using the substrate benzylpenicillin (500 µM final 
concentration). The rate of benzylpenicillin consumption was monitored at 235 nm (ε = 936 M-1 
cm-1). 
 
 
